score,preferred,last_name,first_name,researcher_id
43610,Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial,Thacker,Paul D,ur.07637527753.21
34655,The proximal origin of SARS-CoV-2,Holmes,Edward C.,ur.012501436222.04
34655,The proximal origin of SARS-CoV-2,Lipkin,W. Ian,ur.01306555033.15
34655,The proximal origin of SARS-CoV-2,Garry,Robert F.,ur.01051136257.59
34655,The proximal origin of SARS-CoV-2,Rambaut,Andrew,ur.0633743356.16
34655,The proximal origin of SARS-CoV-2,Andersen,Kristian G.,ur.0701117322.53
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Nielsen,Pernille B.,ur.016667625517.12
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Winsløw,Ulrik C.,ur.01102110041.14
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Iversen,Kasper,ur.01062445725.16
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Skovgaard,Kerstin,ur.01271546226.31
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Goecke,Nicole Bakkegård,ur.014717043577.60
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Norsk,Jakob Boesgaard,ur.01315441730.00
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Hasselbalch,Rasmus,ur.010606445621.72
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Bundgaard,Henning,ur.012145504404.94
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Benfield,Thomas,ur.0614447562.23
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Fogh,Kamille,ur.01325361164.72
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Ullum,Henrik,ur.01010523770.22
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Vissing,Christoffer Rasmus,ur.01106157206.06
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Todsen,Tobias,ur.01174112266.29
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Raaschou-Pedersen,Daniel Emil Tadeusz,ur.07632553764.45
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,von Buchwald,Christian,ur.01240540000.69
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Pries-Heje,Mia M.,ur.012201406621.61
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Kristensen,Jonas H.,ur.011121203567.05
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Ringgaard,Anna,ur.016523561354.65
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Torp-Pedersen,Christian,ur.0663477273.08
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Andersen,Mikkel Porsborg,ur.011415007345.05
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Trebbien,Ramona,ur.0703430276.76
32167,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers,Bundgaard,Johan Skov,ur.011125127544.81
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Lockhart,Stephen,ur.01155017074.41
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Gurtman,Alejandra,ur.0766540106.68
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Hammitt,Laura L,
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Nell,Haylene,ur.01051056763.52
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Şahin,Uğur,
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Frenck,Robert W,
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Perez,John L,
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Koury,Kenneth,ur.01252412675.84
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Ünal,Serhat,ur.01115453237.24
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Absalon,Judith,ur.0726712623.28
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Cooper,David,
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Kalina,Warren V,ur.0577211724.06
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Li,Ping,
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Dormitzer,Philip R,ur.01124563153.82
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Türeci,Özlem,
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Swanson,Kena A,ur.0720727651.67
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Moreira,Edson D,ur.016320742232.37
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Schaefer,Axel,
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Zerbini,Cristiano,ur.0616437273.35
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Jansen,Kathrin U,
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Gruber,William C,
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Kitchin,Nicholas,ur.01343436707.36
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Pérez Marc,Gonzalo,ur.014352732673.49
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Polack,Fernando P,
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Thomas,Stephen J,ur.01250631625.48
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Roychoudhury,Satrajit,ur.01075070035.40
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Bailey,Ruth,
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Tresnan,Dina B,ur.011115233157.53
31672,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,Mather,Susan,
31574,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections,Peretz,Asaf,ur.012567230737.98
31574,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections,Perez,Galit,ur.011771650337.75
31574,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections,Gazit,Sivan,ur.07713722763.04
31574,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections,Ben-Tov,Amir,ur.01142707457.76
31574,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections,Cohen,Dani,ur.014616340532.12
31574,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections,Muhsen,Khitam,ur.016624613147.07
31574,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections,Shlezinger,Roei,
31574,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections,Lotan,Roni,ur.011237776664.19
31574,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections,Chodick,Gabriel,ur.01046761047.26
31574,Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections,Patalon,Tal,ur.015363271451.24
30864,"Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines",Dowswell,Therese,ur.01041473720.52
30864,"Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines",Tham,Tony C.,ur.016422726541.27
30864,"Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines",Bryant,Andrew,ur.0670762332.64
30864,"Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines",Fordham,Edmund J.,ur.011140031773.84
30864,"Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines",Mitchell,Scott,ur.014336521675.06
30864,"Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines",Hill,Sarah R.,ur.012532772773.22
30864,"Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines",Lawrie,Theresa A.,ur.0604517746.21
28698,Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line,Rasmussen,Magnus,ur.01016143627.49
28698,Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line,Yang,Daowei,ur.014111275010.54
28698,Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line,Falla,Francisko Olofsson,
28698,Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line,De Marinis,Yang,ur.01273103257.24
28698,Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line,Barghouth,Mohammad,ur.015150553773.14
28698,Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line,Luan,Cheng,ur.01270246417.54
28698,Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line,Aldén,Markus,ur.011611560364.98
26100,Physical interventions to interrupt or reduce the spread of respiratory viruses,Clark,Justin,ur.0734347735.52
26100,Physical interventions to interrupt or reduce the spread of respiratory viruses,Hoffmann,Tammy C,ur.0674537760.65
26100,Physical interventions to interrupt or reduce the spread of respiratory viruses,Ferroni,Eliana,ur.01325542557.35
26100,Physical interventions to interrupt or reduce the spread of respiratory viruses,van Driel,Mieke L,ur.01123705141.19
26100,Physical interventions to interrupt or reduce the spread of respiratory viruses,Jones,Mark A,ur.0712645702.33
26100,Physical interventions to interrupt or reduce the spread of respiratory viruses,Bawazeer,Ghada A,ur.01053224250.68
26100,Physical interventions to interrupt or reduce the spread of respiratory viruses,Conly,John M,ur.0612603027.67
26100,Physical interventions to interrupt or reduce the spread of respiratory viruses,Dooley,Liz,ur.01114051654.03
26100,Physical interventions to interrupt or reduce the spread of respiratory viruses,Beller,Elaine M,ur.01061550363.13
26100,Physical interventions to interrupt or reduce the spread of respiratory viruses,Glasziou,Paul P,ur.010361417657.66
26100,Physical interventions to interrupt or reduce the spread of respiratory viruses,Al-Ansary,Lubna A,ur.01257427357.51
26100,Physical interventions to interrupt or reduce the spread of respiratory viruses,Jefferson,Tom,ur.0745413111.75
26027,COVID UPDATE: What is the truth?,Blaylock,Russell L,ur.0627573165.01
26012,Abstract 10712: Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines,Gundry,Steven R,ur.015025514477.37
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Popova,Olga,ur.013305514767.59
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Ozharovskaya,Tatiana A,ur.014700455767.04
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Logunov,Denis Y,ur.013400453014.35
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Shcherbinin,Dmitry N,ur.0676211633.27
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Naroditsky,Boris S,ur.0765430416.14
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Erokhova,Alina S,ur.013400504014.55
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Grousova,Daria M,ur.011127543255.28
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Favorskaya,Irina A,ur.01262710301.02
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Smolyarchuk,Elena A,ur.011220662101.12
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Simakova,Yana V,ur.014725130503.04
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Group,Gam-COVID-Vac Vaccine Trial,
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Zyryanov,Sergey K,ur.016664012316.14
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Voronina,Daria V,ur.013466120623.80
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Nikitenko,Natalia A,ur.01271474514.90
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Borisevich,Sergei V,ur.012740611367.66
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Botikov,Andrei G,ur.010317612767.36
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Dzharullaeva,Alina S,ur.0717221603.78
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Tokarskaya,Elizaveta A,ur.016677776513.42
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Esmagambetov,Ilias B,ur.0613537044.27
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Zrelkin,Denis I,ur.012556247567.54
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Kovyrshina,Anna V,ur.010365412723.34
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Zubkova,Olga V,ur.012317133513.16
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Semikhin,Alexander S,ur.07636460767.47
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Egorova,Daria A,ur.010200566413.95
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Shmarov,Maksim M,ur.07704574167.11
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Gintsburg,Alexander L,ur.01025401416.89
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Gushchin,Vladimir A,ur.01206067372.73
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Tukhvatulin,Amir I,ur.01166523007.34
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Dolzhikova,Inna V,ur.0630076433.53
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Lubenets,Nadezhda L,ur.014217323767.55
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Shcheblyakov,Dmitry V,ur.01023565540.40
25840,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,Izhaeva,Fatima M,ur.010061074133.30
24308,The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients—A Large Population-Based Study,Tuvali,Ortal,ur.010675667001.53
24308,The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients—A Large Population-Based Study,Afek,Arnon,ur.0751232476.92
24308,The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients—A Large Population-Based Study,Derazne,Estela,ur.01047717742.44
24308,The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients—A Large Population-Based Study,Haberman,Dan,ur.013563460634.58
24308,The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients—A Large Population-Based Study,George,Jacob,ur.0642435445.82
24308,The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients—A Large Population-Based Study,Sella,Gal,ur.016634141604.36
24308,The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients—A Large Population-Based Study,Tshori,Sagi,ur.0702402153.79
24308,The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients—A Large Population-Based Study,Hannuna,Rebecca Regina,
23972,COVID-19: stigmatising the unvaccinated is not justified,Kampf,Günter,ur.01335361256.43
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,Bushmaker,Trenton,ur.01255664334.11
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,de Wit,Emmie,ur.01357410457.53
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,van Doremalen,Neeltje,ur.01364235606.88
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,Munster,Vincent J,ur.01334105063.89
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,Gerber,Susan I,ur.0577650272.59
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,Holbrook,Myndi G,ur.010005564531.45
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,Harcourt,Jennifer L,ur.01131526114.79
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,Gamble,Amandine,ur.07456113165.27
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,Thornburg,Natalie J,ur.0606700201.50
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,Lloyd-Smith,James O,ur.0755477044.60
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,Morris,Dylan H,ur.016527372177.19
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,Tamin,Azaibi,ur.0730465355.70
23864,Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1,Williamson,Brandi N,ur.013210433407.71
23172,Increases in COVID-19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States,Kumar,Akhil,ur.015554747430.84
23172,Increases in COVID-19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States,Subramanian,S. V.,ur.012105053737.07
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Chen,Guang,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",El-harakeh,Amena,ur.011437632161.41
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Piggott,Thomas,ur.0717335233.16
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Schünemann,Holger J,ur.01126365241.80
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Chamseddine,Fatimah,ur.012430114525.36
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Lotfi,Tamara,ur.01012672102.94
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Chu,Derek K,ur.01243425011.37
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Zhao,Hong,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Morgano,Gian Paolo,ur.016012651117.18
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Neumann,Ignacio,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Yaacoub,Sally,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",authors,COVID-19 Systematic Urgent Review Group Effort study,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Smith,Maureen,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Khamis,Assem,ur.016202427703.42
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",AbiHanna,Pierre,ur.012457735437.99
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Hajizadeh,Anisa,ur.015155604211.92
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Hneiny,Layal,ur.015217550115.32
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Stalteri,Rosa,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Borowiack,Ewa,ur.01256111676.51
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Harris,David J,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Zhang,Yuan,ur.01275145343.86
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Duda,Stephanie,ur.01015732361.56
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Harrison,Leila,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Schünemann,Finn,ur.013677071611.00
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Izcovich,Ariel,ur.0623171704.35
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Bognanni,Antonio,ur.07510325725.65
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Rossi,Paolo Giorgi,ur.015617015653.79
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Yaacoub,Sally,ur.016145263725.25
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Solo,Karla,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Bak,Anna,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Akl,Elie A,ur.01267162113.26
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Chan,Jeffrey,ur.010547071116.08
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Reinap,Marge,ur.0641247327.27
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Akl,Elie A,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Rizk,Nesrine,ur.01060630057.17
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Loeb,Mark,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Saad,Zahra,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Schünemann,Holger J,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Solo,Karla,ur.014320225103.71
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Khabsa,Joanne,ur.013613023177.92
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Baldeh,Tejan,ur.0627740226.32
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Schünemann,Giovanna E U Muti,ur.012163571131.34
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Cuello-Garcia,Carlos A,ur.01356653655.33
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",El-khoury,Rayane,ur.012200514401.55
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Chu,Derek K,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Chen,Chen,
23097,"Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis",Duda,Stephanie,
21999,The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro,Jans,David A.,ur.0717574257.23
21999,The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro,Wagstaff,Kylie M.,ur.01216667427.77
21999,The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro,Caly,Leon,ur.0711021347.62
21999,The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro,Druce,Julian D.,ur.01351056174.11
21999,The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro,Catton,Mike G.,ur.07460304345.02
21990,RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis,Patel,Amit N,ur.01236157777.59
21990,RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis,Ruschitzka,Frank,ur.01103006423.90
21990,RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis,Desai,Sapan S,ur.01127714712.17
21990,RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis,Mehra,Mandeep R,ur.0604020344.51
21621,The epidemiological relevance of the COVID-19-vaccinated population is increasing,Kampf,Günter,ur.01335361256.43
21498,Dying in a Leadership Vacuum,Editors,The,
21445,Ten scientific reasons in support of airborne transmission of SARS-CoV-2,Jimenez,Jose L,ur.01051427102.20
21445,Ten scientific reasons in support of airborne transmission of SARS-CoV-2,Greenhalgh,Trisha,ur.0734302623.84
21445,Ten scientific reasons in support of airborne transmission of SARS-CoV-2,Fisman,David,ur.01335612470.01
21445,Ten scientific reasons in support of airborne transmission of SARS-CoV-2,Schooley,Robert,ur.0577053102.12
21445,Ten scientific reasons in support of airborne transmission of SARS-CoV-2,Tufekci,Zeynep,ur.0666761160.27
21445,Ten scientific reasons in support of airborne transmission of SARS-CoV-2,Prather,Kimberly A,ur.0576263513.15
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Song,Fujian,ur.0666572462.51
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Gong,Jie,
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Gong,Yanhong,ur.01036515375.80
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Gan,Yong,ur.012546351675.42
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Lu,Zuxun,ur.01340600266.50
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Yin,Xiaoxv,ur.01046303600.60
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Lv,Chuanzhu,ur.01351333725.15
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Lu,Kai,ur.016001174724.04
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Bachmann,Max,ur.0616413132.36
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Shen,Xin,ur.014147064253.04
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Wang,Chao,ur.011311311457.81
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Wang,Tiantian,ur.010270736507.15
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Wei,Shanbo,
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Cao,Shiyi,ur.0773674666.74
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Li,Liqing,ur.01300217462.49
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Huang,Yuchai,ur.010211257727.61
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Xu,Hongbin,ur.013240614661.99
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Tian,Qingfeng,ur.011337143776.74
21156,"Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China",Jiang,Heng,ur.0642725560.82
20225,Global impact of the first year of COVID-19 vaccination: a mathematical modelling study,Toor,Jaspreet,ur.01006721462.02
20225,Global impact of the first year of COVID-19 vaccination: a mathematical modelling study,Watson,Oliver J,ur.01177743716.54
20225,Global impact of the first year of COVID-19 vaccination: a mathematical modelling study,Winskill,Peter,ur.01353114200.76
20225,Global impact of the first year of COVID-19 vaccination: a mathematical modelling study,Ghani,Azra C,ur.0645140152.06
20225,Global impact of the first year of COVID-19 vaccination: a mathematical modelling study,Hogan,Alexandra B,ur.01101164236.07
20225,Global impact of the first year of COVID-19 vaccination: a mathematical modelling study,Barnsley,Gregory,ur.013641270702.09
20004,Long-term cardiovascular outcomes of COVID-19,Xu,Evan,ur.015100372457.77
20004,Long-term cardiovascular outcomes of COVID-19,Bowe,Benjamin,ur.0736221463.48
20004,Long-term cardiovascular outcomes of COVID-19,Xie,Yan,ur.0737732757.38
20004,Long-term cardiovascular outcomes of COVID-19,Al-Aly,Ziyad,ur.0756001054.57
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Ellington,Sascha R,ur.0677274441.07
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Panagiotakopoulos,Lakshmi,ur.010264130325.91
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Kim,Shin Y,ur.0667416735.50
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Licata,Charles,ur.012602215653.24
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Green,Caitlin J,ur.014122426325.54
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Chang,Karen T,ur.011673624633.72
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Moro,Pedro L,ur.01042551035.04
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Myers,Tanya R,ur.0702220537.00
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Olson,Christine K,ur.012517214455.28
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Martin,Stacey W,ur.0644351603.39
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Zhang,Bicheng C,ur.015515367325.91
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Meaney-Delman,Dana M,ur.01165144247.57
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Liu,Ruiling,ur.010756577653.97
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Mba-Jonas,Adamma,ur.01263626416.03
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Oduyebo,Titilope,ur.01043565252.17
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Marquez,Paige L,ur.015021244217.45
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Gee,Julianne M,ur.01220225706.45
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Burkel,Veronica K,ur.011230732017.59
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Smoots,Ashley N,ur.012150716217.99
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Shimabukuro,Tom T,ur.0613726743.13
19796,Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons,Alimchandani,Meghna,ur.01310074614.10
19723,"Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs",Nigh,Greg,ur.010456757550.38
19723,"Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs",Seneff,Stephanie,ur.013114653342.26
19723,"Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs",Kyriakopoulos,Anthony M,ur.01075475635.32
19723,"Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs",McCullough,Peter A,ur.01115457467.68
19310,An evidence review of face masks against COVID-19,Shaikh,Reshama,ur.013400773007.71
19310,An evidence review of face masks against COVID-19,Ramirez,Christina M.,ur.01364560072.61
19310,An evidence review of face masks against COVID-19,Fridman,Lex,ur.012043706717.56
19310,An evidence review of face masks against COVID-19,Watson,Gregory L.,ur.010652706355.25
19310,An evidence review of face masks against COVID-19,Hernandez,Danny,ur.014773734007.20
19310,An evidence review of face masks against COVID-19,Bax,Christina E.,ur.014233434131.43
19310,An evidence review of face masks against COVID-19,Tang,Lei-Han,ur.0603516671.14
19310,An evidence review of face masks against COVID-19,van der Westhuizen,Helene-Mari,ur.01343561706.02
19310,An evidence review of face masks against COVID-19,Chu,Larry F.,ur.012005257157.34
19310,An evidence review of face masks against COVID-19,Howard,Jeremy,ur.011142336207.52
19310,An evidence review of face masks against COVID-19,Tufekci,Zeynep,ur.0666761160.27
19310,An evidence review of face masks against COVID-19,Questier,Frederik,ur.01222422244.46
19310,An evidence review of face masks against COVID-19,Zdimal,Vladimir,ur.01372030103.18
19310,An evidence review of face masks against COVID-19,Li,Zhiyuan,ur.01267230422.34
19310,An evidence review of face masks against COVID-19,Tang,Viola,ur.011210451407.54
19310,An evidence review of face masks against COVID-19,Price,Amy,ur.01202173745.21
19310,An evidence review of face masks against COVID-19,von Delft,Arne,ur.0662427706.54
19310,An evidence review of face masks against COVID-19,Rimoin,Anne W.,ur.0733353421.37
19310,An evidence review of face masks against COVID-19,Huang,Austin,ur.011737716607.35
19252,Identifying airborne transmission as the dominant route for the spread of COVID-19,Zhang,Renyi,ur.01000271572.35
19252,Identifying airborne transmission as the dominant route for the spread of COVID-19,Molina,Mario J,ur.01003651151.08
19252,Identifying airborne transmission as the dominant route for the spread of COVID-19,Wang,Yuan,ur.0633166465.17
19252,Identifying airborne transmission as the dominant route for the spread of COVID-19,Li,Yixin,ur.014317046633.22
19252,Identifying airborne transmission as the dominant route for the spread of COVID-19,Zhang,Annie L,ur.0653003706.15
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Peiris,J. S. Malik,ur.01311553066.30
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Seto,Wing-Hong,ur.011302404554.81
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Hau,Benien J. P.,ur.010655675015.17
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Shiu,Eunice Y. C.,ur.01061747024.07
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Cowling,Benjamin J.,ur.07675207637.48
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Leung,Nancy H. L.,ur.01255605525.91
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Chu,Daniel K. W.,ur.010457424472.22
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Ip,Dennis K. M.,ur.013361110614.84
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Milton,Donald K.,ur.0771763124.46
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Chan,Kwok-Hung,ur.07671422302.12
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Li,Yuguo,ur.01055536240.99
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,McDevitt,James J.,ur.0747043771.77
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Leung,Gabriel M.,ur.0665764620.02
19220,Respiratory virus shedding in exhaled breath and efficacy of face masks,Yen,Hui-Ling,ur.01154432301.58
18986,Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk,Hanna,Nazeeh,ur.0665307560.18
18986,Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk,Botros,Bishoy,ur.013351127573.60
18986,Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk,Nayak,Amrita,ur.012744420123.59
18986,Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk,De Mejia,Claudia Manzano,ur.015541451173.10
18986,Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk,Lin,Xinhua,ur.016606376323.21
18986,Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk,Heffes-Doon,Ari,ur.013701064435.87
18986,Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk,Gurzenda,Ellen,ur.0713057157.88
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Gabriel,Stacey B.,ur.012151177437.05
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Foreman,Anne,
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Sabo,Rebecca T.,
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Madoff,Lawrence C.,ur.01151361612.58
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Laney,A. Scott,ur.01260401342.17
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Vostok,Johanna,ur.0705760737.02
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Harik,Vaira,ur.010627552344.74
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Sami,Samira,ur.010675100323.38
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Brock-Fisher,Taylor,ur.012222513344.35
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Arvidson,Deirdre,ur.011425132744.85
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",MacInnis,Bronwyn,ur.0714005542.35
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Kearns,Amanda,
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Gharpure,Radhika,ur.013767704355.26
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Park,Daniel J.,ur.012700305067.67
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Siddle,Katherine J.,ur.01104734126.20
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Fink,Timelia,ur.014404625343.72
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Gallagher,Glen R.,ur.01320425150.53
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Brown,Catherine M.,ur.01061610666.60
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Schubert,Petra L.,ur.015071330200.37
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Dunn,Molly,
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Hall,Noemi,ur.01060724642.51
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Burns,Meagan,ur.011550743624.26
18960,"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021",Johnson,Hillary,ur.014276606344.24
18459,Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis,Ruschitzka,Frank,ur.01103006423.90
18459,Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis,Mehra,Mandeep R,ur.0604020344.51
18459,Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis,Patel,Amit N,ur.01236157777.59
18392,Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine,Hagen,Amanda,ur.012607611220.35
18392,Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine,Nowacki,Amy S.,ur.01046134373.87
18392,Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine,Gordon,Steven M.,ur.014424253062.35
18392,Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine,Shrestha,Nabin K.,ur.014530171213.52
18392,Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine,Simon,James F.,ur.012012230620.73
18392,Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine,Burke,Patrick C.,ur.016236544425.44
18372,Informed consent disclosure to vaccine trial subjects of risk of COVID‐19 vaccines worsening clinical disease,Cardozo,Timothy,ur.016514320327.25
18372,Informed consent disclosure to vaccine trial subjects of risk of COVID‐19 vaccines worsening clinical disease,Veazey,Ronald,ur.01044367264.64
18365,Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave,Jaffe,Eli,ur.01023307027.30
18365,Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave,Levi,Retsef,ur.015603330425.35
18365,Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave,Sun,Christopher L. F.,ur.010664173762.42
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Shay,David K.,ur.0755163267.37
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Thompson,Deborah L.,
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Su,John R.,
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,DeStefano,Frank,ur.01046724144.46
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Reagan-Steiner,Sarah,ur.01115112341.20
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Campbell,M. Jay,ur.010014710437.77
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Strid,Penelope,ur.015224416223.33
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Sperling,Laurence S.,ur.01315662510.65
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Gee,Julianne,
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Lopes,Renato D.,
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Pugsley,River,ur.0732633334.12
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Marquez,Paige L.,ur.015021244217.45
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Creech,C. Buddy,ur.0742031600.29
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Broder,Karen R.,ur.01110664235.25
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Ruberg,Frederick L.,ur.01054052222.12
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Smith,Michael J.,
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Shimabukuro,Tom T.,ur.0613726743.13
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Soslow,Jonathan H.,ur.0751434251.89
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Lang,Sean M.,
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Oster,Matthew E.,ur.01261525574.45
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Baumblatt,Jane A.,ur.01015507310.91
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Schlaudecker,Elizabeth,ur.0663755534.60
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Edwards,Kathryn,
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Barnett,Elizabeth D.,ur.01337222013.43
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Woo,Jared,
18267,Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021,Dendy,Jeffrey M.,ur.0665131425.02
17914,Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults,Doshi,Peter,ur.01366522556.38
17914,Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults,Fraiman,Joseph,ur.015342476012.46
17914,Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults,Whelan,Patrick,ur.011027746212.71
17914,Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults,Greenland,Sander,ur.01272101171.42
17914,Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults,Jones,Mark,ur.0712645702.33
17914,Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults,Erviti,Juan,ur.01245717144.10
17914,Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults,Kaplan,Robert M,ur.010716514154.97
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Quinn,Valerie,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Luca,Constanta,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Tejpal,Chitra,ur.011046736647.22
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Dunning,Jake,ur.01045204130.34
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Varro,Robert,ur.016341410647.57
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Lalvani,Ajit,ur.01032123356.36
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Hakki,Seran,ur.016130610673.61
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",McDermott,Eimear,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Madon,Kieran J,ur.011645362340.99
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Charlett,Andre,ur.0723065546.38
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Whitfield,Michael G,ur.0717451135.30
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Badhan,Anjna,ur.0772545710.84
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Evetts,Samuel,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Narean,Janakan Sam,ur.010152400040.59
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Ahmad,Shazaad,ur.016023350453.40
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Barclay,Wendy,ur.0733033550.69
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Dustan,Simon,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Bremang,Samuel,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Fenn,Joe,ur.015062676247.33
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Samuel,Jada,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Lackenby,Angie,ur.01365604606.54
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Freemont,Paul S,ur.01277020030.75
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Anderson,Charlotte,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Hammett,Sarah,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Conibear,Emily,ur.016540757527.32
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Koycheva,Aleksandra,ur.012541114132.97
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Pillay,Timesh,ur.01016426445.03
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Singanayagam,Anika,ur.0725512277.22
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Miah,Shahjahan,ur.0637415305.56
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Cutajar,Jessica,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Investigators,ATACCC Study,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Crone,Michael A,ur.015266142447.65
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Ellis,Joanna,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Taylor,Graham P,ur.016136424052.65
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Ketkar,Anjeli V,ur.012675453400.73
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Jackson,David,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Houston,Hamish,ur.014310011047.83
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Poh,John,
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Zambon,Maria,ur.0756427106.18
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Derqui-Fernandez,Nieves,ur.016226225340.33
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Kundu,Rhia,ur.014104017140.12
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Ferguson,Neil M,ur.01346743312.51
17912,"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study",Barnett,Jack L,ur.012561225000.30
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Jain,Seema,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Myers,Jennifer F.,ur.015363164005.96
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Dong,Zheng N.,ur.012061144250.06
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Spencer,Maya,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Lewnard,Joseph A.,ur.01070176112.68
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Park,Hyemin,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Miller,Monique,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Kaur,Amandeep,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Xavier,Erin,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Dabbagh,Najla,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Corredor,Savannah,ur.015752107666.48
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Li,Sophia S.,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Felipe,Diana,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Cornejo,Adrian F.,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Walas,Nikolina,ur.011565441417.55
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Saretha,Shrey,ur.016614455114.79
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Pry,Jake M.,ur.015667033557.18
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Openshaw,John,ur.016166247303.08
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Fang,Anna T.,ur.016373674050.39
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Poindexter,Diana J.,ur.012233612114.64
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Andrejko,Kristin L.,ur.015224230077.22
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Cheunkarndee,Julia,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",DeGuzman,Jennifer L.,ur.014203352450.37
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Bermejo,Miriam I.,ur.011504344714.15
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Fukui,Nozomi,ur.015106414066.38
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Ho,Timothy,ur.011373324077.10
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Samani,Helia,ur.012165476714.17
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Javadi,Mahsa H.,ur.07627530501.08
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Team,California COVID-19 Case-Control Study,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Frost,Paulina M.,ur.011263563650.71
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Spinosa,Michelle M.,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Wan,Christine,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Tran,Vivian H.,ur.07670622650.47
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Abdulrahim,Yasmine,ur.012764205666.10
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Dyke,Ashly,ur.010641777466.52
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Lam,Amanda,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Barbaduomo,Camilla M.,ur.013560437714.29
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Team,California COVID-19 Case-Control Study,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Watt,James P.,
17751,"Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021",Ni,Jessica,
17644,"Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19",Yagisawa,M.,ur.064707763.30
17644,"Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19",McCullough,P.A.,ur.01115457467.68
17644,"Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19",Santin,A.D.,ur.01134001475.57
17644,"Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19",Scheim,D.E.,ur.012674273313.42
17644,"Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19",Borody,T.J.,ur.013224704715.56
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,McKay,Paula,
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Boulware,David R,ur.01361554135.48
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Reis,Gilmar,ur.01171607346.41
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Ferreira,Thiago S,ur.015252315322.46
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Neto,Adhemar D F,
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Forrest,Jamie I,ur.01231641307.87
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Thabane,Lehana,
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Rowland-Yeo,Karen,ur.01210733121.04
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Ruton,Hinda,ur.01272116662.36
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Callegari,Eduardo D,ur.016521555770.15
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Ribeiro,Luciene B,ur.013663173725.36
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Oliveira,Rosemary,
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Guo,Christina M,
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Silva,Eduardo A S M,
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Rayner,Craig R,ur.01371760723.88
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Silva,Daniela C M,ur.015460062375.98
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Milagres,Aline C,ur.011472652325.66
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Mills,Edward J,ur.01070350152.95
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Campos,Vitoria H S,ur.015501446154.00
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Sprague,Sheila,
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Nogueira,Ana M R,
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Savassi,Leonardo C M,ur.013575413710.95
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Harari,Ofir,ur.014473657624.43
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Dos Santos,Castilho V Q,ur.016255442775.21
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Simplicio,Maria I C,ur.013065613325.10
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,Guyatt,Gordon H,ur.0773167774.48
17596,Effect of Early Treatment with Ivermectin among Patients with Covid-19,de Almeida,Ana P F G,
17557,COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room,Vaillant,Michel,ur.01367323233.36
17557,COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room,Torreele,Els,ur.01113742726.12
17557,COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room,Olliaro,Piero,ur.01074272363.42
17509,Acute and postacute sequelae associated with SARS-CoV-2 reinfection,Bowe,Benjamin,ur.0736221463.48
17509,Acute and postacute sequelae associated with SARS-CoV-2 reinfection,Al-Aly,Ziyad,ur.0756001054.57
17509,Acute and postacute sequelae associated with SARS-CoV-2 reinfection,Xie,Yan,ur.0737732757.38
17492,Current Causes of Death in Children and Adolescents in the United States,Carter,Patrick M,ur.01360657654.02
17492,Current Causes of Death in Children and Adolescents in the United States,Cunningham,Rebecca M,ur.01252653704.77
17492,Current Causes of Death in Children and Adolescents in the United States,Goldstick,Jason E,ur.0653021152.30
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Nichols,Thomas E.,ur.01215612447.63
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Taschler,Bernd,ur.01360405072.52
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Douaud,Gwenaëlle,ur.01166163003.88
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Matthews,Paul M.,ur.0627601545.87
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Keating,Peter,ur.07664620674.73
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Griffanti,Ludovica,ur.01100670414.73
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Winkler,Anderson M.,ur.012257341037.21
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Allen,Naomi,ur.0577003004.68
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Collins,Rory,ur.0641770103.91
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Alfaro-Almagro,Fidel,ur.0716352241.41
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Lange,Frederik,ur.015317232313.52
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Jbabdi,Saad,ur.0640053733.88
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Arthofer,Christoph,ur.010406044274.04
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Wang,Chaoyue,ur.010652627334.40
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Smith,Stephen M.,ur.010600757634.92
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Lee,Soojin,ur.0611571742.47
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Miller,Karla L.,ur.0741446577.58
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,McCarthy,Paul,ur.011245227127.42
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Duff,Eugene,ur.0730450433.34
17368,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Andersson,Jesper L. R.,ur.01033614353.71
17327,Had COVID? You’ll probably make antibodies for a lifetime,Callaway,Ewen,
17130,Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period,Lipsitch,Marc,ur.0750403636.04
17130,Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period,Tedijanto,Christine,ur.015044722040.49
17130,Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period,Grad,Yonatan H,ur.01214071203.94
17130,Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period,Kissler,Stephen M,ur.01332232310.36
17130,Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period,Goldstein,Edward,ur.01276044315.01
16772,Facemasks in the COVID-19 era: A health hypothesis,Vainshelboim,Baruch,ur.0642446661.43
16711,Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study,Hansen,Christian Holm,ur.01200434327.28
16711,Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study,Krause,Tyra Grove,ur.0675313141.36
16711,Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study,Valentiner-Branth,Palle,ur.0635002126.70
16711,Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study,Moustsen-Helm,Ida Rask,
16711,Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study,Emborg,Hanne-Dorthe,ur.0627177741.34
16711,Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study,Schelde,Astrid Blicher,ur.01163301220.16
16711,Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study,Mølbak,Kåre,ur.0730116643.78
16687,"Long COVID: major findings, mechanisms and recommendations",Davis,Hannah E.,ur.011540161735.06
16687,"Long COVID: major findings, mechanisms and recommendations",McCorkell,Lisa,ur.015317277775.32
16687,"Long COVID: major findings, mechanisms and recommendations",Vogel,Julia Moore,ur.011424051676.68
16687,"Long COVID: major findings, mechanisms and recommendations",Topol,Eric J.,ur.0731336524.18
16412,"Early Release - COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Lai,Zhisheng,
16412,"Early Release - COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Lu,Jianyun,ur.0673730506.80
16412,"Early Release - COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Li,Kuibiao,ur.01256400201.92
16412,"Early Release - COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Zhou,Deqian,
16412,"Early Release - COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Xu,Bin,
16412,"Early Release - COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Yang,Zhicong,
16412,"Early Release - COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Su,Wenzhe,ur.01337744346.72
16412,"Early Release - COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Yu,Chao,
16412,"Early Release - COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Gu,Jieni,
16412,"Early Release - COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Xu,Conghui,ur.011564476651.96
16234,Assessing mandatory stay‐at‐home and business closure effects on the spread of COVID‐19,Ioannidis,John P. A.,ur.015607417277.46
16234,Assessing mandatory stay‐at‐home and business closure effects on the spread of COVID‐19,Bendavid,Eran,ur.0642551050.54
16234,Assessing mandatory stay‐at‐home and business closure effects on the spread of COVID‐19,Oh,Christopher,ur.014632347207.42
16234,Assessing mandatory stay‐at‐home and business closure effects on the spread of COVID‐19,Bhattacharya,Jay,ur.011146443737.37
16156,Adverse effects of COVID-19 vaccines and measures to prevent them,Yamamoto,Kenji,ur.011027413543.04
15975,Airborne transmission of respiratory viruses,Marr,Linsey C,ur.0653376160.71
15975,Airborne transmission of respiratory viruses,Jimenez,Jose L,ur.01051427102.20
15975,Airborne transmission of respiratory viruses,Tufekci,Zeynep,ur.0666761160.27
15975,Airborne transmission of respiratory viruses,Lakdawala,Seema S,ur.01110703600.04
15975,Airborne transmission of respiratory viruses,Wang,Chia C,ur.01252041604.44
15975,Airborne transmission of respiratory viruses,Prather,Kimberly A,ur.0576263513.15
15975,Airborne transmission of respiratory viruses,Sznitman,Josué,ur.01233415165.52
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Dabrera,Gavin,ur.01126326577.27
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Edmunds,Matt,ur.010644447061.16
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Lopez Bernal,Jamie,ur.014617266115.94
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Chand,Meera,ur.01075267170.20
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Hopkins,Susan,ur.0652465564.00
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Zambon,Maria,ur.0756427106.18
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Andrews,Nick,ur.01305560754.17
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Amirthalingam,Gayatri,ur.01117717665.12
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Campbell,Colin N J,ur.0725205665.13
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Gower,Charlotte,ur.014767232451.73
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Gallagher,Eileen,ur.014544160061.97
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Brown,Kevin E,ur.01300524520.49
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Stowe,Julia,ur.01372520505.11
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Groves,Natalie,ur.014434516755.72
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Simmons,Ruth,ur.011107167572.72
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Ramsay,Mary,ur.010566414272.00
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Myers,Richard,ur.0732415167.30
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Tessier,Elise,ur.013240153404.51
15936,Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,Thelwall,Simon,ur.0763614361.88
15849,Reducing transmission of SARS-CoV-2,Wang,Chia C,ur.01252041604.44
15849,Reducing transmission of SARS-CoV-2,Schooley,Robert T,ur.0577053102.12
15849,Reducing transmission of SARS-CoV-2,Prather,Kimberly A,ur.0576263513.15
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Bendavid,Eran,ur.0642551050.54
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Shah,Soleil,ur.011731064555.50
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Sood,Neeraj,ur.01322775714.41
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Ioannidis,John P.A.,ur.015607417277.46
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Lai,Cara,ur.014167521355.72
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Gupta,Ribhav,ur.0751453151.09
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Tversky,Dona,
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Tedrow,Jim,ur.010006560573.06
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Mulaney,Bianca,ur.013255712355.14
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Bromley-Dulfano,Rebecca,ur.010404236755.55
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Bogan,Andrew,ur.015101330355.22
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Weissberg,Zoe,ur.014342001574.58
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Bhattacharya,Jay,ur.011146443737.37
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Kupiec,Thomas,ur.010566600555.16
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Ling,Emilia,ur.011744066637.03
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Saavedra-Walker,Rodrigo,ur.013125405171.02
15776,"COVID-19 Antibody Seroprevalence in Santa Clara County, California",Eichner,Daniel,ur.0663441417.72
15702,SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro,Mei,Ya-Fang,ur.0711414253.21
15702,SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro,Jiang,Hui,ur.0673353475.83
15376,Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19,Iglesias,Jose,ur.01103440404.84
15376,Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19,Meduri,Gianfranco Umberto,ur.0753215304.40
15376,Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19,Kory,Pierre,ur.01263214251.87
15376,Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19,Varon,Joseph,ur.01130172604.54
15376,Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19,Marik,Paul E.,ur.0671623136.80
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Leung,Gabriel M.,ur.0665764620.02
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Zhang,Fuchun,ur.01117244366.33
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Deng,Xilong,ur.01216373063.50
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Li,Fang,ur.010417455611.83
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Cowling,Benjamin J.,ur.07675207637.48
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Zhao,Lingzhai,ur.0647021730.15
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Mo,Xiaoneng,ur.016257033211.10
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Hao,Xinxin,ur.011533453517.35
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,He,Xi,ur.011420075403.62
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Lau,Eric H. Y.,ur.011341514222.36
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Tan,Xinghua,ur.01301606166.54
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Wu,Peng,ur.01021644616.05
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Zhong,Mingqiu,ur.013337244411.06
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Liao,Baolin,ur.0757066404.34
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Wu,Yanrong,ur.014134625011.59
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Chen,Yanqing,ur.07553762011.05
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Chen,Weilie,ur.01167010155.48
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Zhang,Qing,ur.012541664011.43
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Wong,Jessica Y.,ur.01115120141.84
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Wang,Jian,ur.010656550751.20
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Lau,Yiu Chung,ur.014632675070.01
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Guan,Yujuan,ur.010663522133.27
15315,Temporal dynamics in viral shedding and transmissibility of COVID-19,Hu,Fengyu,ur.0725541261.48
15065,Covid‐19 vaccination BNT162b2 temporarily impairs semen concentration and total motile count among semen donors,Kedem,Alon,ur.0715563442.25
15065,Covid‐19 vaccination BNT162b2 temporarily impairs semen concentration and total motile count among semen donors,Baum,Micha,ur.01072542017.35
15065,Covid‐19 vaccination BNT162b2 temporarily impairs semen concentration and total motile count among semen donors,Gat,Itai,ur.01040657632.95
15065,Covid‐19 vaccination BNT162b2 temporarily impairs semen concentration and total motile count among semen donors,Umanski,Ana,ur.015420636662.42
15065,Covid‐19 vaccination BNT162b2 temporarily impairs semen concentration and total motile count among semen donors,Dviri,Michal,ur.01254536776.87
15065,Covid‐19 vaccination BNT162b2 temporarily impairs semen concentration and total motile count among semen donors,Levi,Matan,
15065,Covid‐19 vaccination BNT162b2 temporarily impairs semen concentration and total motile count among semen donors,Hourvitz,Ariel,ur.0670062053.56
14995,Low-cost measurement of face mask efficacy for filtering expelled droplets during speech,Warren,Warren S.,ur.01032731101.10
14995,Low-cost measurement of face mask efficacy for filtering expelled droplets during speech,Westman,Eric,ur.01057311523.26
14995,Low-cost measurement of face mask efficacy for filtering expelled droplets during speech,Grass,David,ur.0673646525.45
14995,Low-cost measurement of face mask efficacy for filtering expelled droplets during speech,Fischer,Martin C.,ur.01143770277.25
14995,Low-cost measurement of face mask efficacy for filtering expelled droplets during speech,Fischer,Emma P.,ur.016663512727.54
14995,Low-cost measurement of face mask efficacy for filtering expelled droplets during speech,Henrion,Isaac,
14763,Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2),Song,Yimeng,ur.016066423150.37
14763,Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2),Pei,Sen,ur.01267143031.88
14763,Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2),Chen,Bin,ur.011751053723.18
14763,Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2),Zhang,Tao,ur.011725557241.33
14763,Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2),Li,Ruiyun,ur.0623010466.42
14763,Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2),Shaman,Jeffrey,ur.01135117442.37
14763,Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2),Yang,Wan,ur.0616021610.71
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Veighey,Kristin,ur.01324027753.08
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Peng,Yanchun,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Howe,Elizabeth,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Blackwell,Luke,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Smee,Heather,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Hill,Jennifer,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Goulston,Lyndsey,ur.01313233217.29
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Barnes,Eleanor,ur.012157567677.07
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Thomson-Hill,Samantha,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Grabau,Caroline,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Crocker,Wendy E.M.,ur.012202032227.52
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Elmore,Michael J.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Rohde,Cornelius,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Smith,Catherine C.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Donnellan,Francesca R.,ur.012431050117.63
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Galiza,Eva,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Cooper,Rachel,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Baleanu,Ioana,ur.014362651427.74
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Osborne,Piper,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Flaxman,Amy L,ur.01371075243.05
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Saich,Stephen,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Welham,Benjamin,ur.011235341123.72
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Adams,Kelly,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Thomas,Tonia M.,ur.07774724142.44
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Clutterbuck,Elizabeth A,ur.0715146175.41
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Steele,Amy,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Khan,Uzma,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Pollard,Andrew J,ur.01027121051.13
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Brunt,Emily,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Themistocleous,Andreas,ur.0705744303.67
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Burge,Sharon,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Taylor,Iona Jennifer,ur.015575141333.31
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Osborn,Mairead,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Elias,Sean C.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Bewley,Kevin R.,ur.01035117350.51
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Watson,Marion E.E.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Talbot,Helen,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Meddaugh,Gretchen,ur.015677424344.36
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Allison,Jennifer L.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Cook,Aislinn,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Hill,Adrian V S,ur.010475203247.10
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Madhavan,Meera,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Koleva,Stanislava,ur.014710653667.85
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Tran,Nguyen,ur.0603111201.92
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Arbe-Barnes,Edward H.,ur.016377711315.52
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Cosgrove,Catherine A.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Cathie,Katrina,ur.0600477345.34
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Ballaminut,Juliana,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Batten,Alexander,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Group,Oxford COVID Vaccine Trial,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Oguti,Blanché,ur.012157012177.37
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Carter,Victoria,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Keen,Jade,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Shaik,,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Douglas,Naomi,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Silk,Sarah,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Romani,Rossana,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Datoo,Mehreen S.,ur.012440662217.69
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Allen,Elizabeth,ur.0620560743.21
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Berrie,Eleanor,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Clark,Helen,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Lemm,Nana-Marie,ur.013546367667.11
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Rhead,Sarah,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Silva-Reyes,Laura,ur.01245675241.25
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Baker,Philip,ur.014700215704.13
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Yau,Yasmine,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Stockdale,Lisa,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Morris,Susan Jane,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Dunachie,Susanna Jane,ur.01041133025.01
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Folegatti,Pedro M,ur.014140042217.03
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",O'Brien,Katie,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Taylor,Victoria,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Felle,Sally,ur.013416024245.17
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Clark,Elizabeth,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Belij-Rammerstorfer,Sandra,ur.01250612323.91
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Munster,Vincent J.,ur.01334105063.89
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Challis,Ruth J.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Morshead,Gertraud,ur.011313574167.85
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Anslow,Rachel,ur.012653462027.76
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Harrison,Daisy,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Patrick-Smith,Maia,ur.013441643467.08
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Beveridge,Amy,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Semple,Calum,ur.01236063723.79
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Larkworthy,Colin W.,ur.014161406467.62
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Drake,Jonathan,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Carr,Melanie,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",King,Lloyd,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Rudiansyah,Indra,ur.012666334050.54
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Green,Catherine,ur.01052521673.91
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Varughese,Rachel,ur.01224121070.54
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Cifuentes,Liliana,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Hodgson,Susanne H.C.,ur.0747322416.74
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Henry,John Aaron,ur.012534205043.12
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Pfafferott,Katja,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Roberts,Hannah,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Coy,Karen,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Vichos,Iason,ur.011401113767.18
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Sanders,Katherine,ur.014357313567.36
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Angus,Brian,ur.01261526154.92
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Di Maso,Claudio,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Hutlin,Cecilia,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Ford,Karen J.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Harris,Stephanie A.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Edwards,Nick J.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Drury,Ruth Elizabeth,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Radia,Kajal,ur.07431545167.52
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Puig,Ingrid Cabera,ur.012244304327.28
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Mabesa,Francesca,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Pearce,Jennifer,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Shea,Adam,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Worth,Andrew T.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Coombes,Naomi S.,ur.015031462165.27
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Lees,Emily A,ur.012225442604.54
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Kupke,Alexandra,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Wheat,Julie,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",McEwan,Joanne,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Jackson,Frederic,ur.013662310713.48
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Knapper,Francesca,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Roche,Sophie,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Killen,Annabel,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Cao,Michelangelo,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Bibi,Sagida,ur.01123243761.16
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Turner,Nicola,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Gray,Zoe,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Beadon,Kirsten,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Robinson,Hannah,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Guthrie,Lucy Belle,ur.014170555627.81
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Nugent,Fay L.,ur.01064464603.23
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Pipini,Dimitra,ur.015367104553.46
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Charlton,Sue,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Conlon,Christopher P.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Francis,Emma,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Carroll,Miles W.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Calvert,Anna,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Riddell,Amy,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Hamilton,Elizabeth,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Marlow,Emma,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Rollier,Christine S.,ur.01126636541.15
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Pollock,Katrina M,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Tarrant,Richard,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Lias,Amelia M.,ur.015736711267.11
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Muller,Jilly,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Kingham-Page,Lucy,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Kelly,Dearbhla,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Cho,Jee-Sun,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Legge,Helen,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Truby,Adam,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Ali,Aabidah,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Colin-Jones,Rachel,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Sayce,Chloe,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Gilbride,Ciaran,ur.07450134035.32
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Liu,Shuchang,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Presland,Laura,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Cole,Tom,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Babbage,Gavin,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Hawkins,Sophia,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Berry,Lisa,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Faust,Saul N,ur.0727576315.70
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Blundell,Caitlin L.,ur.07555172527.18
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Riera,Lidia Sanchez,ur.013022254747.07
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Plested,Emma,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Tree,Julia A.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Payne,Victoria,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Lelliott,Alice,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Snape,Matthew,ur.010062135107.44
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Oliveira,Catarina,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Feng,Shuo,ur.01166404654.25
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Mansatta,Kushal,ur.016125114167.98
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Provstgaard-Morys,Samuel,ur.015113337704.57
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Lopez,Fernando Ramos,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",O'Connor,Daniel,ur.01034434167.27
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Jackson,Susan,ur.014034470333.32
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Aley,Parvinder K,ur.01144267763.20
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Karampatsas,Konstantinos,ur.01123776160.05
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Hart,Thomas C.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Gilbert,Sarah C,ur.0762502203.86
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Emary,Katherine R.W.,ur.0664315206.68
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Tahiri-Alaoui,Abdessamad,ur.0665376020.28
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Klenerman,Paul,ur.01366404500.15
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Mweu,Philomena,ur.011317353266.17
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Owen,Cathy,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Byard,Nicholas,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Lawrie,Alison M.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Fowler,Jamie,ur.011524541327.74
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Selby,Beatrice,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Sajjad,Sara,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Themistocleous,Yrene,ur.010272223741.46
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Edwards,Chris J.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Hallis,Bassam,ur.01127251360.63
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Knott,Daniel,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Lwin,May,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",White,Caroline,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Schofield,Ella,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Wright,Danny,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Halwe,Sandro,ur.016220461460.25
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Lee,Kim Yee Ngan,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Heath,Paul,ur.01117742447.91
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Kinch,Jasmin,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Van Doremalen,Neeltje,ur.01364235606.88
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Brown-O'Sullivan,Charlie,ur.010535114727.33
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Pacurar,Mihaela,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Jones,Elizabeth,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Lazarus,Rajeka,ur.0763261375.07
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Smith,David J.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Becker,Stephan,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Ratcliffe,Helen,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Poulton,Ian,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Gracie,Lara,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Field,Samantha,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Kailath,Reshma,ur.07516247235.83
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",De Graaf,Hans,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Tait,Moira,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Douglas,Alexander D,ur.01224573004.25
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Cicconi,Paola,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Harris,Andrew,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Voysey,Merryn,ur.01043520166.14
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Linder,Aline,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Morrison,Hazel,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Spencer,Alexandra J.,ur.0630046341.05
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Tanner,Rachel,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Aboagye,Jeremy,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Thomas,Merin,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Munro,Alasdair,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",McInroy,Lorna,ur.012705421567.36
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Cunningham,Christina J.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Camara,Susana,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Shelton,Holly,ur.01225762650.91
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Borthwick,Nicola,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Thakur,Nazia,ur.012657513127.04
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Damratoski,Brad E.,ur.0710065340.52
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Kerr,David,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Khan,Liaquat,ur.014522145527.44
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Bittaye,Mustapha,ur.0655457677.68
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Lipworth,Samuel,ur.01133517346.28
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Fletcher,Clare,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Bates,Louise,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Gbesemete,Diane,ur.0676357211.34
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Beckley,Rebecca,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Walker,Laura,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Jones,Christine E.,ur.01226112464.02
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Turner,Cheryl,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Ikram,Sabina,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Dietrich,Isabelle,ur.0616057105.93
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Yao,Xin Li,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Morgan,Victoria,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Stefanova,Elena,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Dando,Lynne,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Finn,Adam,ur.01160253315.45
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Downing,Charlotte,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Martin,Jane,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Murphy,Sarah,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Edwards,Frances D.L.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Bellamy,Duncan,ur.011416433554.65
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Harrison,Clare,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Gorini,Giacomo,ur.01356760141.15
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Ramasamy,Maheshi,ur.0773236364.40
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Chelysheva,Irina,ur.016204413317.06
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Laskey,Anna,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Naude,Rebecca Te Water,ur.011420075633.86
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Fuskova,Michelle,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Lambe,Teresa,ur.01343506651.11
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Robson,Joanna,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Jones,Bryony,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Nuthall,Elizabeth,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Boyd,Amy,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Szigeti,Anna,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Marinou,Spyridoula,ur.013205325367.57
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Noé,Andrés,ur.0662074350.04
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Minassian,Angela M,ur.01237421066.88
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Dong,Tao,ur.01007343554.07
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Kerridge,Simon,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Parker,Kaye,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Harding,Irasha,ur.015220027273.14
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Boland,Elena,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Isitt,Catherine,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Lee,Arlene,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Alvarez,Marco Polo Peralta,ur.016577734437.47
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Drake-Brockman,Rachael,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Pollock,Katrina,ur.0707316513.65
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Ewer,Katie J,ur.01066421140.67
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Owens,Daniel,ur.01343271615.71
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Bingham,Tracey,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Ulaszewska,Marta,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Morey,Ella,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Jenkin,Daniel,ur.011650637135.21
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Moore,Maria,ur.010341141325.62
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Burbage,Jamie,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Dold,Christina,ur.01030672752.86
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Demissie,Tesfaye,ur.07402333127.69
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Stafford,Elizabeth,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Larwood,Jessica P.J.,ur.013215143065.17
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Godwin,Kerry,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Barrett,Jordan,ur.016333574555.34
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",White,Rachel,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Wright,Suzie,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Cappuccini,Federica,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Bright,Philip D.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Thompson,Amber,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Turner,Sally,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Bolam,Emma,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Kelly,Sarah,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Furze,Julie,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Verheul,Marije K.,ur.0673177445.34
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Hackett,Mark,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Haskell,Louise,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Screaton,Gavin,ur.01355002316.56
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Song,Rinn,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Munro,Claire,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Parracho,Helena,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",O'Reilly,Peter John,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Vitale,Elia,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Brenner,Tanja,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Morter,Richard,ur.0706024053.03
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Sharpe,Hannah R.,ur.0665716007.14
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Rawlinson,Thomas,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Rand,Jade,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Skelly,Donal T.,ur.01132001330.15
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",King,Thomas B.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Ramon,Raquel Lopez,ur.01120177760.87
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Munera-Huertas,Tatiana,ur.01360601535.30
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Davies,Hannah,ur.010014663013.69
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Hanumunthadu,Brama,ur.010034637473.04
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Tomlins,Jennifer,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Sapaun,Shari,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Baker,Megan,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Marshall,Julia L.,ur.010633404271.60
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",English,Marcus Rex,ur.011342177527.86
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Baker,Natalie,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Mentzer,Alexander J.,ur.01260434061.14
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",King,Jade,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Tonks,Susan,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Oliver,Jennifer L.,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Howell,Nicola,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Ritchie,Adam John,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Knight,Julian C.,ur.0613306061.55
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Moran,Edward,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Pluess-Hall,Helen,ur.07616373110.61
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Hou,Mimi M.,ur.011650472127.74
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Fox,Polly,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Sanders,Helen,ur.012166772167.99
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Iveson,Poppy,ur.013301060517.26
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Mirtorabi,Neginsadat,ur.015512075367.40
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Tuthill,Toby,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Owino,Nelly,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Bijker,Else Margreet,ur.01352054134.76
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Liu,Xinxue,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Buttigieg,Karen R.,ur.01172213764.64
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Jones,Kathryn,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Hamlyn,Joseph,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Head,Ian,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Frater,John,ur.0600756740.23
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Baillie,Kenneth,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",James,William,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Mallett,Garry,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Perring,James,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Jenkins,Megan,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Turkentine,Kate,ur.013340760367.34
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Makinson,Rebecca,ur.014164111007.49
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Bower,Thomas,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Mujadidi,Yama F.,ur.011600027201.23
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Fixmer,Carine,ur.011456426127.40
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Pulido,David,ur.01032251457.80
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Salvador,Stephannie,ur.015704141367.47
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Fagerbrink,Susanne,ur.014330101527.94
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Marcal,Ines,
14760,"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",Towner,James,
14725,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting,Hernán,Miguel A,ur.01015164244.47
14725,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting,Dagan,Noa,ur.01004303625.18
14725,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting,Katz,Mark A,ur.013674246222.35
14725,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting,Lipsitch,Marc,ur.0750403636.04
14725,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting,Kepten,Eldad,ur.01116013660.40
14725,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting,Barda,Noam,ur.013466722350.84
14725,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting,Miron,Oren,ur.0725436037.15
14725,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting,Perchik,Shay,ur.011030511033.77
14725,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting,Balicer,Ran D,ur.0776006416.71
14725,BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting,Reis,Ben,ur.01273221262.54
14454,Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination,Hartmann,Laura,ur.016053703046.56
14454,Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination,Schirmacher,Peter,ur.01072556301.62
14454,Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination,Stenzinger,Albrecht,ur.0642700650.98
14454,Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination,Longerich,Thomas,ur.01302256406.10
14454,Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination,Schwab,Constantin,ur.01015646447.61
14454,Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination,Domke,Lisa Maria,ur.012443537200.43
14382,Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag,Pandey,Ashutosh Kumar,ur.013025013166.79
14382,Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag,Pradhan,Prashant,ur.015453007007.87
14382,Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag,Gupta,Parul,ur.012276134465.55
14382,Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag,Gomes,James,ur.01364221333.30
14382,Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag,Vivekanandan,Perumal,ur.01057233073.65
14382,Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag,Mishra,Akhilesh,ur.016531551615.14
14382,Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag,Tripathi,Praveen Kumar,ur.016606621403.13
14382,Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag,Kundu,Bishwajit,ur.01173173576.58
14382,Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag,Menon,Manoj Balakrishnan,
14322,Experimental Assessment of Carbon Dioxide Content in Inhaled Air With or Without Face Masks in Healthy Children,Kappes,Anna,ur.016431141731.49
14322,Experimental Assessment of Carbon Dioxide Content in Inhaled Air With or Without Face Masks in Healthy Children,Diemer,Andreas,ur.015036200731.36
14322,Experimental Assessment of Carbon Dioxide Content in Inhaled Air With or Without Face Masks in Healthy Children,Prentice,Juliane,ur.014240620331.33
14322,Experimental Assessment of Carbon Dioxide Content in Inhaled Air With or Without Face Masks in Healthy Children,Walach,Harald,ur.01233335475.03
14322,Experimental Assessment of Carbon Dioxide Content in Inhaled Air With or Without Face Masks in Healthy Children,Weikl,Ronald,ur.013443237731.36
14322,Experimental Assessment of Carbon Dioxide Content in Inhaled Air With or Without Face Masks in Healthy Children,Traindl,Helmut,ur.015633561331.48
14322,Experimental Assessment of Carbon Dioxide Content in Inhaled Air With or Without Face Masks in Healthy Children,Hockertz,Stefan,ur.011121723217.68
14301,Two metres or one: what is the evidence for physical distancing in covid-19?,Larwood,Jessica P J,ur.013215143065.17
14301,Two metres or one: what is the evidence for physical distancing in covid-19?,Jones,Nicholas R,ur.011100744207.38
14301,Two metres or one: what is the evidence for physical distancing in covid-19?,Greenhalgh,Trisha,ur.0734302623.84
14301,Two metres or one: what is the evidence for physical distancing in covid-19?,Qureshi,Zeshan U,ur.0601036300.16
14301,Two metres or one: what is the evidence for physical distancing in covid-19?,Temple,Robert J,ur.014343207333.53
14301,Two metres or one: what is the evidence for physical distancing in covid-19?,Bourouiba,Lydia,ur.0614114533.26
14279,Heart-disease risk soars after COVID — even with a mild case,Sidik,Saima May,ur.01272474516.98
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Gao,Zhancheng,ur.01011230276.16
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Wei,Yuan,
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Gu,Xiaoying,ur.01323674617.33
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Hu,Yi,
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Liu,Min,
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Guo,Li,ur.01321416447.08
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Xie,Xuelei,
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Wang,Yeming,ur.016672650674.30
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Wu,Wenjuan,ur.01067070441.49
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Xie,Jungang,ur.01325464511.43
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Li,Xingwang,
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Xu,Jiuyang,ur.013600600671.13
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Yu,Ting,ur.015434422625.35
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Gao,Hong,
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Zhang,Li,
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Jiang,Rongmeng,ur.01105621275.90
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Xia,Jiaan,ur.013244101225.90
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Fan,Guohui,ur.014755044646.73
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Jin,Qi,ur.01261226002.08
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Li,Hui,ur.01237377613.47
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Zhao,Jianping,ur.01271747272.97
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Cheng,Zhenshun,ur.013624060373.43
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Ren,Lili,ur.01033321702.75
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Huang,Chaolin,ur.011027413601.66
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Xiao,Yan,
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Wang,Guangfa,
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Yin,Wen,ur.015053524317.53
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Wang,Jianwei,ur.010416750634.52
14083,"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",Cao,Bin,ur.0641123655.02
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Irving,Stephanie A.,ur.0650546576.33
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Williams,Jeremiah,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Fry,Alicia M.,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Lewis,Ned,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Embi,Peter J.,ur.01211132371.14
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Dascomb,Kristin,ur.01370274060.21
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Klein,Nicola P.,ur.0635371743.68
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Butterfield,Kristen A.,ur.010650564574.62
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",DeSilva,Malini B.,ur.011104331065.67
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Verani,Jennifer R.,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Grannis,Shaun J.,ur.01130072644.70
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Dixon,Brian E.,ur.01352730150.38
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Dickerson,Monica,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Rowley,Elizabeth A.,ur.010317376445.54
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Grisel,Nancy,ur.012053604017.06
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Blanton,Lenee,ur.01136115305.95
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Porter,Rachael M.,ur.015367670061.19
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Barron,Michelle,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Goddard,Kristin,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Natarajan,Karthik,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Murthy,Kempapura,ur.01122121311.29
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Bozio,Catherine H.,ur.015564666542.00
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Valvi,Nimish R.,ur.016642370065.46
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Reese,Sarah E.,ur.01040674245.23
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Stenehjem,Edward,ur.01153660213.43
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Patel,Palak,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Olson,Natalie,ur.014327660650.08
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",McEvoy,Charlene,ur.0634253661.82
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Arndorfer,Julie,ur.015425534531.12
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Reynolds,Sue,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Ball,Sarah W.,ur.01021155161.10
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Thompson,Mark G.,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Raiyani,Chandni,ur.016344755553.34
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Schrag,Stephanie J.,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Yang,Duck-Hye,ur.012412776237.12
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Ferdinands,Jill,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Azziz-Baumgartner,Eduardo,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Birch,Rebecca J.,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Rao,Suchitra,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",McMorrow,Meredith,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Gaglani,Manjusha,ur.01161416743.98
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Han,Jungmi,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Kharbanda,Anupam B.,ur.01126076021.08
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Ong,Toan C.,ur.0720400132.93
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Naleway,Allison L.,ur.0764213046.95
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Steffens,Andrea,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Fireman,Bruce,ur.01233525220.55
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Liao,I-Chia,ur.01012720242.23
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Levy,Matthew E.,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Mitchell,Patrick K.,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Griggs,Eric P.,
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Fadel,William F.,ur.0735743314.36
13949,"Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021",Zerbo,Ousseny,ur.01234546532.18
13855,Cannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants,Tafesse,Fikadu G.,ur.01035476504.06
13855,Cannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants,van Breemen,Richard B.,ur.01314335713.28
13855,Age-stratified infection fatality rate of COVID-19 in the non-elderly population,Axfors,Cathrine,ur.010232432033.00
13855,Age-stratified infection fatality rate of COVID-19 in the non-elderly population,Contopoulos-Ioannidis,Despina G,ur.01312540565.55
13855,Age-stratified infection fatality rate of COVID-19 in the non-elderly population,Ioannidis,John P A,
13855,Age-stratified infection fatality rate of COVID-19 in the non-elderly population,Pezzullo,Angelo Maria,ur.01117056265.13
13855,Cannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants,Farley,Scotland,ur.012044222533.48
13855,Cannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants,Muchiri,Ruth N.,ur.012621353060.20
13855,Cannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants,Bates,Timothy A.,ur.010451261533.33
13855,Cannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants,Weinstein,Jules B.,ur.012031346540.48
13855,Cannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants,Leier,Hans C.,ur.013475555366.37
13855,Age-stratified infection fatality rate of COVID-19 in the non-elderly population,Apostolatos,Alexandre,ur.016346251612.77
13803,Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting,Ohana,Reut,ur.01213567352.50
13803,Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting,Waxman,Jacob,ur.011022401734.42
13803,Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting,Dagan,Noa,ur.01004303625.18
13803,Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting,Kohane,Isaac,ur.015317453537.75
13803,Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting,Netzer,Doron,ur.013222005241.14
13803,Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting,Reis,Ben Y,ur.01273221262.54
13803,Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting,Lipsitch,Marc,ur.0750403636.04
13803,Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting,Ben-Shlomo,Yatir,ur.014103217147.74
13803,Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting,Kepten,Eldad,ur.01116013660.40
13803,Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting,Barda,Noam,ur.013466722350.84
13803,Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting,Hernán,Miguel A,ur.01015164244.47
13803,Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting,Balicer,Ran D,ur.0776006416.71
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Doria-Rose,Nicole A,ur.01134103612.24
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,O'Dell,Sijy,ur.0700652546.79
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Swanson,Phillip A,ur.07452027655.99
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Pikaart-Tautges,Rhonda,ur.014117715477.20
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Bennett,Hamilton,
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Pruijssers,Andrea J,ur.013350270127.12
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Peters,Etza,ur.010334433077.07
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Makowski,Mat,
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,McDermott,Adrian,ur.01056403462.04
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Sun,Wellington,
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Cross,Kaitlyn,
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Morabito,Kaitlyn M,ur.01165401712.09
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Corbett,Kizzmekia S,ur.0743773701.54
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,McCullough,Michele P,ur.011044240571.56
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Schmidt,Stephen D,
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Flach,Britta,ur.016174010477.26
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Chappell,James D,
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Roberts,Paul C,
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Ledgerwood,Julie E,ur.01363374036.00
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Coler,Rhea N,ur.0642452033.34
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Buchanan,Wendy,
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Denison,Mark R,ur.0712064037.54
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Makhene,Mamodikoe,ur.013431550264.74
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Padilla,Marcelino,ur.014051602277.20
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Mascola,John R,ur.01270042052.88
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Graham,Barney S,ur.01210715522.53
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Neuzil,Kathleen M,ur.0761006623.40
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Rouphael,Nadine G,ur.01360550342.49
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Anderson,Evan J,ur.01057271127.29
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Beigel,John H,ur.0604106525.13
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Jackson,Lisa A,ur.01322066072.33
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Albert,Jim,
13724,An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,Stevens,Laura J,
13510,"Covid-19: politicisation, “corruption,” and suppression of science",Abbasi,Kamran,ur.0627346562.75
13346,COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities,Bardosh,Kevin,ur.01253246524.87
13346,COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities,Baral,Stefan,ur.07352547220.85
13346,COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities,Keshavjee,Salmaan,ur.01101124045.64
13346,COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities,Krug,Allison,ur.012544524740.70
13346,COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities,Lemmens,Trudo,ur.0640055046.19
13346,COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities,Makary,Marty A,ur.015037650413.26
13346,COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities,Høeg,Tracy Beth,ur.01044166575.20
13346,COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities,Jamrozik,Euzebiusz,ur.01150606074.87
13346,COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities,Prasad,Vinay,ur.01126071747.46
13288,"Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021",Derk,Raymond C.,ur.01156056615.02
13288,"Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021",Lindsley,William G.,ur.01235026624.13
13288,"Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021",Coyle,Jayme P.,ur.01135412746.35
13288,"Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021",Noti,John D.,ur.01135617517.19
13288,"Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021",Brooks,John T.,ur.016124243522.51
13288,"Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021",Blachere,Francoise M.,ur.0767016232.29
13288,"Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and Reduce SARS-CoV-2 Transmission and Exposure, 2021",Beezhold,Donald H.,ur.01221216361.21
13227,A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19,Mörz,Michael,
13170,6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records,Husain,Masud,ur.01274035212.39
13170,6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records,Luciano,Sierra,ur.014736302723.99
13170,6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records,Taquet,Maxime,ur.01170177602.97
13170,6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records,Geddes,John R,ur.010743477572.37
13170,6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records,Harrison,Paul J,ur.011112526240.39
13095,Covid-19 — Navigating the Uncharted,Lane,H Clifford,ur.01057003240.61
13095,Covid-19 — Navigating the Uncharted,Fauci,Anthony S,ur.01314336573.76
13095,Covid-19 — Navigating the Uncharted,Redfield,Robert R,ur.01324563532.36
12994,"Ivermectin, a potential anticancer drug derived from an antiparasitic drug",Li,Jiangyan,
12994,"Ivermectin, a potential anticancer drug derived from an antiparasitic drug",Yao,Xin,ur.015631666711.26
12994,"Ivermectin, a potential anticancer drug derived from an antiparasitic drug",Tang,Mingyang,ur.012600303521.52
12994,"Ivermectin, a potential anticancer drug derived from an antiparasitic drug",Hu,Xiaodong,
12994,"Ivermectin, a potential anticancer drug derived from an antiparasitic drug",Cheng,Fuying,
12994,"Ivermectin, a potential anticancer drug derived from an antiparasitic drug",Zhang,Wei,
12994,"Ivermectin, a potential anticancer drug derived from an antiparasitic drug",Fang,Qiang,ur.01145071110.10
12994,"Ivermectin, a potential anticancer drug derived from an antiparasitic drug",Yu,Chenying,
12994,"Ivermectin, a potential anticancer drug derived from an antiparasitic drug",Wang,Yi,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kelly,Elizabeth J.,ur.010623611357.52
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Yao,Andy,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Stamford,Imogen,ur.07761636051.37
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kelly,Sarah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Jackson,Frederic,ur.013662310713.48
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Edwards,Nick J.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bermejo,Laura,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Morris,Sheila,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",O'Reilly,Paula,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Joshi,Amar,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Adewetan,Gbadebo,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mnyakeni,Sibusiso,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Dong,Tao,ur.01007343554.07
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Szigeti,Anna,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mujadidi,Yama F,ur.011600027201.23
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pollock,Katrina M,ur.0707316513.65
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Nana,Anusha,ur.012033077535.78
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Jenkin,Daniel,ur.011650637135.21
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Farmer,Eoghan,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Samson,Annette D.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Liu,Shuchang,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Driver,Kimberley,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Fraiman,Pedro H.A.,ur.07650602535.99
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Wallis,Erica,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kasanyinga,Mwila,ur.011433727475.26
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Phillips,Jennifer,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lloyd,Adam,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Webb,Stewart,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ramasamy,Maheshi N,ur.0773236364.40
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Akhalwaya,Yasmeen,ur.012263554535.63
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Charlton,Sue,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Chadwick,Jim,ur.010670606670.78
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Collins,Andrea M,ur.0763041014.30
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mugodi,Yvonne,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Poulton,Ian,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Myasaki,Celia Hatsuko,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Freire,Marilúcia S.M.,ur.013071142575.33
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Resuello-Dauti,Mila,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Conlon,Christopher P.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cox,Tony,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Di Marco,Stefania,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Matshidiso,Kedidimetse,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Salman,Ahmed M.,ur.0705700051.57
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Payne,Ruth O.,ur.014167250015.69
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Fofie,Hazel,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Brown-O'Sullivan,Charlie,ur.010535114727.33
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Grossi,Leonardo,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Royal,Simon,ur.0742242054.46
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Barbosa,Marcella A.S.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ulaszewska,Marta,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Barlow,Gavin D.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bruce,Scott,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Marshall,Julia L.,ur.010633404271.60
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Alvarez,Marco Polo Peralta,ur.016577734437.47
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Clutterbuck,Elizabeth A.,ur.0715146175.41
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Castro,Thais,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Clarke,Andrea,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Buttigieg,Karen R.,ur.01172213764.64
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Salvador,Stephannie,ur.015704141367.47
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bijker,Else,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Jorge,Marianna Rocha,ur.012760555275.14
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pollard,Andrew J,ur.01027121051.13
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pieterse,Sonja,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Brown,Phillip,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lipworth,Samuel,ur.01133517346.28
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pooley,Jennifer,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mukhopadhyay,Ekta,ur.016006427357.30
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Galian-Rubio,Pablo,ur.011335043571.64
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Turner,Richard,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sala,Claudia,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Singh,Nisha,ur.01041400576.85
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Msomi,Sibekezelo,ur.010710323375.80
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Stockwell,Lisa V.,ur.015735442051.93
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Izu,Alane,ur.01051426511.85
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Houlihan,Catherine,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mentzer,Alexander J.,ur.01260434061.14
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Essack,Yakub Moosa,ur.011361753175.86
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Noal,Helena,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",West,Alison,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Warimwe,George,ur.01255275505.20
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Webster,Angela,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Thompson,Amber,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mweu,Philomena,ur.011317353266.17
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Field,Samantha,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sturdy,Ann,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Spencer,Alexandra J.,ur.0630046341.05
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Muller,Jilly,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Calvert,Anna,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tahiri-Alaoui,Abdessamad,ur.0665376020.28
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Davis,Judith,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Odam,Miranda,ur.0602671475.19
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Davis,Elizabeth,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bird,Adam,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Duncan,Christopher J A,ur.0702456546.95
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Stein,Ricardo,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Beadon,Kirsten,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Farrar,Madi,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pulido,David,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bull,Melanie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Adelaja,Yemi A.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bellei,Nancy,ur.0650755203.60
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mendes,Ana V A,ur.012451675302.27
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Loew,Lisa,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bodalia,Pritesh,ur.011241663475.06
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Galiza,Eva,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Karampatsas,Konstantinos,ur.01123776160.05
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Burhan,Hassan,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Harris,Clair,ur.016657651055.57
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Wroblewska,Marzena,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Jones,Elizabeth,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",McGregor,Alastair,ur.07642556135.34
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sanders,Helen,ur.012166772167.99
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Chester,Oliver,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Smith,Catherine C.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pipini,Dimitra,ur.015367104553.46
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Grab,Janet,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Da Silva,Carla Ferreira,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Petkar,Sahir,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",van Eck,Samual,ur.012706600775.38
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Heath,Paul T,ur.01117742447.91
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Farooq,Mutjaba,ur.012754714175.53
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Datoo,Mehreen S.,ur.012440662217.69
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Knapper,Francesca,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Parsons,Karen,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hyams,Catherine,ur.0750212163.87
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Phillips,Daniel J.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Barr,Andrew S.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Borthwick,Nicola,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ivan,Monica,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Linder,Aline,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",dos Santos,Thainá G.,ur.01256174165.72
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Marinou,Spyridoula,ur.013205325367.57
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Schwarzbold,Alexandre V,ur.01122663254.27
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kinch,Jasmin,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Molapo,Kgaogelo,ur.012764416375.83
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Fisher,Richard,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Patel,Kelly,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lazarus,Erica M.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pabon,Emilia Reyes,ur.014456400571.31
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Edwards,Mandy,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Verbart,Dennis,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kinch,Patrick,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Boettger,Bruno C.,ur.013021724307.82
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Moghaddas,Fiona,ur.01011516141.40
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Liu,Xinxue,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Gibbons,Karyna A.,ur.012345536475.33
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cooper,Cushla,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Horne,Elizea,ur.016361476075.96
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lees,Emily A.,ur.012225442604.54
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Towner,James,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cullen,Dan,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Beales,Emily,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Masenya,Masebole,ur.015714736755.26
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Shea,Adam,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rea,David,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rand,Jade,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Thomas,Kelly,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Madhi,Shabir A,ur.01165655111.49
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rawlinson,Tom,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cunningham,Christina,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rabara,Ria,ur.013544571571.63
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Boyd,Amy,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Seddiqi,Samiullah,ur.016260612775.30
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Welch,Jessica,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sutherland,Rebecca K,ur.0704534163.40
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Demissie,Tesfaye,ur.07402333127.69
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Head,Ian,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Parkinson,Sivapriyai,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Noé,Andrés,ur.0662074350.04
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Berry,Lisa,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hanrath,Aidan T.,ur.011353437246.04
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Gilbert,Sarah C,ur.0762502203.86
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Baker,Kenneth F.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rampling,Tommy,ur.0714513761.47
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cosgrove,Catherine,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Batten,Alexander,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Silk,Sarah E.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Quaid,Sheena,ur.013405211463.39
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Camara,Susana,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Fok,Henry,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Watson,Ekaterina,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sanders,Katherine,ur.014357313567.36
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Carvalho,José A.M.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hamilton,Elizabeth,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mapetla,Katlego,ur.07614152575.57
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",San Francisco Ramos,Alberto,ur.010303057150.16
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Barnes,Eleanor,ur.012157567677.07
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lang,Gail,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Masters,Shauna K.,ur.010457646375.06
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Harris,Stephanie A.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hill,Helen,ur.010323710135.22
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Watkins,Bridget,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tarr,Alexander W.,ur.01234272560.04
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bletchly,Heather,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pittella,Ana,ur.016343737472.03
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Jones,Kathryn,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Francis,Emma,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bird,Olivia,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Huson,Claire,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lowthorpe,Vicki,ur.015770640214.26
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Dinesh,Tanya,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Humphries,Holly E.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Groenewald,Marisa M.,ur.011067024075.12
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",O'Brien,Katie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Fedosyuk,Sofiya,ur.0767456552.13
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Turner,David P J,ur.016223771242.38
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Warbick,Deborah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Marshall,Richard P.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Appleby,Matthew,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Goncalves,Maria,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sharrocks,Katherine,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kana,Faeeza,ur.010040766475.50
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lemm,Nana-Marie,ur.013546367667.11
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Makinson,Rebecca,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kidd,Sarah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Screaton,Gavin,ur.01355002316.56
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Njenga,Cecilia,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Esmail,Alisgair,ur.010564372575.90
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Khozoee,Baktash,ur.013743443371.13
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bibi,Sagida,ur.01123243761.16
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hodgson,Susanne H C,ur.0747322416.74
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bowring,Francesca,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Warren,Sarah C.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kwatra,Gaurav,ur.01340446423.72
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Burbage,Jamie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Zimmer,Rafael,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Libri,Vincenzo,ur.01256064600.37
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Underwood,Benjamin R.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Nunes,Géssika,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Owen,David R.J.,ur.01206630115.21
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Gupta,Gaurav,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Furze,Julie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bhorat,Asad E.,ur.0662711531.90
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Darton,Thomas C,ur.01024704614.49
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Patel,Dipak,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Drake-Brockman,Rachael,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Herrera,Macarena Hermosin,ur.07677630471.80
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Chapman,David,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cunha,Debora R.M.F.,ur.010265602375.60
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Emary,Katherine R W,ur.0664315206.68
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sosa-Rodriguez,Tiffany,ur.015753757337.97
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Patel,Faeezah,ur.01076006342.03
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Muhanna,Omar M. El,ur.015077122375.34
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bhorat,Qasim E,ur.016706671635.11
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tighe,Patrick J.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ritchie,Adam J.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",van der Loeff,Ina Schim,ur.014320540477.22
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Solórzano,Carla,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rajapaska,Durga,ur.014363220475.31
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mirtorabi,Neginsadat,ur.015512075367.40
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Naik,Gurudutt,ur.01127672743.18
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Russell,Amy L. Ross,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kadziola,Joanne,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Jones,Christopher,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Vekemans,Johan,ur.012147326135.61
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Owino,Nelly,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lora,Leandro,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sampaio,Milla,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Moore,Maria,ur.010341141325.62
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",McRobert,Nicky,ur.01362212336.93
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Fuskova,Michelle,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sayed,Aakifah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Robbins,Alexander J.,ur.011307146537.95
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rajeswaran,Thurkka,ur.016710765446.45
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hyder-Wright,Angela,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hay,Jodie,ur.014361727775.70
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lambe,Teresa,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Perring,James,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Iyer,Vidyashankara,ur.01055057001.26
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mainwaring,David O.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pennington,Anna,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Klenerman,Paul,ur.01366404500.15
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mathew,Moncy,ur.015717151627.91
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Geddes,Ailsa,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Phohu,Mary Kgomotso,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Taylor,Iona Jennifer,ur.015575141333.31
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cathie,Katrina,ur.0600477345.34
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Spina,Fernanda,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cifuentes,Liliana,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Turner,Cheryl,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mansatta,Kushal,ur.016125114167.98
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Beckley,Rebecca,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Schmid,Annina B.,ur.01256350601.85
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bolam,Emma,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Madhavan,Meera,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pueschel,Sophie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Morris,Susan,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",de M. Carvalho,Yasmin,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Fairlie,Lee,ur.01072731604.87
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lelliott,Alice,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Aban,Marites,ur.011315125537.89
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Almeida,Thamires C. D. S. C,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",McLenaghan,Daniela,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Dos Santos,Tannyth,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Stockdale,Lisa,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Abayomi,Fatola,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Presa,Fernando B.,ur.011551501446.08
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Adams,Kirsty,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Plank,Mary,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Soares,Tiago,ur.014635041667.14
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ricamara,Marivic,ur.010206511504.89
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Birch,Geeta,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Carr,Melanie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Li,Yuanyuan,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rose,Louisa,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rollier,Christine,ur.01126636541.15
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Briner,Carmen,ur.013525042277.44
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Moloi,Mapule,ur.013561776775.26
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lessa,Alvaro,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Dinelli,Maria I.S.,ur.0767050633.18
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Blackstone,Katherine,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Desai,Amisha,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Williams,Rachel L.,ur.012615420075.39
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Thomson,Emma C,ur.01115422445.14
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Khan,Liaquat,ur.014522145527.44
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Oguti,Blanche,ur.012157012177.37
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Fudge,Sabrina,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Godwin,Kerry,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Thompson,Fawziyah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Malahleha,Mookho,ur.0732276355.01
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Murphy,Sarah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Munro,Claire,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Adam,Matthew,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cicconi,Paola,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Henry,John,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Starinskij,Igor,ur.014605264063.07
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sinha,Jaisi,ur.01217601337.07
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Crocker,Wendy E.M.,ur.012202032227.52
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Olchawski,Victoria,ur.016643061071.83
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Berzenyi,Daniella,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Gracie,Lara,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Harrison,Thomas D.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hill,Catherine,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Palhares,Edna M.F.,ur.07551700475.45
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cornelissen,Lynne,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mallett,Garry,ur.015525623750.06
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Da Guarda,Suzete N. Farias,ur.0771654615.24
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Aley,Parvinder K,ur.01144267763.20
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Patrick-Smith,Maia,ur.013441643467.08
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Burn,Aileen,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Blackwell,Luke,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tree,Julia,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Perumal,Rubeshan,ur.01324247612.44
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Flaxman,Amy,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Meijs,Wilma,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mottal,Lynelle,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Radford,Alexandra,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Greenland,Melanie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Souza,Alessandra R.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Vieira,Taiane,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bormans,Daan,ur.015407414171.66
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Killen,Annabel,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cullen,Lorraine,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hirsch,Ian,ur.011121270535.39
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Wells,Jeanette,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hurley,Katrina,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Greffrath,Johann,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Liatsikos,Kostas,ur.014610034375.16
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sale,Jessica,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Santos,Erika,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Salvador,Natalia,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pooran,Anil,ur.01274610013.05
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ahmed,Khatija,ur.01137624014.14
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Luz,Kleber,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Drury,Ruth,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Elmore,Mike,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Gorini,Giacomo,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tomasicchio,Michele,ur.0620352343.02
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Webb-Bridges,Alice,ur.014142245675.93
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Jones,Bryony,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Saunders,Jack E.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Feng,Shuo,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Jaumdally,Shameem,ur.0614312533.55
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Spoors,Louise,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Blundell,Caitlin L.,ur.07555172527.18
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Law,Rebecca,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tsheko,Betty Lebogang,ur.012433056275.21
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Fowler,Jamie,ur.011524541327.74
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Thompson,Ameeka,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Easom,Nicholas J.W.,ur.01046161130.34
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Coombes,Naomi,ur.015031462165.27
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Smith,David J.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Dutra,Lidiana,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hammersley,Daniel,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Oliveira,Marianne G.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Morter,Richard,ur.0706024053.03
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Brown,Claire,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tanner,Rachel,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Harris,Tara,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hart,Thomas C.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pollard,Samuel,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Robinson,Hannah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rhead,Sarah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",McIntyre,Zoe,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Segireddy,Rameswara R.,ur.010560202057.79
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Alves,Mariana P.S.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cuthbertson,Fiona C.,ur.01117716126.95
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Iveson,Poppy,ur.013301060517.26
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",McSwiggan,Steve,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",MacDonald,Jonathan C.,ur.012552634035.15
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hill,Jennifer,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Song,Rinn,ur.0730726247.60
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",McCaughan,Hugh,ur.01342267757.78
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Philip,Tricia,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Durham,Benjamin S.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hanumunthadu,Brama,ur.010034637473.04
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ishwarbhai,Alka,ur.014736052012.31
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Keen,Jade,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Clark,Matthew,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bates,Louise,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Blundell,Susannah R.,ur.015341300771.80
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Woodyer,Mark,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rocchetti,Talita T.,ur.01027761714.17
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Azi,Paula,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Watson,Marion E E,ur.016561207175.37
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Wardell,Theresa,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mazzella,Andrea,ur.0724713116.42
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Nazir,Abida,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",De Oliveira Kalid,Lis Moreno,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Marques,Gabriela N.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Shepherd,Amy,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ramon,Raquel Lopez,ur.01120177760.87
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Leung,Stephanie,ur.012767450521.67
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Provstgaard-Morys,Samuel,ur.015113337704.57
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Peng,Yanchun,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",English,Marcus,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Faulkner,Beverley,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Group,Oxford COVID Vaccine Trial,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Thomson,Julia,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Angus,Brian,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bandeira,Danieli,ur.07675760313.28
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lazarus,Rajeka,ur.0763261375.07
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Douglas,Naomi,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Belij-Rammerstorfer,Sandra,ur.01250612323.91
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Franco,Marilia M.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Oelofse,Suzette,ur.016120036357.51
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Parracho,Helena M.R.T.,ur.01075431027.44
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Penn,Elizabeth J.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Thomas,Merin,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tran,Nguyen,ur.0603111201.92
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Perry,Nicola,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Elias,Sean C.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Boland,Elena,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Finn,Adam,ur.01160253315.45
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Waddington,Claire S.,ur.0756571414.68
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cooper,Rachel,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Marriott,Paula,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Silva-Junior,Gilberto,ur.01171724252.60
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Green,Christopher A,ur.0603753333.19
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Koleva,Stanislava,ur.014710653667.85
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ratcliffe,Helen,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Danos,Zsofia,ur.01331353015.14
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Gilbride,Ciaran,ur.07450134035.32
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hill,Adrian V S,ur.010475203247.10
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",da Silva,Larissa P.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Brenner,Tanja,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Wright,Danny,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Trillana,Gerry,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Baker,Megan,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cashen,Paul,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sutton,Natalina,ur.0615252606.91
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",McGlashan,Joanna,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tonks,Susan,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hettle,David B.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Palmer,Susan,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Schofield,Ella,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Davis,John,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Williams,Christopher J,ur.01167250565.13
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Thomas,Tonia M.,ur.07774724142.44
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Baillie,Vicky L,ur.01235513461.21
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ikram,Sabina,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Davids,Malika,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ewer,Katie J,ur.01066421140.67
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Baleanu,Ioana,ur.014362651427.74
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",De Jager,Jeanne,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Marchevsky,Natalie G.,ur.014735571175.69
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hartnell,Birgit,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Goodman,Anna L,ur.01175716171.37
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Taoushanis,Carol,ur.010354501503.45
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Davies,Sarah L.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Smith,Daniel C.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lias,Amelia M.,ur.015736711267.11
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Dold,Christina,ur.01030672752.86
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Drake,Jonathan,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Smith,Holly E.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Richter,Alex,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Jose,Aylin,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ribiero,Carla M.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Powers,Claire,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Byard,Nicholas,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hallis,Bassam,ur.01127251360.63
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Garlant,Harriet,ur.015715706571.57
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Haughney,John,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Donnellan,Francesca R.,ur.012431050117.63
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mitton,Celia,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rossouw,Lindie,ur.010516550503.21
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Wand,Matthew,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Gokani,Karishma,ur.016131021075.86
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bhorat,Zaheda E.,ur.016303660475.87
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Green,Catherine M,ur.01052521673.91
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mehdipour,Savviz,ur.014126374426.20
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Trinham,Charlotte,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tinoco,Lygia Accioly,ur.010772002075.63
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Castro,Lucia Carratala,ur.010674760075.46
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Dearlove,David,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lopez,Fernando Ramos,ur.07405352245.46
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Faust,Saul N,ur.0727576315.70
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Darroch,Paula,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bara,Anna,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rees,Byron,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Patel,Bhumika,ur.014640742371.81
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Adlou,Syed,ur.010670613535.06
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Robinson,Ryan E.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Baker,Philip,ur.014700215704.13
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",O’Reilly,Peter J,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Arbe-Barnes,Edward H.,ur.016377711315.52
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bhikha,Sutika,ur.011647423403.19
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Taylor,Justin,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Makambwa,Edson,ur.0666133137.35
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",da Silva Moraes,Antonio Carlos,ur.014406710247.76
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Naude,Rebecca te Water,ur.011420075633.86
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Jesudason,Natasha,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Koen,Anthonet,ur.01050512507.64
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Morselli,Franca,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Babbage,Gavin,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Akhalwaya,Saajida,ur.013061135135.85
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Shiham,Farah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sorley,Kim,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lloyd,Stephanie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Harrison,Daisy,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ariaans,Mark P.,ur.0701367313.06
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rocha,Beatriz Pinho,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Truby,Adam,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",King,Thomas B.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Corrah,Tumena,ur.01062737475.85
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ford,Karen J.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lawrie,Alison M,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Larkworthy,Colin W.,ur.014161406467.62
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Allen,Elizabeth R.,ur.0620560743.21
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Arruda,Laiana,ur.016115152335.94
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Themistocleous,Andreas,ur.0705744303.67
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Goldoni,Ursula Carvalho,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sprinz,Eduardo,ur.01305160123.16
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Dunachie,Susanna J.,ur.01041133025.01
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Reiné,Jesús,ur.01344541711.26
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Smith,Andrew,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ferreira,Daniela M,ur.012446116335.41
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ritchie,Neil,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Williams,Paul,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sorio,Guilherme L.,ur.016443154575.74
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Masilela,Mduduzi,ur.07662265775.54
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sanchez-Gonzalez,Amada,ur.01275354243.50
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Chelysheva,Irina,ur.016204413317.06
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Moran,Marni,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Glynn,Sharon,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Thombrayil,Asha,ur.013110347175.40
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",MacGregor,Gordon,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mpelembue,Mushiya,ur.011504545415.76
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hamaluba,Mainga,ur.01200260500.93
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Morrison,Hazel,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Souza,Bruno S.D.F.,ur.016006103112.29
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Barrett,Jessica,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Aboagye,Jeremy,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Moya,Nathifa,ur.016616014175.15
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Larwood,Jessica P.J.,ur.013215143065.17
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Roberts,Hannah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Chita,Sunder,ur.01002675033.11
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Nugent,Fay L.,ur.01064464603.23
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Smith,Nick,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Naker,Kush,ur.015226455127.67
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Morgans,Róisín,ur.015017443071.16
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bisnauthsing,Karen,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Carroll,Miles W.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Snape,Matthew D,ur.010062135107.44
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tladinyane,Bonolo,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Roche,Sophie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Marlow,Emma,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bellamy,Duncan,ur.011416433554.65
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Munro,Alasdair,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",de Ávila Kfouri,Renato,ur.010735212231.78
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Shah,Rajiv,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Soares,Airanuédida,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Beveridge,Amy,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Leach,Amanda,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",King,Lloyd D.W.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Török,M Estée,ur.01254430354.80
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Verheul,Marije,ur.0673177445.34
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Fry,Samantha H.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Morey,Ella,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Azi,Lorena,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Maoko,Takalani,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Douglas,Alexander D,ur.01224573004.25
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Stuart,Arabella C.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Walker,Laura,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Thornton-Jones,Viv,ur.013665210151.75
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Howell,Nicola,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Abeyskera,Kushala,ur.013610402335.42
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Zuidewind,Peter,ur.011070357333.62
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cutland,Clare L,ur.014745402454.20
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cho,Jee-Sun,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Novaes,Gabrielle,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sidhom,Emad,ur.0734634264.19
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bulbulia,Yusuf A.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Saich,Stephen,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Clemens,Sue Ann Costa,ur.01360235121.76
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Barker,Debbie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Clark,Elizabeth,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Dantas,Maria T.D.C.,ur.015444025775.18
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Price,Vivien,ur.01320664733.67
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Silveira,Anderson D.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Vichos,Iason,ur.011401113767.18
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Moultrie,Andrew,ur.015432706003.74
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Knight,Julian C.,ur.0613306061.55
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hodges,Gina,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Neffa,Fabio,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ali,Aabidah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Gavrila,Madita,ur.010605576371.33
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kingham,Lucy,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hamlyn,Joseph,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Dos Santos,Erika Pachecho,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Themistocleous,Yrene,ur.010272223741.46
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Morris,Helen C.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Berg,Adam,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Baldwin,Lisa,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Shepherd,James G.,ur.07640026677.98
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Downing,Charlotte,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Villafana,Tonya L,ur.01160651642.84
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Price,David A.,ur.07655016052.39
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Radia,Kajal,ur.07431545167.52
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Barnabas,Shaun L,ur.01077552167.43
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Howe,Elizabeth,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Oldfield,Neil J.,ur.01004240202.63
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Calderon,Gloria,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kailath,Reshma,ur.07516247235.83
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Voysey,Merryn,ur.01043520166.14
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cao,Michelangelo,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",White,Rachel,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Trivett,Rose,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tomic,Adriana,ur.011666565147.73
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Senger,Roberta,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bradley,Penny,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Greenwood,Nicola,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kerridge,Simon,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Steven,Jill,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Docksey,Claire,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Barrett,Jordan R.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bailey,Catherine,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Owens,Daniel,ur.01343271615.71
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Guerra,Mayara F.S. Santos,ur.07507426375.34
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Owen,Lydia,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",O'Connor,Daniel,ur.01034434167.27
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Nastouli,Eleni,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Shaik,,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mazur,Olga,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Frater,John,ur.0600756740.23
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Feng,Shuo,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Berrie,Eleanor,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Milan,Eveline P,ur.01253775040.00
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Winslow,Rebecca,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Andritsou,Foteini,ur.011534307335.15
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Rudiansyah,Indra,ur.012666334050.54
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Joe,Carina C D,ur.011036005727.59
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hou,Mimi M.,ur.011650472127.74
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Morshead,Gertraud,ur.011313574167.85
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bell,Jonathan,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Datta,Chandrabali,ur.015575617071.16
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hawkins,Sophia,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Colin-Jones,Rachel,ur.014202743227.76
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tiongson,Gerlynn,ur.011567362475.19
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",De Nobrega,Maristela M.D.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Strickland,Louise H.,ur.010224667305.94
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Matlebjane,Hosea,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Oosthuizen,Angela,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Connarty,Sean,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Turabi,Aadil,ur.010752135323.31
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Souza,Cinthia M.C.D.L.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kelly,Debbie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Jeffers,Helen,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Birch,Sarah,ur.011173550275.69
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Piper,Jo,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Taylor,Ursula,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pacurar,Mihaela,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Proud,Pamela C.,ur.010621363131.10
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Brunt,Emily,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Sharpe,Hannah E.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Belton,Sue,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Alcock,Andrew,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Worth,Andrew T.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Martins,Flávia J.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Adamson,James,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Skelly,Donal T.,ur.01132001330.15
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ndlovu,Bongani,ur.0654574633.78
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Fletcher,James,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Collins,Sarah L.K.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Gill,Hardeep,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Farrugia,Leonard,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Padayachee,Sherman D,ur.013426040535.84
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Oliveira,Catarina,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kelly,Dearbhla M.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Malamatsho,Ross,ur.07645227454.09
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Puig,Ingrid Cabera,ur.012244304327.28
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Knott,Daniel,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Crosbie,Sarah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Moraes-Pinto,M. Isabel,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lillie,Patrick J,ur.01141716161.48
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Silva-Reyes,Laura,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Jackson,Susan,ur.014034470333.32
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Megson,Clare,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Gonzalez,Isabela G.S.,ur.01045365142.13
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mendonça,Renata N.Á.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",McInroy,Lorna,ur.012705421567.36
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Allen,Lauren,ur.0600226653.15
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Minassian,Angela M,ur.01237421066.88
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",McEwan,Joanne,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Humphreys,Jonathan,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Lang,Matilda,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Primeira,Marcelo,ur.011360436343.85
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Dheda,Keertan,ur.01257776220.51
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Goondiwala,Amina,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cerbino-Neto,José,ur.0771146726.47
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Anslow,Rachel,ur.012653462027.76
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Pickup,Lorinda,ur.012056450475.12
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Buchan,Ruaridh,ur.0671063661.15
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Saunders,Caroline,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Ruiz,Sarah,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Paiva,Brenda V.B.,ur.010004402746.53
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Baker,Natalie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Mallory,Raburn,ur.01335745362.87
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Serrano,Sonia,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bewley,Kevin R.,ur.01035117350.51
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Stafford,Lizzie,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Júnior,Eduardo A.M.S.,ur.015151076675.51
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cappuccini,Federica,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Damratoski,Brad E.,ur.0710065340.52
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Davies,Hannah,ur.010014663013.69
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Kerr,David,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",White,Caroline,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Zizi,Dalila,ur.016013257451.26
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Varughese,Rachel,ur.01224121070.54
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Satti,Iman,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Arns,Beatriz,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Weckx,Lily Y,ur.0705415217.20
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Taylor,Keja,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Thompson,Kevin,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Goodwin,Jayne,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cavey,Ana,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Silveira,Mariana B.V.,ur.01202137332.07
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hackett,Mark,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Hassan,Shadin,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Di Maso,Claudio,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Plested,Emma,ur.01177370146.35
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bittaye,Mustapha,ur.0655457677.68
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Folegatti,Pedro M,ur.014140042217.03
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Felle,Sally,ur.013416024245.17
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Bexhell,Helen,ur.0757502125.80
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Cardoso,João R.,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Osborne,Piper,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Tarrant,Richard,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Toshner,Mark,ur.01171665572.31
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Budd,William,ur.015670641675.05
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Casey,Helen R.,ur.01140263262.59
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Shaw,Robert,ur.010240754613.97
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Du Plessis,Joan,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Carson-Stevens,Andrew,
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Gordon-Quayle,Katherine,ur.010124444371.23
12965,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",Amorim,Fabio,
12824,In Pursuit of PPE,Artenstein,Andrew W,ur.01140466024.72
12808,Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),Escher,Felicitas,ur.01115116016.24
12808,Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),Shchendrygina,Anastasia,ur.0623260655.43
12808,Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),Carerj,M. Ludovica,ur.015052211543.02
12808,Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),Arendt,Christophe,ur.07404774737.38
12808,Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),Vasa-Nicotera,Mariuca,ur.01367061320.45
12808,Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),Vehreschild,Maria,ur.07376441107.88
12808,Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),Puntmann,Valentina O.,ur.01315130631.13
12808,Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),Zeiher,Andreas M.,ur.0752717701.20
12808,Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),Fahim,Masia,
12808,Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),Wieters,Imke,ur.01354057714.68
12808,Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),Hoffmann,Jedrzej,ur.0677002551.50
12808,Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19),Nagel,Eike,ur.01322265565.22
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Tomashek,Kay M,ur.01330455046.03
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Ohmagari,Norio,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Dodd,Lori E,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Kortepeter,Mark G,ur.01111437444.98
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Zingman,Barry S,ur.01144235663.73
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Hsieh,Lanny,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Lye,David Chien,ur.010714562317.26
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Patterson,Thomas F,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Short,William R,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Benfield,Thomas,ur.0614447562.23
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Sweeney,Daniel A,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Osinusi,Anu,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Kalil,Andre C,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Lane,H Clifford,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Hohmann,Elizabeth,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Fätkenheuer,Gerd,ur.01004110612.33
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Lopez de Castilla,Diego,ur.015061040061.25
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Mehta,Aneesh K,ur.01342366100.32
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Neaton,James D,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Nayak,Seema,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Green,Michelle,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Babiker,Abdel G,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Dierberg,Kerry,ur.01156737440.73
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Kline,Susan,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Touloumi,Giota,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Chu,Helen Y,ur.01061320510.90
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Burgess,Timothy H,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Tapson,Victor,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Oh,Myoung-Don,ur.0753553026.28
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Beigel,John H,ur.0604106525.13
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Bonnett,Tyler,ur.015746335217.12
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Pett,Sarah,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Paredes,Roger,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Ruiz-Palacios,Guillermo M,ur.014601161265.59
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Creech,C Buddy,ur.0742031600.29
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Finberg,Robert W,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Lundgren,Jens,ur.014244312601.82
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Makowski,Mat,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Atmar,Robert L,
12753,Remdesivir for the Treatment of Covid-19 — Final Report,Luetkemeyer,Annie,
12717,"High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.",Lee,Jaxon,
12717,"High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.",Ball,Amelia,
12717,"High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.",Narwal,Simranjit,
12717,"High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.",Leibrand,Howard,
12717,"High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.",Capron,Ian,
12717,"High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.",Patrick,Dale,
12717,"High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.",Jordan,Amber,
12717,"High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.",Russell,Sam,
12717,"High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.",Dubbel,Polly,
12717,"High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.",Hamner,Lea,
12717,"High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.",Ross,Andy,
12717,"High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.",Lynn,Joanne,
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Barrett,Catherine E.,ur.012026274713.25
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Pavkov,Meda E.,ur.0673130377.56
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Mahon,Barbara E.,ur.0741377144.38
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Lundeen,Elizabeth A.,ur.012711370533.26
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Gray,Simone,ur.012524431766.19
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Gundlapalli,Adi V.,ur.0611305711.53
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Perrine,Cria G.,ur.0674553132.85
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Rolka,Deborah B.,ur.01276760531.36
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Wiltz,Jennifer L.,ur.015515642117.23
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Remley,Karen,
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Saydah,Sharon,ur.01070035533.29
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Goodman,Alyson B.,ur.01337544064.62
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Chow,Wilson,
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Siegel,David A.,ur.01200444435.71
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Koyama,Alain K.,ur.01125447222.91
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Bull-Otterson,Lara,ur.01074740164.32
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Kompaniyets,Lyudmyla,ur.010442441237.37
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Boehmer,Tegan K.,ur.01033040015.24
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Tauxe,Robert V.,ur.01363352244.13
12669,"Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021",Alvarez,Pablo,ur.014051257566.46
12636,Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards?,Kisielinski,Kai,ur.01167300426.38
12636,Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards?,Kempski,Oliver,ur.01116272755.36
12636,Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards?,Klosterhalfen,Bernd,ur.010743050164.68
12636,Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards?,Hirsch,Oliver,ur.0670230011.24
12636,Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards?,Graessel,David,
12636,Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards?,Prescher,Andreas,ur.0751171625.75
12636,Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards?,Funken,Stefan,ur.012441275655.43
12636,Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards?,Giboni,Paul,
12621,SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis,Høeg,Tracy Beth,ur.01044166575.20
12621,SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis,Stevenson,Josh,ur.014414244010.14
12621,SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis,Krug,Allison,ur.012544524740.70
12621,SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis,Mandrola,John,ur.01301632147.65
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Lozano,Rafael,ur.01352437070.24
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Gallagher,John,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Comfort,Haley,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Sorensen,Reed J D,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Paulson,Katherine R,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Olana,Latera Tesfaye,ur.016625530256.33
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Deen,Amanda,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",May,Erin A,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Monasta,Lorenzo,ur.01254131200.93
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Jones,Darwin Phan,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Lindstrom,Akiaja,ur.016057117140.28
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Hay,Simon I,ur.01107433531.31
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Shaw,David H,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Wiysonge,Charles Shey,ur.0667111132.59
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Månsson,Johan,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Adolph,Christopher,ur.0777053267.35
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Fullman,Nancy,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Daoud,Farah,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Dai,Xiaochen,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Herrera,Ana M Mantilla,ur.07645507401.80
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Bisignano,Catherine,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Dangel,William James,ur.013630247011.14
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Watson,Stefanie,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Chattopadhyay,Jhilik,ur.016540251140.22
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Allorant,Adrien,ur.015567574603.50
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Penberthy,Louise,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Worku,Nahom Alemseged,ur.015712470301.54
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Kereselidze,Maia,ur.011423540260.46
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Aravkin,Aleksandr Y,ur.016512500276.24
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",O'Halloran,James Kevin,ur.07426022240.20
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Guo,Gaorui,ur.07354535613.64
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Gamkrelidze,Amiran,ur.01114263770.47
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Fuller,John E,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Frisch,Meghan E,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Reiner,Robert C,ur.0762501566.31
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Troeger,Christopher E,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Walcott,Rebecca,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Cogen,Rebecca M,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Henry,Nathaniel J,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Syailendrawati,Ruri,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Naik,Paulami,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Castro,Emma,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Wang,Haidong,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Ribeiro,Antonio Luiz P,ur.0727731754.29
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Collins,James K,ur.013010347361.78
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Malta,Deborah Carvalho,ur.01011613642.30
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",O'Brien,Edward G,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Abbafati,Cristiana,ur.011606002626.99
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Amlag,Joanne O,ur.010564445140.83
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Santomauro,Damian Francesco,ur.01212734545.84
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Chakrabarti,Suman,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Sholokhov,Aleksei,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Walker,Ally,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Bertolacci,Gregory J,ur.07522010213.53
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Ferrari,Alize J,ur.0760121476.27
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Nomura,Shuhei,ur.0614603360.41
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Barber,Ryan M,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Lim,Stephen S,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Lazzar-Atwood,Alice,ur.012764103213.95
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Collaborators,COVID-19 Excess Mortality,ur.015650654724.76
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Cooperrider,Kimberly,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Mokdad,Ali H,ur.01004203213.05
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Topor-Madry,Roman,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Helak,Monika,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Lotufo,Paulo A,ur.01057113165.47
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Carter,Austin,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Fedosseeva,Tatiana,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Murray,Christopher J L,ur.012310237337.47
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Zigler,Bethany,ur.012462037440.98
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Alam,Tahiya,ur.015716244537.16
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Bang-Jensen,Bree,ur.013111757755.03
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Linebarger,Emily,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Bloom,Sabina S,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Magistro,Beatrice,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Pease,Spencer A,ur.012003131743.21
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",LeGrand,Kate E,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Frostad,Joseph Jon,ur.012240745161.45
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Misganaw,Awoke Temesgen,ur.011220276650.32
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Dapper,Carolyn,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Naghavi,Mohsen,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Ostroff,Samuel M,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Erickson,Megan,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Sheena,Brittney S,ur.014542607561.83
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Mirkuzie,Alemnesh H,ur.01164313400.46
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Gakidou,Emmanuela,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Pigott,David M,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",He,Jiawei,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Huntley,Bethany M,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Ewald,Samuel B,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Duncan,Bruce B,ur.01063570142.27
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Spurlock,Emma Elizabeth,ur.014424215133.01
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Marinho,Fatima,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Reinke,Grace,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Schmidt,Maria Inês,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Zheng,Peng,
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Hulland,Erin N,ur.012127730655.85
12571,"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21",Skhvitaridze,Natia,ur.0725737155.17
12525,"Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School — Marin County, California, May–June 2021",Duncan,Lael,ur.010172417074.86
12525,"Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School — Marin County, California, May–June 2021",Santora,Lisa,
12525,"Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School — Marin County, California, May–June 2021",Lam-Hine,Tracy,ur.016510157652.56
12525,"Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School — Marin County, California, May–June 2021",Corbett-Detig,Russell,ur.01040473735.39
12525,"Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School — Marin County, California, May–June 2021",Willis,Matthew,ur.01261325350.20
12525,"Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School — Marin County, California, May–June 2021",McCurdy,Stephen A.,ur.01231223077.65
12525,"Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School — Marin County, California, May–June 2021",Kapusinszky,Beatrix,ur.0742702744.32
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Cao,Bin,ur.0641123655.02
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Du,Ronghui,ur.01315007443.03
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Zhou,Fei,ur.0660664046.17
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Yu,Ting,ur.015434422625.35
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Xiang,Jie,ur.015342143401.07
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Zhang,Yi,ur.015173541671.41
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Song,Bin,ur.016520367471.42
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Liu,Zhibo,ur.014330046071.14
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Wang,Yeming,ur.016672650674.30
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Tu,Shengjin,ur.014376161271.49
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Xu,Jiuyang,ur.013600600671.13
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Gu,Xiaoying,ur.01323674617.33
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Li,Hui,ur.01237377613.47
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Guan,Lulu,ur.010612676671.49
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Wei,Yuan,ur.011410257271.24
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Wu,Xudong,ur.013003220271.51
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Liu,Ying,ur.011711346717.61
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Fan,Guohui,ur.014755044646.73
12523,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Chen,Hua,ur.015771122271.42
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Dormitzer,Philip R.,ur.01124563153.82
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Bailey,Ruth,
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Lockhart,Stephen,ur.01155017074.41
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Thomas,Stephen J.,ur.01250631625.48
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Liberator,Paul,ur.01135672564.57
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Roychoudhury,Satrajit,ur.01075070035.40
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Absalon,Judith,ur.0726712623.28
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Zerbini,Cristiano,
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Swanson,Kena A.,ur.0720727651.67
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Cooper,David,
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Polack,Fernando P.,ur.0705247414.83
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Nell,Haylene,ur.01051056763.52
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Group,C4591001 Clinical Trial,
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Tresnan,Dina B.,ur.011115233157.53
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Jansen,Kathrin U.,
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Gurtman,Alejandra,ur.0766540106.68
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Kalina,Warren V.,ur.0577211724.06
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Gruber,William C.,ur.0735756071.23
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Frenck,Robert W.,ur.01157665701.10
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Şahin,Uğur,ur.0657734236.08
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Koury,Kenneth,ur.01252412675.84
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Yang,Qi,
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Perez,John L.,
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Mather,Susan,
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Schaefer,Axel,ur.015457303071.05
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Moreira,Edson D.,ur.016320742232.37
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Xu,Xia,
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Bouguermouh,Salim,ur.01264006673.59
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Türeci,Özlem,ur.01237100335.34
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Kitchin,Nicholas,ur.01343436707.36
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Ünal,Serhat,ur.01115453237.24
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Marc,Gonzalo Pérez,ur.014603713133.90
12323,Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,Hammitt,Laura L.,
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Liu,Lei,ur.01041525526.29
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Jiang,Yujing,
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Wei,Jinli,ur.016345352071.21
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Xu,Zhixiang,ur.07456645400.96
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Liu,Yingxia,ur.0665250005.15
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Yang,Minghui,ur.01143233707.33
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Zhao,Fang,
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Xiao,Haixia,ur.0706573560.72
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Liu,Dongjing,ur.012664435561.15
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Yuan,Jing,ur.01001476405.17
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Yang,Yang,ur.01322656721.17
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Peng,Ling,ur.01037027174.72
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Qu,Jiuxin,ur.01014627374.19
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Li,Jinxiu,ur.01114025171.91
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Xing,Li,ur.07403155541.25
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Chen,Li,ur.011236726534.85
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Wang,Zhaoqin,ur.014170563271.59
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Li,Yanjie,ur.012624612415.09
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Zheng,Haixia,ur.011775126657.84
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Wang,Fuxiang,ur.0723435536.66
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Qing,Ling,ur.015467622001.14
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Huang,Kun,ur.015474371342.03
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Shen,Chenguang,ur.0775151634.79
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Chen,Feng,
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Yang,Yan,
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Zhang,Zheng,ur.01264275476.71
12291,Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma,Li,Delin,ur.011761116615.81
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Chen,Juan,ur.01242532114.18
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Huang,Ai-Long,ur.01163316712.45
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Deng,Hai-Jun,ur.01177345206.59
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Wu,Bo,ur.016211012173.40
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Su,Kun,ur.014020470573.76
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Xu,Wei,ur.016044066747.48
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Gong,Jiang,
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Hu,Jie-Li,ur.01142525355.23
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Zhang,Fan,
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Yuan,Jun,ur.015757655551.70
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Liu,Xia-Mao,ur.016441007551.50
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Lv,Fa-Jin,ur.0600271705.30
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Long,Quan-Xin,ur.01164516071.99
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Li,Jin-Jing,
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Shi,Qiu-Lin,
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Tang,Xiao-Jun,ur.011431300205.46
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Li,Qin,
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Zhang,Yong,ur.011644743257.36
12194,Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections,Qiu,Jing-Fu,ur.0626445711.32
12172,Face masks: what the data say,Peeples,Lynne,
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Dionne,Audrey,
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Senussi,Yasmeen,ur.014477150731.13
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Arditi,Moshe,ur.0654651335.30
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Walt,David R.,ur.01126017715.90
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Swank,Zoe,ur.0677367177.87
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Burns,Madeleine D.,ur.011314020421.12
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Davis,Jameson P.,ur.012467762705.01
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Fasano,Alessio,ur.01007715271.18
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Novak,Tanya,ur.010072206415.33
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Randolph,Adrienne G.,ur.01042045326.26
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Burgess,Eleanor,ur.014432125442.29
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Bartsch,Yannic C.,ur.0706564236.09
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Cheng,Chi-An,ur.012330742504.28
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Yonker,Lael M.,ur.01315443731.68
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Loiselle,Maggie,ur.012151244651.15
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Boribong,Brittany P.,ur.011100165500.52
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Julg,Boris,ur.0776011377.87
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Alter,Galit,ur.01216077501.34
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Lahoud-Rahme,Manuella,ur.01040037067.92
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Balaguru,Duraisamy,ur.01063655370.65
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Kane,Abigail,ur.016554333642.81
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Edlow,Andrea G.,ur.0723176517.18
12116,Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis,Chou,Janet,ur.01133462632.56
11997,Household Transmission of SARS-CoV-2,Yang,Yang,ur.0755311740.38
11997,Household Transmission of SARS-CoV-2,Madewell,Zachary J.,ur.010413677113.52
11997,Household Transmission of SARS-CoV-2,Longini,Ira M.,ur.0642222407.69
11997,Household Transmission of SARS-CoV-2,Halloran,M. Elizabeth,ur.01207126007.09
11997,Household Transmission of SARS-CoV-2,Dean,Natalie E.,ur.0763377255.09
11975,Persistent Symptoms in Patients After Acute COVID-19,Bernabei,Roberto,ur.01354704305.45
11975,Persistent Symptoms in Patients After Acute COVID-19,Carfì,Angelo,ur.0764551272.50
11975,Persistent Symptoms in Patients After Acute COVID-19,Landi,Francesco,ur.01303775235.56
11953,Mass infection is not an option: we must do more to protect our young,Reicher,Stephen,ur.016551203565.33
11953,Mass infection is not an option: we must do more to protect our young,West,Robert,ur.01062131237.07
11953,Mass infection is not an option: we must do more to protect our young,Katzourakis,Aris,ur.0757514737.12
11953,Mass infection is not an option: we must do more to protect our young,Pagel,Christina,ur.0734746616.07
11953,Mass infection is not an option: we must do more to protect our young,Haque,Zubaida,ur.012726460435.25
11953,Mass infection is not an option: we must do more to protect our young,Ziauddeen,Hisham,ur.01371624753.15
11953,Mass infection is not an option: we must do more to protect our young,Yates,Christian,ur.0653042471.04
11953,Mass infection is not an option: we must do more to protect our young,Michie,Susan,ur.01067023110.81
11953,Mass infection is not an option: we must do more to protect our young,Hyde,Zoë,ur.01250055705.84
11953,Mass infection is not an option: we must do more to protect our young,Gurdasani,Deepti,ur.01342153057.51
11953,Mass infection is not an option: we must do more to protect our young,Griffin,Stephen,ur.01104606706.02
11953,Mass infection is not an option: we must do more to protect our young,Greenhalgh,Trisha,ur.0734302623.84
11953,Mass infection is not an option: we must do more to protect our young,Roberts,Alice,
11953,Mass infection is not an option: we must do more to protect our young,McKee,Martin,ur.01367673420.84
11953,Mass infection is not an option: we must do more to protect our young,Drury,John,ur.07453117513.98
11933,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",Assagra,Washington Luiz,
11933,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",Proença,Fernando Carlos,ur.016046413366.69
11933,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",Lobo,Raysildo B.,ur.0730356724.74
11933,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",Hibberd,Jennifer A.,ur.010542422303.49
11933,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",Assagra,Washington Luiz O.,
11933,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",Proença,Fernando Carlos,ur.012022371770.41
11933,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",Cadegiani,Flavio A.,ur.011314721135.77
11933,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",Kory,Pierre,ur.01263214251.87
11933,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",Chamie-Quintero,Juan J.,
11933,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",Lobo,Raysildo,
11933,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",Baldi,Fernando,ur.0662707420.57
11933,"Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching",Kerr,Lucy,ur.012263130766.55
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Kalimuddin,Shirin,ur.0633106776.32
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Bertoletti,Antonio,ur.01214412542.39
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Low,Jenny Guek-Hong,ur.014006317762.66
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Chia,Adeline,ur.01053275626.05
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Chen,Mark I-Cheng,ur.0634357115.84
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Tambyah,Paul Anantharajah,ur.010711506654.18
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Tan,Yee-Joo,ur.010325421667.68
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Hafezi,Morteza,ur.010243343661.22
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Tan,Nicole,ur.07514076461.86
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Wang,Lin-Fa,ur.01044121035.54
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Linster,Martin,ur.01027074767.94
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Chng,Melissa Hui Yen,ur.015016575237.49
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Tan,Anthony T.,ur.01304414637.46
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Chia,Wan Ni,ur.0620472632.66
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Le Bert,Nina,ur.01275057114.47
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Tham,Christine Y. L.,ur.01160074204.70
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Kunasegaran,Kamini,ur.01226152732.10
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Lin,Meiyin,ur.015421567261.52
11779,"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls",Ooi,Eng Eong,ur.01054245212.87
11776,Infection fatality rate of COVID-19 in community-dwelling populations with emphasis on the elderly: An overview,Axfors,Cathrine,ur.010232432033.00
11776,Infection fatality rate of COVID-19 in community-dwelling populations with emphasis on the elderly: An overview,Ioannidis,John P A,ur.015607417277.46
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Libreros,Gerardo,
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Jaramillo,Roberto,
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Avendaño,Ana C.,
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Ramirez,Oscar,ur.0744154532.90
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Hurtado,Isabel C.,ur.01254720550.91
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Toro,Dilian F.,
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Torres,Miyerlandi,ur.014167070167.01
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Díazgranados,Jesus A.,ur.013703745321.46
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,López,Pío,ur.0676373023.00
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,López-Medina,Eduardo,ur.01155355233.52
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Caicedo,Isabella,
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Herrera,Sócrates,ur.0652062167.09
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Parra,Beatriz,ur.0655242211.54
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Martínez,Ernesto,ur.01343565366.17
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Rios,Carlos A.,
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Lesmes,Maria C.,ur.013242050615.84
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Oñate,José M.,ur.016065645175.77
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Chavarriaga,Hector,
11756,Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19,Dávalos,Diana M,ur.0651561367.03
11724,"Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021",Bull-Otterson,Lara,ur.01074740164.32
11724,"Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021",Adjei,Stacey,ur.010130345357.28
11724,"Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021",Boehmer,Tegan K.,ur.01033040015.24
11724,"Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021",Baca,Sarah,ur.011127663030.05
11724,"Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021",Gray,Simone,ur.012524431766.19
11724,"Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021",Saydah,Sharon,ur.01070035533.29
11724,"Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021",Harris,Aaron M.,ur.01353376407.16
11695,"Covid-19 vaccines and treatments: we must have raw data, now",Godlee,Fiona,ur.0675461762.55
11695,"Covid-19 vaccines and treatments: we must have raw data, now",Doshi,Peter,ur.01332606320.34
11695,"Covid-19 vaccines and treatments: we must have raw data, now",Abbasi,Kamran,ur.0627346562.75
11672,"Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After Exposure at a Hair Salon with a Universal Face Covering Policy - Springfield, Missouri, May 2020.",Findley,Kendra,
11672,"Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After Exposure at a Hair Salon with a Universal Face Covering Policy - Springfield, Missouri, May 2020.",Walde,Charles,ur.07372362673.72
11672,"Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After Exposure at a Hair Salon with a Universal Face Covering Policy - Springfield, Missouri, May 2020.",Trotman,Robin,ur.0622261361.14
11672,"Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After Exposure at a Hair Salon with a Universal Face Covering Policy - Springfield, Missouri, May 2020.",Hendrix,M Joshua,ur.015377145367.75
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Russell,Neal,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Phe,Thong,ur.01227412620.40
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Aravkin,Aleskandr,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Fell,Frederick,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Ngoun,Chanpheaktra,ur.0667766457.53
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Ramdin,Tanusha,ur.01257307266.24
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Haines-Woodhouse,Georgina,ur.012721224103.21
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Berkley,James A,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Khorana,Meera,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Robles Aguilar,Gisela,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Stoeva,Temenuga,ur.01041612411.98
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Gray,Authia,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Chaurasia,Suman,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Bekker,Adrie,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Roca,Anna,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Thwaites,Guy,ur.01135151135.80
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Hay,Simon I,ur.01107433531.31
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Jacobs,Jan,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Olivas-Martinez,Antonio,ur.011735360564.05
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,De Luca,Maia,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Kostyanev,Tomislav,ur.0764316145.79
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Hopkins,Susan,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Hackett,Sean,ur.01110316643.55
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Lim,Cherry,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Chansamouth,Vilada,ur.01253507507.13
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Scott,John Anthony Gerard,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Raad,Mathieu,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Holm,Marianne,ur.0646623346.43
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Naghavi,Mohsen,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Stewardson,Andrew James,ur.0615561666.34
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Rosenthal,Victor Daniel,ur.01223265151.56
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Basnyat,Buddha,ur.01007546730.36
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Cunningham,Matthew,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Clotaire Donatien,Rafai,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Musila,Lilian A,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Sader,Helio S,ur.0600623436.15
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Turner,Claudia,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Bethou,Adhisivam,ur.01225052017.00
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Perrone,Carlo,ur.011352114634.09
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Velaphi,Sithembiso,ur.01210760225.04
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Seekaew,Samroeng,ur.014651057041.50
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Mussi-Pinhata,Marisa Marcia,ur.01327504072.11
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Dokova,Klara,ur.0576075123.46
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Saengchan,Weerawut,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Darboe,Saffiatou,ur.0765737235.67
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Moore,Catrin,ur.012056061132.23
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Eckmanns,Tim,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,van Doorn,H Rogier,ur.01076204103.30
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Krapp,Fiorella,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Bukosia,James,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Forrest,Karen,ur.016515552341.71
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Krumkamp,Ralf,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,McManigal,Barney,ur.010362324616.49
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Han,Chieh,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Eibach,Daniel,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Zheng,Peng,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Boonkasidecha,Suppawat,ur.01307471674.29
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,May,Jürgen,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Nangia,Sushma,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Achalapong,Sureeruk,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Schnall,Jesse,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Khusuwan,Suwimon,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Emami,Amir,ur.01100245517.42
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Ma,Jianing,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Manoharan,Anand,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Walsh,Timothy,ur.015230634637.87
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Bender,Rose,ur.011413467404.78
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Naidu,Ravi Narayan,ur.014647620231.10
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Chiurchiù,Sara,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Young Sharma,Tracey E M W,ur.016527241464.84
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Rao,Puja,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Chipeta,Michael Give,ur.015714341317.94
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Yu,Kalvin C,ur.014131661257.44
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Sartorius,Benn,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Vu,Huong,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Riddell,Amy,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Kashef Hamadani,Bahar H,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Ochoa,Theresa J,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Ortiz-Brizuela,Edgar,ur.01267630731.52
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Wool,Eve,ur.07421753313.25
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Dramowski,Angela,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Dunachie,Susanna J,ur.01041133025.01
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Novotney,Amanda,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Chowdhury,Fazle,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Jarovsky,Daniel,ur.016404550403.19
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Peleg,Anton Yariv,ur.01224771217.08
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Day,Nicholas P J,ur.013570515662.78
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Newton,Paul,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Murray,Christopher J L,ur.012310237337.47
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Paredes,Jose Luis,ur.012035440763.55
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Castañeda-Orjuela,Carlos,ur.0774730463.89
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Agarwal,Ramesh,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Mayxay,Mayfong,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Kobeissi,Elsa,ur.014433322005.30
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Olliaro,Piero,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Rattanavong,Sayaphet,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Akech,Samuel,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Steenkeste,Nicolas,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Kissoon,Niranjan,ur.014150672735.74
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Pak,Gideok D,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Cressey,Tim R,ur.01133314220.50
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Thaiprakong,Areerat,ur.012556507316.62
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Simpson,Andrew J,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Cook,Aislinn J,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Nanavati,Ruchi,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Giref,Ababi Zergaw,ur.015235661205.53
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Criollo-Mora,Elia,ur.011547203647.18
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Ikuta,Kevin Shunji,ur.012136772647.91
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Shivamallappa,Madhusudhan,ur.010377437675.97
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Iregbu,Kenneth C,ur.07430440737.19
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Mturi,Neema,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Wozniak,Teresa,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Ooko,Ednah,ur.011047317716.62
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Cooper,Ben,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Lopez,Alan D,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Babin,François-Xavier,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Plakkal,Nishad,ur.01056026153.27
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Bielicki,Julia,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Tigoi,Caroline,ur.01336376351.27
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Swetschinski,Lucien,ur.016156010421.90
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Browne,Annie J,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Carvalheiro,Cristina,ur.01012345246.20
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Turner,Paul,ur.01014312410.03
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Amuasi,John,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Kyu,Hmwe Hmwe,ur.01371376226.74
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Roberts,Tamalee,ur.01177062766.15
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Fisher-Pearson,Natasha,ur.011135247043.47
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Phommasone,Koukeo,ur.0736206206.04
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Obiero,Christina W,ur.01061211575.13
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Loftus,Michael James,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Marks,Florian,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Munera-Huertas,Tatiana,ur.01360601535.30
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Ashley,Elizabeth,ur.01027065073.98
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Jenney,Adam W J,ur.01366172437.24
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Greer,Rachel Claire,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Andrews,Jason,ur.01174536050.55
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Sharara,Fablina,ur.07616451443.08
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Hsia,Yingfen,ur.01011537763.34
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Kumar,Ajay,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Kumaran,Emmanuelle A P,ur.01102545046.61
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Tasak,Nidanuch,ur.011761126716.51
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Duong Bich,Thuy,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Ponce-de-Leon,Alfredo,ur.0620270056.08
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Gupta,Vikas,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Bailey,Freddie,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Feasey,Nicholas,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Baker,Stephen,ur.0642552367.39
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Lim,Kruy,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Wannapinij,Prapass,ur.01022533340.67
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Robotham,Julie Victoria,ur.01103323427.11
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Ounchanum,Pradthana,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Bisignano,Catherine,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Haselbeck,Andrea,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Sifuentes-Osornio,Jose,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Musicha,Patrick,ur.012264744313.55
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Garrett,Denise,ur.0767122610.13
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Lunn,Miles,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Walson,Judd L,ur.01201222046.89
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Vongsouvath,Manivanh,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Stergachis,Andy,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Haller,Sebastian,ur.01302724427.54
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Limmathurotsakul,Direk,ur.0735502346.54
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Sharland,Mike,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Albertson,Samuel,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Gastmeier,Petra,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Rudd,Kristina E,ur.01347606766.36
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Nwakanma,Davis,ur.01243564376.63
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Garcia,Coralith,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Javanmardi,Fatemeh,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Vongpradith,Avina,ur.012347220741.35
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Nakamura,Tomoka,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Wangrangsimakul,Tri,ur.01115425733.16
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Waner,Seymour,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Johnson,Sarah C,
11564,Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,Dolecek,Christiane,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Self,Wesley H.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Prekker,Matthew E.,ur.01263045061.55
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Henning,Daniel J.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Marcet,Paula L.,ur.01201724506.22
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",,,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Kim,Sara S.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Tan,Hsi-nien,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Hager,David N.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Smith,Emily R.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",McClellan,Robert,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Sciarratta,Courtney N.,ur.013441316413.03
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Wu,Michael,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Plata,Zuwena,ur.015767031413.71
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Griggs,Eric P.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Kim,Kaylee,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Ginde,Adit A.,ur.0750734154.48
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Olson,Samantha M.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Grear,Brittany,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",,,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Casey,Jonathan D.,ur.013171062427.33
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Gibbs,Kevin W.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Grijalva,Carlos G.,ur.01247261255.44
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Baughman,Adrienne,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Exline,Matthew C.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Tenforde,Mark W.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Talbot,H. Keipp,ur.01272421651.57
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Patel,Manish M.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Mlynarczyk,Kristin,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",,,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",,,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Ogokeh,Constance E.,ur.012223240205.69
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Peltan,Ithan D.,ur.01357525642.33
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Brown,Samuel M.,ur.01116631602.39
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Erickson,Heidi L.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Richards,Bridget,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Files,D. Clark,ur.01225026435.34
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Robinson,Sonya,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Marzano,Luc,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Shapiro,Nathan I.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Rice,Todd W.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Caplan,Alexis,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Kassem,Ahmed M.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Hart,Kimberly W.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Hennesy,Nora A.,ur.012203547013.89
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Feldstein,Leora R.,ur.0705636116.22
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",,,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Wilson,Jennifer G.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Lindsell,Christopher J.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Steingrub,Jay S.,ur.0717663645.19
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Fisher,Kiva A.,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",Flannery,Brendan,
11515,"Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020",,,
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Kocharian,Anna,ur.011452761651.95
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Haddock,Luis A.,ur.010225474777.44
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Bateman,Allen,ur.07421666057.89
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Halfmann,Peter J.,ur.0760532211.48
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Riemersma,Kasen K.,ur.01371233315.73
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Minor,Nicholas,ur.016545434640.17
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Jeppson,Gunnar E.,ur.013455564274.11
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Westergaard,Ryan,ur.01003466053.17
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Florek,Kelsey R.,ur.016023467407.85
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Kita-Yarbro,Amanda,ur.016563072051.02
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Wilson,Nancy A.,ur.01010162617.43
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Eickhoff,Jens,ur.0771651015.61
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Kawaoka,Yoshihiro,ur.01261074774.41
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Grande,Katarina M.,ur.0745505666.26
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Friedrich,Thomas C.,ur.01351225117.35
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Grogan,Brittany E.,ur.010710327017.28
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,Segaloff,Hannah E.,ur.012150465057.10
11486,Shedding of Infectious SARS-CoV-2 Despite Vaccination,O’Connor,David H.,ur.01327421644.56
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Allen,Naomi,ur.0577003004.68
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Smith,Stephen M.,ur.010600757634.92
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Andersson,Jesper L.R.,ur.01033614353.71
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Matthews,Paul M.,ur.0627601545.87
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Taschler,Bernd,ur.01360405072.52
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Arthofer,Christoph,ur.010406044274.04
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,McCarthy,Paul,ur.011245227127.42
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Lange,Frederik,ur.015317232313.52
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Alfaro-Almagro,Fidel,ur.0716352241.41
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Jbabdi,Saad,ur.0640053733.88
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Douaud,Gwenaëlle,ur.01166163003.88
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Wang,Chaoyue,ur.010652627334.40
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Winkler,Anderson M.,ur.012257341037.21
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Duff,Eugene,ur.0730450433.34
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Collins,Rory,ur.0641770103.91
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Miller,Karla L.,ur.0741446577.58
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Griffanti,Ludovica,ur.01100670414.73
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Lee,Soojin,ur.0611571742.47
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Keating,Peter,ur.07664620674.73
11484,SARS-CoV-2 is associated with changes in brain structure in UK Biobank,Nichols,Thomas E.,ur.01215612447.63
11466,Clinical outcomes associated with Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California,Lipsitch,Marc,ur.0750403636.04
11466,Clinical outcomes associated with Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California,Hong,Vennis X.,ur.011674320630.08
11466,Clinical outcomes associated with Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California,Kahn,Rebecca,ur.013061020330.26
11466,Clinical outcomes associated with Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California,Patel,Manish M.,ur.012437622427.17
11466,Clinical outcomes associated with Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California,Lewnard,Joseph A.,ur.01070176112.68
11466,Clinical outcomes associated with Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California,Tartof,Sara Y.,ur.01321346607.96
11367,Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff,Cowger,Tori L,ur.015571050263.45
11367,Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff,Ojikutu,Bisola O,ur.01125441115.20
11367,Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff,Bassett,Mary T,ur.01241376077.77
11367,Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff,Sánchez,Sarimer M,ur.014014243515.27
11367,Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff,Hall,Kathryn T,ur.016647424200.04
11367,Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff,Clarke,Jaylen,ur.016602545112.27
11367,Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff,Linos,Natalia,ur.01003500754.19
11367,Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff,Murray,Eleanor J,ur.01250205632.37
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Mateus,Jose,ur.010331064057.40
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Rayaprolu,Vamseedhar,ur.01336033462.81
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Rawlings,Stephen A,ur.01052460632.32
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Faliti,Caterina E,ur.01243106746.30
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Sette,Alessandro,ur.016527313277.78
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Hastie,Kathryn M,ur.0744155426.63
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Haupt,Sonya,ur.016513324173.25
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Krammer,Florian,ur.0615754253.47
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Nakao,Catherine,ur.011753342527.07
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Saphire,Erica Ollmann,ur.01212305166.45
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Crotty,Shane,ur.01312261077.26
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Yu,Esther Dawen,ur.01226366503.73
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Grifoni,Alba,ur.01314176576.29
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Peters,Bjoern,ur.07447331037.97
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Dan,Jennifer M,ur.01265515227.13
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Simon,Viviana,ur.01162355556.40
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Frazier,April,ur.01253340356.82
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Kato,Yu,ur.01336657534.64
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Smith,Davey M,ur.011615110604.77
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Ramirez,Sydney I,ur.01067126700.43
11352,Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection,Weiskopf,Daniela,ur.0602150374.89
11247,IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein,Uversky,Vladimir N.,ur.0645213650.30
11247,IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein,Makis,William,ur.0675163676.16
11247,IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein,Redwan,Elrashdy M.,ur.01003506500.01
11247,IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein,Rubio-Casillas,Alberto,ur.01163503166.94
11183,Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine,Shrestha,Nabin K,ur.014530171213.52
11183,Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine,Hagen,Amanda,ur.012607611220.35
11183,Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine,Nowacki,Amy S,ur.01046134373.87
11183,Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine,Gordon,Steven M,ur.014424253062.35
11183,Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine,Simon,James F,ur.012012230620.73
11183,Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine,Burke,Patrick C,ur.016236544425.44
11155,An upper bound on one-to-one exposure to infectious human respiratory particles,Bodenschatz,Eberhard,ur.0711013636.49
11155,An upper bound on one-to-one exposure to infectious human respiratory particles,Bagheri,Gholamhossein,ur.014714104776.40
11155,Face-masks save us from SARS-CoV-2 transmission,Bagheri,Gholamhossein,ur.014714104776.40
11155,Face-masks save us from SARS-CoV-2 transmission,Thiede,Birte,ur.014363115361.28
11155,An upper bound on one-to-one exposure to infectious human respiratory particles,Schlenczek,Oliver,ur.011727062210.13
11155,An upper bound on one-to-one exposure to infectious human respiratory particles,Thiede,Birte,ur.014363115361.28
11155,Face-masks save us from SARS-CoV-2 transmission,Bodenschatz,Eberhard,ur.0711013636.49
11155,An upper bound on one-to-one exposure to infectious human respiratory particles,Hejazi,Bardia,ur.010157764554.09
11155,Face-masks save us from SARS-CoV-2 transmission,Schlenczek,Oliver,ur.011727062210.13
11155,Face-masks save us from SARS-CoV-2 transmission,Hejazi,Bardia,ur.010157764554.09
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Levy,Joshua I.,ur.07631771242.52
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Rambaut,Andrew,ur.0633743356.16
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Pekar,Jonathan E.,ur.015550101561.47
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Worobey,Michael,ur.0700465211.96
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Holmes,Edward C.,ur.012501436222.04
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Garry,Robert F.,ur.01051136257.59
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Kraemer,Moritz U. G.,ur.014532552104.23
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Koopmans,Marion P. G.,ur.013117453357.11
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Robertson,David L.,ur.0772431062.48
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Lemey,Philippe,ur.01261447574.28
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Serrano,Lorena Malpica,
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Suchard,Marc A.,ur.0727404600.67
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Rasmussen,Angela L.,ur.01356032601.42
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Crits-Christoph,Alexander,ur.0616304706.07
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Goldstein,Stephen A.,ur.01127506467.34
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Andersen,Kristian G.,ur.0701117322.53
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Newman,Chris,ur.01016202742.60
11150,The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic,Wertheim,Joel O.,ur.0753416214.99
11141,Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents,Todt,D,ur.0702601104.68
11141,Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents,Kampf,G,ur.01335361256.43
11141,Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents,Pfaender,S,ur.01061146555.26
11141,Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents,Steinmann,E,ur.01136220330.04
11089,Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients,Harrison,Paul J,ur.011112526240.39
11089,Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients,Zhu,Lena,
11089,Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients,Sillett,Rebecca,
11089,Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients,Camplisson,Isabella,
11089,Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients,Dercon,Quentin,ur.013564123230.35
11089,Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients,Taquet,Maxime,ur.01170177602.97
11089,Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients,Mendel,Jacob,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Brown,Rachel T.,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Stefanski,Elisha,ur.01116114565.27
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Beitel,Shawn,ur.01025005330.35
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Dunnigan,Kayan,ur.013617013071.09
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Lutrick,Karen,ur.016710333305.09
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Kuntz,Jennifer L.,ur.0666663173.50
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Fowlkes,Ashley,ur.01217254024.10
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Thompson,Mark G.,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Burgess,Jefferey L.,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Ellingson,Katherine,ur.01037117207.93
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Herring,Meghan K.,ur.011010675523.47
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Wesley,Meredith G.,ur.011540142723.49
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Zunie,Tnelda,ur.010416672733.70
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Arvay,Melissa L.,ur.0725714642.40
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Groom,Holly C.,ur.01267740503.12
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Meece,Jennifer,ur.01264016034.54
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Olsho,Lauren E.W.,ur.01074225010.50
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Ivacic,Lynn,ur.010742562323.28
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Naleway,Allison L.,ur.0764213046.95
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Smith,Michael E.,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Kutty,Preeta,ur.01014731074.18
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Hunt,Danielle R.,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Mak,Josephine,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Odean,Marilyn J.,ur.011533776363.56
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Sun,Xiaoxiao,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Gerald,Joe,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Harris,Katherine M.,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Phillips,Andrew L.,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Yoon,Sarang K.,ur.016126742205.16
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Yoo,Young M.,ur.016121005723.08
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Thiese,Matthew S.,ur.01351723662.61
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Rivers,Patrick,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Gaglani,Manjusha,ur.01161416743.98
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Hegmann,Kurt T.,ur.01303610462.69
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Grant,Lauren,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Joseph,Gregory,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Groover,Kimberly D.,ur.015323425323.19
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Schaefer-Solle,Natasha,ur.014720743375.55
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Edwards,Laura J.,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Lamberte,Julie Mayo,ur.012335523323.12
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Tyner,Harmony L.,ur.01205511651.40
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Fry,Alicia M.,
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Morrill,Tyler C.,ur.0751361361.56
11078,"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021",Caban-Martinez,Alberto J.,ur.0777514233.48
11051,COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study,Zelenko,Vladimir,ur.010106054037.44
11051,COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study,Derwand,Roland,ur.01207033706.57
11051,COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study,Scholz,Martin,ur.013574143142.63
11026,SARS-CoV-2 Transmission From People Without COVID-19 Symptoms,Steele,Molly,ur.015470021625.11
11026,SARS-CoV-2 Transmission From People Without COVID-19 Symptoms,Johansson,Michael A.,ur.01221326713.13
11026,SARS-CoV-2 Transmission From People Without COVID-19 Symptoms,Quandelacy,Talia M.,ur.01354734546.50
11026,SARS-CoV-2 Transmission From People Without COVID-19 Symptoms,Butler,Jay C.,ur.014370367252.07
11026,SARS-CoV-2 Transmission From People Without COVID-19 Symptoms,Prasad,Pragati Venkata,ur.010535145253.08
11026,SARS-CoV-2 Transmission From People Without COVID-19 Symptoms,Kada,Sarah,ur.013770642765.38
11026,SARS-CoV-2 Transmission From People Without COVID-19 Symptoms,Slayton,Rachel B.,ur.01014561047.56
11026,SARS-CoV-2 Transmission From People Without COVID-19 Symptoms,Biggerstaff,Matthew,ur.0613754145.98
11026,SARS-CoV-2 Transmission From People Without COVID-19 Symptoms,Brooks,John T.,ur.016124243522.51
10992,Investigate the origins of COVID-19,Chan,Yujia Alina,ur.01310017500.30
10992,Investigate the origins of COVID-19,Medzhitov,Ruslan,ur.01067015604.71
10992,Investigate the origins of COVID-19,Bjorkman,Pamela J.,ur.01047140724.31
10992,Investigate the origins of COVID-19,Patterson,Nick,
10992,Investigate the origins of COVID-19,Gupta,Ravindra,
10992,Investigate the origins of COVID-19,Baric,Ralph S.,ur.016314333017.37
10992,Investigate the origins of COVID-19,Iwasaki,Akiko,ur.01242622003.20
10992,Investigate the origins of COVID-19,Fisman,David N.,ur.01335612470.01
10992,Investigate the origins of COVID-19,van Nimwegen,Erik,ur.01124042215.22
10992,Investigate the origins of COVID-19,Lipsitch,Marc,ur.0750403636.04
10992,Investigate the origins of COVID-19,Stearns,Tim,ur.01305160340.56
10992,Investigate the origins of COVID-19,Worobey,Michael,ur.0700465211.96
10992,Investigate the origins of COVID-19,Deverman,Benjamin E.,ur.01330200365.19
10992,Investigate the origins of COVID-19,Relman,David A.,ur.0612224366.06
10992,Investigate the origins of COVID-19,Cobey,Sarah,ur.0654167572.26
10992,Investigate the origins of COVID-19,Bloom,Jesse D.,ur.01032756546.65
10992,Investigate the origins of COVID-19,Neher,Richard A.,ur.01071667415.77
10992,Investigate the origins of COVID-19,Nielsen,Rasmus,ur.014743012100.28
10915,Evaluation of science advice during the COVID-19 pandemic in Sweden,Steadson,David,
10915,Evaluation of science advice during the COVID-19 pandemic in Sweden,Breland,Sofia,ur.07553133410.34
10915,Evaluation of science advice during the COVID-19 pandemic in Sweden,Steineck,Gunnar,ur.01122375673.65
10915,Evaluation of science advice during the COVID-19 pandemic in Sweden,Ewing,Andrew,ur.014477404442.02
10915,Evaluation of science advice during the COVID-19 pandemic in Sweden,Stilhoff Sörensen,Jens,
10915,Evaluation of science advice during the COVID-19 pandemic in Sweden,Brusselaers,Nele,ur.0623055705.80
10915,Evaluation of science advice during the COVID-19 pandemic in Sweden,Bergmann,Sigurd,ur.011254203214.04
10915,Evaluation of science advice during the COVID-19 pandemic in Sweden,Bjorklund,Kelly,ur.016256204610.15
10888,"SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties",Sridhar,Devi,ur.01333123514.93
10888,"SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties",Oliu-Barton,Miquel,ur.014711655201.19
10888,"SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties",Kickbusch,Ilona,ur.01162703763.93
10888,"SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties",Vanderslott,Samantha,ur.01272011112.21
10888,"SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties",Pradelski,Bary S R,ur.011456304775.85
10888,"SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties",Lazarus,Jeffrey V,ur.016271461132.15
10888,"SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties",Artus,Patrick,ur.013572617721.68
10888,"SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties",Aghion,Philippe,ur.010523064103.95
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Ye,Yingchun,ur.011751313047.33
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Wang,Chen,ur.01206770537.35
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Liu,Zhibo,ur.014330046071.14
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Ye,Xianzhi,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Wang,Yeming,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Zhang,Dingyu,ur.015256703335.14
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Horby,Peter W,ur.01006107443.13
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Wang,Ke,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Yang,Chengqing,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Wu,Feng,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Wang,Shuzhen,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Gu,Xiaoying,ur.01323674617.33
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Yang,Jie,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Du,Guanhua,ur.01333150065.29
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Cao,Bin,ur.0641123655.02
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Jaki,Thomas,ur.01244503315.04
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Lu,Yang,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Ruan,Shunan,ur.016662104701.48
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Guo,Tingting,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Li,Huadong,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Jin,Yang,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Jiang,Yushen,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Hu,Yi,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Cao,Lianjun,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Cheng,Zhenshun,ur.013624060373.43
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Xu,Jiuyang,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Luo,Guangwei,ur.01027736726.06
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Zhao,Jianping,ur.01271747272.97
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Wan,Yan,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Qin,Hong,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Liu,Bing,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Tang,Xin,ur.07510627453.70
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Hayden,Frederick G,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Wang,Aili,ur.010517336031.29
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Ding,Dan,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Shang,Lianhan,ur.01224670515.65
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Mei,Chunlin,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Zhou,Fei,ur.0660664046.17
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Du,Ronghui,ur.01315007443.03
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Fu,Shouzhi,ur.011727735231.13
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Lu,Qiaofa,ur.010551412705.10
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Yin,Wen,ur.016713316145.22
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Gao,Ling,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Zhang,Yi,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Wang,Yi,
10879,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",Fan,Guohui,ur.014755044646.73
10841,Bacterial and fungal isolation from face masks under the COVID-19 pandemic,Tsunoda,Ikuo,ur.0601334315.07
10841,Bacterial and fungal isolation from face masks under the COVID-19 pandemic,Khadka,Sundar,ur.013326147525.61
10841,Bacterial and fungal isolation from face masks under the COVID-19 pandemic,Sato,Fumitaka,ur.01065104477.07
10841,Bacterial and fungal isolation from face masks under the COVID-19 pandemic,Hashiwaki,Kazuki,
10841,Bacterial and fungal isolation from face masks under the COVID-19 pandemic,Omura,Seiichi,ur.01064773256.01
10841,Bacterial and fungal isolation from face masks under the COVID-19 pandemic,Park,Ah-Mee,ur.01372700631.40
10841,Bacterial and fungal isolation from face masks under the COVID-19 pandemic,Fujita,Mitsugu,ur.016027322261.18
10791,Universal Masking in Hospitals in the Covid-19 Era,Sinclair,Julia,
10791,Universal Masking in Hospitals in the Covid-19 Era,Morris,Charles A,ur.07453146115.69
10791,Universal Masking in Hospitals in the Covid-19 Era,Shenoy,Erica S,ur.01206604356.00
10791,Universal Masking in Hospitals in the Covid-19 Era,Klompas,Michael,ur.0760071531.26
10791,Universal Masking in Hospitals in the Covid-19 Era,Pearson,Madelyn,ur.011046107115.18
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Team,COVID-19 Forecasting,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Coberly,Kaleb,ur.016515351162.15
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Byrne,Sam,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Vos,Theo,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Hulland,Erin N,ur.012127730655.85
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Pigott,David M,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Dalos,Jeremy,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Kinzel,Kasey E,ur.015766103762.72
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Nassereldine,Hasan,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Gakidou,Emmanuela,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Deen,Amanda,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Amlag,Joanne O,ur.010564445140.83
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Mokdad,Ali H,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Huntley,Bethany M,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Pham,Tom,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Stein,Caroline,ur.011032014526.11
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Bisignano,Catherine,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Reiner,Robert C,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Collins,James K,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Castro,Emma,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Sorensen,Reed J D,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Murray,Christopher J L,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Daoud,Farah,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Lozano,Rafael,ur.01352437070.24
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Hay,Simon I,ur.01107433531.31
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Giles,John R,
10789,Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis,Lim,Stephen S,
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Chavatte,Jean-Marc,ur.01364752670.80
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Mak,Tze-Minn,ur.01343535352.33
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Chiew,Calvin J,ur.013426731032.95
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Wang,Linfa,ur.01044121035.54
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Young,Barnaby Edward,ur.01054444555.60
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Lee,Vernon J,ur.0760054051.35
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Tan,Chee Wah,ur.01233310303.04
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Leo,Yee-Sin,ur.01057360426.59
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Tan,Seow Yen,ur.015454532033.95
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Chia,Po Ying,ur.015166322353.88
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Cui,Lin,ur.0723754433.61
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Chia,Wan Ni,ur.0620472632.66
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Ang,Li Wei,ur.011314147642.13
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Chai,Louis Yi Ann,ur.013012247202.29
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Lye,David Chien,ur.010714562317.26
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Lin,Raymond Tzer Pin,ur.011501270142.11
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Kalimuddin,Shirin,ur.0633106776.32
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Ong,Sean Wei Xiang,ur.010471027417.57
10705,Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study,Zheng,Shuwei,ur.013676555701.25
10696,Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report,Dewispelaere,Laurent,ur.011027700767.83
10696,Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report,Bron,Dominique,ur.01141604715.80
10696,Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report,Tousseyn,Thomas,ur.01303337457.76
10696,Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report,Goldman,Serge,ur.015374662172.27
10696,Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report,Cogan,Elie,ur.01176407177.35
10696,Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report,Vierasu,Irina,ur.01326676603.41
10696,Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report,Goldman,Michel,ur.01133254734.49
10696,Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report,Heimann,Pierre,ur.0627600777.79
10690,A study on infectivity of asymptomatic SARS-CoV-2 carriers,Gao,Ming,ur.016012151715.20
10690,A study on infectivity of asymptomatic SARS-CoV-2 carriers,Chen,Zixing,ur.07361055015.03
10690,A study on infectivity of asymptomatic SARS-CoV-2 carriers,Chen,Xuefu,ur.011477422115.46
10690,A study on infectivity of asymptomatic SARS-CoV-2 carriers,Yang,Lihui,ur.010104461115.03
10690,A study on infectivity of asymptomatic SARS-CoV-2 carriers,Xu,Hanyi,ur.016060265115.73
10690,A study on infectivity of asymptomatic SARS-CoV-2 carriers,Gao,Xinglin,ur.010754016015.07
10690,A study on infectivity of asymptomatic SARS-CoV-2 carriers,Deng,Yiyu,ur.0647576147.39
10690,A study on infectivity of asymptomatic SARS-CoV-2 carriers,Yang,Shifang,ur.014465324115.69
10662,Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant,Dorabawila,Vajeera,ur.0601477675.61
10662,Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant,Hoefer,Dina,ur.01221267667.35
10662,Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant,Bassett,Mary T.,ur.01241376077.77
10662,Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant,Lutterloh,Emily,ur.0576300304.23
10662,Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant,Rosenberg,Eli S.,ur.01316004736.66
10662,Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant,Bauer,Ursula E.,ur.01365567140.07
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Palich,Romain,ur.01144232161.98
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Maggi,Fabrizio,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Antinori,Andrea,ur.016207120157.75
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Florence,Eric,ur.01114233633.21
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Mussini,Cristina,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Nori,Achyuta,ur.0757203340.11
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Pintado,Claire,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Boesecke,Christoph,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Walmsley,Sharon,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Makofane,Keletso,ur.01124650362.33
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Pourcher,Valerie,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Hansen,Ann-Brit E.,ur.016616564162.48
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Klein,Marina B.,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Migaud,Pascal,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Sendagorta,Elena,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Vandekerckhove,Linos,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Lezama,Jezer I.,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Barkati,Sapha,ur.0706340720.77
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Tan,Darrell,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Hoffmann,Christian,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Harrison,Luke B.,ur.01307216365.25
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Yakubovsky,Michal,ur.010034740103.98
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Maltez,Fernando M.,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Blanco,Jose L.,ur.07602075252.07
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Goorhuis,Abraham,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Noe,Sebastian,ur.0622474522.33
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Reeves,Iain,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Habibi,Maximillian S.,ur.01311056276.25
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Rockstroh,Juergen,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Thornhill,John P.,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Apea,Vanessa,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Cattelan,AnnaMaria,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Moschese,Davide,ur.0737603042.86
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Nozza,Silvia,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Orkin,Chloe M.,
10621,Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022,Nemeth,Johannes,ur.0763560362.60
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Kumanogoh,Atsushi,ur.01244566417.20
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Arase,Hisashi,ur.016103316617.74
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Arase,Noriko,ur.01102046262.89
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Fujimoto,Manabu,ur.01204161315.51
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Nakai,Wataru,ur.0752261655.41
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Ono,Chikako,ur.0654110463.33
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Kato,Takayuki,ur.0751217431.96
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Standley,Daron M.,ur.0765571504.11
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Jin,Hui,ur.01217025134.11
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Li,Songling,ur.01143533606.45
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Okada,Masato,ur.010336404300.38
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Arakawa,Akemi,ur.012002577321.19
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Matsuura,Yoshiharu,ur.015706136162.56
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Kishikawa,Jun-ichi,ur.01346075627.07
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Akamatsu,Kanako,ur.010437423230.35
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Liu,Yafei,ur.016525437351.16
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Nakagawa,Atsushi,ur.011042354025.34
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Kishida,Kazuki,ur.01336477435.57
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Kohyama,Masako,ur.0677714745.06
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Tada,Asa,ur.011205216721.07
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Matsuoka,Sumiko,ur.0736421466.41
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Hirose,Mika,ur.01170624203.56
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Nakagami,Hironori,ur.01153005450.14
10600,The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines,Yamagishi,Yoshiaki,ur.0731477446.32
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Rajasingham,Radha,ur.0760317327.45
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Kelly,Lauren E,ur.0623747103.35
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Nicol,Melanie R,ur.01227136162.84
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Marten,Nicole,ur.013161702657.72
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,LaBar,Derek,
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Pastick,Katelyn A,ur.010353267002.86
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,MacKenzie,Lauren J,ur.01161135503.68
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Lee,Todd C,ur.01357623642.21
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Lofgren,Sarah M,ur.014227513073.51
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Engen,Nicole W,ur.016622331475.40
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Skipper,Caleb P,ur.014535360644.48
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Zarychanski,Ryan,ur.0617260043.47
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Cheng,Matthew P,ur.0763066411.12
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Nascene,Alanna A,ur.011457456377.29
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Drobot,Glen,ur.015324707105.32
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,McDonald,Emily G,ur.01115454076.06
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Lother,Sylvain A,ur.011700774373.13
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Abassi,Mahsa,ur.01273606205.20
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Bangdiwala,Ananta S,ur.01142142553.35
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Hullsiek,Kathy H,ur.014371414530.31
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Pullen,Matthew F,ur.01112602310.82
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Okafor,Elizabeth C,ur.011332706241.89
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Schwartz,Ilan S,ur.01227413622.61
10599,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,Boulware,David R,ur.01361554135.48
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Zhong,Jingchuan,ur.010411077173.15
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Zhang,Dingyu,ur.015256703335.14
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Luo,Jianfeng,ur.011167071467.31
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Liu,Min,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Ren,Lili,ur.01033321702.75
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Li,Xia,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Wang,Chen,ur.01206770537.35
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Cao,Bin,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Xie,Wuxiang,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Huang,Lixue,ur.013703020247.63
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Guo,Li,ur.01321416447.08
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Chen,Li,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Wang,Geng,ur.011050614307.56
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Huang,Zhenghui,ur.012457311535.96
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Xu,Decui,ur.015020467267.77
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Zhao,Yue,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Li,Caihong,ur.015731661753.20
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Fan,Guohui,ur.014755044646.73
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Peng,Lu,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Xu,Jiuyang,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Wang,Yeming,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Li,Yong,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Zhou,Xing,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Kang,Liang,ur.011126104633.98
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Huang,Chaolin,ur.011027413601.66
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Cui,Dan,ur.014262274132.15
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Gu,Xiaoying,ur.01323674617.33
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Li,Yanping,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Wang,Ying,
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Shang,Lianhan,ur.01224670515.65
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Tu,Shengjin,ur.014376161271.49
10530,6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,Wang,Jianwei,ur.010416750634.52
10527,The tangled history of mRNA vaccines,Dolgin,Elie,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Miller,Jacqueline,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Diemert,David,ur.01242002577.16
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Graham,Barney S,ur.01210715522.53
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Polakowski,Laura,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Schwartz,Howard,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Fierro,Carlos,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Mascola,John,ur.01270042052.88
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Segall,Nathan,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Han,Shu,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Zaks,Tal,ur.01235155252.39
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Janes,Holly,ur.01030703355.44
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Ivarsson,Melanie,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Brosz,Adam,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Leav,Brett,ur.01117301745.76
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Gilbert,Peter,ur.01055251367.37
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Follmann,Dean,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Zhou,Honghong,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Deng,Weiping,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Essink,Brandon,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Kotloff,Karen,ur.0705402071.41
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Creech,C Buddy,ur.0742031600.29
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Neuzil,Kathleen,ur.0761006623.40
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Corey,Larry,ur.015456006072.18
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Novak,Rick,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Khetan,Shishir,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,McGettigan,John,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Knightly,Conor,ur.016430536657.05
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,El Sahly,Hana M,ur.0704342267.05
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Bennett,Hamilton,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Rouphael,Nadine,ur.01360550342.49
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Marovich,Mary,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Solis,Joel,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Ledgerwood,Julie,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Frey,Sharon,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Baden,Lindsey R,ur.0750725460.01
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Spector,Stephen A,
10521,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,Pajon,Rolando,ur.01065164423.47
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Kim,Jieun,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Ryu,Boyeong,ur.01177222467.54
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Kim,Seong Sun,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Park,Young Joon,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Song,Jeongsuk,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Kim,Young-Man,ur.0673231253.00
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Choe,Young June,ur.01351440537.03
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Kweon,Sanghui,ur.01047272216.91
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Park,Ok,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Shin,Seung Hwan,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Kim,Hwami,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Jang,Yoon Suk,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Yi,Seonju,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Kim,Dongwook,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Yoo,Hyosoon,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Choi,Seung Woo,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Kim,Miyoung,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Jin,Yeowon,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Gwack,Jin,ur.01271307643.98
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Hyun,Junghee,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Woo,Yeonhee,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Jeon,Byoung-Hak,ur.010316104451.45
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Jeong,Eun Kyeong,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Center,Epidemiology and Case Management Team on behalf of the COVID-19 National Emergency Response,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Lee,Hyeyoung,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Kim,Hee Kyoung,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Park,Eunmi,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Park,Shin Young,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Lee,Jin,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Choi,Si Won,
10490,"Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC",Lee,Sangeun,
10489,COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign,Kirsch,Steve,ur.013275377632.55
10489,COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign,McCullough,Peter A,ur.016524005242.08
10489,COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign,Mead,M. Nathaniel,ur.015171772112.29
10489,COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign,Wolfinger,Russ,ur.011105056232.67
10489,COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign,Denhaerynck,Kris,ur.01174676234.43
10489,COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign,Rose,Jessica,ur.010036210353.24
10489,COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign,Seneff,Stephanie,ur.013114653342.26
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Shankar-Hari,Manu,ur.01242172705.25
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Channon,Keith M.,ur.01215026665.66
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Dixon,Sharon,ur.016707314172.43
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Coupland,Carol A. C.,ur.0635076355.31
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Harnden,Anthony,ur.015444577125.35
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Patone,Martina,ur.07760251517.54
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Hippisley-Cox,Julia,ur.01027557547.88
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Sheikh,Aziz,ur.01125214207.48
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Khunti,Kamlesh,ur.0641072534.04
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Mei,Xue W.,ur.011010116731.45
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Mills,Nicholas L.,ur.01052613263.54
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Watkinson,Peter,ur.01152420736.35
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Zaccardi,Francesco,ur.01360153731.10
10476,"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection",Handunnetthi,Lahiru,ur.0606603643.01
10465,Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China,Wu,Zunyou,ur.010031116537.26
10465,Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China,McGoogan,Jennifer M.,ur.0766370500.55
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Yuan,Zu-Yi,ur.01010246732.43
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Hepokoski,Mark,ur.0737743021.97
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Shadel,Gerald S.,ur.01370412312.65
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Yin,Qian,ur.014134556273.52
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Cho,Yoshitake,ur.01140552455.21
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Wang,Shengpeng,ur.01115661641.77
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Lei,Yuyang,ur.012400747245.04
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Andrade,Leonardo,ur.01114710701.03
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Zhang,Jiao,ur.0743664137.89
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Wang,Hongliang,ur.01305075435.14
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Manor,Uri,ur.01016322674.95
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,He,Ming,ur.0706455436.44
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Shyy,John Y-J.,ur.01020513763.11
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Zhang,Yichi,ur.016215451325.16
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Chen,Lili,ur.016666205373.32
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Lei,Ting,ur.015666355347.01
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Malhotra,Atul,ur.0575374141.00
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Schiavon,Cara R.,ur.010160670251.03
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Yuan,Jason X.-J.,ur.016407716147.47
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Zhang,Jin,ur.01154567611.18
10455,SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,Shen,Hui,ur.013665023677.16
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Van Vinh Chau,Nguyen,ur.01221731345.27
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Group,OUCRU COVID-19 Research,
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Yen,Lam Minh,ur.01120337050.41
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Anh,Nguyen To,
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Thwaites,Guy,ur.01135151135.80
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Tien,Nguyen Thi My,
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Phong,Nguyen Thanh,ur.015114563553.00
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Man,Dinh Nguyen Huy,ur.01206413640.26
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Dung,Nguyen Thanh,ur.014631702062.19
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Quang,Vo Minh,ur.01245271437.56
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Phat,Voong Vinh,ur.01336607676.76
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Truc,Nguyen Huynh Thanh,ur.014371215334.18
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Thao,Huynh Phuong,ur.010477141177.99
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Ho The Bao,,ur.015350316562.42
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Choisy,Marc,ur.01313526757.49
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Le Mau Toan,,
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Le Thi Tam Uyen,,
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Tai,Ngo Tan,ur.012543734703.80
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Nhung,Huynh Thi Kim,ur.016675765334.72
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Truong,Nguyen Thanh,ur.0663317740.16
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Tuyen,Nguyen Thi Kim,ur.0576371146.81
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Le Nguyen Truc Nhu,,ur.012544523073.03
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Ty,Dinh Thi Bich,ur.014734256303.52
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Tam,Tran Thi Thanh,
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Huy,Nguy Cam,ur.015355000634.65
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Nguyet,Lam Anh,
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Hong,Nguyen Thi Thu,
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Le Manh Hung,,ur.010021657131.84
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Khoa,Dao Bach,ur.0671336210.61
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",That,Bui Thi Ton,ur.016427141737.96
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Ngoc,Nghiem My,ur.0747010357.20
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Tu,Tran Nguyen Hoang,ur.011111722141.85
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Vuong,Vo Trong,ur.014136675703.86
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Thao,Tran Nguyen Phuong,ur.015463523503.44
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Ny,Nguyen Thi Han,
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Thanh,Tran Tan,
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Minh,Nguyen Thi Ngoc,
10449,"Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam",Le Van Tan,,
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Gorzalski,Andrew,ur.01306114457.33
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Jackson,David,ur.07424600637.47
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Tillett,Richard L,ur.0604343653.23
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Hartley,Paul D,ur.015674057453.86
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Verma,Subhash C,ur.014616475547.09
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Laverdure,Chris,ur.011637631527.56
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Pandori,Mark,ur.0616636161.68
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Van Hooser,Stephanie,ur.01356027731.81
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Crawford,Natalie,ur.013665354137.98
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Rossetto,Cyprian C,ur.01331523046.53
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Farrell,Megan J,ur.011017541637.32
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Sevinsky,Joel R,ur.011361327653.85
10426,Genomic evidence for reinfection with SARS-CoV-2: a case study,Kerwin,Heather,ur.012272413137.15
10419,Indoor transmission of SARS-CoV-2,Miao,Te,ur.011312326055.36
10419,Indoor transmission of SARS-CoV-2,Qian,Hua,ur.012453016665.88
10419,Indoor transmission of SARS-CoV-2,Zheng,Xiaohong,ur.01366315437.55
10419,Indoor transmission of SARS-CoV-2,Liu,Li,ur.011237663174.58
10419,Indoor transmission of SARS-CoV-2,Li,Yuguo,ur.01055536240.99
10419,Indoor transmission of SARS-CoV-2,Luo,Danting,ur.015562025071.15
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Chen,Yu,
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Cluver,Lucie,ur.01204305732.85
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Donnelly,Christl A,ur.01305160526.54
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Flaxman,Seth,ur.0640410710.66
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Sherr,Lorraine,ur.01321440243.14
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Rawlings,Laura,ur.015405701532.60
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Villaveces,Andrés,ur.01301257547.91
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Hillis,Susan D,ur.015360521217.92
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Nelson,Charles A,ur.01310632425.78
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Ratmann,Oliver,ur.0760341634.14
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Bhatt,Samir,ur.01306675612.93
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Goldman,Philip S,ur.01364670252.20
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Butchart,Alexander,ur.01042542215.53
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Bachman,Gretchen,ur.01103532663.09
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Green,Phil,ur.010232142773.63
10356,Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study,Unwin,H Juliette T,ur.012651002370.79
10287,"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness",Taylor,Bob,ur.013374002421.99
10287,"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness",Robertson,Chris,ur.010645627372.31
10287,"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness",McMenamin,Jim,ur.0752566006.99
10287,"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness",Sheikh,Aziz,ur.01125214207.48
10287,"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness",Collaborators,Public Health Scotland and the EAVE II,
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Lubenets,Nadezhda L,ur.014217323767.55
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Nikitenko,Natalia A,ur.01271474514.90
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Morozova,Lola F,ur.01331675117.40
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Gintsburg,Alexander L,ur.01025401416.89
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Zubkova,Olga V,ur.012317133513.16
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Shcherbinin,Dmitry N,ur.0676211633.27
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Botikov,Andrei G,ur.010317612767.36
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Shcheblyakov,Dmitry V,ur.01023565540.40
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Dzharullaeva,Alina S,ur.0717221603.78
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Logunov,Denis Y,ur.013400453014.35
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Esmagambetov,Ilias B,ur.0613537044.27
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Tukhvatullin,Amir I,ur.07454117167.71
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Egorova,Daria A,ur.010200566413.95
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Smolyarchuk,Elena A,ur.011220662101.12
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Favorskaya,Irina A,ur.01262710301.02
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Shmarov,Maksim M,ur.07704574167.11
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Grousova,Daria M,ur.011127543255.28
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Erokhova,Alina S,ur.013400504014.55
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Tokarskaya,Elizaveta A,ur.016677776513.42
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Simakova,Yana V,ur.014725130503.04
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Borisevich,Sergei V,ur.012740611367.66
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Zrelkin,Denis I,ur.012556247567.54
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Semikhin,Alexander S,ur.07636460767.47
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Kovyrshina,Anna V,ur.010365412723.34
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Naroditsky,Boris S,ur.0765430416.14
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Voronina,Daria V,ur.013466120623.80
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Izhaeva,Fatima M,ur.010061074133.30
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Kryukov,Evgeny V,
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Dolzhikova,Inna V,ur.0630076433.53
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Popova,Olga,ur.013305514767.59
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Ozharovskaya,Tatiana A,ur.014700455767.04
10276,"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia",Babira,Vladimir F,ur.015425125213.03
10208,Autopsy Histopathologic Cardiac Findings in 2 Adolescents Following the Second COVID-19 Vaccine Dose.,Duncanson,Emily,ur.011250203142.74
10208,Autopsy Histopathologic Cardiac Findings in 2 Adolescents Following the Second COVID-19 Vaccine Dose.,Tashjian,Randy,ur.010452622542.18
10208,Autopsy Histopathologic Cardiac Findings in 2 Adolescents Following the Second COVID-19 Vaccine Dose.,Gill,James R,ur.0623623177.07
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Cohn,Amanda,ur.01015137256.63
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Ritchey,Matthew,ur.016662260311.66
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",,,
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Gierke,Ryan,ur.01143507404.75
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Ellington,Sascha,ur.0677274441.07
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Chow,Nancy,ur.016054432671.94
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Bialek,Stephanie,ur.01304450426.55
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Reed,Nia,
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",,,
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Pilishvili,Tamara,ur.01367231565.17
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Dowling,Nicole,ur.01300573713.68
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Razzaghi,Hilda,ur.0643346134.51
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Boundy,Ellen,ur.01066271055.50
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",,,
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",MacNeil,Jessica,ur.01053207340.31
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Hall,Aron,ur.0732265520.71
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Sauber-Schatz,Erin,ur.01230642417.40
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Bowen,Virginia,ur.01034554525.87
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Peacock,Georgina,ur.01207243376.37
10194,"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020",Patel,Priti,
10191,Mobility network models of COVID-19 explain inequities and inform reopening,Leskovec,Jure,ur.014131712635.08
10191,Mobility network models of COVID-19 explain inequities and inform reopening,Chang,Serina,ur.013324676423.01
10191,Mobility network models of COVID-19 explain inequities and inform reopening,Grusky,David,ur.0650223654.54
10191,Mobility network models of COVID-19 explain inequities and inform reopening,Koh,Pang Wei,ur.01235301520.48
10191,Mobility network models of COVID-19 explain inequities and inform reopening,Redbird,Beth,ur.012716061517.36
10191,Mobility network models of COVID-19 explain inequities and inform reopening,Gerardin,Jaline,ur.01364575560.37
10191,Mobility network models of COVID-19 explain inequities and inform reopening,Pierson,Emma,ur.012121457037.56
10168,Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine,Rutherford,George W,ur.013173452305.46
10168,Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine,Gandhi,Monica,ur.0621775311.42
10130,COVID-19 rarely spreads through surfaces. So why are we still deep cleaning?,Lewis,Dyani,ur.0750460111.91
10104,Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US,Lyu,Wei,ur.011122021367.75
10104,Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US,Wehby,George L,ur.0576353746.22
10086,A case of fatal multi-organ inflammation following COVID-19 vaccination,Kurata,Hiromitsu,ur.011704245133.13
10086,A case of fatal multi-organ inflammation following COVID-19 vaccination,Tokunaga,Itsuo,ur.01164260754.52
10086,A case of fatal multi-organ inflammation following COVID-19 vaccination,Nushida,Hideyuki,ur.0755102643.41
10086,A case of fatal multi-organ inflammation following COVID-19 vaccination,Ito,Asuka,ur.015633124306.35
10086,A case of fatal multi-organ inflammation following COVID-19 vaccination,Iseki,Hirofumi,ur.011320374506.27
10086,A case of fatal multi-organ inflammation following COVID-19 vaccination,Umemoto,Hitomi,ur.01170143146.51
10086,A case of fatal multi-organ inflammation following COVID-19 vaccination,Nishimura,Akiyoshi,ur.01054335425.74
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,O’Halloran,Jane A.,ur.012117122514.96
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,Rauseo,Adriana M.,ur.012260452026.80
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,Ellebedy,Ali H.,ur.01240714756.18
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,Hansen,Lena,ur.07656463624.32
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,Goss,Charles W.,ur.010730753641.19
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,Presti,Rachel M.,ur.01005073641.61
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,Kim,Wooseob,ur.015625534373.10
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,Haile,Alem,ur.014615440767.54
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,Schmitz,Aaron J.,ur.012603730727.87
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,Turner,Jackson S.,ur.07616026727.34
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,Klebert,Michael K.,ur.016210401767.47
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,Pusic,Iskra,ur.0763451205.32
10061,SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,Kalaidina,Elizaveta,ur.012061005614.42
9999,RETRACTED ARTICLE: The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article,Zaidi,Asiya Kamber,ur.013104011422.23
9999,RETRACTED ARTICLE: The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article,Dehgani-Mobaraki,Puya,ur.01101513523.87
9955,"Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020",Ahmad,Farida B.,ur.014427246561.46
9955,"Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020",Sutton,Paul,ur.0744364622.06
9955,"Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020",Rossen,Lauren M.,ur.01077510533.62
9955,"Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020",Branum,Amy M.,ur.01052451531.07
9955,"Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020",Anderson,Robert N.,ur.0677745234.87
9927,Evidence for a connection between coronavirus disease-19 and exposure to radiofrequency radiation from wireless communications including 5G.,Brown,Robert R,
9927,Evidence for a connection between coronavirus disease-19 and exposure to radiofrequency radiation from wireless communications including 5G.,Rubik,Beverly,ur.0676576261.53
9889,Ivermectin for preventing and treating COVID‐19,Kranke,Peter,ur.0611354226.51
9889,Ivermectin for preventing and treating COVID‐19,Stegemann,Miriam,ur.010556426211.20
9889,Ivermectin for preventing and treating COVID‐19,Skoetz,Nicole,ur.01011101617.98
9889,Ivermectin for preventing and treating COVID‐19,Weibel,Stephanie,ur.01001125470.10
9889,Ivermectin for preventing and treating COVID‐19,Popp,Maria,ur.015410615535.48
9889,Ivermectin for preventing and treating COVID‐19,Gould,Susan,ur.011213662331.00
9889,Ivermectin for preventing and treating COVID‐19,Meybohm,Patrick,ur.01245055555.72
9889,Ivermectin for preventing and treating COVID‐19,Metzendorf,Maria-Inti,ur.0673646704.91
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Selvachandran,Somesh,ur.011500202133.63
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Chen,Liyuan,
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Steves,Claire J,ur.0624116417.81
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Ourselin,Sebastien,ur.0731256650.39
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Spector,Tim D,ur.014424006237.85
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Hammers,Alexander,ur.0622704043.68
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Polidori,Lorenzo,ur.013622410333.48
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Penfold,Rose S,ur.01207531644.11
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Graham,Mark S,ur.012242234421.59
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Murray,Benjamin,
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Canas,Liane S,ur.011150563134.84
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Hu,Christina,
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Österdahl,Marc F,ur.013211513365.51
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Modat,Marc,ur.01024265042.96
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Deng,Jie,
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Merino,Jordi,ur.0636004443.35
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Sudre,Carole H,ur.01023457345.27
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Pujol,Joan Capdevila,ur.011612413713.08
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Klaser,Kerstin,ur.014757717416.43
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Cheetham,Nathan J,ur.013226336667.11
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Berry,Sarah,
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Antonelli,Michela,
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Molteni,Erika,ur.0666071557.67
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Wolf,Jonathan,
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Duncan,Emma L,ur.01066220204.44
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Nguyen,Long H,ur.01315726247.16
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Drew,David A,ur.010536402121.69
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",May,Anna,
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Kerfoot,Eric,ur.01204520201.47
9877,"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study",Chan,Andrew T,ur.01012742716.99
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Bogaert,Debby,
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Hodcroft,Emma B,ur.0711545652.00
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Goldman,Lynn R,ur.0657466477.74
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Sridhar,Devi,ur.01333123514.93
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Yamey,Gavin,
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,McNally,Alan,ur.0760443116.97
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Nouri,Ali,ur.016101767055.13
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Priesemann,Viola,ur.01160643464.40
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Greenhalgh,Trisha,ur.0734302623.84
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Burgess,Rochelle Ann,ur.01052604342.29
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Hyde,Zoë,ur.01250055705.84
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,McKee,Martin,ur.01367673420.84
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Ziauddeen,Hisham,ur.01371624753.15
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Beale,Rupert,ur.01250034406.34
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Kelly-Irving,Michelle,ur.01216121733.10
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Hanage,William P,ur.01022047017.82
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Lipsitch,Marc,ur.0750403636.04
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Krammer,Florian,
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Eckerle,Isabella,ur.01332324706.32
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Alwan,Nisreen A,ur.016636522307.95
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Walensky,Rochelle P,ur.0723304767.87
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Hamdy,Adam,ur.015666154671.75
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Kellam,Paul,ur.01214773044.05
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Dowd,Jennifer,
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Bhadelia,Nahid,ur.0732715763.98
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Gurdasani,Deepti,ur.01342153057.51
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Silver,Joshua,
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Swanton,Charles,ur.0610422247.65
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Rutter,Harry,ur.0724550215.02
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Pimenta,Dominic,
9874,Scientific consensus on the COVID-19 pandemic: we need to act now,Ashworth,Simon,ur.012670370175.48
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Drosten,Christian,ur.010432516417.62
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Daszak,Peter,ur.01031576106.79
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Golding,Josie,ur.014330465151.88
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Mazet,Jonna,ur.014650763657.76
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Perlman,Stanley,ur.01307305176.50
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Field,Hume,ur.014522731762.92
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Poon,Leo,
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Subbarao,Kanta,ur.01365136616.70
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Farrar,Jeremy,ur.0640227120.31
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Corley,Ronald B,ur.0740045117.18
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Keusch,Gerald T,ur.01057377330.23
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Karesh,William B,ur.0667173364.03
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Madoff,Larry,ur.015127436023.14
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Mackenzie,John S,ur.0657704272.22
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Roizman,Bernard,
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Lubroth,Juan,ur.01366562024.09
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Haagmans,Bart,ur.015465550657.43
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Hughes,James M,
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Colwell,Rita,
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Gorbalenya,Alexander,ur.060350135.78
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Saif,Linda,
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Carroll,Dennis,
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Palese,Peter,
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Calisher,Charles,
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Enjuanes,Luis,ur.01135715410.45
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Lam,Sai Kit,ur.01034132376.55
9848,"Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19",Turner,Mike,
9790,It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19),Milton,Donald K,ur.0771763124.46
9790,It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19),Morawska,Lidia,ur.01150411026.43
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Valluri,Srinivas R,ur.0710402111.04
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Gray,Sharon,ur.0746254371.97
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Pan,Kaije,ur.07574412760.36
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Fischer,Heidi,ur.016130500615.10
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Slezak,Jeff M,ur.012332433624.92
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Ackerson,Bradley K,ur.0714063765.33
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Tartof,Sara Y,ur.01321346607.96
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Hong,Vennis,ur.011674320630.08
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Angulo,Frederick J,ur.0776560405.13
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,McLaughlin,John M,ur.01176414361.89
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Jodar,Luis,ur.01160352670.87
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Zamparo,Joann M,ur.014371103464.05
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Frankland,Timothy B,ur.013341247307.02
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Ogun,Oluwaseye A,ur.01046440610.06
9785,Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study,Ranasinghe,Omesh N,ur.015504660736.17
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Hui,David S C,ur.013176417252.14
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Zhu,Shao-Yong,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Xiang,Jie,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Qiu,Shao-Qin,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Zhong,Nan-Shan,ur.010176701342.18
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Lei,Chun-Liang,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,He,Jian-Xing,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Zeng,Guang,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Ye,Chang-Jiang,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Li,Gang,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Ni,Zheng-Yi,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Peng,Peng,ur.010423634125.12
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Wang,Tao,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Yuen,Kwok-Yung,ur.0652735016.56
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Li,Shi-Yue,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Zheng,Zhi-Jian,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Chen,Ru-Chong,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Wang,Jin-Lin,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Hu,Yu,ur.01347426606.33
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Liu,Yong,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Chen,Zhong,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Guan,Wei-Jie,ur.01074701510.82
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Peng,Yi-Xiang,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Shan,Hong,ur.01016630446.33
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Liang,Zi-Jing,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Li,Lan-Juan,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Ou,Chun-Quan,ur.01047604173.10
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Luo,Jie,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Chen,Ping-Yan,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Wei,Li,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Hu,Ya-Hua,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Wang,Jian-Ming,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Liu,Lei,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Liu,Ji-Yang,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Tang,Chun-Li,
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Du,Bin,ur.01332032602.93
9695,Clinical Characteristics of Coronavirus Disease 2019 in China,Liang,Wen-Hua,
9654,Outcomes of SARS-CoV-2 Reinfection,Xie,Yan,ur.0737732757.38
9654,Outcomes of SARS-CoV-2 Reinfection,Al-Aly,Ziyad,ur.0756001054.57
9654,Outcomes of SARS-CoV-2 Reinfection,Bowe,Benjamin,ur.0736221463.48
9606,Necessity of COVID-19 Vaccination in Persons who have Already had COVID-19,Terpeluk,Paul,ur.01276263071.17
9606,Necessity of COVID-19 Vaccination in Persons who have Already had COVID-19,Gordon,Steven M.,ur.014424253062.35
9606,Necessity of COVID-19 Vaccination in Persons who have Already had COVID-19,Nowacki,Amy S.,ur.01046134373.87
9606,Necessity of COVID-19 Vaccination in Persons who have Already had COVID-19,Burke,Patrick C.,ur.016236544425.44
9606,Necessity of COVID-19 Vaccination in Persons who have Already had COVID-19,Shrestha,Nabin K.,ur.014530171213.52
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Lagier,Jean-Christophe,ur.01004721606.00
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Honoré,Stéphane,ur.01015152417.03
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Chabrière,Eric,ur.01217027034.13
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Gautret,Philippe,ur.010522236477.17
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Giordanengo,Valérie,ur.01115224174.08
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Brouqui,Philippe,ur.01131114571.12
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Mailhe,Morgane,ur.01362130711.53
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Courjon,Johan,ur.01051410320.24
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Colson,Philippe,ur.01067702353.52
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Vieira,Vera Esteves,ur.011762543511.27
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Parola,Philippe,ur.01037660672.57
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Doudier,Barbara,ur.01043157515.40
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Meddeb,Line,ur.0766521615.58
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Raoult,Didier,ur.013145671557.48
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Tissot Dupont,Hervé,ur.01241224446.10
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Rolain,Jean-Marc,ur.0576561277.28
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,La Scola,Bernard,ur.01222300615.47
9604,Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,Hoang,Van Thuan,ur.015734404554.49
9586,First Case of 2019 Novel Coronavirus in the United States,Spitters,Christopher,
9586,First Case of 2019 Novel Coronavirus in the United States,Diaz,George,ur.016375424165.69
9586,First Case of 2019 Novel Coronavirus in the United States,Ericson,Keith,
9586,First Case of 2019 Novel Coronavirus in the United States,Tural,Ahmet,
9586,First Case of 2019 Novel Coronavirus in the United States,Wiesman,John,
9586,First Case of 2019 Novel Coronavirus in the United States,Bruce,Hollianne,ur.012612141565.23
9586,First Case of 2019 Novel Coronavirus in the United States,DeBolt,Chas,ur.01367616544.39
9586,First Case of 2019 Novel Coronavirus in the United States,Lofy,Kathy H,
9586,First Case of 2019 Novel Coronavirus in the United States,Pillai,Satish K,
9586,First Case of 2019 Novel Coronavirus in the United States,Holshue,Michelle L,ur.01370725533.36
9586,First Case of 2019 Novel Coronavirus in the United States,Kim,Lindsay,ur.01052761225.15
9586,First Case of 2019 Novel Coronavirus in the United States,Gerber,Susan I,ur.0577650272.59
9586,First Case of 2019 Novel Coronavirus in the United States,Uyeki,Timothy M,ur.016246174177.13
9586,First Case of 2019 Novel Coronavirus in the United States,Patel,Anita,
9586,First Case of 2019 Novel Coronavirus in the United States,Lindquist,Scott,ur.01054656411.50
9586,First Case of 2019 Novel Coronavirus in the United States,Lu,Xiaoyan,
9586,First Case of 2019 Novel Coronavirus in the United States,Biggs,Holly M,ur.01364200263.41
9586,First Case of 2019 Novel Coronavirus in the United States,Fox,LeAnne,
9586,First Case of 2019 Novel Coronavirus in the United States,Pallansch,Mark A,ur.01111264720.65
9586,First Case of 2019 Novel Coronavirus in the United States,Cohn,Amanda,
9586,First Case of 2019 Novel Coronavirus in the United States,Wilkerson,Sara,
9586,First Case of 2019 Novel Coronavirus in the United States,Lindstrom,Steve,
9586,First Case of 2019 Novel Coronavirus in the United States,Weldon,William C,ur.07367571027.66
9586,First Case of 2019 Novel Coronavirus in the United States,Tong,Suxiang,ur.01112726511.13
9538,Correlation Between Mask Compliance and COVID-19 Outcomes in Europe,Spira,Beny,ur.0647104054.72
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,Gerber,Susan I.,ur.0577650272.59
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,Gamble,Amandine,ur.07456113165.27
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,Tamin,Azaibi,ur.0730465355.70
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,Harcourt,Jennifer L.,ur.01131526114.79
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,Holbrook,Myndi G.,ur.010005564531.45
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,Thornburg,Natalie J.,ur.0606700201.50
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,Bushmaker,Trenton,ur.01255664334.11
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,Munster,Vincent J.,ur.01334105063.89
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,de Wit,Emmie,ur.01357410457.53
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,van Doremalen,Neeltje,ur.01364235606.88
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,Morris,Dylan H.,ur.016527372177.19
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,Williamson,Brandi N.,ur.013210433407.71
9535,Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1,Lloyd-Smith,James O.,ur.0755477044.60
9510,RETRACTED ARTICLE: Stay-at-home policy is a case of exception fallacy: an internet-based ecological study,Pumi,G.,ur.016155254453.18
9510,RETRACTED ARTICLE: Stay-at-home policy is a case of exception fallacy: an internet-based ecological study,Kunst,R.,ur.010747231577.00
9510,RETRACTED ARTICLE: Stay-at-home policy is a case of exception fallacy: an internet-based ecological study,Savaris,R. F.,ur.0704473055.47
9510,RETRACTED ARTICLE: Stay-at-home policy is a case of exception fallacy: an internet-based ecological study,Dalzochio,J.,ur.015515022347.27
9473,Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19,Chang,Amy,ur.010261375070.90
9473,Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19,Alejo,Jennifer L.,ur.01005224674.46
9473,Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19,Chiang,Teresa P. Y.,ur.010010134731.23
9473,Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19,Massie,Allan B.,ur.0766720321.91
9473,Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19,Mitchell,Jonathan,ur.010762607734.08
9473,Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19,Segev,Dorry L.,ur.01217305616.11
9473,Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19,Makary,Martin A.,ur.0734060716.73
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Dan,Jennifer M,ur.01265515227.13
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Krammer,Florian,ur.0615754253.47
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Carlin,Aaron F,ur.0674046076.97
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Marrama,Daniel,ur.07672376241.09
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Ramirez,Sydney I,ur.01067126700.43
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Premkumar,Lakshmanane,ur.01150126507.16
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Mateus,Jose,ur.010331064057.40
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Sette,Alessandro,ur.016527313277.78
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Moderbacher,Carolyn Rydyznski,ur.013407545441.26
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Crotty,Shane,ur.01312261077.26
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Smith,Davey M,ur.011615110604.77
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Peters,Bjoern,ur.07447331037.97
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Weiskopf,Daniela,ur.0602150374.89
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Greenbaum,Jason A,ur.01147567650.98
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Sutherland,Aaron,ur.010654151463.18
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Frazier,April,ur.01253340356.82
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Jadi,Ramesh S,ur.0603411113.33
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,de Silva,Aravinda M,ur.01230210257.19
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Rawlings,Stephen A,ur.01052460632.32
9436,Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals,Grifoni,Alba,ur.01314176576.29
9428,Face masks effectively limit the probability of SARS-CoV-2 transmission,Ma,Nan,ur.013452245362.18
9428,Face masks effectively limit the probability of SARS-CoV-2 transmission,Andreae,Meinrat O,ur.01246537155.46
9428,Face masks effectively limit the probability of SARS-CoV-2 transmission,Pöschl,Ulrich,ur.01233116263.36
9428,Face masks effectively limit the probability of SARS-CoV-2 transmission,Rapp,Steffen,ur.01227213725.12
9428,Face masks effectively limit the probability of SARS-CoV-2 transmission,Wild,Philipp S,ur.01153221560.54
9428,Face masks effectively limit the probability of SARS-CoV-2 transmission,Cheng,Yafang,ur.0677546167.23
9428,Face masks effectively limit the probability of SARS-CoV-2 transmission,Witt,Christian,ur.07405301723.37
9428,Face masks effectively limit the probability of SARS-CoV-2 transmission,Su,Hang,ur.01306723667.24
9390,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,Darley,David R.,ur.01173240321.37
9390,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,Burrell,Louise M.,ur.01104715537.24
9390,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,Munier,C. Mee Ling,ur.0616214526.65
9390,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,Phetsouphanh,Chansavath,ur.0620020406.19
9390,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,Juno,Jennifer A.,ur.01255501013.30
9390,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,Wilson,Daniel B.,ur.012203156642.96
9390,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,Howe,Annett,ur.0676015035.15
9390,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,Patel,Sheila K.,ur.01362127111.32
9390,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,Dore,Gregory J.,ur.016460625577.77
9390,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,Kelleher,Anthony D.,ur.010073114737.96
9390,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,Matthews,Gail V.,ur.01167443654.10
9390,Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection,Kent,Stephen J.,ur.016400433202.30
9358,Considerations in boosting COVID-19 vaccine immune responses,Henao-Restrepo,Ana-Maria,ur.016210655523.53
9358,Considerations in boosting COVID-19 vaccine immune responses,Higgins,Julian P T,ur.01164572174.67
9358,Considerations in boosting COVID-19 vaccine immune responses,Rees,Helen,ur.01236160743.30
9358,Considerations in boosting COVID-19 vaccine immune responses,Boutron,Isabelle,ur.01072011676.03
9358,Considerations in boosting COVID-19 vaccine immune responses,Gaspar,Rogerio,ur.015141275755.50
9358,Considerations in boosting COVID-19 vaccine immune responses,Arora,Narendra,ur.0755120671.15
9358,Considerations in boosting COVID-19 vaccine immune responses,Krause,Philip R,ur.01333564071.30
9358,Considerations in boosting COVID-19 vaccine immune responses,Fleming,Thomas R,ur.015246340032.74
9358,Considerations in boosting COVID-19 vaccine immune responses,Cravioto,Alejandro,ur.01054116134.41
9358,Considerations in boosting COVID-19 vaccine immune responses,Pan,Hongchao,ur.0702153606.07
9358,Considerations in boosting COVID-19 vaccine immune responses,Ryan,Michael J,ur.012541333661.72
9358,Considerations in boosting COVID-19 vaccine immune responses,Peto,Richard,ur.0611006023.05
9358,Considerations in boosting COVID-19 vaccine immune responses,Gruber,Marion F,ur.01151042106.29
9358,Considerations in boosting COVID-19 vaccine immune responses,Swaminathan,Soumya,ur.01017756724.35
9358,Considerations in boosting COVID-19 vaccine immune responses,Kazi,Fatema,
9358,Considerations in boosting COVID-19 vaccine immune responses,Longini,Ira M,ur.0642222407.69
9358,Considerations in boosting COVID-19 vaccine immune responses,Figueroa,J Peter,ur.01124712610.07
9358,Considerations in boosting COVID-19 vaccine immune responses,Sterne,Jonathan A C,ur.013231735677.15
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Alroy-Preis,Sharon,ur.01061334326.15
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Angulo,Frederick J,ur.0776560405.13
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Pan,Kaijie,ur.01012435746.38
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Mircus,Gabriel,ur.01345261210.90
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Haas,Eric J,ur.01132143134.04
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Brooks,Nati,ur.015763767521.91
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Khan,Farid,ur.012460373364.66
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",McLaughlin,John M,ur.01176414361.89
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Levy,Yeheskel,ur.011517353121.44
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Southern,Jo,ur.01221772520.19
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Singer,Shepherd R,ur.015155253562.16
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Anis,Emilia,ur.01263023362.59
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Swerdlow,David L,ur.01022172145.03
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Smaja,Meir,
9308,"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data",Jodar,Luis,ur.01160352670.87
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Chen,Xiaohong,
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Duan,Shengbao,ur.0740361641.05
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Chen,Yezhou,ur.0762215245.36
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Meng,Qinglin,ur.0637367446.16
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Yu,Nong,
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Li,Yong,ur.01305265241.25
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Wei,Shuangshi,ur.0672246441.45
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Wang,Hongmei,ur.0714102045.25
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Ding,Shaohua,ur.01030330445.18
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Zhang,Xinglin,
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Ge,Pingju,ur.014135062517.29
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Xie,Jinsong,
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Liu,Xiaomei,ur.01330164567.21
9307,Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2,Tian,Jingjing,ur.01144557045.79
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Low,Lee Lee,ur.016303225161.75
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Hwong,Wen Yea,ur.013476247305.33
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Teh,Keng Long,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lee,Kee Tat,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohamed,Shafarul Halimi,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chandra Kumar,Logadharshini,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Kamaruddin,Siti Izzatul Annis,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Khalid,Khairil Erwan,ur.012572270243.89
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lim,Mei San,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Thong,Kah Mean,ur.01176071704.00
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Yap,Chun Fei,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohd Zahari,Muhammad Ariffadilah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Wong,Zhun Han,ur.016267004660.15
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Abdul Wahid,Nabilah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Hamidi,Muhammad Syafiq,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Tang,Xing Yi,ur.011261163041.23
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohamad Rasli,Mohd Hafiz,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Tay,Kim Heng,ur.014137243405.28
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohamed Nor,Lisa,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ismail,Nadiah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Teoh,Yee Jie,ur.010203311162.16
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohd Suan,Mohd Azri,ur.01352364711.54
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Tew,Mei Mei,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Seman,Noraini,ur.012630441350.22
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Cheng,Joo Thye,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Devesahayam,Philip Rajan,ur.012237327411.71
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Viswanathan,Thilagavathi Thanusia,ur.010112772525.67
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lee,Yi Lin,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Leong,Chee Loon,ur.01231000302.16
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ow,Ji Ken,ur.012075042362.34
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Syed Alwi,Syed Omar Farouk,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chee,Yun Lee,ur.010421265313.50
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Syed Badaruddin,Syarifah Nurul Ain,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Narayanan,Lavanya,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Raja Lope Ahmad,Raja Ahmad Reza,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Bidin,Farah Nadiah,ur.011007130261.38
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Raja Nahar Putra,Raja Nurulain,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Supparmaniam,Prathiv,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lekh Raj Sharma,Viknesh Dev,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ahmad Zubaidi,Aisyah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chin,Mann Leon,ur.015141665522.15
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Kamaludeen,Shaharudeen,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Wong,E Jinq,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohan Raja,Darshinnee,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Shamsuddin,Amira Naziffa,ur.011773366741.55
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Muniandy,Balasurindiran,ur.012026727162.01
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Leong,Kar Nim,ur.0602145064.20
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Wan Zainudin,Wan Mohd Khairul,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohd Mustapha,Nur Syuhada,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Jaafar,Noorfarzlina,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Razali,Muhammad Hazazi,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Arokisamy,Jennifer,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ampalakan,Iswaran,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Peariasamy,Kalaiarasu M.,ur.010046337121.69
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lim,Yi Fang,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Voo,James Yau Hon,ur.012456557672.15
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Gopalakrishnan,Prethivan Pillai,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Rajantran,Shageetha,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ismail,Ismaliza,ur.0610676321.49
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Jaya Selan,Sangeetha,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Othman Andu,Delarina Frimawati,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lim,Steven Chee Loon,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Tan,Wen Hao,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Guan,Han Lin,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mah Hassan,Nur Suriana,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Kamarudin,Nurnadiah,ur.07454043762.30
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Pathmanathan,Mohan Dass,ur.016262021055.61
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Tan,Shin Wuei,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Hanafi,Muhammad Na'imuddin'alim,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Cheah,Wee Kooi,ur.0716257411.18
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Kum,Yik Zhi,ur.015427647762.07
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Prabhaharan,Ambika Nair,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lee,Siew Huang,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohd Hassan,Puteri Amira,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lim,Chit Yeh,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Tay,Eek Poei,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Muthi,V. Rubini Nair,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ko,Andy Tze Yang,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Rasliza,Ruhaizad,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,R Selvarajah,Dariel,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Huang,Poh Ching,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ang,Wei Chern,ur.011030022057.68
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Embok Ungah,Nurul Atiqah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Gemini,Kalaiarasan,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chuah,Chuan Huan,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Choong,Khai Sin,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Khuan,Jen Fai,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lim,Yen Li,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Saw,Pamela Varn Teing,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ravi,Tharmini,ur.011752777562.06
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Teow,Sheng Hao,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chen,Wendy Tyng Tyng,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Retnasamy,Jasmine,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Abdul Rashid,Wan Nur Farra’Ain,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Hamzah,Muhammad Luqman,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Vijayasingham,Shalini,ur.013170273252.01
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Abdullah,Rafidah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Santokh Singh,Thaanveer Singh,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Supramaniam,Thamarai,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Yusoff,Mohd Yusran,ur.07515620260.29
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Wong,Peng Shyan,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Murat,Mohamad Shamirul Afiq,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Othman,Mohd Khairi,ur.014102253704.45
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Domnic,Gregory,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Anuar,Amalina,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Koh,Hui Moon,ur.011770351547.35
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ngua,Ching Zin,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Phua,Sook Hui,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Abdullah,Ammar Rashidi,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Abdul Mutalib,Nurul Miza Shasheiha,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Tuan Mat,Tuan Norhafiza,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Jeevaraj,Lavanya,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ishak,Khairul Nisa',
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Tuan Ismail @Tuan Manah,Tuan Muhd Fairuz,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Izhar,Izarin Izmir,ur.010260312701.26
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohd Unit,Hazfadzila,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Abu Bakar Sayuti,Asma Usa’diyah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Wong,Jeanette Qiu Yi,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohd Zin,Ahmad Fikhri,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lee,Kok Soon,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lee,Tung Meng,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Bahrudin,Mohd Fyzal,ur.012300105247.34
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,King,Teck Long,ur.012524275005.68
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Low,Ee Vien,ur.010611263367.22
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chew,Ee Lin,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ab Wahab,Suhaila,ur.010534153460.90
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Roslan,Zulaika,ur.013077134440.10
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ooi,Cheng Lee,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Izhar Hisham,Syaza,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Thong,Kah Shuen,ur.014051373227.19
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chidambaram,Suresh Kumar,ur.016041271630.05
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Tengku,Muhammad Fursanallah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Kong,Kent Kian Keong,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ng,Ru Shing,ur.01041636412.51
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Song,Li Herng,ur.015063207531.89
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chun,Siew Theng,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohd Nadzir,Sharmila,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Jamaludin,Mohd Akmal,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Low,One Ling,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Goh,Kiam Seong,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Kaisbain,Neerusha,ur.013533610471.30
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ahmad Shanizza,Qhairyl Iylman,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Khoo,Song Weng Ryan,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ker,Hong Bee,ur.07717063313.55
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Leong,Caryn Jia Wern,ur.013463444460.23
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Soh,Yih Harng,ur.07421537121.45
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mat Jelani,Anilawati,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohd Mansor,Syafiqah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mahamad Azazis,Muhammad Syafiq,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chow,Ting Soo,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohd Shukri,Nor Atikah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Yah,Lin Ye,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Wahab,Noor Hidayu,ur.010672172262.24
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ang,Jian-Gang,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Loo,Wai Yang,ur.014144576460.48
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ismail,Ibtisam,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Teoh,Sze Kye,ur.012214440774.50
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Nasruddin,Azraai Bahari,ur.01206416740.02
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Kang,Huan Yean,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Krishnan,Kesavathy,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mushaddik,Irma Liyana,ur.013563403673.32
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Loh,Jia Hui,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Wong,Chee Kong,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lai,Nai Ming,ur.0770044474.62
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Purusothman,Peacchaima,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Choo,Xin Hui,ur.014467202301.84
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Tan,Kok Tong,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohd Shohaime,Nabilah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Hamdan,Nor Syahirah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Zaid,Masliza,ur.01302473231.56
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Saat,Nurul Hasanah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Zaidan,Nor Zaila,ur.016500166652.97
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Hor,Chee Peng,ur.0607670675.80
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ibrahim,Khairul Azmi,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Zainal Abidin,Azrin Nurfarahin,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohamed Yusoff,Ahmad Lutfi,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Khoo,Pei Jie,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ooi,Calvin Gim Seong,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Gunaraj,Daleni,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Sidek,Norsima Nazifah,ur.01044345523.07
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ad Suhadak,Husna,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Sayed Sahul Hamid Gani,Mohammad,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chang,Andrew Kean Wei,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ooi,Way Ti,ur.010463602441.79
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chaw,Chun Lian,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Beh,Boon Cong,ur.012325213301.49
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lim,Kah Chuan,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Nadarajan,Reshaini,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Zainol,Mohamad Izwan,ur.013426640467.96
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Liew,Boon Seng,ur.011703127417.02
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chan,Yew Chung,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ramadas,Anitha,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Sarban Singh,Karamjit Kaur,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Tiong,Xun Ting,ur.014560744222.10
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Thung,Su Fui,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohd Noor,Maizatul Akmal,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Harun,Rozila,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lingam,Rakesh,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Muthusamy,Shanthini,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Abdul Rani,Siti Norizan,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohamad,Zulkefli,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lim,Han Hua,ur.016525611671.36
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Wong,Kee Cheong,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Teoh,Lee Rhui,ur.013574031760.00
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Arumugam,Minalosani,ur.07401371660.45
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Md Tahir,Siti Hir Huraizah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Sim,Pearly Kim Aik,ur.016277502267.42
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ayub,Ainun Jariah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Othman,Nurul Huda,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Perumalu,Kunaraj,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chua,Kin Wei,ur.014524012440.29
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chan,Kam Veng,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ab Rahman,Mazilah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Abu Salim,Seri Rabiatul Nur,ur.015351334560.10
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chan,Yon Quan,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Murugan,Hemaarubeni,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Natarajan,Peter Andrew,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Ibrahim,Nur Munirah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Mohd Unit,Hazfadzila,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Vun,Lee Kuen,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Lee,Soon Leng,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Chua,Hock Hin,ur.016216150325.16
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,An,Noralfazita,ur.010445537221.48
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Burahan,Haslina,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Zakaria,Siti Sha’ada,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Zaharudin,Nur Shakirah,
9294,Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities,Aminuddi,Irdina,
9247,More than 50 long-term effects of COVID-19: a systematic review and meta-analysis,Perelman,Carol,ur.013656730265.31
9247,More than 50 long-term effects of COVID-19: a systematic review and meta-analysis,Sepulveda,Rosalinda,ur.0676515206.60
9247,More than 50 long-term effects of COVID-19: a systematic review and meta-analysis,Villapol,Sonia,ur.0704206665.91
9247,More than 50 long-term effects of COVID-19: a systematic review and meta-analysis,Cuapio,Angelica,ur.01165454157.98
9247,More than 50 long-term effects of COVID-19: a systematic review and meta-analysis,Lopez-Leon,Sandra,ur.01160110130.16
9247,More than 50 long-term effects of COVID-19: a systematic review and meta-analysis,Wegman-Ostrosky,Talia,ur.0606243464.48
9247,More than 50 long-term effects of COVID-19: a systematic review and meta-analysis,Rebolledo,Paulina A.,ur.01122672223.09
9213,Cognitive deficits in people who have recovered from COVID-19,Patrick,Fiona,ur.013375751717.37
9213,Cognitive deficits in people who have recovered from COVID-19,Grant,Jon E.,ur.01112527053.52
9213,Cognitive deficits in people who have recovered from COVID-19,Chamberlain,Samuel R,ur.01052452375.41
9213,Cognitive deficits in people who have recovered from COVID-19,Jolly,Amy E.,ur.015313607635.58
9213,Cognitive deficits in people who have recovered from COVID-19,Mazibuko,Ndaba,ur.010456163117.74
9213,Cognitive deficits in people who have recovered from COVID-19,Trender,William,ur.015675554467.65
9213,Cognitive deficits in people who have recovered from COVID-19,Hampshire,Adam,ur.01113744141.77
9213,Cognitive deficits in people who have recovered from COVID-19,Mehta,Mitul A,ur.0707731033.92
9213,Cognitive deficits in people who have recovered from COVID-19,Williams,Steve CR,ur.015032043474.03
9213,Cognitive deficits in people who have recovered from COVID-19,Barnby,Joseph M,ur.01254126013.68
9213,Cognitive deficits in people who have recovered from COVID-19,Hellyer,Peter,ur.01033574204.74
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Chang,Karen T.,ur.011354642013.41
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Shah,Jaina A.,
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Szablewski,Christine M.,ur.0636427150.44
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Kirking,Hannah L.,ur.01207235456.14
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Stewart,Rebekah J.,ur.016640073627.11
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Mohammed,Asfia,
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Schwartz,Noah G.,ur.01175057401.46
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Tate,Jacqueline E.,ur.01117172520.09
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Mayweather,Erin,
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Dirlikov,Emilio,ur.01353454405.16
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Lumsden,Maranda,
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",McDaniel,Clinton J.,ur.012162541117.19
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Brown,Marie M.,ur.012152222413.47
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Lanzieri,Tatiana M.,ur.0662233523.04
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Montierth,Robert,
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Yousaf,Anna R.,ur.013545163413.32
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Aryee,Peter A.,
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Drenzek,Cherie,ur.0662331351.38
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Chu,Victoria T.,ur.012747603013.40
9205,"SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020",Anyalechi,Ndubuisi,
9198,Dexamethasone in Hospitalized Patients with Covid-19,Linsell,Louise,
9198,Dexamethasone in Hospitalized Patients with Covid-19,Chappell,Lucy C,ur.0640761653.38
9198,Dexamethasone in Hospitalized Patients with Covid-19,Montgomery,Alan,ur.0615610741.77
9198,Dexamethasone in Hospitalized Patients with Covid-19,Horby,Peter,ur.01006107443.13
9198,Dexamethasone in Hospitalized Patients with Covid-19,Jeffery,Katie,ur.0740113744.45
9198,Dexamethasone in Hospitalized Patients with Covid-19,Mafham,Marion,ur.0602774577.44
9198,Dexamethasone in Hospitalized Patients with Covid-19,Lim,Wei Shen,ur.012720025352.64
9198,Dexamethasone in Hospitalized Patients with Covid-19,Juszczak,Edmund,ur.01100071474.12
9198,Dexamethasone in Hospitalized Patients with Covid-19,Brightling,Christopher,
9198,Dexamethasone in Hospitalized Patients with Covid-19,Rege,Kanchan,ur.014351350277.65
9198,Dexamethasone in Hospitalized Patients with Covid-19,Landray,Martin J,ur.01055716346.74
9198,Dexamethasone in Hospitalized Patients with Covid-19,Jaki,Thomas,ur.01244503315.04
9198,Dexamethasone in Hospitalized Patients with Covid-19,Staplin,Natalie,ur.0625132654.06
9198,Dexamethasone in Hospitalized Patients with Covid-19,Rowan,Kathryn,ur.010700674464.41
9198,Dexamethasone in Hospitalized Patients with Covid-19,Bell,Jennifer L,
9198,Dexamethasone in Hospitalized Patients with Covid-19,Ustianowski,Andrew,ur.016002143770.89
9198,Dexamethasone in Hospitalized Patients with Covid-19,Haynes,Richard,ur.0705124452.81
9198,Dexamethasone in Hospitalized Patients with Covid-19,Green,Christopher,ur.0603753333.19
9198,Dexamethasone in Hospitalized Patients with Covid-19,Faust,Saul N,ur.0727576315.70
9198,Dexamethasone in Hospitalized Patients with Covid-19,Prudon,Benjamin,
9198,Dexamethasone in Hospitalized Patients with Covid-19,Baillie,J Kenneth,ur.01174436654.78
9198,Dexamethasone in Hospitalized Patients with Covid-19,Felton,Timothy,
9198,Dexamethasone in Hospitalized Patients with Covid-19,Elmahi,Einas,ur.013310232176.09
9198,Dexamethasone in Hospitalized Patients with Covid-19,Chadwick,David,ur.01167720002.71
9198,Dexamethasone in Hospitalized Patients with Covid-19,Fegan,Christopher,ur.016125252357.00
9198,Dexamethasone in Hospitalized Patients with Covid-19,Emberson,Jonathan R,ur.01203752460.78
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Milagres,Aline Cruz,ur.011472652325.66
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Callegari,Eduardo Diniz,ur.016521555770.15
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Harari,Ofir,ur.014473657624.43
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Savassi,Leonardo Cançado Monteiro,ur.013575413710.95
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Simplicio,Maria Izabel Campos,ur.013065613325.10
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Glushchenko,Alla V,ur.014711215414.78
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",dos Santos Moreira-Silva,Eduardo Augusto,ur.01053600442.22
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Nogueira,Ana Maria Ribeiro,
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Reis,Gilmar,ur.01171607346.41
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Lenze,Eric J,ur.01332734075.53
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Oliveira,Rosemary,
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Ferreira,Thiago Santiago,ur.015252315322.46
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",de Figueiredo Neto,Adhemar Dias,ur.010347752175.29
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Ribeiro,Luciene Barra,ur.013663173725.36
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",de Almeida,Ana Paula Figueiredo Guimaraes,
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",investigators,for the TOGETHER,
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Reiersen,Angela M,ur.01305431771.28
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Rayner,Craig R,ur.01371760723.88
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Guyatt,Gordon H,ur.0773167774.48
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Ruton,Hinda,ur.01272116662.36
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Sprague,Sheila,ur.01300410160.40
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Thabane,Lehana,ur.016443325203.30
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Silva,Daniela Carla Medeiros,ur.015460062375.98
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",dos Santos,Castilho Vitor Quirino,ur.016255442775.21
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Forrest,Jamie I,
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",Mills,Edward J,ur.01070350152.95
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",de Souza Campos,Vitoria Helena,ur.013436216464.62
9194,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",McKay,Paula,ur.01116447251.24
9136,High Temperature and High Humidity Reduce the Transmission of COVID-19,Tang,Ke,
9136,High Temperature and High Humidity Reduce the Transmission of COVID-19,Wang,Jingyuan,
9136,High Temperature and High Humidity Reduce the Transmission of COVID-19,Lv,Weifeng,
9136,High Temperature and High Humidity Reduce the Transmission of COVID-19,Feng,Kai,
9123,Inferring the effectiveness of government interventions against COVID-19,Norman,Alexander John,ur.014077343513.60
9123,Inferring the effectiveness of government interventions against COVID-19,Mikulik,Vladimir,ur.010154436377.25
9123,Inferring the effectiveness of government interventions against COVID-19,Gavenčiak,Tomáš,ur.010563673711.46
9123,Inferring the effectiveness of government interventions against COVID-19,Stephenson,Anna B,ur.013442341721.06
9123,Inferring the effectiveness of government interventions against COVID-19,Leech,Gavin,ur.015260705477.53
9123,Inferring the effectiveness of government interventions against COVID-19,Altman,George,ur.016653646477.34
9123,Inferring the effectiveness of government interventions against COVID-19,Ge,Hong,ur.013221465211.27
9123,Inferring the effectiveness of government interventions against COVID-19,Sharma,Mrinank,ur.010700042477.65
9123,Inferring the effectiveness of government interventions against COVID-19,Kulveit,Jan,ur.0704352143.45
9123,Inferring the effectiveness of government interventions against COVID-19,Salvatier,John,ur.011105704213.20
9123,Inferring the effectiveness of government interventions against COVID-19,Brauner,Jan M,ur.01247420130.51
9123,Inferring the effectiveness of government interventions against COVID-19,Mindermann,Sören,ur.015042015475.64
9123,Inferring the effectiveness of government interventions against COVID-19,Gal,Yarin,ur.010562303320.20
9123,Inferring the effectiveness of government interventions against COVID-19,Besiroglu,Tamay,ur.010016554531.02
9123,Inferring the effectiveness of government interventions against COVID-19,Johnston,David,ur.013665744477.12
9123,Inferring the effectiveness of government interventions against COVID-19,Teh,Yee Whye,ur.012725616466.05
9123,Inferring the effectiveness of government interventions against COVID-19,Hartwick,Meghan A,ur.011032443337.87
9123,Inferring the effectiveness of government interventions against COVID-19,Monrad,Joshua Teperowski,ur.010544622607.79
9123,Inferring the effectiveness of government interventions against COVID-19,Chindelevitch,Leonid,ur.01012765363.27
9070,Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa,von Gottberg,Anne,ur.0731567025.04
9070,Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa,Groome,Michelle J.,ur.01173734524.78
9070,Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa,Mlisana,Koleka,ur.013651367133.55
9070,Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa,Dushoff,Jonathan,ur.0710610176.82
9070,Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa,van Schalkwyk,Cari,ur.0667630645.67
9070,Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa,Govender,Nevashan,ur.01110241044.33
9070,Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa,Cohen,Cheryl,ur.01077665046.14
9070,Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa,Moultrie,Harry,ur.01211705764.13
9070,Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa,Pulliam,Juliet R.C.,ur.01003773403.60
9009,The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission,Bax,Christina E,ur.014233434131.43
9009,The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission,Bax,Adriaan,ur.011324007057.32
9009,The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission,Anfinrud,Philip,ur.01322163327.22
9009,The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission,Stadnytskyi,Valentyn,ur.0673220022.43
8998,The Leading Causes of Death in the US for 2020,Ahmad,Farida B,ur.014427246561.46
8998,The Leading Causes of Death in the US for 2020,Anderson,Robert N,ur.0677745234.87
8990,Assessment of Myocardial 18F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2-vaccinated and Nonvaccinated Patients.,Miyazawa,Raita,ur.013026202452.13
8990,Assessment of Myocardial 18F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2-vaccinated and Nonvaccinated Patients.,Narula,Jagat,
8990,Assessment of Myocardial 18F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2-vaccinated and Nonvaccinated Patients.,Tonda,Kai,ur.012601172276.22
8990,Assessment of Myocardial 18F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2-vaccinated and Nonvaccinated Patients.,Jinzaki,Masahiro,ur.01362623133.24
8990,Assessment of Myocardial 18F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2-vaccinated and Nonvaccinated Patients.,Antoniades,Charalambos,ur.01134002444.30
8990,Assessment of Myocardial 18F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2-vaccinated and Nonvaccinated Patients.,Nakahara,Takehiro,ur.0631021003.96
8990,Assessment of Myocardial 18F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2-vaccinated and Nonvaccinated Patients.,Shiga,Tohru,ur.014174133276.70
8990,Assessment of Myocardial 18F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2-vaccinated and Nonvaccinated Patients.,Strauss,H William,ur.01127776011.61
8990,Assessment of Myocardial 18F-FDG Uptake at PET/CT in Asymptomatic SARS-CoV-2-vaccinated and Nonvaccinated Patients.,Iwabuchi,Yu,ur.012322042267.53
8962,The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application,Lauer,Stephen A,ur.01105155330.57
8962,The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application,Bi,Qifang,ur.01212204137.56
8962,The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application,Lessler,Justin,ur.0775017522.46
8962,The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application,Meredith,Hannah R,ur.016527252751.15
8962,The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application,Zheng,Qulu,ur.011053722021.50
8962,The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application,Grantz,Kyra H,ur.07636400475.34
8962,The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application,Jones,Forrest K,ur.010256341421.49
8962,The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application,Reich,Nicholas G,ur.01261453404.52
8962,The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application,Azman,Andrew S,ur.01153520222.87
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Zange,Sabine,ur.0667147020.04
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Vollmar,Patrick,ur.0621033620.86
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Wölfel,Roman,ur.01011523753.14
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Froeschl,Guenter,ur.01013360622.01
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Hoelscher,Michael,ur.0775601074.81
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Janke,Christian,ur.01021365515.24
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Wallrauch,Claudia,ur.010020740124.47
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Zimmer,Thorbjörn,ur.012605231645.14
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Seilmaier,Michael,ur.01076545541.08
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Thiel,Verena,ur.015573133645.57
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Drosten,Christian,ur.010432516417.62
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Schunk,Mirjam,ur.0662462212.10
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Rothe,Camilla,ur.01307554615.45
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Bretzel,Gisela,ur.01363117570.63
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Zwirglmaier,Katrin,ur.01314277614.98
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Sothmann,Peter,ur.0636253431.89
8957,Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany,Guggemos,Wolfgang,ur.01212774141.45
8942,First case of postmortem study in a patient vaccinated against SARS-CoV-2,Schulz,Birte,ur.012105620071.54
8942,First case of postmortem study in a patient vaccinated against SARS-CoV-2,Tebbe,Johannes Josef,ur.01172561350.45
8942,First case of postmortem study in a patient vaccinated against SARS-CoV-2,Titze,Ulf,ur.01001004624.09
8942,First case of postmortem study in a patient vaccinated against SARS-CoV-2,Kulamadayil-Heidenreich,Nidhi Su Ann,
8942,First case of postmortem study in a patient vaccinated against SARS-CoV-2,Weise,Michael,
8942,First case of postmortem study in a patient vaccinated against SARS-CoV-2,Wilkens,Ludwig,ur.01102077257.42
8942,First case of postmortem study in a patient vaccinated against SARS-CoV-2,Röcken,Christoph,ur.011714711304.99
8942,First case of postmortem study in a patient vaccinated against SARS-CoV-2,Glombitza,Sabine,ur.010025665120.40
8942,First case of postmortem study in a patient vaccinated against SARS-CoV-2,Hansen,Torsten,ur.0765477662.47
8899,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study,Tsaneva-Atanasova,Krasimira,ur.0774332016.44
8899,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study,Challen,Robert,ur.015200013113.10
8899,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study,Danon,Leon,ur.01230557674.96
8899,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study,Dyson,Louise,ur.01016337616.25
8899,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study,Brooks-Pollock,Ellen,ur.0737215707.07
8899,Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study,Read,Jonathan M,ur.0657526176.73
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Álvarez,Oscar Suárez,ur.01020355704.78
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Group,ENE-COVID Study,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",del Campo,Dúnia Pérez,ur.011513543676.50
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Sanz,María Ederra,ur.015521707777.09
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Miota,Teresa Ugarte,ur.011024616377.82
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Almagro,Cristóbal Ramírez,ur.013331366377.29
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Muñoz-Montalvo,Juan F.,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Gomila,Carlos Javier Villafáfila,ur.010573040167.10
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Sanchís,Margarita Cases,ur.010161122577.28
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Navarro,Saturnino Mezcua,ur.013026735077.10
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Cruz,Israel,ur.01364467677.05
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Hernán,Miguel A,ur.01015164244.47
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Pascual,Montserrat Hernández,ur.012236743325.92
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Aguilera,Antonio,ur.0732436710.52
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Quintana,María Noemí González,ur.013744405177.45
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Blanco,Faustino,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Baquedano,Carmen Ezpeleta,ur.01150572400.06
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Pastor-Barriuso,Roberto,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Pollán,Marina,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",de la Villa,Antonia Vázquez,ur.07706676546.11
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Gascón,Ana María Calvo,ur.014470011277.86
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Castro,Natalia Cabrera,ur.013177205263.19
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Saladrigas,Lluis Carbo,ur.013352364605.50
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Martín,Leopoldo Martín,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Martín,Mariano,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Betancor,María Araceli Hernández,ur.015337346177.21
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Cuenca-Estrella,Manuel,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Muñoz-Montalvo,Juan F,ur.013534476653.35
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Molina,Marta,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Rodríguez-Iglesias,Manuel,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Fernández,Adoración Hurtado,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Casals,Ariadna Mas i,ur.07477770577.28
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Merino-Amador,Paloma,ur.01243042105.66
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Suárez,Ignacio Donate,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Fernández-García,Aurora,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Jiménez,Ana Belén Pérez,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Blanco,Faustino,ur.015127437653.32
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Iglesias,Jesús Oteo,ur.01275025704.22
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Cruz,Israel,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Tamayo,Susana Iglesias,ur.07720047565.72
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Ciruela,Pilar,ur.0765076402.21
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Otazua,Luis Elorduy,ur.011207160177.10
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Alcaine,María Luz Lou,ur.015265371677.29
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Fernández,María Natalia Vallés,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Aguirre,José Manuel Rumbao,ur.011502107277.52
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Pérez-Gómez,Beatriz,ur.0575620737.12
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Marí,José M. Navarro,ur.01007463303.29
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Lobeiras,María Sinda Blanco,ur.015453574577.94
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",de Larrea,Nerea Fernández,ur.01335410233.69
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Fernández,Roberto Alonso,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Fernández-Navarro,Pablo,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Merino-Amador,Paloma,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Bellido,Juan Luis Muñoz,ur.014434012737.63
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Paniagua,Jose León,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Pérez,María Sagrario Celada,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",De Benito Población,Inés,ur.011617432120.28
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Fernández-García,Aurora,ur.01001636674.45
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Arranz,Miguel Villa,ur.014012520377.83
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Botías,Maria Doladé,ur.013215517655.94
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Oteo,Jesús,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Fernández,José María Barrasa,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Molina,Marta,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Sanmartín,Jose L,ur.012073422453.23
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Pérez-Gómez,Beatriz,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",del Cura González,Isabel,ur.01027700260.00
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Rodríguez-Cabrera,Francisco D.,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Fedele,Giovanni,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Hernández,Matías Salinero,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Benarroch,Rebeca Benarroch,ur.012004540577.89
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Lizcano,Aurora Tomás,ur.012534005777.88
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",González,Marta Domínguez-Gil,ur.013173441016.78
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Caro,Yolanda,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Rodríguez-Cabrera,Francisco,ur.07751214253.57
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Maeso,M. Angeles Marcos,ur.010704623600.11
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Avellón,Ana,ur.01253702703.28
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Fernández-Natal,Isabel,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Retamosa,Maria Francisca Elías,ur.014060633577.04
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",López,Luis-Mariano López,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Losada,Alberto Fuentes,ur.016251155177.94
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Ramírez,Ramón Limón,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Pérez-Olmeda,Mayte,ur.01302365144.72
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Paniagua,José León,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Flores,Jesús Lopera,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Lobón,Gregoria Megías,ur.012573460667.25
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Hernández,Manuel Segovia,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Yotti,Raquel,ur.01241640604.02
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Borrás,Begoña Palop,ur.013660446263.39
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Pollán,Marina,ur.01146477655.80
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Blanco,Luis Miguel Soria,ur.011435724461.65
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Feliciano,Elías Castro,ur.013147024577.75
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Elizaga,Nieves Ascunce,ur.015603522770.17
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Bou,German,ur.01044666030.87
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Marauri,Noemí,ur.016473775313.76
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Fernández,Rodrigo Gutiérrez,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Pastor-Barriuso,Roberto,ur.01345625371.73
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",de Larrea,Nerea Fernández,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Pérez,Mercedes Rodríguez,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Olmeda,María Teresa Pérez,ur.016612217477.04
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Oliver,Antonio,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",de Castro,Antonio Félix,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Bascaran,Ana Bustinduy,ur.012047664457.38
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Martín,Mariano,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",González,Manuela Rubio,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Yotti,Raquel,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Sanmartín,Jose L.,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Martinez,Maria Elena Fernandez,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Fernández,Susana Padrones,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Enríquez,Tomás Maté,ur.013215137777.46
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Hernán,Miguel A.,
8890,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",Febles,Melisa Hernández,ur.01364466774.51
8815,The Safety of COVID-19 Vaccinations—We Should Rethink the Policy,Walach,Harald,ur.01233335475.03
8815,Will covid-19 vaccines save lives? Current trials aren’t designed to tell us,Doshi,Peter,ur.01332606320.34
8815,The Safety of COVID-19 Vaccinations—We Should Rethink the Policy,Klement,Rainer J.,ur.01100312000.11
8815,The Safety of COVID-19 Vaccinations—We Should Rethink the Policy,Aukema,Wouter,ur.014416753435.74
8812,Ranking the effectiveness of worldwide COVID-19 government interventions,Pinior,Beate,ur.0651715564.82
8812,Ranking the effectiveness of worldwide COVID-19 government interventions,Haug,Nina,ur.010353505404.18
8812,Ranking the effectiveness of worldwide COVID-19 government interventions,Loreto,Vittorio,ur.01144041011.33
8812,Ranking the effectiveness of worldwide COVID-19 government interventions,Klimek,Peter,ur.0671225727.99
8812,Ranking the effectiveness of worldwide COVID-19 government interventions,Londei,Alessandro,ur.015446650733.54
8812,Ranking the effectiveness of worldwide COVID-19 government interventions,Desvars-Larrive,Amélie,ur.011207560135.21
8812,Ranking the effectiveness of worldwide COVID-19 government interventions,Thurner,Stefan,ur.0744506447.96
8812,Ranking the effectiveness of worldwide COVID-19 government interventions,Geyrhofer,Lukas,ur.01212577511.22
8812,Ranking the effectiveness of worldwide COVID-19 government interventions,Dervic,Elma,ur.014500425325.43
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Xu,Jinfang,
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Zhang,Huina,ur.012320321417.42
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Liu,Qi,
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Shi,Yiqi,ur.010726663740.59
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Xing,Zhonggang,
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Zhou,Liqiang,ur.01165520417.46
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Zhu,Rong,ur.010131303340.25
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Shen,Zihao,
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Zhang,Chunxue,ur.07404373717.56
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Zhu,Wenmin,ur.011576220640.88
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Shao,Jinliang,
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Lin,Quan,
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Wang,Congrong,ur.01332173225.09
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Deng,Yaxuan,ur.016702467740.19
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Chen,Wei,
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Wang,Junbang,
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Liu,Zhongmin,ur.01323332120.39
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Liu,Jiping,ur.011522741017.16
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Gao,Wenxia,ur.015100076713.34
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Sun,Yi E.,ur.01352541350.89
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Zheng,Changhong,ur.012160310113.13
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Wang,Yue,
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Yang,Xuejiao,
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Shi,Jiayu,
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Xia,Han,ur.01072126242.17
8810,Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines,Wu,Li,
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Vijay,Kris,ur.014007462211.20
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Katz,Nevin,ur.0610531303.48
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,De Ferrari,Gaetano M,ur.01100764635.66
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Risch,Harvey A,ur.0733254420.37
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Kelly,Ronan J,ur.01162666661.84
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Palazzuoli,Alberto,ur.01015654467.60
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Singh,Bhupinder,ur.01007776200.11
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Lerma,Edgar,ur.0620504430.12
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,McCullough,Peter A,ur.01115457467.68
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,O'Neill,William W,ur.01177720704.50
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Ruocco,Gaetano,ur.0643332474.12
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Wheelan,Kevin R,ur.0641630512.68
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Bhambi,Brijesh K,ur.01001711702.16
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Safder,Taimur,ur.014317460740.98
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Tumlin,James,ur.01010246266.22
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Lepor,Norman E,ur.01274031134.27
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,McCullough,Sean P,ur.016200003611.43
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Wang,Dee Dee,ur.01104032056.73
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Milligan,Gregory P,ur.011432613065.78
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Zervos,Marcus,ur.01023233156.63
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Carter,Harvey,
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,McKinnon,John E,ur.01264146064.21
8808,Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,Tecson,Kristen M,ur.0675103137.81
8779,Why are we vaccinating children against COVID-19?,Vlachoyiannopoulos,Panayiotis,ur.01343115706.48
8779,Why are we vaccinating children against COVID-19?,Svistunov,Andrey A.,ur.01050331300.04
8779,Why are we vaccinating children against COVID-19?,Kostoff,Ronald N.,ur.014145507414.31
8779,Why are we vaccinating children against COVID-19?,Calina,Daniela,ur.01355027531.22
8779,Why are we vaccinating children against COVID-19?,Kanduc,Darja,ur.0701505523.70
8779,Why are we vaccinating children against COVID-19?,Briggs,Michael B.,ur.013065453663.33
8779,Why are we vaccinating children against COVID-19?,Tsatsakis,Aristidis,ur.0664605063.96
8773,Sputnik V COVID-19 vaccine candidate appears safe and effective,Roy,Polly,ur.01000752176.11
8773,Sputnik V COVID-19 vaccine candidate appears safe and effective,Jones,Ian,ur.0721567750.06
8762,Long COVID after breakthrough SARS-CoV-2 infection,Xie,Yan,ur.0737732757.38
8762,Long COVID after breakthrough SARS-CoV-2 infection,Bowe,Benjamin,ur.0736221463.48
8762,Long COVID after breakthrough SARS-CoV-2 infection,Al-Aly,Ziyad,ur.0756001054.57
8758,Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues,Hughes,Stephen H.,ur.011212474757.30
8758,Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues,Barrasa,M. Inmaculada,ur.0610666702.55
8758,Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues,Young,Richard A.,ur.011705017367.87
8758,Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues,Richards,Alexsia,ur.013173563727.52
8758,Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues,Zhang,Liguo,ur.012453120735.06
8758,Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues,Jaenisch,Rudolf,ur.015376426517.48
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Corden,Sally,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Shirley,Lesley,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Dias,Joana,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jones,Christopher,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Frost,Lucy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Moore,Nathan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Brown,Julianne,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Irish-Tavares,Dianne,ur.010526625525.23
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Groves,Natalie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Oliver,Karen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Paul,Hannah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Park,Naomi,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Eltringham,Gary,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Howe,Robin,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Fraser,Christophe,ur.01117563357.14
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,BoYes,John,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,de Oliveira Martins,Leonardo,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Green,Angie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,de Cesare,Mariateresa,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Beer,Robert,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Witele,Eric,ur.07714025447.71
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Southgate,Joel,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Grammatopoulos,Dimitris,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Mather,Alison,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Louka,Stavroula,ur.015641070617.09
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Barrett,Jeff,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Pandey,Sarojini,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Brown,Rebecca,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Leek,Danielle,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Helmer,Thomas,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Nebbia,Gaia,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Platt,Steven,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Palmer,Sophie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Aranday-Cortes,Elihu,ur.0753106737.29
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Justice,Anita,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Kane,Leanne,ur.0745047764.93
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Fleming,Vicki,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,McGuigan,Samantha,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gemmell,Matthew,ur.07662543371.38
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bonsall,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ledesma,Juan,ur.0762751017.30
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hartley,John,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Manley,Robin,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Unnikrishnan,Meera,ur.0667106130.10
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jahun,Aminu,ur.014165622147.65
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Mirza,Jeremy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Angyal,Adrienn,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Smith,Louise,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Elliott,Scott,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Munn,Robert,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Smith,Colin,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Fina,Laia,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Smollett,Katherine,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Tucker,Rachel,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bibby,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Coll,Francesc,ur.01104634220.10
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Poplawski,Radoslaw,ur.015733243277.95
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Curran,Martin,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bewshea,Claire,ur.01340017125.47
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Parker,Matthew,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Harris,Ross J,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Graham,Lee,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Price,James,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hall,Grant,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Balcazar,Carlos,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Li,Kathy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bourgeois,Yann,ur.015325636451.50
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Charlett,Andre,ur.0723065546.38
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Dadrah,Ashok,ur.011037253017.54
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Young,Jamie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Shah,Rajiv,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hutchings,Stephanie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Manesis,Nikos,ur.015747323225.09
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Williams,Chris,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Thurston,Scott,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Mbisa,Tamyo,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Rowe,Will,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Prieto,Jacqui,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Partridge,David,ur.014634502124.06
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Brooks,Ellena,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Mair,Daniel,ur.013233061315.77
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Rajatileka,Shavanthi,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gilbert,Lauren,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bicknell,Kelly,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gallis,Marta,ur.012656256447.22
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bassett,Andrew,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Aliabadi,Shirin,ur.010630613451.77
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Chapman,Michael,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gallagher,Eileen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Dent,Hannah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Thornton,Alicia,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Vattipally,Sreenu,ur.01077414743.99
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ramsay,Mary,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,McKerr,Caoimhe,ur.0766422172.67
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Glaysher,Sharon,ur.0715230666.99
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Myers,Richard,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hiscox,Julian,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Eyre,David,ur.015076066434.76
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ott,Sascha,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Rainbow,Lucille,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Adams,Helen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Afifi,Safiah,ur.012670713163.51
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Nelson,Rachel,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Maksimovic,Joshua,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Tang,Julian,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jones,Carl,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Collins,Jennifer,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Dervisevic,Samir,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Johnston,Ian,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Campbell,Sharon,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Young,Gregory,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Peacock,Sharon,ur.01336666543.60
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Chauhan,Anoop,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Templeton,Kate,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gill,Harmeet,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Dewar,Rebecca,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Liddle,Jennifier,ur.012455564757.50
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Farr,Ben,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ash,Amy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Storey,Nathaniel,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Coombes,Jason,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Quick,Joshua,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Meader,Emma,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Wang,Dennis,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hesketh,Andrew,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hartman,Hassan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Webster,Hermione,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Carlile,Matthew,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bridgewater,Hannah,ur.07540052624.19
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gallagher,Eileen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Clark,Gemma,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Cottrell,Simon,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Alam,Mohammad,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Symmonds,Amanda,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Tong,Lily,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lensing,Stefanie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Palmer,Steve,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,James,Keith,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Nunez,Rocio Martinez,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Orton,Richard,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Shankar,Giri,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Wyatt,Tim,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Williamson,Kathleen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Downing,Fatima,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Constantinidou,Chrystala,ur.0643413400.18
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Davidson,Rose,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hughes,Margaret,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hilvers,Ember,ur.07536631453.25
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Impey,Robert,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,de Silva,Thushan,ur.01062173617.58
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Trotter,Alexander,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ellard,Sian,ur.01304432307.14
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Richter,Alex,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Kristiansen,Mark,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Masoli,Jane,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Menegazzo,Mirko,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Loveson,Katie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Johnson,Rob,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Signell,Adrian,ur.015516515071.07
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gulliver,Huw,ur.011723661425.25
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Edwards,Sue,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Kidd,Stephen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Page,Andrew,ur.0634014222.97
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Williams,Charlotte,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Raghwani,Jayna,ur.01140726025.94
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Zhang,Peijun,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Blane,Beth,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Buck,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Baker,Paul,ur.07426032065.29
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Foulser,Luke,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Acheson,Erwan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Pusok,Monika,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bayzid,Nadua,ur.010674421057.37
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Miah,Shahjahan,ur.0637415305.56
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Cormie,Claire,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Evans,Johnathan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Swindells,Emma,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Stark,Richard,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bolt,Frances,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Wierzbicki,Claudia,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Chappell,Joseph,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Osman,Husam,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hadjirin,Nazreen,ur.0766405154.25
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Davies,Robert,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,McHugh,Martin,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Parmar,Surendra,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jackson,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Twohig,Katherine A,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Holmes,Nadine,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lynch,Jessica,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jorgensen,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hopes,Richard,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Cheng,Jeffrey,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Carabelli,Alessandro,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Pelosi,Emanuela,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Martincorena,Inigo,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jones,Sophie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Michell,Stephen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Morgan,Sian,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Presanis,Anne M,ur.01047105633.51
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jesudason,Natasha,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bellis,Katherine,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Patel,Vineet,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Twohig,Katherine,ur.013160131130.06
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Geidelberg,Lily,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Best,Angus,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Livett,Rich,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Snell,Luke,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lo,Stephanie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Morgan,Mari,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Brown,Paul,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gregory,Richard,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Muir,Peter,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Johnson,Natasha,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Koshy,Cherian,ur.01225314607.40
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,De Lacy,Elen,ur.01137524323.53
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bedford,Luke,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Vipond,Ian,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jones,Katie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Halstead,Fenella,ur.01247362146.16
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Yeats,Corin,ur.01264330077.34
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jackson,Chris,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Kermack,Leanne,ur.012424220025.45
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Robson,Samuel,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ahmad,Shazaad,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Khakh,Manjinder,ur.016653531527.95
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Mahanama,Adhyana,ur.016210535641.58
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Howson-Wells,Hannah,ur.016317721351.53
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Vernet,Gabrielle,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,du Plessis,Louis,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hope,Russell,ur.0700317371.43
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Xu-McCrae,Li,ur.015166542724.53
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Pybus,Oliver,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Leonard,Steven,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gunson,Rory,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Kumziene-SummerhaYes,Sara,ur.012674554263.73
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Drury,Eleanor,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Liggett,Steven,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Malone,Cassandra,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Taylor,Graham,ur.016136424052.65
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Nelson,Charlotte,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Guest,Martyn,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Adams,Alexander,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Paterson,Steve,ur.01200662120.37
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Spellman,Karla,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Percival,Benita,ur.015645504640.85
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Blakey,Victoria,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,McManus,Georgina,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bashton,Matthew,ur.0634066330.17
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Dabrera,Gavin,ur.01126326577.27
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Quail,Michael,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Chalker,Vicki,ur.0706742105.09
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Patel,Amita,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Breen,Cassie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ratcliffe,Liz,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Harrison,Ewan,ur.01145533134.10
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Redshaw,Nicholas,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Carmichael,Stephen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Durham,Jillian,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,McNally,Alan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Cook,Kate,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Meadows,Lizzie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Atkinson,Laura,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jamrozy,Dorota,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Barton,Edward,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Maes,Mailis,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Studholme,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Manso,Carmen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jeffries,Aaron,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Vasylyeva,Tetyana,ur.01260463060.16
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lyons,Ronan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Levett,Lisa,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Mayhew,Megan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Mollett,Guy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Debebe,Johnny,ur.015614104713.68
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gourtovaia,Marina,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Robertson,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Chatterton,Wendy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Michelsen,Michelle,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Craine,Noel,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Zamudio,Marina Escalera,ur.011543755757.53
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Aydin,Alp,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bosworth,Andrew,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lowe,Hannah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Saeed,Kordo,ur.0723560332.57
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Beckett,Angela,ur.011532676771.51
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Fuller,William,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Cox,Alison,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Whitehead,Mark,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Warwick-Dugdale,Joanna,ur.015174544764.68
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Baker,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,John,Michaela,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Underwood,Anthony,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Fearn,Christopher,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Samaraweera,Buddhini,ur.014134525140.98
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lowe,Helen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Aanensen,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Sivaprakasam,Venkat,ur.01356757700.15
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Patel,Minal,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Harris,Kathryn,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Holmes,Christopher,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Shaaban,Sharif,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Sluga,Graciela,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jones,Hannah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Coupland,Lindsay,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Harrison,James,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Auckland,Cressida,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Georgana,Iliana,ur.010063724275.52
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Madona,Pinglawathee,ur.012723722527.14
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Wyles,Matthew,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Allara,Elias,ur.0746307425.24
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Scarlett,Garry,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Birchley,Alec,ur.011701310505.66
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Tonkin-Hill,Gerry,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Smith,Darren,ur.01202723203.65
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Scott,Carol,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Rowan,Aileen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Higginson,Ellen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,McCarthy,Shane,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Baxter,Laura,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Goudarzi,Salman,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Makunin,Alex,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Moore,Catherine,ur.01117406462.18
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Todd,John,ur.01134314703.76
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Loman,Nicholas,ur.011763744757.36
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Shepherd,James,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Betteridge,Emma,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Farbos,Audrey,ur.01367315356.55
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Sheriff,Nicola,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Raza,Mohammad,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Stonehouse,Susanne,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Whitwham,Andrew,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bucca,Giselda,ur.01171356772.13
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ellaby,Nicholas,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Carden,Holli,ur.013636752117.10
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Prestwood,Liam,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Wyllie,Sarah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Joseph,Amelia,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Maclean,Alasdair,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Boyd,Olivia,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,De Angelis,Daniela,ur.01021331434.10
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ariani,Cristina,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Eccles,Richard,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Haque,Tanzina,ur.01050664710.73
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Smith,Nikki,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Taylor-Joyce,Grace,ur.010244072400.47
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jeremiah,Sarah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hogsden,Wendy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Mookerjee,Siddharth,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lewis,Kevin,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Fenton,Melisa,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Keatley,Jon-Paul,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,da Silva Filipe,Ana,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Robinson,Trevor,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hale,Antony,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bird,Paul,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Fairley,Derek,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gupta,Ravi,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Kenyon,Anita,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gatica-Wilcox,Bree,ur.011301613263.64
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Williams,Rachel,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Heyburn,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Beale,Mathew,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lopez-Bernal,Jamie,ur.014617266115.94
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Kay,Sally,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Crawford,Liam,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gallagher,Michael,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Williams,Lesley-Anne,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Moore,Jonathan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Silveira,Siona,ur.010755574317.47
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Groves,Danielle,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Randell,Paul,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,O'Brien,Sarah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Molnar,Zoltan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Willingham,Iona,ur.015662220113.35
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Turtle,Lance,ur.01133171523.79
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Alikhan,Nabil-Fareed,ur.0654411565.28
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Davies,Alisha,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lackenby,Angie,ur.01365604606.54
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Asamaphan,Patawee,ur.015464470657.95
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Thompson,Thomas,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Pymont,Hannah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Fisher,Chloe,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Breuer,Judith,ur.010725774377.15
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bronner,Iraad,ur.07402037717.83
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Connor,Thomas,ur.011521017502.76
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Sinnathamby,Mary A,ur.01256205775.01
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Asad,Hibo,ur.016251245457.35
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Peto,Timothy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jackson,Leigh,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Dabrera,Gavin,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Knight,Bridget,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Raviprakash,Veena,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Wantoch,Michelle,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Iturriza-Gomara,Miren,ur.01015332114.66
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Forrest,Sally,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Golubchik,Tanya,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Wilson-Davies,Eleri,ur.01143450763.98
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Payne,Brendan,ur.012471310512.04
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Dorman,Matthew,ur.016257440717.88
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Nichols,Jenna,ur.014765767507.00
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Levene,Nick,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Volz,Erik,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Merrick,Ian,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Megram,Oliver,ur.010222511261.49
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Stockton,Joanne,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Wise,Emma,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Letchford,Laura,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bradley,Declan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Niebel,Marc,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ashcroft,Fiona,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hassan-Ibrahim,Mohammed,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Whiteley,Max,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Berry,Louise,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Curran,Tanya,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Harrison,Ian,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,George,Ryan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,O'Toole,Elaine,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Loose,Matthew,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Taha,Yusri,ur.01203457037.91
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Holmes,Alison,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Johnson,Kate,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Amato,Roberto,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Thomson,Emma,ur.01115422445.14
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lee,Jack,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hart,Jennifer,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bonner,Stephen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gifford,Laura,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Westhorpe,Adam,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Cronin,Michelle,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Yew,Wen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Chaudhry,Yasmin,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Moll,Robin,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bresner,Catherine,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Goncalves,Sonia,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Danesh,John,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Sambles,Christine,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Kay,Gemma,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Scott,Garren,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,O'Grady,Justin,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Batra,Rahul,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Holden,Matthew,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Siveroni,Igor,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jannoo,Riaz,ur.010431476711.59
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Pearson,Clare,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Charalampous,Themoula,ur.010035306020.95
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Zarebski,Alex,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Cogger,Benjamin,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jackson,Kathryn,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bull,Matthew,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Kraemer,Moritz,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Cowell,Angela,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Smith,Kim,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Walsh,Sarah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Fallon,Karlie,ur.013063665103.74
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Vamos,Edith,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Beggs,Andrew,ur.01053215324.80
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Darby,Alistair,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Reynolds,Nicola,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Heaney,Judith,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Macfarlane-Smith,Louissa,ur.0746717542.36
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Wilson,Harry,ur.0722154747.28
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Beaver,Charlotte,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Padgett,Debra,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Nascimento,Fabricia F.,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Plimmer,Amy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,McCann,Clare,ur.01307300202.38
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Thelwall,Simon,ur.0763614361.88
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Alcolea-Medina,Adela,ur.01175254447.45
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Boswell,Tim,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Taylor,Sarah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,O'Toole,Áine,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Evans,Cariad,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Green,Luke,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Cotic,Marius,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Galai,Katerina,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Burton-Fanning,Shirelle,ur.014254076743.87
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Starinskij,Igor,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ruis,Chris,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Price,Anna,ur.012404766604.16
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Awan,Ali,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Alderton,Alex,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Williams,Thomas,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lawniczak,Mara,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Simpson,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Aggarwal,Dinesh,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Rey,Sara,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Cortes,Nick,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Smith,Wendy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Wright,Victoria,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Watts,Joanne,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Chand,Meera,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Karamani,Angeliki,ur.013025044154.92
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Wilson,Rebekah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Trebes,Amy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,McCluggage,Kathryn,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Perry,Malorie,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Le-Viet,Thanh,ur.0726107165.12
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,consortium,COVID-19 Genomics UK,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Williams,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Crook,Derrick,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Eldirdiri,Sahar,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Rajan,Diana,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Pinckert,Malte,ur.012711510333.14
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gaskin,Amy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Taylor,Ben,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Davis,Thomas,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Essex,Sarah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,McKenna,James,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Marchbank,Angela,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lucaci,Anita,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Waugh,Sheila,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Haldenby,Sam,ur.01164717632.64
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Workman,Trudy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ludden,Catherine,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lindsey,Benjamin,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Seaman,Shaun R,ur.01267563145.13
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Rudder,Steven,ur.011151605647.79
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Rushton,Steven,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hosmillo,Myra,ur.0641332372.02
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Illingworth,Chris,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Kitchen,Christine,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Gutierrez,Bernardo,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Nomikou,Kyriaki,ur.01010154476.92
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Nyberg,Tommy,ur.0716200406.24
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Goodwin,Scott,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ensell,Leah,ur.015675666311.46
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Sloan,Tim,ur.0700062673.14
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Shah,Divya,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Wastenge,Elizabeth,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Freeman,Timothy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Nelson,Andrew,ur.01300622124.29
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Williams,Rebecca,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Girgis,Sophia,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Sang,Fei,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Flaviani,Flavia,ur.011355167767.30
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Machin,Nicholas,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ragonnet-Cronin,Manon,ur.0671776511.11
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Nicholls,Sam,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Moses,Samuel,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Sillitoe,John,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Aigrain,Louise,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Tsoleridis,Theocharis,ur.01167222243.53
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Churcher,Carol,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Singer,Joshua,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Saluja,Tranprit,ur.01127526421.41
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Andersson,Monique,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bradley,Amanda,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Casey,Anna,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Greenaway,Jane,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Broos,Alice,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Betancor,Gilberto,ur.01121542327.36
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bonfield,James,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Monaghan,Lynn,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,McClure,Patrick,ur.07672453775.20
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Langford,Cordelia,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Weldon,Danni,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Mahungu,Tabitha,ur.014572544417.56
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Edgeworth,Jonathan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Moore,Christopher,ur.0603026624.09
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Mason,Jenifer,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Torok,M. Estee,ur.01254430354.80
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,MacIntyre-Cockett,George,ur.013011344704.55
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bishop,Chloe,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Warne,Ben,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Roy,Sunando,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Sridhar,Sushmita,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Mori,Matilde,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Graham,Clive,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Chapman,Michael Spencer,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Harper,Katherine,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Parsons,Paul,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Ball,Jonathan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Temperton,Ben,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Cumley,Nicola,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Merrill,Tammy,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Abudahab,Khalil,ur.012311601425.89
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Stanton,Thomas,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Stanley,Rachael,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Watkins,Joanne,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Jones,Rachel,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lister,Michelle,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hughes,Joseph,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lloyd,Allyson,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hill,Verity,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Attwood,Stephen,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Moles-Garcia,Emma,ur.013517062473.47
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Duckworth,Nichola,ur.010154321427.66
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Robinson,Esther,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Francois,Sarah,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Blacow,Rachel,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Lee,David,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Goodfellow,Ian,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Zaidi,Asad,ur.013001150267.26
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Bradshaw,Daniel,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Kwiatkowski,Dominic,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Pacchiarini,Nicole,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Rooke,Stefan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Schaefer,Ulf,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Nickbakhsh,Seema,ur.07762612057.35
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hubb,Jonathan,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Cerda,Alberto,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Keeley,Alexander,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Tovar-Corona,Jaime,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Puethe,Christoph,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Rambaut,Andrew,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,McMurray,Claire,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Berry,Lisa,
8731,Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study,Hamilton,William,
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Handunnetthi,Lahiru,ur.0606603643.01
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Mills,Nicholas L,ur.01052613263.54
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Watkinson,Peter,ur.01152420736.35
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Zaccardi,Francesco,ur.01360153731.10
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Sheikh,Aziz,ur.01125214207.48
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Channon,Keith M.,ur.01215026665.66
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Hippisley-Cox,Julia,ur.01027557547.88
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Shankar-Hari,Manu,ur.01242172705.25
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Patone,Martina,ur.07760251517.54
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Coupland,Carol AC,ur.0635076355.31
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Khunti,Kamlesh,ur.0641072534.04
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Harnden,Anthony,ur.015444577125.35
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Mei,Xue W,ur.011010116731.45
8710,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Dixon,Sharon,ur.016707314172.43
8696,Transmissibility of SARS-CoV-2 among fully vaccinated individuals,Franco-Paredes,Carlos,ur.01332201654.41
8696,Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients,Cohen,Deborah A,ur.0664060722.61
8696,Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients,Smith,Gary N,ur.0667743706.44
8696,Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients,Young,Deborah Rohm,ur.07516515612.57
8696,Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients,Sallis,James F,ur.014130225017.04
8696,Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients,Tartof,Sara Y,ur.01321346607.96
8696,Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients,Sallis,Robert,ur.01163037206.71
8696,Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients,Li,Qiaowu,ur.01060415726.37
8696,Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients,Sall,Jeevan,ur.016373715017.34
8584,"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study",Ndlela,Busani,ur.016714660114.37
8584,"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study",Lopez-Bernal,Jamie,ur.014617266115.94
8584,"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study",Elliss-Brookes,Lucy,ur.0624317054.28
8584,"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study",Falcaro,Milena,ur.01055751712.33
8584,"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study",Sasieni,Peter,ur.01257735610.85
8584,"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study",Checchi,Marta,ur.01037110062.35
8584,"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study",Castañon,Alejandra,ur.0765456637.52
8584,"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study",Soldan,Kate,ur.0622430047.31
8580,Covid 19 vaccines and the misinterpretation of perceived side effects clarity on the safety of vaccines,Palmer,Raymond D,
8553,Universal Screening for SARS-CoV-2 in Women Admitted for Delivery,Sutton,Desmond,ur.011332702617.85
8553,Universal Screening for SARS-CoV-2 in Women Admitted for Delivery,Fuchs,Karin,ur.01027244561.33
8553,Universal Screening for SARS-CoV-2 in Women Admitted for Delivery,Goffman,Dena,ur.01071415011.12
8553,Universal Screening for SARS-CoV-2 in Women Admitted for Delivery,D'Alton,Mary,ur.012033157660.74
8551,"Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed",Zin Tun,Gloria Shwe,ur.016665652266.32
8551,"Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed",Al-Joudeh,Amer,ur.016455615715.84
8551,"Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed",Gleeson,Dermot,ur.01307202357.72
8551,"Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed",Dube,Asha,ur.0675175115.72
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,van Rij,Ronald P.,ur.01363517363.10
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,GeurtsvanKessel,Corine,ur.0645750705.70
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Li,Yang,ur.011700722153.19
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Oever,Jaap ten,ur.011751107001.19
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Bulut,Ozlem,ur.012154350675.58
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,de Jonge,Marien I.,ur.0576021076.41
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,van de Veerdonk,Frank L.,ur.01311216724.81
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Hoogerwerf,Jacobien J.,ur.01121206515.35
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Joosten,Leo A.B.,ur.014645240657.77
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Haagmans,Bart L.,ur.015465550657.43
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Liu,Zhaoli,ur.012645124324.02
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Müller,Lisa,ur.015652433305.49
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Ostermann,Philipp Niklas,ur.016673450557.03
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Netea,Mihai G.,ur.01263677437.18
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Simonetti,Elles,ur.0613035641.96
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Röring,Rutger J.,ur.012326724714.39
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,van Crevel,Reinout,ur.01021435034.00
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Föhse,Konstantin,ur.010573413702.20
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Overheul,Gijs J.,ur.0624362731.05
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Domínguez-Andrés,Jorge,ur.0752265343.59
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Schaal,Heiner,ur.01212301073.03
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Zoodsma,Martijn,ur.010360204520.10
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Geckin,Büsra,ur.014323036600.42
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,van de Maat,Josephine S.,ur.01023116217.06
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Kilic,Gizem,ur.013666052117.10
8548,The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses,Adams,Ortwin,ur.0651313507.89
8529,Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure,Boon,Denali,ur.0625333425.89
8529,Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure,Laeyendecker,Oliver,ur.01211447140.05
8529,Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure,Kucirka,Lauren M,ur.01330033546.14
8529,Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure,Lessler,Justin,ur.0775017522.46
8529,Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure,Lauer,Stephen A,ur.01105155330.57
8525,"Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden",Larsson,Emma,ur.0732152005.12
8525,"Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden",Engerström,Lars,ur.0617025411.99
8525,"Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden",Nordenhäll,Charlotta,ur.015172057127.90
8525,"Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden",Ludvigsson,Jonas F,ur.014450452222.48
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Reynolds,Zahra,
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Melberg,Meghan,ur.015620456664.48
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Chamberlin,Grace C,ur.011120124635.48
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Choudhary,Manish C,ur.0771646136.40
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Flynn,James P,
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Barczak,Amy K,ur.0757700425.57
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Uddin,Rockib,ur.014611167370.94
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Li,Yijia,ur.016005442265.77
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Li,Jonathan Z,ur.0777407262.04
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Siedner,Mark J,ur.01362575676.38
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Vyas,Jatin M,ur.01074165632.34
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Liew,May Y,ur.012632554664.73
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Boucau,Julie,ur.0725205721.17
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Kittilson,Autumn,ur.015023076264.22
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Goldberg,Marcia B,
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Stuckwisch,Ashley M,
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Lipiner,Taryn,ur.014732221737.52
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Singh,Arshdeep,
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Chen,Geoffrey,
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Marino,Caitlin,
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Gilbert,Rebecca F,
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Regan,James,
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Lemieux,Jacob E,ur.07410411465.28
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Mathews,Josh,
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Iyer,Surabhi L,ur.07415465230.40
8522,Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection,Vyas,Tammy D,ur.010264437353.21
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Xu,Wei,ur.011734500507.76
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Ilic,Dragan,ur.01265252377.36
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Talic,Stella,ur.012257723143.40
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Shah,Shivangi,ur.07503061320.04
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Gasevic,Danijela,ur.01060654316.00
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Maharaj,Ashika,ur.013242127014.77
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Rostron,Jasmin,ur.015456665320.96
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Theodoratou,Evropi,ur.011173242767.55
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Motee,Ashmika,ur.0733364710.61
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Ademi,Zanfina,ur.01157504471.57
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Mesa-Eguiagaray,Ines,ur.012052756055.31
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Li,Xue,ur.013176031701.35
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Liew,Danny,ur.01116407763.87
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Zhang,Xiaomeng,ur.013246642163.88
8475,The coronavirus is here to stay — here’s what that means,Phillips,Nicky,
8475,"Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis",Wild,Holly,ur.010300441720.20
8443,A living WHO guideline on drugs for covid-19,Relan,Pryanka,ur.0671555100.46
8443,A living WHO guideline on drugs for covid-19,Rochwerg,Bram,ur.01074314153.02
8443,A living WHO guideline on drugs for covid-19,Jacobs,Michael,ur.01337155074.89
8443,A living WHO guideline on drugs for covid-19,Ismail,Mohamed,
8443,A living WHO guideline on drugs for covid-19,Tshokey,Tshokey,ur.01177262235.67
8443,A living WHO guideline on drugs for covid-19,Shen,Yinzhong,ur.07560456374.34
8443,A living WHO guideline on drugs for covid-19,Lamontagne,François,ur.01321064225.67
8443,A living WHO guideline on drugs for covid-19,Ugarte,Sebastian,ur.01265564167.50
8443,A living WHO guideline on drugs for covid-19,Wijewickrama,Ananda,ur.0646221721.76
8443,A living WHO guideline on drugs for covid-19,De Sutter,An,ur.01202650507.15
8443,A living WHO guideline on drugs for covid-19,Ranganathan,Shalini S,ur.010364460732.00
8443,A living WHO guideline on drugs for covid-19,Vuyiseka,Dubula,ur.016107376321.19
8443,A living WHO guideline on drugs for covid-19,Lytvyn,Lyubov,ur.0731734435.92
8443,A living WHO guideline on drugs for covid-19,Kawano-Dourado,Leticia,ur.01352615461.58
8443,A living WHO guideline on drugs for covid-19,Alhadyan,Ahmed,
8443,A living WHO guideline on drugs for covid-19,Chacko,Binila,ur.01101122525.06
8443,A living WHO guideline on drugs for covid-19,Peter,Jessica,
8443,A living WHO guideline on drugs for covid-19,Migliori,Giovanni Battista,
8443,A living WHO guideline on drugs for covid-19,Owen,Andrew,ur.01272724425.53
8443,A living WHO guideline on drugs for covid-19,Qadir,Nida,ur.015576262577.09
8443,A living WHO guideline on drugs for covid-19,Siemieniuk,Reed AC,ur.011772212064.79
8443,A living WHO guideline on drugs for covid-19,Sharland,Michael,
8443,A living WHO guideline on drugs for covid-19,Hunt,Beverley J,ur.01004530171.07
8443,A living WHO guideline on drugs for covid-19,Zeraatkar,Dena,ur.012625264361.31
8443,A living WHO guideline on drugs for covid-19,Kissoo,Niranjan,
8443,A living WHO guideline on drugs for covid-19,Kuppalli,Krutika,ur.01270715413.61
8443,A living WHO guideline on drugs for covid-19,Zeng,Linan,ur.015033054203.06
8443,A living WHO guideline on drugs for covid-19,Curiel,Evangelina Vazquez,ur.010335576170.01
8443,A living WHO guideline on drugs for covid-19,Hui,David,
8443,A living WHO guideline on drugs for covid-19,Leo,Yee-Sin,ur.01057360426.59
8443,A living WHO guideline on drugs for covid-19,Diaz,Janet,
8443,A living WHO guideline on drugs for covid-19,Agarwal,Arnav,
8443,A living WHO guideline on drugs for covid-19,Uyeki,Timothy,
8443,A living WHO guideline on drugs for covid-19,Vandvik,Per Olav,ur.0725536712.92
8443,A living WHO guideline on drugs for covid-19,Amin,Wagdy,ur.07511226037.66
8443,A living WHO guideline on drugs for covid-19,Haider,Muhammad,ur.016245106076.50
8443,A living WHO guideline on drugs for covid-19,Ge,Long,ur.012345736167.30
8443,A living WHO guideline on drugs for covid-19,Brignardello-Petersen,Romina,ur.01176342751.88
8443,A living WHO guideline on drugs for covid-19,Kim,Yae-Jean,
8443,A living WHO guideline on drugs for covid-19,da Silva,André Ricardo Araujo,ur.01170535266.11
8443,A living WHO guideline on drugs for covid-19,Harley,Nerina,ur.01333565267.03
8443,A living WHO guideline on drugs for covid-19,Macdonald,Helen,
8443,A living WHO guideline on drugs for covid-19,Freedman,Stephen,
8443,A living WHO guideline on drugs for covid-19,Askie,Lisa,ur.01365624700.62
8443,A living WHO guideline on drugs for covid-19,Aryal,Diptesh,
8443,A living WHO guideline on drugs for covid-19,Tran,Lien,ur.011600142643.98
8443,A living WHO guideline on drugs for covid-19,Kanda,Seema,
8443,A living WHO guideline on drugs for covid-19,Kwizera,Arthur,ur.01100610423.42
8443,A living WHO guideline on drugs for covid-19,Sabzwari,Saniya,ur.0764633074.71
8443,A living WHO guideline on drugs for covid-19,Castro-Rial,Marta Lado,ur.07500534002.51
8443,A living WHO guideline on drugs for covid-19,Agoritsas,Thomas,ur.01350052471.83
8443,A living WHO guideline on drugs for covid-19,Bartoszko,Jessica J,ur.07621074172.89
8443,A living WHO guideline on drugs for covid-19,Souza,Joao P,ur.01217330164.46
8443,A living WHO guideline on drugs for covid-19,Cecconi,Maurizio,ur.0602475235.35
8443,A living WHO guideline on drugs for covid-19,Geduld,Heike,ur.0672101771.28
8443,A living WHO guideline on drugs for covid-19,Chanda,Duncan,ur.01014370312.01
8443,A living WHO guideline on drugs for covid-19,Mino,Greta,
8443,A living WHO guideline on drugs for covid-19,Mendelson,Marc,ur.01002704250.29
8443,A living WHO guideline on drugs for covid-19,Gee,Patrick,
8443,A living WHO guideline on drugs for covid-19,Lodha,Rakesh,
8443,A living WHO guideline on drugs for covid-19,Lisboa,Thiago,ur.014550127446.36
8443,A living WHO guideline on drugs for covid-19,Krishna,Sanjeev,
8443,A living WHO guideline on drugs for covid-19,Rylance,Jamie,
8443,A living WHO guideline on drugs for covid-19,Du,Bin,
8443,A living WHO guideline on drugs for covid-19,Manai,Hela,ur.011750677207.13
8443,A living WHO guideline on drugs for covid-19,Jehan,Fyezah,ur.01172707627.82
8443,A living WHO guideline on drugs for covid-19,Hashmi,Madiha,ur.0746706646.68
8443,A living WHO guideline on drugs for covid-19,Shankar-Hari,Manu,ur.01242172705.25
8443,A living WHO guideline on drugs for covid-19,Stegemann,Miriam,ur.010556426211.20
8443,A living WHO guideline on drugs for covid-19,Gotte,Matthias,
8443,A living WHO guideline on drugs for covid-19,Nsutebu,Emmanuel,ur.0716665471.60
8443,A living WHO guideline on drugs for covid-19,Sarin,Rohit,ur.01103441174.02
8443,A living WHO guideline on drugs for covid-19,Preller,Jacobus,ur.013716274643.40
8443,A living WHO guideline on drugs for covid-19,Barragan,Fabian A Jaimes,ur.01323714676.87
8443,A living WHO guideline on drugs for covid-19,Bausch,Frederique J,ur.015756073221.26
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Brown,Kevin A.,ur.01214242362.02
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Wilson,Kumanan,ur.0752064471.44
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Austin,Peter C.,ur.0634366426.10
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Nasreen,Sharifa,ur.01361701717.54
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Schwartz,Kevin L.,ur.0715135655.95
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Tadrous,Mina,ur.01102202064.28
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Gubbay,Jonathan B.,ur.0606342443.98
8443,A living WHO guideline on drugs for covid-19,Venkatapuram,Sridhar,ur.01306057376.02
8443,A living WHO guideline on drugs for covid-19,Swanstrom,Ronald,ur.07676555777.80
8443,A living WHO guideline on drugs for covid-19,Guyatt,Gordon,ur.0773167774.48
8443,A living WHO guideline on drugs for covid-19,Calfee,Carolyn S,ur.01222460111.09
8443,A living WHO guideline on drugs for covid-19,Kabra,Sushil K,ur.01027572452.34
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Sundaram,Maria E.,ur.0643467524.40
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Chung,Hannah,ur.012210115161.41
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Wilson,Sarah E.,ur.0756764723.10
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Kwong,Jeffrey C.,ur.0753123554.47
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Buchan,Sarah A.,ur.013701471741.64
8443,Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes,Fell,Deshayne B.,ur.0603710300.79
8443,A living WHO guideline on drugs for covid-19,Burhan,Erlina,ur.01321161567.42
8443,A living WHO guideline on drugs for covid-19,Muna,Al-Maslamani,
8443,A living WHO guideline on drugs for covid-19,Dat,Vu Quoc,ur.01117147533.20
8443,A living WHO guideline on drugs for covid-19,Pshenichnaya,Natalia,ur.01325204232.01
8443,A living WHO guideline on drugs for covid-19,Mahaka,Imelda,ur.012557177477.16
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Sprouse,Kaitlin R,ur.016150241301.78
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Virgin,Herbert W,ur.01252531616.22
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Guastalla,Sonja Bernasconi,
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Corti,Davide,ur.01340264536.63
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Bassi,Jessica,ur.013050677513.81
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,De Marco,Anna,ur.014507234055.41
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Pizzuto,Matteo Samuele,ur.0761277112.16
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Garzoni,Christian,ur.0776426700.95
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Rosen,Laura E,ur.014375525313.56
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Pellanda,Alessandra Franzetti,ur.0757743444.82
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Culap,Katja,ur.012020760021.34
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Pinto,Dora,ur.01116527452.43
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Saliba,Christian,ur.013621135473.11
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Jaconi,Stefano,ur.014167254733.71
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Chen,Alex,
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Tortorici,M Alejandra,ur.01314262545.68
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Bowen,John E,ur.010217024773.08
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Silacci-Fregni,Chiara,ur.012632631565.21
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Telenti,Amalio,ur.01162002733.02
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Piccoli,Luca,ur.01167566253.97
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Cameroni,Elisabetta,ur.010645354037.63
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,McCallum,Matthew,
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Di Iulio,Julia,ur.0703116662.37
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Walls,Alexandra C,
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Van Voorhis,Wesley C,ur.0633073157.20
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Veesler,David,ur.01002414777.95
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Bianchi,Siro,ur.0614660436.33
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Bona,Giovanni,ur.013217350725.89
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Agostini,Maria,ur.016441763603.06
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Tilles,Sasha W,ur.013476145253.70
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Snell,Gyorgy,ur.012067073221.02
8437,SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern,Navarro,Mary-Jane,
8403,Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?,Fantini,Jacques,ur.01260141627.67
8403,Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?,Chahinian,Henri,ur.0640116473.95
8403,Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?,Yahi,Nouara,ur.0606426467.27
8391,Turbulent Gas Clouds and Respiratory Pathogen Emissions,Bourouiba,Lydia,ur.0614114533.26
8363,COVID-19 Vaccine Boosters for Young Adults: A Risk-Benefit Assessment and Five Ethical Arguments against Mandates at Universities,Høeg,Tracy Beth,ur.01044166575.20
8363,COVID-19 Vaccine Boosters for Young Adults: A Risk-Benefit Assessment and Five Ethical Arguments against Mandates at Universities,Keshavjee,Salmaan,ur.01101124045.64
8363,COVID-19 Vaccine Boosters for Young Adults: A Risk-Benefit Assessment and Five Ethical Arguments against Mandates at Universities,Baral,Stefan,ur.01213025046.15
8363,COVID-19 Vaccine Boosters for Young Adults: A Risk-Benefit Assessment and Five Ethical Arguments against Mandates at Universities,Jamrozik,Euzebiusz,ur.01150606074.87
8363,COVID-19 Vaccine Boosters for Young Adults: A Risk-Benefit Assessment and Five Ethical Arguments against Mandates at Universities,Krug,Allison,ur.012544524740.70
8363,COVID-19 Vaccine Boosters for Young Adults: A Risk-Benefit Assessment and Five Ethical Arguments against Mandates at Universities,Lemmens,Trudo,ur.0640055046.19
8363,COVID-19 Vaccine Boosters for Young Adults: A Risk-Benefit Assessment and Five Ethical Arguments against Mandates at Universities,Makary,Martin A.,ur.0734060716.73
8363,COVID-19 Vaccine Boosters for Young Adults: A Risk-Benefit Assessment and Five Ethical Arguments against Mandates at Universities,Prasad,Vinay,ur.01126071747.46
8363,COVID-19 Vaccine Boosters for Young Adults: A Risk-Benefit Assessment and Five Ethical Arguments against Mandates at Universities,Bardosh,Kevin,ur.01253246524.87
8349,Visualizing Speech-Generated Oral Fluid Droplets with Laser Light Scattering,Anfinrud,Philip,ur.01322163327.22
8349,Visualizing Speech-Generated Oral Fluid Droplets with Laser Light Scattering,Bax,Adriaan,ur.011324007057.32
8349,Visualizing Speech-Generated Oral Fluid Droplets with Laser Light Scattering,Stadnytskyi,Valentyn,ur.0673220022.43
8349,Visualizing Speech-Generated Oral Fluid Droplets with Laser Light Scattering,Bax,Christina E,ur.014233434131.43
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Van Steen,Frederic,ur.010052574241.29
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Van Loco,Joris,ur.01216323270.62
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Waegeneers,Nadia,ur.01143142577.80
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Blaude,Marie-Noelle,ur.01310736573.41
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Cheyns,Karlien,ur.0607600253.15
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Mast,Jan,ur.01145213362.37
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Nkenda,Régis,
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Vleminckx,Christiane,ur.0637516370.44
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Machiels,Ronny,
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,De Vos,Sandra,ur.015131103010.26
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Brassinne,Frédéric,ur.012530310137.22
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Ledecq,Marina,ur.010272247143.11
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Verleysen,Eveline,ur.016440216720.73
8345,Titanium dioxide particles frequently present in face masks intended for general use require regulatory control,Siciliani,Lisa,ur.015110201220.54
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Burns,Alistair,
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Livingston,Gill,ur.0772746311.04
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Ames,David,
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Howard,Robert,ur.01334130047.19
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Ballard,Clive,ur.01016501547.47
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Gitlin,Laura N,
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Costafreda,Sergi G,ur.01027461313.92
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Fox,Nick,ur.07535502757.16
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Schneider,Lon S,ur.013114470017.13
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Cohen-Mansfield,Jiska,ur.01256465000.27
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Ogunniyi,Adesola,ur.01236300013.27
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Cooper,Claudia,ur.014272327206.44
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Larson,Eric B,ur.0740630142.67
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Huntley,Jonathan,ur.01213321706.26
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Kales,Helen C,ur.01300740701.55
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Dias,Amit,ur.0647730367.44
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Teri,Linda,ur.0623501633.89
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Rockwood,Kenneth,ur.01026507566.78
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Orgeta,Vasiliki,ur.0613232554.32
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Selbæk,Geir,ur.01044411633.86
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Mukadam,Naaheed,ur.0602472277.51
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Sampson,Elizabeth L,ur.01277466133.74
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Banerjee,Sube,ur.01035046401.71
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Kivimäki,Mika,ur.01152202075.77
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Samus,Quincy,ur.0724626654.96
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Sommerlad,Andrew,ur.016336210643.06
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Ritchie,Karen,ur.01042104705.91
8342,"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission",Brayne,Carol,ur.01161250642.42
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Zaman,Khalequ,ur.016445236657.15
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Khan,Wasif Ali,ur.011600234552.10
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Sumiya,Mariya Kibtiya,ur.010472235510.28
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Clemens,John D,ur.01001762452.22
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Ahmed,Sabeena,ur.01020552426.24
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Phru,Ching Swe,ur.014053016637.32
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Aziz,Asma Binte,ur.016657663235.84
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Yasmin,Rubina,
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Kabir,Ahmedul,ur.015061746357.70
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Somani,Jyoti,ur.015166525461.52
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Hossain,Mohammad Sharif,ur.01320315124.68
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Rahman,Mustafizur,ur.013447570122.67
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Ross,Allen G,ur.01265066572.08
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Karim,Mohammad Mahbubul,ur.0610214435.01
8339,A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness,Hasnat,Mohammad Abul,ur.015056260227.49
8305,"Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021",Thoroughman,Douglas,ur.0666512407.82
8305,"Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021",Winter,Kathleen,ur.012501327644.73
8305,"Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021",Glick,Connor,ur.011703747244.76
8305,"Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021",Cavanaugh,Alyson M.,ur.0604733532.73
8305,"Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021",Spicer,Kevin B.,ur.010514557057.72
8188,COVID-19: endemic doesn’t mean harmless,Katzourakis,Aris,ur.0757514737.12
8188,Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19,Narendran,Siddharth,ur.011161221223.53
8188,Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19,Sutton,S Scott,ur.016056200107.12
8188,Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19,Pereira,Felipe,ur.016547411567.01
8188,Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19,Magagnoli,Joseph,ur.01234372615.40
8188,Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19,Hardin,James W,ur.010736657577.32
8188,Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19,Cummings,Tammy,ur.0750773217.54
8188,Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19,Ambati,Jayakrishna,ur.0733426416.91
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Sullivan,C.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Walsh,D.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Gentile,A.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Paynter,J.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Clothier,H.J.,ur.0751514610.57
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Naus,M.,ur.01043427011.13
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Faksova,K.,ur.016065345727.24
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Cui,F.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Lu,H.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Grange,Z.,ur.015136165764.89
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Janjua,N.Z.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Shetty,A.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Phillips,A.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Kwong,J.C.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Black,S.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Sepulveda,G.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Cullen,L.,ur.014023304500.54
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Artama,M.,ur.0655560777.78
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Hviid,A.,ur.0631535524.27
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Macartney,K.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Batty,K.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Nasreen,S.,ur.01361701717.54
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Griffin,J.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Escolano,S.,ur.01025210630.80
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Pillsbury,A.,ur.01123255374.38
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Vo,T.,ur.01355102345.28
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Hovi,P.,ur.0703577173.74
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Gidding,H.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Deng,L.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Jiang,Y.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Petousis-Harris,H.,ur.0762441146.00
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Perälä,J.,ur.014156506375.38
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Giglio,N.,
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Buttery,J.,ur.01317447167.26
8168,COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals,Naveed,Z.,ur.011732642425.61
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Zhou,Xia,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Wang,Ke,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Li,Kunxia,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Lu,Sixia,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Cheng,Fang,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Xie,Xuelei,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Liu,Ying,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Wei,Ming,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Li,Huadong,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Fan,Guohui,ur.014755044646.73
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Huang,Chaolin,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Pan,Lihong,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Zhang,Dingyu,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Jia,Chunmin,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Xu,Jiuyang,ur.013600600671.13
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Xia,Jiaan,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Song,Bin,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Zhang,Yi,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Wang,Chen,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Gu,Xiaoying,ur.01323674617.33
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Bai,Tao,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Cai,Yanping,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Dong,Xuan,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Guo,Li,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Wen,Danning,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Liu,Zhibo,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Qu,Zhaohui,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Chen,Hua,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Yu,Ting,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Wang,Jingli,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Chen,Nanshan,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Cao,Bin,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Luo,Shanshan,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Zhan,Haiyan,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Jaki,Thomas,ur.01244503315.04
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Zhang,Li,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Ruan,Lianguo,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Dong,Chongya,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Wang,Shuzhen,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Li,Caihong,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Li,Xingwang,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Ge,Qin,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Liu,Wen,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Zhou,Fei,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Wang,Juan,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Horby,Peter W,ur.01006107443.13
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Ruan,Shunan,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Wu,Jing,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Huang,Hanping,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Xiang,Jie,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Peng,Lu,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Yuan,Ye,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,He,Jing,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Tu,Shengjing,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Zou,Jun,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Wu,Xudong,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Wei,Yuan,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Hayden,Frederick G,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Qiu,Fang,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Hu,Xujuan,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Gong,Fengyun,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Wang,Yeming,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Liu,Xia,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Li,Hui,
8167,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Shang,Lianhan,ur.01224670515.65
8152,The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries,group,Usher Network for COVID-19 Evidence Reviews,
8152,The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries,Kulkarni,Durga,ur.011236410455.83
8152,Effectiveness of Mask Wearing to Control Community Spread of SARS-CoV-2,Butler,Jay C.,
8152,The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries,Campbell,Harry,ur.01262170300.25
8152,The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries,Li,You,ur.0621264055.29
8152,The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries,Nair,Harish,ur.01372252340.53
8152,Effectiveness of Mask Wearing to Control Community Spread of SARS-CoV-2,Brooks,John T.,ur.016124243522.51
8152,The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries,Harpur,Alice,ur.013576603325.37
8152,The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries,Nundy,Madhurima,ur.013053162352.23
8152,The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries,Wang,Xin,ur.01035522225.26
8140,A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products,Rose,Jessica,
8140,A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products,McCullough,Peter A,
8125,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study,Barda,Noam,ur.013466722350.84
8125,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study,Balicer,Ran D,ur.0776006416.71
8125,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study,Kohane,Isaac S,ur.015317453537.75
8125,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study,Hernán,Miguel A,ur.01015164244.47
8125,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study,Cohen,Cyrille,
8125,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study,Lipsitch,Marc,ur.0750403636.04
8125,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study,Dagan,Noa,ur.01004303625.18
8125,Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study,Reis,Ben Y,ur.01273221262.54
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Li,Xingwang,
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Song,Jingdong,ur.01231340372.18
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Shi,Weifeng,ur.0711212027.68
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Lu,Roujian,ur.01223312003.08
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Zhan,Faxian,ur.0647317470.93
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Zhang,Dingyu,
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Zhu,Na,ur.01301202165.60
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Xu,Wenbo,ur.01046374136.89
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Tan,Wenjie,ur.01143221111.34
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Niu,Peihua,ur.01224402300.11
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Ma,Xuejun,ur.0656467260.27
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Zhao,Xiang,ur.01017434041.16
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Huang,Baoying,ur.01150543636.95
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Gao,George F,ur.01072733407.19
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Wang,Dayan,ur.01032364301.95
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Yang,Bo,ur.01360275057.53
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Wang,Wenling,ur.01102430436.06
8116,"A Novel Coronavirus from Patients with Pneumonia in China, 2019",Wu,Guizhen,ur.01370730353.32
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Rypka,Katelyn J,ur.016566652112.19
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Proper,Jennifer L,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Johnson,Darrell M,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Dunn,Alex T,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Odde,David J,ur.0776376562.12
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Murray,Thomas A,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Watson,Ray HB,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Kuehl,Erik A,ur.011245740622.59
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Mohamud,Zeinab,ur.016424164222.19
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Patel,Barkha,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Boulware,David R,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Belani,Hrishikesh K,ur.01217450462.15
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Reddy,Naveen,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Deng,Nikita,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Buse,John B,ur.0707447615.57
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Murray,Thomas A,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Mehta,Tanvi,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Sherwood,Nancy,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Stauffer,Maxwell T,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Nicklas,Jacinda M,ur.0756363673.51
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Ngonyama,Rumbidzai,ur.010376200414.60
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Odde,David J,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Bramante,Carolyn T,ur.0641465355.41
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Thompson,Jennifer,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Proper,Jennifer L,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Snyder,Andrew,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Siegel,Lianne K,ur.012645434777.52
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Broedlow,Courtney A,ur.012475145767.17
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Puskarich,Michael A,ur.01225534041.68
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Challa,Anup,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Erickson,Spencer M,ur.014064140546.43
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Fairbairn,Faith M,ur.015512355222.77
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Klatt,Nichole R,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Klatt,Nichole R,ur.011251314567.60
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Lindberg,Sarah,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Simmons,Lucas,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Lee,Samuel,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Thompson,Jennifer L,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Hagen,Aubrey A,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Nicklas,Jacinda M,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Tignanelli,Christopher J,ur.01045103044.18
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Beckman,Kenneth B,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Anderson,Blake J,ur.010104063635.54
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Rao,Via,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Singh,Palak,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Charles,Jill,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Zaman,Adnin,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Datta,Srijani,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Pullen,Matthew,ur.01112602310.82
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Hartman,Katrina M,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Beckman,Kenny B,ur.07470436022.18
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Fricton,Regina D,ur.012206722461.43
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Tople,Tannon L,ur.07611705214.44
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Parra,Daniela,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Ingraham,Nicholas E,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Bramante,Carolyn T,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Seloadji,Paula,ur.016167233206.37
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Campora,Paula,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Avula,Nandini,ur.012443162215.30
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Rose,Michael R,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Tordsen,Walker J,ur.011144351746.48
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Siegel,Lianne K,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Jeng,Arthur C,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Zinkl,Lena,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Fenno,Sarah L,ur.011673617146.53
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Pullen,Matthew F,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Wirtz,Esteban Lemus,ur.012662512414.97
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Belani,Hrishikesh K,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Liebovitz,David M,ur.01224273630.83
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Saveraid,Hanna G,ur.010346771346.95
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Buse,John B,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Cohen,Ken,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Wu,Beiqing,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Liebovitz,David M,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Parrens,Elliott,ur.012707015022.12
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Erickson,Spencer M,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Sinelli,Isabella,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Huling,Jared D,ur.011563633135.69
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Hendrickson,Audrey F,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Tignanelli,Christopher J,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Griffiths,Gwen,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Cohen,Ken,ur.016712510457.50
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",LaBar,Derek D,ur.012043321222.51
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Machicado,Rosario,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Christensen,Grace,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Bhat,Neeta S,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Brea,Jannis,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Shahriar,Arman,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Karger,Amy B,ur.015443341661.45
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Puskarich,Michael A,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Griffiths,Gwendolyn,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Reddy,Neha V,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Zolik,Madeline R,ur.011476415622.39
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Anderson,Blake,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Team,the COVID-OUT Study,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Sherwood,Nancy E,ur.014410350257.03
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Luke,Darlette G,ur.015474715266.08
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Atwater,Riannon C,ur.014662167767.27
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Boulware,David R,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Fenno,Sarah L,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Karger,Amy B,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Hartman,Katrina M,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Christiansen,Theresa,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Lindberg,Sarah M,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Fraser,Daniel J,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Patel,Barkha,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Connelly,Bo,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Huling,Jared D,
8115,"Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial",Siegart,Jamie L,ur.011516357165.88
8094,Climate change increases cross-species viral transmission risk,Olival,Kevin J.,ur.0765024442.22
8094,Climate change increases cross-species viral transmission risk,Zipfel,Casey M.,ur.011436213643.12
8094,Climate change increases cross-species viral transmission risk,Carlson,Colin J.,ur.0733413314.13
8094,Climate change increases cross-species viral transmission risk,Merow,Cory,ur.014241143375.58
8094,Climate change increases cross-species viral transmission risk,Bansal,Shweta,ur.01057322647.84
8094,Climate change increases cross-species viral transmission risk,Albery,Gregory F.,ur.01331075120.22
8094,Climate change increases cross-species viral transmission risk,Ross,Noam,ur.010634644701.08
8094,Climate change increases cross-species viral transmission risk,Trisos,Christopher H.,ur.0740404244.19
8094,Climate change increases cross-species viral transmission risk,Eskew,Evan A.,ur.01333552675.45
8079,"Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study",Ballin,Marcel,ur.011152402455.96
8079,"Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study",Nordström,Anna,ur.0762155014.34
8079,"Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study",Nordström,Peter,ur.01155463721.93
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Sieber,Raphael Niklaus,ur.015224113043.40
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Nielsen,Claus,ur.012060571327.31
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Kirkeby,Carsten Thure,ur.0760116314.14
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Rasmussen,Morten,ur.07604510130.84
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Krause,Tyra Grove,ur.0675313141.36
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Spiess,Katja,ur.0674562512.31
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Stegger,Marc,ur.01006173021.02
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Cohen,Arieh Sierra,ur.0735444064.54
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Skov,Robert Leo,ur.01146671601.91
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Lassaunière,Maria Magdalena,ur.010734244116.04
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Fomsgaard,Anders,ur.01127321406.44
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Møller,Camilla Holten,ur.0717577074.27
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Møller,Frederik Trier,ur.0716134556.84
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Mølbak,Kåre,ur.0730116643.78
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Overvad,Maria,ur.013635401536.53
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Denwood,Matthew J.,ur.0736765666.51
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Christiansen,Lasse Engbo,ur.01371012123.34
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Mortensen,Laust Hvas,ur.01113025205.88
8034,SARS-CoV-2 Omicron VOC Transmission in Danish Households,Lyngse,Frederik Plesner,ur.016623162563.78
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Lapuente,Dennis,ur.012424500355.39
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Wytopil,Monika,ur.010140063147.07
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Schober,Kilian,ur.0647371763.88
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Bogdan,Christian,ur.01166137245.29
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Überla,Klaus,ur.01046515654.90
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Nganou-Makamdop,Krystelle,ur.01253325270.41
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Winkler,Thomas H,ur.01347421311.19
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Beileke,Stephanie,ur.01251370016.23
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Held,Jürgen,ur.0732667360.84
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Krey,Thomas,ur.01341027035.41
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Habenicht,Katharina,ur.014274244127.34
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Falcone,Valeria,ur.01353263331.52
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Gerling,Juliane,ur.012417777762.98
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Tenbusch,Matthias,ur.01117723625.93
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Kocher,Katharina,ur.015163302657.35
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Irrgang,Pascal,ur.013040376275.75
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Hengel,Hartmut,ur.01061476374.53
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Zhong,Jahn,ur.010275571562.02
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Peter,Antonia Sophia,ur.015227676577.57
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Schäfer,Simon,ur.012213326524.04
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Ssebyatika,George,
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Steininger,Philipp,ur.01272544120.68
8032,"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination",Schülein,Christine,ur.013263473562.58
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Hammers,Alexander,ur.0622704043.68
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Duncan,Emma L,ur.01066220204.44
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Canas,Liane S,ur.011150563134.84
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Hughes,Robert C,ur.015427252622.55
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Kläser,Kerstin,ur.014757717416.43
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Absoud,Michael,ur.01320770474.02
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Molteni,Erika,ur.0666071557.67
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Selvachandran,Somesh,ur.011500202133.63
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Modat,Marc,ur.01024265042.96
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Read,Kenneth,ur.07503572225.37
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Kerfoot,Eric,ur.01204520201.47
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Antonelli,Michela,ur.010230774161.66
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Sudre,Carole H,ur.01023457345.27
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Hu,Christina,ur.010157215433.71
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Ourselin,Sebastien,ur.0731256650.39
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Deng,Jie,ur.014613702425.94
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Bhopal,Sunil S,ur.01132527633.41
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Pujol,Joan Capdevila,ur.011612413713.08
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Steves,Claire J,ur.0624116417.81
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Chen,Liyuan,ur.014016322025.40
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Murray,Benjamin,ur.013430343311.17
8029,Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2,Spector,Tim D,ur.014424006237.85
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Pizarro,Alejandra,ur.016045703241.64
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,González,Cecilia,ur.013243200773.14
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Suárez,Pamela,ur.011302435745.91
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Paredes,Fabio,ur.012306113477.53
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Leon,Francisco,ur.016412546145.28
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Fontecilla,Tomás,
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Leo,Katherinne,ur.016046416144.07
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Acevedo,Johanna,ur.0631503026.87
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Jara,Alejandro,ur.0625741743.56
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Sans,Carlos,
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Araos,Rafael,ur.01313303231.83
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Jara,Gonzalo,
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,García-Escorza,Heriberto,ur.012100016345.27
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Undurraga,Eduardo A,ur.0664506534.53
8021,Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,Leighton,Paulina,ur.010505055345.29
8016,"Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19",Dercon,Quentin,ur.013564123230.35
8016,"Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19",Taquet,Maxime,ur.01170177602.97
8016,"Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19",Geddes,John R.,ur.010743477572.37
8016,"Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19",Harrison,Paul J.,ur.011112526240.39
8016,"Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19",Luciano,Sierra,ur.014736302723.99
8016,"Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19",Husain,Masud,ur.01274035212.39
8005,Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7,Keogh,Ruth H.,ur.0627311005.83
8005,Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7,Davies,Nicholas G.,ur.0760610156.85
8005,Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7,Diaz-Ordaz,Karla,ur.01243447530.42
8005,Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7,Jarvis,Christopher I.,ur.012767253533.11
8005,Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7,Edmunds,W. John,ur.01211713667.68
8005,Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7,Jewell,Nicholas P.,ur.01356231700.87
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Czeisler,Charles A.,ur.0707242143.09
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Robbins,Rebecca,ur.01070503050.93
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Czeisler,Mark É.,ur.014636216235.86
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Petrosky,Emiko,ur.0605003366.40
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Facer-Childs,Elise R.,ur.01265620772.08
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Howard,Mark E.,ur.01356050747.08
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Barger,Laura K.,ur.01010177351.65
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Weaver,Matthew D.,ur.01204523643.17
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Christensen,Aleta,
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Rajaratnam,Shantha M.W.,ur.0745512444.01
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Njai,Rashid,ur.0723011047.57
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Wiley,Joshua F.,ur.0760460710.88
8000,"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020",Lane,Rashon I.,ur.01321135422.97
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Zervos,Marcus,ur.01023233156.63
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Brar,Indira,ur.0620313010.98
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Ruhala,Joseph,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Lanfranco,Odaliz Abreu,ur.01023565412.81
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Parraga,Tommy,ur.0720421140.54
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Force,Henry Ford COVID-19 Task,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Gardner-Gray,Jayna,ur.01014167675.34
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Herc,Erica,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Ackerman,Adam M.,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Nadeem,Owais,ur.013550617343.18
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Suleyman,Geehan,ur.0757370027.60
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Nauriyal,Varidhi,ur.010130276557.79
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Maki,Gina,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Jacobsen,Gordon,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",McKinnon,John E.,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Bhargava,Pallavi,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Wang,Dee Dee,ur.01104032056.73
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Godfrey,Amanda,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Gudipati,Smitha,ur.011575214057.25
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Shallal,Anita,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Fadel,Raef,ur.016326377733.43
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Chaudhry,Zohra S.,ur.07542721227.51
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Arshad,Samia,ur.01044275231.43
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Yared,Nicholas,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",O’Neill,William,ur.01177720704.50
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Kilgore,Paul,ur.0672463314.51
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Lezotte,Jonathan,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Swiderek,Jennifer,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Huitsing,Kylie,ur.014761216543.82
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Hamed,Asif Abdul,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Williams,Johnathan,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Vahia,Amit,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Tariq,Zain,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Alangaden,George J.,ur.01050506313.08
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Reyes,Katherine,
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Ramesh,Mayur S.,ur.0672415661.25
7983,"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19",Jennings,Jeffrey,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Yo,Kikuo,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,DeZure,Adam,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Chelliah,Daniel,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Cohen,Stuart H,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,L'Her,Erwan,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Telep,Laura,ur.013656455076.15
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Chihara,Shingo,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Cunningham,Jennifer,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Massari,Marco,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Tan,Susanna K,ur.013132510371.44
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Mera,Robertino,ur.01366265737.52
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Kato,Hideaki,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,D'Arminio Monforte,Antonella,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Oda,Rentaro,ur.012725157705.93
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Lapadula,Giuseppe,ur.011154253474.49
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Maeno,Toshitaka,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Winterbourne,Lucinda,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Ismail,Saad,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Nicastri,Emanuele,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Brainard,Diana M,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Mutoh,Yoshikazu,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Myers,Robert P,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Green,Gary,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Timbs,Leighann,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Flanigan,Timothy,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Quiros-Roldan,Eugenia,ur.01307066107.92
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Osinusi,Anu O,ur.011471106367.46
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Asperges,Erika,ur.015141711127.86
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Zoufaly,Alexander,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Cao,Huyen,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Ohmagari,Norio,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Bernett,Jorge,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Mora-Rillo,Marta,ur.0625114312.32
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Grein,Jonathan,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Verweij,Ewa,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Desai,Polly,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Zhao,Yang,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Henne,Ilana,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Redinski,John,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Diaz,George,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Ahmed,Seema,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Lescure,François-Xavier,ur.0774765255.29
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Castagna,Antonella,ur.0615450407.15
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Elboudwarej,Emon,ur.01027702724.84
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Sellers,Scott,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Shin,Daniel,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Nguyen,Duc,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Childs,Richard,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Feldt,Torsten,ur.0647064560.93
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Chen,Danny,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Chokkalingam,Anand,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Majumder,Sumit,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Studemeister,Alex,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Gaggar,Anuj,ur.01247135210.76
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Green,Margaret L,
7959,Compassionate Use of Remdesivir for Patients with Severe Covid-19,Zhong,Lijie,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Feldstein,Leora R.,ur.0705636116.22
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Steingrub,Jay S.,ur.0717663645.19
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Ginde,Adit A.,ur.0750734154.48
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",,,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",,,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Shapiro,Nathan I.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Hager,David N.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Wu,Michael J.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Marcet,Paula L.,ur.01201724506.22
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Gong,Michelle N.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Wilson,Jennifer G.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Lindsell,Christopher J.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Smith,Emily R.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Siddula,Akshita,ur.013075331570.16
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Aboodi,Michael S.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Tenforde,Mark W.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Ogokeh,Constance E.,ur.012223240205.69
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Khan,Akram,ur.01067174343.39
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Files,D. Clark,ur.01225026435.34
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",,,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Hart,Kimberly W.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Stubblefield,William B.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Rice,Todd W.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Billig Rose,Erica,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Erickson,Heidi L.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",,,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",McClellan,Robert,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Gibbs,Kevin W.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Self,Wesley H.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Smithline,Howard A.,ur.01301063313.68
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Henning,Daniel J.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Sciarratta,Courtney N.,ur.013441316413.03
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Patel,Manish M.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Exline,Matthew C.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Brown,Samuel M.,ur.01116631602.39
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Qadir,Nida,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Kim,Sara S.,ur.014752014553.22
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",,,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Kassem,Ahmed M.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Griggs,Eric P.,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Peltan,Ithan D.,ur.01357525642.33
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",,,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Dorough,Layne,
7955,"Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020",Dzuris,Nicole,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Kitchin,Nicholas,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Xu,Xia,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Mather,Susan,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Sabharwal,Charu,ur.01270112623.27
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Koury,Kenneth,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Perez,John L,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Paulsen,Grant C,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Talaat,Kawsar R,ur.01220170321.73
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Barnett,Elizabeth D,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Pahud,Barbara A,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Lockhart,Stephen,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Kuchar,Ernest,ur.01073214512.51
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Jansen,Kathrin U,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Swanson,Kena A,ur.0720727651.67
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Ma,Hua,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Rojo,Pablo,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Lagkadinou,Eleni,ur.015763054503.38
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Dormitzer,Philip R,ur.01124563153.82
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Rämet,Mika,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Domachowske,Joseph B,ur.01316400061.24
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Gurtman,Alejandra,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Sarwar,Uzma N,ur.0617060716.18
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Walter,Emmanuel B,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Frenck,Robert W,ur.01157665701.10
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Simões,Eric A F,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Şahin,Uğur,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Belanger,Todd J,ur.01320316325.26
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Gruber,William C,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Munjal,Iona,ur.01032205451.37
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Maldonado,Yvonne,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Cooper,David,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Muñoz,Flor M,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Cunliffe,Luke,
7947,Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age,Türeci,Özlem,
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Parag,Kris V,ur.015313465463.78
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",de Souza Santos,Andreza Aruska,ur.011252743054.77
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Nascimento,Vítor H,ur.012614031273.28
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Busch,Michael P,ur.013607550117.29
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Kraemer,Moritz U G,ur.014532552104.23
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Pybus,Oliver G,ur.01015416541.17
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Pereira,Henrique S,ur.011366470313.14
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Prete,Carlos A,ur.011555147707.87
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Buss,Lewis F,ur.013643142351.10
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Cucunuba,Zulma M,ur.01314342114.23
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Carvalho,Maria P S,
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Castro,Márcia C,ur.01044376112.88
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",da Silva Peixoto,Pedro,ur.015772165105.61
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Crispim,Myuki A E,ur.01047416524.49
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Sabino,Ester C,ur.0770401673.22
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Ferguson,Neil M,ur.01346743312.51
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Dye,Christopher,ur.013571057537.22
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Kucharski,Adam,ur.0623443112.40
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Oikawa,Marcio K,ur.01023561355.76
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Fraiji,Nelson A,ur.01231760324.09
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Faria,Nuno R,ur.01053566600.96
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Pereira,Rafael H M,ur.01336264527.94
7940,"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence",Salomon,Tassila,ur.01011446463.02
7939,Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19),Patel,Ami B.,ur.013265464757.59
7939,Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19),Zheng,Xiaotian,ur.01015601031.29
7939,Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19),Heald-Sargent,Taylor,ur.01176653677.19
7939,Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19),Rippe,Jason,ur.011312413333.07
7939,Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19),Kociolek,Larry K.,ur.0776141503.31
7939,Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19),Muller,William J.,ur.015267441452.98
7928,Heat-related mortality in Europe during the summer of 2022,Quijal-Zamorano,Marcos,ur.013234553207.51
7928,Heat-related mortality in Europe during the summer of 2022,Basagaña,Xavier,ur.01064540526.40
7928,Heat-related mortality in Europe during the summer of 2022,Ballester,Joan,ur.01360644410.04
7928,Heat-related mortality in Europe during the summer of 2022,Robine,Jean Marie,ur.0646426466.49
7928,Heat-related mortality in Europe during the summer of 2022,Antó,Josep M.,ur.01023676367.07
7928,Heat-related mortality in Europe during the summer of 2022,Méndez Turrubiates,Raúl Fernando,ur.014200707341.43
7928,Heat-related mortality in Europe during the summer of 2022,Tonne,Cathryn,ur.0723402275.58
7928,Heat-related mortality in Europe during the summer of 2022,Pegenaute,Ferran,ur.016006413314.32
7928,Heat-related mortality in Europe during the summer of 2022,Achebak,Hicham,ur.012452461441.73
7928,Heat-related mortality in Europe during the summer of 2022,Herrmann,François R.,ur.01206175026.02
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",León,Tomás M.,ur.011214437771.17
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Bassett,Mary T.,ur.01241376077.77
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Lutterloh,Emily,ur.0576300304.23
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Rosenberg,Eli S.,ur.01316004736.66
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Backenson,Bryon,ur.07747267525.15
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Silk,Benjamin J.,ur.01344715227.05
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Bauer,Ursula E.,ur.01365567140.07
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Midgley,Claire M.,ur.01234010430.93
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Dorabawila,Vajeera,ur.0601477675.61
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Myers,Jennifer F.,ur.015363164005.96
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Bregman,Brooke,
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Watt,James P.,ur.0725437352.01
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Zhao,Rui,
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Plumb,Ian D.,ur.013415532316.55
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Jain,Seema,ur.01322642644.57
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Henry,Hannah,
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Nelson,Lauren,ur.012350106272.27
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Reese,Heather E.,ur.016546511063.95
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Hoefer,Dina,ur.01221267667.35
7895,"COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021",Briggs-Hagen,Melissa,ur.011153326731.66
7859,"Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects",Proença,Fernando Carlos,ur.016046413366.69
7859,"Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects",Kerr,Lucy,ur.012263130766.55
7859,"Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects",Hibberd,Jennifer A.,ur.010542422303.49
7859,"Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects",Proença,Fernando Carlos,ur.012022371770.41
7859,"Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects",Baldi,Fernando,ur.0662707420.57
7859,"Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects",Cadegiani,Flavio A.,ur.011314721135.77
7859,"Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects",Chamie,Juan J.,
7859,"Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects",Assagra,Washington Luiz,
7859,"Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects",Kory,Pierre,ur.01263214251.87
7859,"Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects",Assagra,Washington Luiz,
7859,"Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects",Lobo,Raysildo,ur.0730356724.74
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Henao-Restrepo,Ana Maria,ur.01026344150.11
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,García,César Hernández,
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Malekzadeh,Reza,ur.01021433041.43
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Peto,Richard,
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,consortium,WHO Solidarity trial,ur.013017406634.28
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Murthy,Srinivas,ur.0740103341.37
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Sathiyamoorthy,Vasee,ur.014502703401.31
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Preziosi,Marie-Pierre,ur.01346415021.54
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Kieny,Marie-Paule,ur.01200022665.94
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Alejandria,Marissa,ur.0650325162.17
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Periago,Mirta Roses,ur.0731330130.07
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Pan,Hongchao,ur.0702153606.07
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Committee,assume responsibility for the content and integrity of this article as the members of the Writing,
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Reddy,Srinath,ur.0576516131.40
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Røttingen,John-Arne,ur.01207073626.16
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Swaminathan,Soumya,ur.01017756724.35
7841,Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results,Karim,Quarraisha Abdool,ur.01350176674.12
7818,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel,Bar-On,Yinon M,ur.0665247076.28
7818,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel,Goldberg,Yair,ur.01051103470.43
7818,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel,Alroy-Preis,Sharon,ur.01061334326.15
7818,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel,Bodenheimer,Omri,ur.016326715244.10
7818,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel,Kalkstein,Nir,ur.016647165135.13
7818,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel,Freedman,Laurence,ur.01154263410.83
7818,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel,Milo,Ron,ur.0774352340.01
7818,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel,Ash,Nachman,ur.01205514201.07
7818,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel,Mizrahi,Barak,ur.015150611707.11
7818,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel,Mandel,Micha,ur.01207744736.07
7818,Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel,Huppert,Amit,ur.01032344140.62
7810,High-dimensional characterization of post-acute sequelae of COVID-19,Xie,Yan,ur.0737732757.38
7810,High-dimensional characterization of post-acute sequelae of COVID-19,Bowe,Benjamin,ur.0736221463.48
7810,High-dimensional characterization of post-acute sequelae of COVID-19,Al-Aly,Ziyad,ur.0756001054.57
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,van Driel,Mieke L,ur.01123705141.19
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Al-Ansary,Lubna A,ur.01257427357.51
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Del Mar,Chris B,ur.015405173575.39
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Beller,Elaine M,ur.01061550363.13
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Jefferson,Tom,ur.0745413111.75
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Glasziou,Paul P,ur.010361417657.66
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Clark,Justin,ur.0734347735.52
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Dooley,Liz,ur.01114051654.03
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Jones,Mark A,ur.0712645702.33
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Thorning,Sarah,ur.0602136457.02
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Bawazeer,Ghada A,ur.01053224250.68
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Ferroni,Eliana,ur.01325542557.35
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Conly,John M,ur.0612603027.67
7780,Physical interventions to interrupt or reduce the spread of respiratory viruses,Hoffmann,Tammy C,ur.0674537760.65
7778,Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines,Dray-Spira,Rosemary,ur.01116233552.72
7778,Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines,Weill,Alain,ur.01241113150.23
7778,Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines,Le Vu,Stéphane,ur.0732327333.16
7778,Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines,Zureik,Mahmoud,ur.01313571440.98
7778,Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines,Baricault,Bérangère,ur.010434334063.01
7778,Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines,Drouin,Jérôme,ur.0663732107.25
7778,Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines,Bertrand,Marion,ur.0745074042.69
7778,Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines,Jabagi,Marie-Joelle,ur.012470325523.85
7778,Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines,Botton,Jérémie,ur.01144751763.38
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",McMullen,Chelsea,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Holtzman,Corinne,ur.01047120125.87
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Blythe,David,ur.01226455661.86
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Fisher,Rebecca,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Duwell,Monique,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Kidrowski,Holly,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Stanislawski,Emma,ur.012423262616.43
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Saupe,Amy,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Griffin,Jennifer,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Duchin,Jeff,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Wilson,Erica,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Nolen,Leisha,ur.01014407704.58
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Kugeler,Kiersten,ur.01326715401.34
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Silk,Benjamin J.,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Sell,Jessica,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Bertolino,Daniel,ur.013276273037.92
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Alden,Nisha B.,ur.01100337767.78
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Hicks,Liam,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Suthar,Amitabh B.,ur.01235454544.49
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Delgadillo,Janelle,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Lewis,Melissa,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Balter,Sharon,ur.0720406272.70
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Sosin,Daniel,ur.07405227470.53
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Hawkins,Eric,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Cadwell,Betsy,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Hand,Julie,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Vest,Hailey,ur.013553537470.19
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Herlihy,Rachel K.,ur.0705764041.81
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Davidson,Sherri,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Devinney,Katelynn,ur.013730203504.83
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Reese,Heather E.,ur.016546511063.95
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Meyer,Stephanie,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Hoskins,Mikhail,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Johnson,Amelia G.,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Pogosjans,Sargis,ur.015745400543.40
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Kim,Curi,ur.07640013564.25
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",MacNeil,Adam,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Scobie,Heather M.,ur.01202464077.58
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Brady,Shane,ur.010310042427.82
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Ritchey,Matthew D.,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Grant,Ashley,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Hanson,Matt,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Stevens,Kelly,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Lyons,Shelby,ur.016425213070.55
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Lynfield,Ruth,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",McCaffrey,Keegan,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Patel,Monita R.,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Milroy,Lauren,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",White,Kelly,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Sokol,Theresa,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Fleischauer,Aaron,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Severson,Rachel,ur.016631337263.27
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Hyun,Judie,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Haddix,Meredith,ur.016446643451.35
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Komatsu,Kenneth,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Kaur,Ramandeep,
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Lyons,B. Casey,ur.014536023535.43
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Cheng,Iris,ur.015772733043.55
7769,"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021",Kay,Meagan,
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Villar-Garcia,Judith,ur.013676322225.40
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Campodarve,Isabel,ur.010654264544.48
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Gimenez-Argente,Carme,ur.0700072715.03
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Pascual,Julio,ur.01057670011.30
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Rodriguez-Morera,Jaime,ur.0610306752.52
7766,Calcifediol Treatment and COVID-19-Related Outcomes,García-Giralt,Natalia,ur.01151755241.30
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Ovejero,Diana,ur.01266471640.47
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Pineda-Moncusí,Marta,ur.013720325634.08
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Quesada-Gomez,J. M.,ur.01015005174.40
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Nogués,Xavier,ur.01207130075.17
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Rial,Abora,ur.015313266634.91
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Guerri-Fernandez,Robert,ur.0576631470.21
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Bouillon,Roger,ur.01126737302.39
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Arenas,Dolores,
7766,Calcifediol Treatment and COVID-19-Related Outcomes,Cos,ML.,ur.016706227634.97
7754,Five reasons why COVID herd immunity is probably impossible,Aschwanden,Christie,
7750,Batch‐dependent safety of the BNT162b2 mRNA COVID‐19 vaccine,Schmeling,Max,ur.011201647372.49
7750,Batch‐dependent safety of the BNT162b2 mRNA COVID‐19 vaccine,Hansen,Peter Riis,ur.012614634717.94
7750,Batch‐dependent safety of the BNT162b2 mRNA COVID‐19 vaccine,Manniche,Vibeke,ur.0775303622.06
7710,"Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020",Lanzieri,Tatiana M.,ur.0662233523.04
7710,"Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020",MacKellar,Duncan,ur.07352645061.03
7710,"Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020",Morris,Elana,ur.01076764267.91
7710,"Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020",Smith-Grant,Jennifer,ur.015002444773.00
7710,"Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020",Aholou,Tiffiany Michelle,ur.010044632421.00
7710,"Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020",Thompson-Paul,Angela M.,ur.01304611114.47
7710,"Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020",Drenzek,Cherie,ur.0662331351.38
7710,"Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020",Haller,Elizabeth,
7710,"Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020",Thomas,Ebony,ur.0743303305.05
7710,"Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020",Rasberry,Catherine,ur.01367773210.92
7710,"Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020",Czarnik,Michaila,ur.013332775257.29
7710,"Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020",Gettings,Jenna,ur.01370463764.36
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Kim,Inhye,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Lee,Hyeyoung,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Kim,Miyoung,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Kim,Hye Kyung,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Kweon,Sanghui,ur.01047272216.91
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Kim,Young-Man,ur.0673231253.00
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Yi,Seonju,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Park,Shin Young,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Park,Yoojin,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Kim,Jung-il,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Na,Baeg-Ju,ur.0735271746.29
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Jeong,Eun Kyeong,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Chang,Yeonhwa,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Choe,Young June,ur.01351440537.03
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Kim,Seong Sun,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Gwack,Jin,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Kim,Kyungnam,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Kim,Hea Sook,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Kim,Chang Bo,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Jang,Hanaram,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Lee,Sangeun,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Yoon,Hyung Jun,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Park,Ok,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Park,Young Joon,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Kim,Young Bok,
7701,"Coronavirus Disease Outbreak in Call Center, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC",Huh,In Sil,ur.01265262253.70
7657,Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,Hripcsak,George,ur.01304304572.48
7657,Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,Sun,Yifei,ur.07455656231.15
7657,Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,Geleris,Joshua,ur.015363347031.27
7657,Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,Manson,Daniel K,ur.012336216633.17
7657,Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,Platt,Jonathan,
7657,Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,Sobieszczyk,Magdalena E,ur.013663325007.07
7657,Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,Baldwin,Matthew,ur.01221273336.94
7657,Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,Schluger,Neil W,ur.0651566106.30
7657,Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,Kubin,Christine,ur.01211413174.02
7657,Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,Barr,R Graham,ur.01053041010.79
7657,Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,Zucker,Jason,ur.0671366471.22
7657,Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19,Labella,Angelena,ur.01014112360.04
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Horne,Elizea,ur.016361476075.96
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Malahleha,Mookho,ur.0732276355.01
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Gilbert,Sarah,ur.0762502203.86
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Taoushanis,Carol,ur.010354501503.45
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Cutland,Clare L,ur.014745402454.20
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Oelofse,Suzette,ur.016120036357.51
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Baillie,Vicky,ur.01235513461.21
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,du Plessis,Jeanine,
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Patel,Faeezah,ur.01076006342.03
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Aley,Parvinder,ur.01144267763.20
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Villafana,Tonya L,ur.01160651642.84
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Durham,Nicholas M,
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Bhiman,Jinal N,ur.01217220246.13
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Izu,Alane,ur.01051426511.85
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Sigal,Alex,
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,van Eck,Samuel,
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Rhead,Sarah,
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Dheda,Keertan,ur.01257776220.51
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Moultrie,Andrew,ur.015432706003.74
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Wibmer,Constantinos K,ur.0603724441.86
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Ahmed,Khatija,ur.016453420063.28
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Kelly,Elizabeth J,ur.010623611357.52
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Molapo,Kgaogelo,ur.012764416375.83
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,de Oliveira,Tulio,ur.01241142544.51
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Rodel,Hylton,ur.013653525017.18
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Laubscher,Matt,ur.012770776712.04
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Voysey,Merryn,ur.01043520166.14
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Masilela,Mduduzi,ur.07662265775.54
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Bhorat,Qasim E,ur.016706671635.11
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Padayachee,Sherman D,ur.013426040535.84
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,McKenzie,Shakeel,ur.011103746703.74
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Barnabas,Shaun L,ur.01077552167.43
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Madhi,Shabir A,ur.01165655111.49
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Hwa,Shi-Hsia,ur.01365630727.00
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Rossouw,Lindie,ur.010516550503.21
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Kwatra,Gaurav,ur.01340446423.72
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Pillay,Sureshnee,ur.0605377427.61
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Lambe,Teresa,
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Briner,Carmen,ur.013525042277.44
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Masenya,Masebole,ur.015714736755.26
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Bhorat,As'ad E,ur.016251104632.02
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Groenewald,Marisa,
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Pollard,Andrew J,
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Jose,Aylin,
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Koen,Anthonet L,ur.01050512507.64
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Moore,Penny L,ur.016541334057.78
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Bhikha,Sutika,ur.011647423403.19
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Fairlie,Lee,ur.01072731604.87
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Tegally,Houriiyah,ur.07544025467.47
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Esmail,Aliasgar,ur.0774746543.48
7644,Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant,Thombrayil,Asha,ur.013110347175.40
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Zuckerman,Neta,ur.01113151555.86
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Rubin,Carmit,ur.0650165263.09
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Lustig,Yaniv,ur.01177755223.26
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Indenbaum,Victoria,ur.012243404525.69
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Tal,Ilana,ur.01203235571.90
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Lipsitch,Marc,ur.0750403636.04
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Bar-Chaim,Adina,ur.0741462573.00
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Gonen,Tal,ur.01315311104.06
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Amit,Sharon,ur.0736316167.73
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Cohen,Carmit,ur.014753132231.81
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Regev-Yochay,Gili,ur.01300073010.49
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Bergwerk,Moriah,ur.016645610717.10
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Kreiss,Yitshak,ur.01175667404.72
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Mandelboim,Michal,ur.01105123653.33
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Levin,Einav Gal,ur.07366365054.48
7633,Covid-19 Breakthrough Infections in Vaccinated Health Care Workers,Zavitan,Malka,
7623,The race for coronavirus vaccines: a graphical guide,Callaway,Ewen,
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Chelico,John D.,ur.0650027671.20
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Kim,Eun Ji,ur.010247325123.07
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Davidson,Karina W.,ur.01361040570.31
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Qiu,Michael,
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Becker,Lance B.,ur.0674122065.88
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Kozel,Zachary M.,ur.012007044607.22
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",McGinn,Thomas,ur.0727355506.22
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Mogavero,Jazmin N.,ur.015740465643.81
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Dominello,Andrew J.,ur.012730154155.01
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Cookingham,Jennifer,ur.010537632555.78
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Cohen,Stuart L.,ur.016553166351.85
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Hirsch,Jamie S.,ur.0631255506.12
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Coppa,Kevin,ur.011335213155.25
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Harvin,Tiffany G.,
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Falzon,Louise,ur.0646035452.06
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Osorio,Gabrielle A.,ur.014371230355.01
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Zanos,Theodoros P.,ur.0761600773.07
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Marrast,Lyndonna M.,ur.01365407576.40
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Gitlin,Jordan,ur.0632404077.18
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Hirschwerk,David A.,ur.01152603332.73
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Richardson,Safiya,ur.01146360247.62
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Duer-Hefele,Joan,ur.0773453707.55
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Hajizadeh,Negin,ur.01266577001.38
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Crawford,James M.,
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Barnaby,Douglas P.,ur.01160246513.37
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Narasimhan,Mangala,ur.01333452212.55
7612,"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",Diefenbach,Michael A.,ur.0666126167.30
7610,Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021,Kuodi,Paul,ur.010630002731.20
7610,Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021,Wiegler,Karine Beiruti,ur.010341266567.10
7610,Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021,Glikman,Daniel,ur.0701103604.83
7610,Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021,Nazzal,Saleh,ur.015360440206.14
7610,Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021,Gorelik,Yanay,ur.012134211025.87
7610,Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021,Zayyad,Hiba,ur.0725716165.10
7610,Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021,Edelstein,Michael,ur.011203002715.06
7610,Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021,Wertheim,Ofir,ur.012372536206.08
7610,Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021,Abu Jabal,Kamal,ur.01232443533.46
7610,Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021,Dror,Amiel A.,ur.01106722432.26
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Medina-Peralta,Manuel,ur.01034723352.84
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Prats,Clara,ur.01323254521.43
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Bassat,Quique,ur.01074511734.95
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Gatell,Anna,ur.015425701363.01
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Alvarez-Lacalle,Enric,ur.0676042470.51
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Alonso,Sergio,ur.0610445501.94
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Mas,Ariadna,ur.015500451707.81
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Fina-Aviles,Francesc,ur.01230127255.99
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Pino,David,ur.016657424717.63
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Coma,Ermengol,ur.0642131244.21
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Hermosilla,Eduardo,ur.0734503577.93
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Méndez-Boo,Leonardo,ur.0750565120.04
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Asso,Laia,ur.013163010714.34
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Català,Martí,ur.013062305037.22
7599,Unravelling the Role of the Mandatory Use of Face Covering Masks for the Control of SARS-CoV-2 in Schools: A Quasi-Experimental Study Nested in a Population-Based Cohort in Catalonia (Spain),Soriano-Arandes,Antoni,ur.010452051364.78
7573,Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing,Parker,Michael,ur.0621200426.94
7573,Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing,Kendall,Michelle,ur.010602206271.36
7573,Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing,Fraser,Christophe,ur.01117563357.14
7573,Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing,Wymant,Chris,ur.07744360620.57
7573,Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing,Zhao,Lele,ur.07621634154.45
7573,Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing,Bonsall,David,ur.01323374357.86
7573,Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing,Abeler-Dörner,Lucie,ur.01226317443.77
7573,Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing,Ferretti,Luca,ur.0604607310.31
7573,Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing,Nurtay,Anel,ur.015201663053.40
7560,Persistent Cardiac Magnetic Resonance Imaging Findings in a Cohort of Adolescents with Post-Coronavirus Disease 2019 mRNA Vaccine Myopericarditis,Schauer,Jenna,ur.011655715647.51
7560,Persistent Cardiac Magnetic Resonance Imaging Findings in a Cohort of Adolescents with Post-Coronavirus Disease 2019 mRNA Vaccine Myopericarditis,Law,Yuk,ur.01137721221.96
7560,Persistent Cardiac Magnetic Resonance Imaging Findings in a Cohort of Adolescents with Post-Coronavirus Disease 2019 mRNA Vaccine Myopericarditis,Sagiv,Eyal,ur.01060517747.29
7560,Persistent Cardiac Magnetic Resonance Imaging Findings in a Cohort of Adolescents with Post-Coronavirus Disease 2019 mRNA Vaccine Myopericarditis,Portman,Michael A,ur.0701446623.05
7560,Persistent Cardiac Magnetic Resonance Imaging Findings in a Cohort of Adolescents with Post-Coronavirus Disease 2019 mRNA Vaccine Myopericarditis,Chikkabyrappa,Sathish Mallenahalli,ur.01007566067.88
7560,Persistent Cardiac Magnetic Resonance Imaging Findings in a Cohort of Adolescents with Post-Coronavirus Disease 2019 mRNA Vaccine Myopericarditis,Buddhe,Sujatha,ur.0757042233.43
7560,Persistent Cardiac Magnetic Resonance Imaging Findings in a Cohort of Adolescents with Post-Coronavirus Disease 2019 mRNA Vaccine Myopericarditis,Studer,Matthew,
7560,Persistent Cardiac Magnetic Resonance Imaging Findings in a Cohort of Adolescents with Post-Coronavirus Disease 2019 mRNA Vaccine Myopericarditis,Colyer,Jessica,ur.01322476371.85
7560,Persistent Cardiac Magnetic Resonance Imaging Findings in a Cohort of Adolescents with Post-Coronavirus Disease 2019 mRNA Vaccine Myopericarditis,Gulhane,Avanti,ur.012340706060.52
7556,"Pandemics Depress the Economy, Public Health Interventions Do Not: Evidence from the 1918 Flu",Correia,Sergio,ur.014225726714.40
7556,"Pandemics Depress the Economy, Public Health Interventions Do Not: Evidence from the 1918 Flu",Verner,Emil,ur.014111334611.18
7556,"Pandemics Depress the Economy, Public Health Interventions Do Not: Evidence from the 1918 Flu",Luck,Stephan,ur.016374306126.79
7551,Myocarditis-induced Sudden Death in South Korea after BNT162b2 mRNA COVID-19 Vaccination: Case Report Focusing on the Histopathological Findings,Yeo,Nam Seok,ur.013165344014.77
7551,Myocarditis-induced Sudden Death in South Korea after BNT162b2 mRNA COVID-19 Vaccination: Case Report Focusing on the Histopathological Findings,Choi,Sangjoon,ur.016101271514.91
7551,Myocarditis-induced Sudden Death in South Korea after BNT162b2 mRNA COVID-19 Vaccination: Case Report Focusing on the Histopathological Findings,Seo,Jeong-Wook,ur.01260123017.19
7551,Myocarditis-induced Sudden Death in South Korea after BNT162b2 mRNA COVID-19 Vaccination: Case Report Focusing on the Histopathological Findings,Lee,Jong Kyu,ur.012367763414.59
7551,Myocarditis-induced Sudden Death in South Korea after BNT162b2 mRNA COVID-19 Vaccination: Case Report Focusing on the Histopathological Findings,Kim,Min-ju,ur.010271164425.16
7551,Myocarditis-induced Sudden Death in South Korea after BNT162b2 mRNA COVID-19 Vaccination: Case Report Focusing on the Histopathological Findings,Jeon,Yo Han,ur.07676024336.94
7551,Myocarditis-induced Sudden Death in South Korea after BNT162b2 mRNA COVID-19 Vaccination: Case Report Focusing on the Histopathological Findings,Lee,SangHan,ur.015417141237.80
7551,Myocarditis-induced Sudden Death in South Korea after BNT162b2 mRNA COVID-19 Vaccination: Case Report Focusing on the Histopathological Findings,Park,Ji Hyun,ur.015373767247.54
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Yan,Bing,ur.015736174547.01
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Shi,Zheng-Li,ur.012321453367.61
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Zhang,Lei,ur.010452676461.21
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Huang,Chao-Lin,ur.013022047745.39
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Xiao,Geng-Fu,ur.0666617712.38
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Guo,Hua,ur.01372202176.19
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Hu,Ben,ur.01234446535.67
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Yang,Xing-Lou,ur.01156515364.78
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Liu,Mei-Qin,ur.016700417747.25
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Jiang,Ren-Di,ur.01241553051.74
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Chen,Ying,ur.010677641545.85
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Liu,Lin-Lin,
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Deng,Fei,ur.01213137713.21
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Chen,Jing,ur.013462476756.04
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Li,Bei,ur.0753460177.80
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Zhou,Peng,ur.0731467610.04
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Chen,Quan-Jiao,ur.010247323047.33
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Zhu,Yan,ur.01115421065.48
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Wang,Xian-Guang,ur.015144256145.08
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Zheng,Xiao-Shuang,ur.015324507366.43
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Zhao,Kai,ur.016277636357.66
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Shen,Xu-Rui,ur.011602602004.01
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Zhan,Fa-Xian,ur.0647317470.93
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Chen,Hui-Dong,ur.013617430345.83
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Wang,Yan-Yi,ur.01212175560.09
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Luo,Yun,ur.013270334654.98
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Wang,Xi,ur.0754142472.56
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Si,Hao-Rui,ur.010422074065.78
7528,A pneumonia outbreak associated with a new coronavirus of probable bat origin,Zhang,Wei,ur.07653266271.21
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Tenbusch,Matthias,ur.01117723625.93
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Bogdan,Christian,ur.01166137245.29
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Moosmann,Carolin,ur.010405760066.65
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Schubert,Benjamin,ur.011130037533.20
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Irrgang,Pascal,ur.013040376275.75
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Bock,Christoph,ur.01101265514.33
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Schülein,Christine,ur.013263473562.58
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Busch,Dirk H,ur.01031367037.65
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Drost,Felix,ur.012234527515.92
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Kocher,Katharina,ur.015163302657.35
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Zhong,Jahn,ur.010275571562.02
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Schober,Kilian,ur.0647371763.88
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Schuster,Ev-Marie,ur.012517452522.03
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Steininger,Philipp,ur.01272544120.68
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Winkler,Thomas H,ur.01347421311.19
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Träger,Johannes,
7511,Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual,Spriewald,Bernd,ur.01027255412.32
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Leung,Wing Hang,ur.01160667611.27
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Li,Ka Wah,ur.016424243657.05
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Wong,Wilfred Hing Sang,ur.013502411032.31
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Lau,Yu Lung,ur.0716701631.65
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Lee,Kwok Piu,ur.012073660351.92
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Wong,Ian Chi Kei,ur.016413064677.57
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Ng,Ming Yen,ur.01003160732.43
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Kan,Elaine,ur.01124564462.66
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Ip,Patrick,ur.012026656517.54
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Tsao,Sabrina Siu Ling,ur.016057742562.82
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Lin,Ying Kit,
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Chan,Victor Chi Man,ur.012064514107.72
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Kwok,Janette,ur.013166240242.92
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Smith,Robert David,ur.011032531413.28
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Fung,Wai Yuk,
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Kwan,Mike Yat Wah,ur.010370437662.35
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Chung,Kin Lai,ur.011300330075.38
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,To,Kelvin Kai Wang,ur.014242120072.04
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Leung,Daniel,ur.010356134717.92
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Chow,Chun Bong,ur.0741641210.89
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Leung,Agnes Sze Yin,ur.013024717367.42
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Lee,Daniel,
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Ma,Johnny,
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Cheung,Edmund Chi Lok,ur.011441343362.60
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Yu,Tak Ching,ur.0615135464.35
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Chua,Gilbert T,ur.014163210054.85
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Chui,Celine S L,ur.07517255252.78
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Chow,Chit Kwong,ur.010754416227.98
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Shek,Chi Chiu,ur.010356130701.34
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Wong,Joshua Sung Chih,ur.012447314411.92
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Chan,Godfrey Chi Fung,ur.011035304002.21
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Ma,Tian,
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Leung,Miriam T Y,ur.013655703734.13
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Tai,Shuk Mui,ur.011217344513.19
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Tsang,Hing Wai,ur.015316741647.73
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Yuen,Kwok Yung,ur.0652735016.56
7480,Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination,Ng,Wing Kei Carol,
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Krammer,Florian,ur.0615754253.47
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Turner,Jackson S.,ur.07616026727.34
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Lei,Tingting,ur.014252030655.11
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Rauseo,Adriana M.,ur.012260452026.80
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Haile,Alem,ur.014615440767.54
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Teefey,Sharlene A.,ur.0716154250.31
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Shi,Pei-Yong,ur.0601361767.18
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Ellebedy,Ali H.,ur.01240714756.18
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,O’Halloran,Jane A.,ur.012117122514.96
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Amanat,Fatima,ur.01147647041.63
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Thapa,Mahima,ur.015653077257.99
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Suessen,Teresa,ur.07505330567.16
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Xie,Xuping,ur.01270762675.88
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Presti,Rachel M.,ur.01005073641.61
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Middleton,William D.,ur.01224041507.64
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Chen,Rita E.,ur.01164430641.45
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Diamond,Michael S.,ur.0757052535.15
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Case,James Brett,ur.01206633375.37
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Zhou,Julian Q.,ur.012366035713.50
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Klebert,Michael K.,ur.016210401767.47
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Kalaidina,Elizaveta,ur.012061005614.42
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Schmitz,Aaron J.,ur.012603730727.87
7469,SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses,Kim,Wooseob,ur.015625534373.10
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Hulkower,Rachel,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Weber,Regen,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Limeres,Alexa,ur.010347025027.88
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",McCord,Russell,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Dunphy,Christopher,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Kompaniyets,Lyudmyla,ur.010442441237.37
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Whitson,Christopher D.,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Lee,Florence C.,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Ukoha,Chelsea,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",,,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Gakh,Maxim,ur.0722012454.03
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Bailey,Moriah,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Omura,John D.,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Tynan,Michael A.,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Pepin,Dawn,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Dugmeoglu,Sebnem,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Shelburne,Julia,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Davison,Robin,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Massetti,Greta M.,ur.013507073627.31
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",,,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Williams,Michael,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",,,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Landsman,Lisa,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Clodfelter,Catherine,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Cramer,Ryan,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Gilchrist,Siobhan,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Popoola,Adebola,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Fitts,Arriana,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Moreland,Amanda,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Sauber-Schatz,Erin,ur.01230642417.40
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",,,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Howard-Williams,Mara,ur.016562740501.84
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Brown,Amanda,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Sunshine,Gregory,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Guy,Gery P.,ur.0757622535.76
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",,,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",,,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Jeong,Gi,
7457,"Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020",Schroeder,Morgan,
7456,Prevalence of Asymptomatic SARS-CoV-2 Infection,Oran,Daniel P,ur.013132603633.16
7456,Prevalence of Asymptomatic SARS-CoV-2 Infection,Topol,Eric J,ur.0731336524.18
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Nishiura,Hiroshi,ur.0711257316.22
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Tsuchiya,Naho,ur.01121573256.39
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Saito,Mayuko,ur.0655334500.60
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Miyahara,Reiko,ur.014314761033.21
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Shobugawa,Yugo,ur.0705347130.37
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Morimoto,Konosuke,ur.0757700203.13
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Suzuki,Motoi,ur.0760460255.82
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Sando,Eiichiro,ur.01301142775.80
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Oshitani,Hitoshi,ur.0665212213.20
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Imamura,Tadatsugu,ur.0752737642.33
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Yasuda,Ikkoh,ur.01302666452.65
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Sunagawa,Tomimasa,ur.0726736603.27
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Jindai,Kazuaki,ur.01066263102.52
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Furuse,Yuki,ur.0751500104.46
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Nagata,Shohei,ur.011766232341.83
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Imamura,Takeaki,ur.016141214301.97
7450,"Early Release - Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC",Ko,Yura K.,ur.010453212331.54
7415,The effect of temperature on persistence of SARS-CoV-2 on common surfaces,Riddell,Shane,ur.01033006446.21
7415,The effect of temperature on persistence of SARS-CoV-2 on common surfaces,Hill,Andrew,
7415,The effect of temperature on persistence of SARS-CoV-2 on common surfaces,Goldie,Sarah,ur.014651547655.18
7415,The effect of temperature on persistence of SARS-CoV-2 on common surfaces,Eagles,Debbie,ur.01073340040.73
7415,The effect of temperature on persistence of SARS-CoV-2 on common surfaces,Drew,Trevor W.,ur.01027024517.50
7406,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study,Mølbak,Kåre,ur.0730116643.78
7406,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study,Michlmayr,Daniela,ur.012715060527.37
7406,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study,Hansen,Christian Holm,ur.01200434327.28
7406,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study,Ethelberg,Steen,ur.073564574.40
7406,Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study,Gubbels,Sophie Madeleine,ur.0634005412.38
7318,Spread of SARS-CoV-2 in the Icelandic Population,Josefsdottir,Kamilla S,ur.01050574670.24
7318,Spread of SARS-CoV-2 in the Icelandic Population,Möller,Alma D,ur.0720667025.34
7318,Spread of SARS-CoV-2 in the Icelandic Population,Jensson,Brynjar O,ur.01045441067.97
7318,Spread of SARS-CoV-2 in the Icelandic Population,Helgason,Agnar,ur.01071376774.64
7318,Spread of SARS-CoV-2 in the Icelandic Population,Kristjansson,Thordur,ur.012456634477.11
7318,Spread of SARS-CoV-2 in the Icelandic Population,Gunnarsdottir,Thora R,ur.011271630555.22
7318,Spread of SARS-CoV-2 in the Icelandic Population,le Roux,Louise,ur.0775432722.04
7318,Spread of SARS-CoV-2 in the Icelandic Population,Saemundsdottir,Jona,ur.01242565121.12
7318,Spread of SARS-CoV-2 in the Icelandic Population,Jonsson,Frosti,ur.011337743755.62
7318,Spread of SARS-CoV-2 in the Icelandic Population,Magnusson,Olafur T,ur.0743534613.73
7318,Spread of SARS-CoV-2 in the Icelandic Population,Gylfason,Arnaldur,ur.01061240155.82
7318,Spread of SARS-CoV-2 in the Icelandic Population,Georgsson,Gudmundur,ur.0664251605.02
7318,Spread of SARS-CoV-2 in the Icelandic Population,Sveinsdottir,Kristin E,ur.013576400555.97
7318,Spread of SARS-CoV-2 in the Icelandic Population,Sveinbjornsson,Gardar,ur.0700374216.54
7318,Spread of SARS-CoV-2 in the Icelandic Population,Stefansson,Kari,
7318,Spread of SARS-CoV-2 in the Icelandic Population,Gretarsdottir,Olafia S,ur.015346221263.18
7318,Spread of SARS-CoV-2 in the Icelandic Population,Sveinsdottir,Maney,ur.012025223351.52
7318,Spread of SARS-CoV-2 in the Icelandic Population,Eiriksdottir,Berglind,ur.0634103045.49
7318,Spread of SARS-CoV-2 in the Icelandic Population,Sigmundsdottir,Gudrun,ur.01346751114.53
7318,Spread of SARS-CoV-2 in the Icelandic Population,Gudnason,Thorolfur,ur.01273315021.17
7318,Spread of SARS-CoV-2 in the Icelandic Population,Kristinsson,Karl G,ur.0720443221.21
7318,Spread of SARS-CoV-2 in the Icelandic Population,Sulem,Patrick,ur.0773127601.34
7318,Spread of SARS-CoV-2 in the Icelandic Population,Agustsdottir,Arna B,ur.01067375637.38
7318,Spread of SARS-CoV-2 in the Icelandic Population,Fridriksdottir,Run,ur.014542162231.55
7318,Spread of SARS-CoV-2 in the Icelandic Population,Melsted,Pall,ur.01014100275.50
7318,Spread of SARS-CoV-2 in the Icelandic Population,Sigurdsson,Asgeir,ur.01067302737.32
7318,Spread of SARS-CoV-2 in the Icelandic Population,Jonsdottir,Ingileif,ur.01220643160.06
7318,Spread of SARS-CoV-2 in the Icelandic Population,Gudbjartsson,Daniel F,ur.0637651205.48
7318,Spread of SARS-CoV-2 in the Icelandic Population,Thorarensen,Emil A,ur.016564302555.56
7318,Spread of SARS-CoV-2 in the Icelandic Population,Jonsson,Hakon,ur.014263416547.25
7318,Spread of SARS-CoV-2 in the Icelandic Population,Löve,Arthur,
7318,Spread of SARS-CoV-2 in the Icelandic Population,Gudmundsson,Kjartan R,ur.013667224107.63
7318,Spread of SARS-CoV-2 in the Icelandic Population,Jonasdottir,Aslaug,ur.0726475763.17
7318,Spread of SARS-CoV-2 in the Icelandic Population,Gardarsdottir,Elisabet E,ur.012616456355.13
7318,Spread of SARS-CoV-2 in the Icelandic Population,Magnusdottir,Droplaug N,ur.0616614047.40
7318,Spread of SARS-CoV-2 in the Icelandic Population,Thorbjornsson,Bjarni,ur.011454172355.50
7318,Spread of SARS-CoV-2 in the Icelandic Population,Masson,Gisli,
7318,Spread of SARS-CoV-2 in the Icelandic Population,Holm,Hilma,ur.01225441541.34
7318,Spread of SARS-CoV-2 in the Icelandic Population,Thorsteinsdottir,Unnur,ur.01277776417.51
7318,Spread of SARS-CoV-2 in the Icelandic Population,Norddahl,Gudmundur L,ur.0771421022.72
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Manenti,Alessandro,ur.0626400205.97
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Bollati,Valentina,ur.01020346242.20
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Marchianò,Alfonso,ur.01360143506.85
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Sestini,Stefano,ur.01365533211.14
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Martinuzzi,Donata,ur.013122622635.61
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Montomoli,Emanuele,ur.0665501301.42
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Hyseni,Inesa,ur.015671543327.43
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Apolone,Giovanni,ur.01101457736.26
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Cantone,Laura,ur.0707374427.53
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Boeri,Mattia,ur.01141347177.26
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Milanese,Gianluca,ur.010532672225.81
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Sabia,Federica,ur.013206641124.47
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Pastorino,Ugo,ur.01326445505.19
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Mazzini,Livia,ur.07443513277.82
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Suatoni,Paola,ur.01021062052.94
7313,Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy,Sozzi,Gabriella,ur.01310706413.46
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Folkesson,Elin,ur.01250570571.23
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Soini,Tea,ur.01356376377.44
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Tullberg,Malin Flodström,ur.014400713743.85
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Kokkinou,Efthymia,ur.07563160533.41
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Chambers,Benedict,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Llewellyn-Lacey,Sian,ur.01016226534.03
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Klingström,Jonas,ur.01066604065.95
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Medina,Laura Palma,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Perez-Potti,André,ur.015041620447.26
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Sandberg,John Tyler,ur.011426221201.88
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Unge,Christian,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Aleman,Soo,ur.0711363011.44
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Michaelsson,Jakob,ur.01266375220.11
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Radler,Lena,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Haroun-Izquierdo,Alvaro,ur.07753231126.84
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Emgård,Johanna,ur.015575517530.38
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Svensson,Mattias,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Bogdanovic,Gordana,ur.01121045442.06
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Ljunggren,Hans-Gustaf,ur.0767614762.77
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Loreti,Marco,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Nauclér,Pontus,ur.01261166405.20
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Malmberg,Karl-Johan,ur.01133307720.21
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Gorin,Jean-Baptiste,ur.010465407330.01
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Bergsten,Helena,ur.01333527105.16
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Muschiol,Sandra,ur.0641776561.55
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Akber,Mira,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Strålin,Kristoffer,ur.01100502653.33
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Brownlie,Demi,ur.010770163300.03
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Von Kries,Andreas,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Allander,Tobias,ur.0702721302.13
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Rivera-Ballesteros,Olga,ur.015672727617.70
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Eriksson,Lars I.,ur.01226225464.66
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Persson,Björn,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Henter,Jan-Inge,ur.01103114150.25
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Olsson,Annika,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Price,David A.,ur.011306064612.17
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Sekine,Takuya,ur.010270202743.21
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Marquardt,Nicole,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Moll,Kirsten,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Group,Karolinska COVID-19 Study,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Ringqvist,Emma,ur.01135600401.99
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Färnert,Anna,ur.01233730001.28
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Dillner,Lena,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Buggert,Marcus,ur.01336246423.09
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Kammann,Tobias,ur.015454001614.58
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Sohlberg,Ebba,ur.01277112270.18
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Brighenti,Susanna,ur.01145564033.91
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Mjösberg,Jenny,ur.0747216575.54
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Wullimann,David J.,ur.014270673473.09
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Nielsen,Morten,ur.013214211121.54
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Albert,Jan,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Tynell,Janne,ur.0644253420.50
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Henriksson,Elizabeth,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Glans,Hedvig,ur.01064775775.15
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Sönnerborg,Anders,ur.01133270323.41
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Gredmark-Russ,Sara,ur.01340073575.25
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Chen,Puran,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Kamal,Habiba,ur.011765432255.80
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Berglin,Lena,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Rooyackers,Olav,ur.01001152421.76
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Jeannin,Martin Cornillet,ur.07403173271.69
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Dzidic,Majda,ur.010611672265.98
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Norrby-Teglund,Anna,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Kvedaraite,Egle,ur.013073225465.25
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Parrot,Tiphaine,ur.014773437471.44
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Lourda,Magalini,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Hertwig,Laura,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Lozano,Isabel Diaz,ur.013162462411.95
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Butrym,Marta,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Muva,Jagadees,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Grip,Jonathan,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Sandberg,Johan K.,ur.0703770576.33
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Maucourant,Christopher,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Björkström,Niklas K.,ur.0634553251.98
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Maleki,Kimia,ur.0725253277.16
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Mårtensson,Johan,ur.0605044025.88
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Kalsum,Sadaf,ur.01213752376.00
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Varnaite,Renata,
7300,Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19,Gomez,Angelica Cuapio,
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Kalina,Warren V,ur.0577211724.06
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Senders,Shelly,
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Şahin,Uğur,ur.0657734236.08
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Xu,Xia,
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Dormitzer,Philip R,ur.01124563153.82
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Tresnan,Dina B,ur.011115233157.53
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Türeci,Özlem,ur.01237100335.34
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Perez,John L,
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Thomas,Stephen J,ur.01250631625.48
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Mather,Susan,ur.012742202221.19
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Ma,Hua,
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Gruber,William C,ur.0735756071.23
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Cooper,David,
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Walter,Emmanuel B,
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Swanson,Kena A,ur.0720727651.67
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Jansen,Kathrin U,ur.01271443577.18
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Jennings,Timothy,
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Absalon,Judith,ur.0726712623.28
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Brandon,Donald M,ur.07754300221.12
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Kitchin,Nicholas,ur.01343436707.36
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Koury,Kenneth,ur.01252412675.84
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Frenck,Robert W,ur.01157665701.10
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Klein,Nicola P,ur.012625753621.99
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Lockhart,Stephen,ur.01155017074.41
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Gurtman,Alejandra,ur.0766540106.68
7297,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",Bailey,Ruth,
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Parker,,ur.013006135411.00
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Bhattacharya,T,ur.01177233546.94
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,de Silva,TI,ur.01062173617.58
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Evans,CM,ur.013002455123.20
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Freeman,TM,
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Foley,B,ur.0711231703.32
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Theiler,J,ur.012475206625.77
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Korber,B,ur.01237531654.86
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Giorgi,EE,ur.01120001244.70
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Abfalterer,W,ur.015555554740.16
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Fischer,,ur.014405433757.03
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Montefiori,DC,ur.01276277760.85
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Partridge,DG,ur.014634502124.06
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,LaBranche,CC,ur.01207706331.91
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Group,on behalf of the Sheffield COVID-19 Genomics,
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Yoon,H,ur.01220320527.35
7266,Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,Gnanakaran,S,ur.01353002606.54
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Lufkin,Bradley,ur.015717654671.13
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Forshee,Richard A,ur.01136442701.70
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Anderson,Steven A,ur.01277261057.91
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Kelman,Jeffrey A,ur.01133564014.33
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,MaCurdy,Thomas,ur.01120560357.68
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Dimova,Rositsa,
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Lloyd,Patricia C,ur.012173055432.77
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Chillarige,Yoganand,ur.010324606561.62
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Hu,Mao,ur.010001617367.23
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Ke Zhou,Cindy,ur.014016676214.13
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Feinberg,Laurie,ur.07730523347.39
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Shoaibi,Azadeh,ur.0715455607.87
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Thompson,Deborah,ur.015112644232.14
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Tworkoski,Ellen,ur.07471271245.38
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Wong,Hui-Lee,ur.0767470642.71
7235,Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older,Do,Rose,ur.016712502434.65
7229,School reopening without robust COVID-19 mitigation risks accelerating the pandemic,Ziauddeen,Hisham,ur.01371624753.15
7229,School reopening without robust COVID-19 mitigation risks accelerating the pandemic,Johnson,Luke,ur.014073437043.49
7229,School reopening without robust COVID-19 mitigation risks accelerating the pandemic,Greenhalgh,Trisha,ur.0734302623.84
7229,School reopening without robust COVID-19 mitigation risks accelerating the pandemic,Rasmussen,Sarah D,ur.011576076573.13
7229,School reopening without robust COVID-19 mitigation risks accelerating the pandemic,Roderick,Paul,ur.014044556617.00
7229,School reopening without robust COVID-19 mitigation risks accelerating the pandemic,Alwan,Nisreen A,ur.016636522307.95
7229,School reopening without robust COVID-19 mitigation risks accelerating the pandemic,Prather,Kimberly A,ur.0576263513.15
7229,School reopening without robust COVID-19 mitigation risks accelerating the pandemic,Reicher,Stephen,ur.016551203565.33
7229,School reopening without robust COVID-19 mitigation risks accelerating the pandemic,McKee,Martin,ur.01367673420.84
7229,School reopening without robust COVID-19 mitigation risks accelerating the pandemic,Hyde,Zoë,ur.01250055705.84
7229,School reopening without robust COVID-19 mitigation risks accelerating the pandemic,Michie,Susan,ur.01067023110.81
7229,School reopening without robust COVID-19 mitigation risks accelerating the pandemic,Gurdasani,Deepti,ur.01342153057.51
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Ghani,Azra C.,ur.0645140152.06
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Donnelly,Christl A.,ur.01305160526.54
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Riley,Steven,ur.01264302000.51
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Vollmer,Michaela A. C.,ur.015433576514.20
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Unwin,H. Juliette T.,ur.012651002370.79
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Zhu,Harrison,ur.013244724635.67
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Eaton,Jeffrey W.,ur.01200671171.13
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Mishra,Swapnil,ur.013337344257.08
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Bhatt,Samir,ur.01306675612.93
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Okell,Lucy C.,ur.01130162544.21
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Whittaker,Charles,ur.014307755137.67
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Monod,Mélodie,ur.015142701605.76
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Mellan,Thomas A.,ur.01316201244.18
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Flaxman,Seth,ur.0640410710.66
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Ferguson,Neil M.,ur.01346743312.51
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Berah,Tresnia,ur.015435246235.54
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Coupland,Helen,ur.015001441711.08
7226,Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe,Gandy,Axel,ur.010152657417.11
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Cheng,Shu-Hsing,ur.01363540027.19
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Naggie,Susanna,ur.01245406074.66
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Jurado-Camacho,Felipe,ur.015514371471.38
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Stout,Jason E.,ur.01276366065.26
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Cohen,Yehuda Z.,ur.01053630363.33
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Remigio-Luna,Arantxa,ur.012464215371.67
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Abella,Benjamin S.,ur.01137211710.36
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Rosa,Rossana,ur.012124473531.64
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Perrin,Laurent,
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Zampieri,Fernando G.,ur.0612476513.54
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Lin,Tse-Hung,ur.016000376173.68
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Schmitt,Andreas M.,ur.015301307263.50
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Kreuels,Benno,ur.01226250534.83
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Ioannidis,John P. A.,ur.015607417277.46
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Derde,Lennie,ur.01063003353.99
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Zhong,Wu,ur.01305463356.23
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Webb,Steve A.,ur.011521610452.05
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Hemkens,Lars G.,ur.0653435747.12
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Nichol,Alistair,ur.011535223620.39
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Goodman,Steven N.,ur.013730377746.73
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Igau,Bruno,ur.012526467471.40
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Mulligan,Mark J.,ur.014352105471.12
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Murthy,Srinivas,ur.0740103341.37
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Morpeth,Susan C.,ur.01015003603.92
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Azhar,Shehnoor,ur.016565532153.89
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,O’Brien,Sean M.,ur.011023141171.43
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Abd-Elsalam,Sherief,ur.01170074253.10
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Thirion-Romero,Ireri,ur.011352062650.20
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Cowan,Lisa N.,ur.011546545271.73
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Turner,Nicholas A.,ur.01174474274.00
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,McVerry,Bryan J.,ur.01203135104.43
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Rockhold,Frank W.,ur.01234336202.82
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Lyngbakken,Magnus Nakrem,ur.0775160631.09
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Lin,Wu-Pu,ur.013035144165.91
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Ulrich,Robert J.,ur.015260505313.82
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Cheng,Chien-Yu,ur.0671556667.42
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Belkhir,Leila,ur.0757107610.07
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Gordon,Anthony C.,ur.01114060235.79
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Seto,Todd B.,ur.01157464043.24
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Rodriguez-Llamazares,Sebastian,ur.016360000713.32
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Perez,Léna,ur.014606423571.33
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Weehuizen,Jesper M.,ur.013407366107.39
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,de Lacerda,Marcus V. G.,ur.011421652101.60
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Chung,Wei-Sheng,ur.01152214070.73
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Perez-Padilla,Rogelio,ur.0722150644.25
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Jin,Ronghua,ur.01074607307.99
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Monteiro,Wuelton M.,ur.01141171601.76
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Hills,Thomas,ur.014672366031.29
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Moher,David,ur.0623641026.30
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Wrenn,Rebekah,ur.01202341257.31
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Meza-Meneses,Patricia,ur.07653523347.08
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,de Almeida e Val,Fernando F.,ur.014577013645.81
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Le,Thuy,ur.07655014071.01
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Shahzad,Muhammad,
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Chen,Cheng-Pin,ur.01134454146.21
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Kremsner,Peter G.,ur.01343213442.31
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Baden,Lindsey R.,ur.0750725460.01
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Axfors,Cathrine,ur.010232432033.00
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Hoepelman,Andy I. M.,ur.012422403557.93
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Huang,Yi-Wen,ur.010670265773.23
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Velinova,Maria,ur.013446143725.40
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Chen,Tsung-Chia,ur.01214564177.32
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Abdo,Ehab F.,ur.07430631357.68
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Benfield,Thomas,ur.0614447562.23
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Hernandez-Cardenas,Carmen M.,ur.01260761617.62
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Wong,Hon-Lai,ur.010024572173.35
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Tseng,Ting-Yu,ur.016611233413.29
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Kuo,Cheng-Yu,ur.01257706476.97
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Khan,Khalid S.,ur.010404261271.25
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Janiaud,Perrine,ur.07756564424.87
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Angus,Derek C.,ur.01013154627.14
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Okeke,Nwora Lance,ur.01145441522.85
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Baker,Arthur W.,ur.010631075171.11
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Dubee,Vincent,ur.0622042677.26
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Novack,Lewis A.,ur.011500432071.42
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Berrevoets,Marvin A. H.,ur.0667506244.83
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Rivera-Martinez,Norma E.,ur.01324140167.49
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Lin,Yi-Chun,ur.0655240431.76
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Troxel,Andrea B.,ur.01322234503.61
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Mourad,Ahmad,ur.012313342071.51
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Elfakir,Anissa,ur.0616076034.66
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Arabi,Yaseen M.,ur.01233210151.86
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Dalgard,Olav,ur.01251455643.00
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Sampaio,Vanderson S.,ur.01146032676.11
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Narayanasamy,Shanti,ur.01217353561.61
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Røsjø,Helge,ur.01232343651.19
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Walsh,Stephen R.,ur.0716075233.28
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,van’t Hooft,Janneke,ur.01030763012.16
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,de Melo,Gisely C.,ur.01060624443.99
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Rolfe,Robert,ur.011734750171.27
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Soliman,Shaimaa,ur.012240245777.05
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Amaravadi,Ravi K.,ur.0734561146.72
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,McArthur,Colin,ur.01364045531.12
7225,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials,Akram,Javed,ur.0720770227.10
7217,Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan,Fukushima,Masanori,
7217,Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan,Kojima,Seiji,
7217,Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan,Gibo,Miki,ur.010130355232.23
7217,Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan,Kikuchi,Takayuki,
7217,Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan,Fujisawa,Akinori,
7216,Response to COVID-19 in Taiwan,Brook,Robert H.,ur.01114465350.73
7216,Response to COVID-19 in Taiwan,Ng,Chun Y.,ur.01021217216.27
7216,Response to COVID-19 in Taiwan,Wang,C. Jason,ur.0604137366.31
7216,"Early Release - High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Hengartner,Nick,ur.011615154651.39
7216,"Early Release - High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Romero-Severson,Ethan,ur.01006407316.84
7216,"Early Release - High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Sanche,Steven,ur.014754213455.33
7216,"Early Release - High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Xu,Chonggang,ur.01126114731.11
7216,"Early Release - High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Lin,Yen Ting,ur.01066703065.48
7216,"Early Release - High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC",Ke,Ruian,ur.0606243351.47
7209,Sperm Parameters Before and After COVID-19 mRNA Vaccination,Ibrahim,Emad,ur.01043047343.16
7209,Sperm Parameters Before and After COVID-19 mRNA Vaccination,Ory,Jesse,ur.013350503631.17
7209,Sperm Parameters Before and After COVID-19 mRNA Vaccination,Khodamoradi,Kajal,ur.012133067247.52
7209,Sperm Parameters Before and After COVID-19 mRNA Vaccination,Nassau,Daniel E.,ur.011532747611.25
7209,Sperm Parameters Before and After COVID-19 mRNA Vaccination,Blachman-Braun,Ruben,ur.01176167522.02
7209,Sperm Parameters Before and After COVID-19 mRNA Vaccination,Gonzalez,Daniel C.,ur.015260555733.38
7209,Sperm Parameters Before and After COVID-19 mRNA Vaccination,Ramasamy,Ranjith,ur.0736323143.52
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Hoh,Ramona A,ur.01262243265.84
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Li,Chunfeng,ur.01165704376.60
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Manohar,Monali,ur.0722347502.55
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Dashdorj,Naranbaatar D,ur.0703633343.28
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Röltgen,Katharina,ur.0715646707.24
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Arunachalam,Prabhu S,ur.014677355705.39
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Lee,Alexandra S,ur.015644145343.84
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Troxell,Megan L,ur.01164103247.95
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Dashdorj,Naranjargal J,ur.0654772000.00
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Solis,Daniel,
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Wang,Aihui,ur.015226036764.42
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Gao,Fei,
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Zhao,Shuchun,
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Charville,Gregory W,ur.01111271077.97
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Mallajosyula,Vamsee,ur.01107033104.51
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Parsons,Ella,ur.07610165556.75
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Natkunam,Yasodha,ur.010324002517.98
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Silva,Oscar,
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Sigal,George B,ur.01212064636.03
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Colburg,Deana,ur.010252123174.03
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Shah,Mihir M,ur.016047507110.23
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Monroe,Robert,ur.014547600064.56
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Costales,Cristina,ur.016673601153.46
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Serrano,Geidy E,ur.01351304431.48
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Chinthrajah,R Sharon,ur.01070553156.18
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Davis,Mark M,ur.010661701022.77
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Boyd,Scott D,ur.0713601023.10
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Pulendran,Bali,ur.01110274346.79
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Younes,Sheren F,ur.0753721403.43
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Shoura,Massa J,ur.011533122317.24
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Sindher,Sayantani B,ur.01346556351.10
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Yang,Fan,
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Nielsen,Sandra C A,ur.01346170246.30
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Liu,James,
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Nadeau,Kari C,ur.01110102656.91
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Beach,Thomas G,ur.014653302237.67
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Chang,Iris,
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Pinsky,Benjamin A,ur.01002245116.32
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Wirz,Oliver F,ur.0710030176.05
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Haraguchi,Emily,
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Zaslavsky,Maxim,ur.016270043244.82
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Wohlstadter,Jacob N,ur.011124674473.95
7193,"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination",Wilbur,James L,ur.011221447777.11
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Hirsiger,Julia R.,ur.07357502517.45
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Buergin,Natacha,
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Banderet,Florian,ur.0730223434.89
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Berger,Christoph T.,ur.012065122272.30
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Glarner,Noemi,ur.015704710747.04
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Median,Daniela,ur.016644316322.18
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Koechlin,Luca,ur.01250010646.55
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Rumora,Klara,ur.010515617430.25
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Herrmann,Timon,
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Battegay,Manuel,
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Lopez‐Ayala,Pedro,ur.012344576223.65
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Rentsch,Katharina,ur.01143003154.94
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Mueller,Christian,ur.0644412053.34
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Mueller,Philip,
7184,Sex‐specific differences in myocardial injury incidence after COVID‐19 mRNA‐1273 booster vaccination,Haaf,Philip,ur.01307513545.82
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Pasovic,Maja,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Flaxman,Abraham D,ur.0650775076.66
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Ferrari,Alize J,ur.0760121476.27
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Castro,Emma,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Monasta,Lorenzo,ur.01254131200.93
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Aravkin,Aleksandr Y,ur.016512500276.24
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Ewald,Samuel B,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Giref,Ababi Zergaw,ur.015235661205.53
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Wiysonge,Charles Shey,ur.0667111132.59
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Abbafati,Cristiana,ur.011606002626.99
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Idrisov,Bulat,ur.0627551516.67
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Castellano,Rachel,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Dai,Xiaochen,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Bertolacci,Gregory J,ur.07522010213.53
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Shadid,Jamileh,ur.011530226601.90
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Collins,James K,ur.013010347361.78
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Fullman,Nancy,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Zigler,Bethany,ur.012462037440.98
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Murray,Christopher J L,ur.012310237337.47
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Hulland,Erin N,ur.012127730655.85
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Chakrabarti,Suman,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Watson,Stefanie,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Erickson,Megan,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Whiteford,Harvey A,ur.01250350433.24
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Lindstrom,Akiaja,ur.016057117140.28
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Walcott,Rebecca,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Ostroff,Samuel M,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Reinke,Grace,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Malta,Deborah Carvalho,ur.01011613642.30
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Helak,Monika,
7117,Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2,Iwatsuki-Horimoto,Kiyoko,ur.0620324666.85
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Vos,Theo,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Dangel,William James,ur.013630247011.14
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Penberthy,Louise,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Collaborators,COVID-19 Mental Disorders,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Guo,Gaorui,ur.07354535613.64
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Pigott,David M,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Reiner,Robert C,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Chattopadhyay,Jhilik,ur.016540251140.22
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Frostad,Joseph Jon,ur.012240745161.45
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Bang-Jensen,Bree L,ur.013111757755.03
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Magistro,Beatrice,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,O'Halloran,James Kevin,ur.07426022240.20
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Santomauro,Damian F,ur.01212734545.84
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Mokdad,Ali H,ur.01004203213.05
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Lozano,Rafael,ur.01352437070.24
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Nomura,Shuhei,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Zheng,Peng,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Bloom,Sabina S,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Deen,Amanda,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,He,Jiawei,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Marinho,Fatima,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Amlag,Joanne O,ur.010564445140.83
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Cogen,Rebecca M,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Dapper,Carolyn,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Månsson,Johan C,ur.011664357251.82
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Hay,Simon I,ur.01107433531.31
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Ashbaugh,Charlie,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Varavikova,Elena,ur.014400447514.61
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Sholokhov,Aleksei,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Naik,Paulami,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Herrera,Ana M Mantilla,ur.07645507401.80
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Ribeiro,Antonio Luiz P,ur.0727731754.29
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Lotufo,Paulo A,ur.01057113165.47
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Linebarger,Emily,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Vo,Anh Truc,ur.013706143133.68
7117,Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2,Kabata,Hiroki,ur.0655642151.07
7117,Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2,Kawaoka,Yoshihiro,ur.01261074774.41
7117,Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2,Furusawa,Yuri,ur.010252313205.95
7117,Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2,Nishimura,Hidekazu,ur.01074402736.14
7117,Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2,Ueki,Hiroshi,ur.010444664130.07
7117,Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2,Imai,Masaki,ur.01355303120.50
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Giles,John R,
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Adolph,Christopher,ur.0777053267.35
7117,Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic,Sorensen,Reed J D,
7114,Offline: COVID-19 and the NHS—“a national scandal”,Horton,Richard,ur.01372435713.34
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Hoertel,Nicolas,ur.01001457020.48
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Priet,Stéphane,ur.01163634565.83
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Nicol,Jérôme,ur.016263512126.40
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Hercberg,Serge,ur.013756742126.68
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Gerbouin-Rérolle,Pascale,ur.012312024626.95
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Severi,Gianluca,ur.010173457526.99
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Laplanche,Camille,ur.013704765626.55
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Ritmi,Anass,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Allegre,Julien,ur.010771040126.10
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Severi,Gianluca,ur.0723015610.17
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Le-Got,Stephane,ur.013575463221.19
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Touvier,Mathilde,ur.014554322526.31
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Ninove,Laetitia,ur.0656337523.51
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Szabo de Edelenyi,Fabien,ur.01227347427.34
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Esseddik,Younes,ur.016101371325.81
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Marchand,Laetitia,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Milcent,Karen,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Matta,Joane,ur.016106031035.17
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Barry,Alpha Amadou,ur.07437664707.80
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Enguix,Mélody,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Correia,Emmanuelle,ur.016075307226.10
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Ribet,Celine,ur.016027174026.96
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Benhammou,Valérie,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Goderel,Isabelle,ur.01115136141.36
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Fourié,Toscane,ur.010153110007.32
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Thierry,Xavier,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Lapidus,Nathanael,ur.01217413105.91
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Gagliolo,Jean-Marie,ur.0751211004.95
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Goldberg,Marcel,ur.01147270007.33
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Ancel,Pierre-Yves,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Druesne-Pecollo,Nathalie,ur.01140621073.75
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Touvier,Mathilde,ur.01027515723.45
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Dorival,Céline,ur.015466131526.72
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Ouili,Ouissam,ur.010424134526.06
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Blanché,Hélène,ur.014141303726.48
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Renuy,Adeline,ur.010622617635.36
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Lemogne,Cédric,ur.01353100711.61
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Ranque,Brigitte,ur.0774476511.08
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Gomes-Rima,Roselyn,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Wiernik,Emmanuel,ur.0624610256.50
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Lai,Cindy,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Lydie,Nathalie,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Pannetier,Gregory,ur.013275610126.23
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Hoang,Lyan,ur.015277726626.10
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Belhadji,Liza,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,de Lamballerie,Xavier,ur.01067672041.84
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Ayhan,Nazli,ur.07674667326.16
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Sébaoun,Jean-Marc,ur.014736664326.99
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Esperou,Hélène,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Rahib,Delphine,ur.01011543323.18
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Gouraud,Clément,ur.014157041102.88
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Artaud,Fanny,ur.011514444226.19
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Zins,Marie,ur.01304253120.07
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Saba Villarroel,Paola Mariela,ur.013412036526.28
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Dufourg,Marie-Noelle,ur.011105566745.06
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Lusivika-Nzinga,Clovis,ur.014000426333.09
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Blanché,Hélène,ur.01017052646.87
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Carrat,Fabrice,ur.0725234060.17
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Couffin-Cadiergues,Sandrine,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Robineau,Olivier,ur.0636331745.36
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Zins,Marie,ur.010717063626.53
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Carrat,Fabrice,ur.07560440726.16
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Morel,Valérie,ur.07626554126.67
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Senina,Nadège,ur.07376077126.63
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Beaudoin,Jean-Christophe,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Zaros,Cécile,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Deleuze,Jean-François,ur.01060742025.61
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Charles,Marie-Aline,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Wiernik,Emmanuel,ur.016624554426.27
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Gressin,Laetitia,ur.016331625326.23
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Simeon,Thierry,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,de Lamballerie,Xavier,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Goldberg,Marcel,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Kab,Sofiane,ur.0751721255.02
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Candea,Adriana,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Amroun,Abdenour,ur.015602360126.56
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Mohamed Ali,Souand,ur.07767526145.40
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Deleuze,Jean-François,ur.011221515126.09
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Geay,Bertrand,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Lordmi,Elodie,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,de Visme,Sophie,
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Pastorino,Boris,ur.0732573130.39
7102,Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic,Seston,Morgan,ur.014556512537.66
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Salmonson,Shawn,
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Ross,Tara,ur.07375516736.48
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Wynn,Nhien Tran,ur.014166637221.50
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Godwin,Eric,ur.016074727036.92
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Ballom,TeCora,
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Nicolae,Lavinia,ur.015507460266.68
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Ogle,Isaac,
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Kirking,Hannah L.,ur.01207235456.14
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Banta,Robert,
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",McCormick,David W.,
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Sheth,Mili,ur.01032174775.42
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Dixon,Thomas,ur.010716503436.55
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Harcourt,Jennifer L.,ur.014553742336.47
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Kim,Gimin,ur.012363420736.38
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",David,Ebenezer,ur.010770457736.05
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Lee,Christine C.,
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Ogden,Charles,
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Browne,Hannah,ur.07443632136.64
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Tamin,Azaibi,ur.0730465355.70
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Salvatore,Phillip P.,ur.01326630643.27
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Bessey,Theresa K.,ur.011013237511.10
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Lowe,Luis,
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Tate,Jacqueline E.,ur.01117172520.09
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Sleweon,Sadia,ur.014275534543.56
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Young,Cristen,ur.013107025036.50
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Dusseau,Charles,ur.016133535170.21
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Hagan,Liesl M.,ur.01044702641.54
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Suppiah,Suganthi,ur.0674200673.33
7086,"Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021",Knipe,Kristen,ur.010121123036.27
7080,Lecanemab in Early Alzheimer’s Disease,Iwatsubo,Takeshi,ur.01235573563.62
7080,Lecanemab in Early Alzheimer’s Disease,Sabbagh,Marwan,ur.0707625530.62
7080,Lecanemab in Early Alzheimer’s Disease,Vellas,Bruno,ur.0772176346.25
7080,Lecanemab in Early Alzheimer’s Disease,Irizarry,Michael,ur.0677014124.21
7080,Lecanemab in Early Alzheimer’s Disease,Aisen,Paul,ur.01172615101.92
7080,Lecanemab in Early Alzheimer’s Disease,Kanekiyo,Michio,ur.012346136554.35
7080,Lecanemab in Early Alzheimer’s Disease,Dhadda,Shobha,ur.0733746374.06
7080,Lecanemab in Early Alzheimer’s Disease,Swanson,Chad J,ur.07674104255.60
7080,Lecanemab in Early Alzheimer’s Disease,Bateman,Randall J,ur.01154033743.97
7080,Lecanemab in Early Alzheimer’s Disease,Reyderman,Larisa,ur.0627241052.36
7080,Lecanemab in Early Alzheimer’s Disease,Kramer,Lynn D,ur.01202270510.73
7080,Lecanemab in Early Alzheimer’s Disease,Gee,Michelle,ur.0610045672.32
7080,Lecanemab in Early Alzheimer’s Disease,Katayama,Sadao,
7080,Lecanemab in Early Alzheimer’s Disease,Cohen,Sharon,ur.015215744414.44
7080,Lecanemab in Early Alzheimer’s Disease,Chen,Christopher,
7080,Lecanemab in Early Alzheimer’s Disease,Li,David,
7080,Lecanemab in Early Alzheimer’s Disease,Watson,David,
7080,Lecanemab in Early Alzheimer’s Disease,Froelich,Lutz,ur.01275517050.87
7080,Lecanemab in Early Alzheimer’s Disease,van Dyck,Christopher H,ur.010314560137.05
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Woodyatt,Wiesia,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Wixted,Donna,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Mughal,Mehmood,ur.016555024336.34
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Da Silva,Carla Ferreira,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Appleby,Kim,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Gutteridge,Helen,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hughes,Rachel,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Underwood,Karen,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Davies-Dear,Sharon,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Patel,Gita,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Bisnauthsing,Karen,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Radford,Helen,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Vamplew,Luke,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Pacurar,Mihaela,ur.011220421775.00
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Drake-Brockman,Rachael,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Mujadidi,Yama F,ur.011600027201.23
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Ronan,Nicholas,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Seenan,John Paul,ur.0712137347.52
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Cullinane,James,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Regan,Karen,ur.016623137536.36
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Lall,Paminder,ur.010146713744.05
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Sharma,Sunil,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Haydock,Helen,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Chiplin,Emily,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",cordeiro,Lillian Goncalves,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Read,Robert C,ur.01333750206.10
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Cooney,Enya,ur.011415745745.28
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Magan,Javier,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Munusamy,Malathi,ur.011701232236.26
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Watson,Tara,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Aley,Parvinder K,ur.01144267763.20
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",James,Rob,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Storton,Kim,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Herbert,Christopher,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Knight,Chanice,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Baxter,David,ur.010322625427.36
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Ricamara,Marivic,ur.010206511504.89
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hansen,Daniel,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Burton,Holly,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Longhurst,Beverley,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Kourampa,Evgenia,ur.014574020017.50
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Bawa,Tanveer,ur.012775403036.75
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Charlton,Sue,ur.011022147657.77
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",van der Klaauw,Agatha A,ur.01141153174.79
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Minnis,Christine,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Nanino,Elisa,ur.014024416365.17
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Rashid-Gardner,Zalina,ur.014575333721.58
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Merida-Morillas,Marta,ur.015623075721.80
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Mullan,Dee,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Janani,Leila,ur.01157404323.48
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Rogers,Chris A,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Owens,Daniel R,ur.01343271615.71
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Garrahy,Sarah,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Lambe,Teresa,ur.01343506651.11
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Goodman,Anna L,ur.01175716171.37
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Thorpe,Jeanette,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Wiselka,Martin,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",dabagh,Maja,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Kumar,Dileep,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hladkiwskyj,John,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Roche,Siobhan,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Richmond,Leah,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Libri,Vincenzo,ur.01256064600.37
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Welham,Benjamin,ur.011235341123.72
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Thomson,Emma C,ur.01115422445.14
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Roy,Subarna,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Tulloch,Hayley,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Aslam,Suahil,ur.012200022436.78
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Nguyen-Van-Tam,Jonathan S,ur.01317574115.29
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Barker,Dominique,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Colquhoun,Suzie,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Presland,Laura,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Clutterbuck,Elizabeth A.,ur.0715146175.41
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Lyon,Rebecca,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",group,COV-BOOST study,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Lee,Kim,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Chalwin,Olivia,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Khan,Mohammed,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Andrews,Antonette,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Kasanyinga,Mwila,ur.011433727475.26
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hale,Colin,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Tunstall,Simon,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Berry,Lisa,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Perkins,Jonathan,ur.011067664776.63
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Osanlou,Rostam,ur.015352620537.49
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hailstone,Jessica,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Egbo,Akamino,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Whitbred,Tim,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Edwards,Christopher J,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Thorp,Helen,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Spencer,Joanne,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Brandon,Jacqueline,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Stuart,Arabella SV,ur.012453520651.22
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hall,Fran,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Suggitt,Debbie,ur.014456346307.86
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Honey,Thomas,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Broadhead,Samantha,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Macdonald,Jonathan,ur.012552634035.15
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Enever,Yvanne,ur.013521007136.91
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Alves,Carlota Pereira Dias,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Reeder,Sally,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Andrews,Nick,ur.01305560754.17
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Domingo,Jason,ur.015254760617.54
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Bibi,Sagida,ur.01123243761.16
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",khan,Farida,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Lewis-Taylor,Jessica,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Beckett,Helen,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Elliott,Scott,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Boubriak,Iryna,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Wenn,Victoria,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Snape,Matthew D,ur.010062135107.44
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Summerton,Eloise,ur.015442512751.44
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Dos Santos,Filipa,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Sheridan,Ray,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Buttigieg,Karren,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Singh,Stephen,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Liu,Xinxue,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Naker,Kush,ur.015226455127.67
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Faust,Saul N,ur.0727576315.70
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Turner,Nicola,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Ahmed,Nabeela Nazir,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Salkeld,Jo,ur.012341753443.85
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Mpelembue,Mushiya,ur.011504545415.76
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Adebambo,Olumide,ur.07644001640.11
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Snashall,Emma,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Piper,Jo,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Fowler,Simon,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",lang,Matilda,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Kinch,Patrick,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Pan,Daniel,ur.014303677634.17
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Fox,Lauren,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Romani,Rossana,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Bennett,Sara,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Bonnaud,Avril,ur.012733130736.96
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Rawlins,Todd,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Saralaya,Dinesh,ur.01222313702.82
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Barcella,Lara,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Keenan,Samantha,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hopkins,NinaSimone,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Stewart,Anna,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Thomas,Steve,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Oliver,Abigail,ur.012440201636.50
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Ambihapathy,Wythehi,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Godwin,Kerry,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Frankham,Jorden,ur.012073276236.96
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Adams,Kirsty,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Brunt,Emily,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Yim,Yee Ting Nicole,ur.07740737023.17
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Longshaw,Laura,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Bula,Marcin,ur.010533105136.52
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Starinskij,Igor,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Osanlou,Orod,ur.01321467135.06
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Makia,Fiona,ur.01122055046.60
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Sabine,Charlotte,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Plested,Emma,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Ramsay,Mary,ur.010566414272.00
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Giddins,Beth,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Chita,Sunder,ur.01002675033.11
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Batham,Sally,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Murira,Jennifer,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Marius,Phedra,ur.0623265130.05
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",White,Rachel,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Westwell,Fran,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Moorbey,Chantelle,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Farrier,Adam,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Shaik,,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Moore,Sophie,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Serafimova,Teona,ur.012563057745.49
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Cox,Stephen,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Haughney,John,ur.01100012763.65
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Coughlan,Tricia,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Warren,Sarah,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Morshead,Gertraud,ur.011313574167.85
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Cathie,Katrina,ur.0600477345.34
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Bell,Judith,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Leung,Stephanie,ur.012767450521.67
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Littlewood,Kelly,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Elliott,Ryan Stephen,ur.016214476771.00
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Fraser,Sara,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Llewelyn,Martin J,ur.01157176136.43
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",McMillan,Gillian,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Champaneri,Trishna,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Galvin,Dominic,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Gordon,Elizabeth,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Osuji,Carool,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Justice,Edwin,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Locke,Emily,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Vail,Dennyl,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Desai,Amisha,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Tasker,Suzanne,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hall,Jane,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Cooper,Chris,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hurdover,Steve,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Rampling,Tommy,ur.0714513761.47
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",McDonnell,Chloe,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hamal,Shama,ur.011504001124.59
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Singh,Michael,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Lingwood,Aidan,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Stackpoole,Michael,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Nguyen,Hanna,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Jackson,Beth,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Lakeman,Nicki,ur.016252721575.93
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Twelves,Chris,ur.016073672336.32
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hughes,Stephen,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Stockport,Jane,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Babbage,Gavin,ur.012475500137.81
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Ladikou,Eleni,ur.016624740364.25
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Munro,Alasdair P S,ur.015512011276.11
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Bentley,Ian,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Brown,Phillip,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Cifuentes,Liliana,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Cole,Christine,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Parungao,Nina,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Smith,David,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hughes,Kerry,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Allen,Lauren,ur.0600226653.15
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hicks,Alexander,ur.014155267473.25
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Branney,Debbie,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Ross-Russell,Amy,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Moore,Patrick,ur.01360731767.84
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",McGregor,Alastair C,ur.014364502736.33
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Peters,Erica,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hardy,Anna,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Todd,Shirley,ur.015276311736.37
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Haskell,Louise,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",de la Haye,Anastasia,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Shamtally,Djamila,ur.010055614236.45
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Driver,Kimberley,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Gardside,Ben,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Harndahl,Linda,ur.016506711136.95
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Ustianowski,Andrew,ur.016002143770.89
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Gowland,Andrew,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Dare,Tracey,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Baryschpolec,Sonia,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Mazzella,Andrea,ur.0724713116.42
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Calderwood,James,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Kwok,Jonathan,ur.012174161336.64
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Dodd,Kate,ur.012723426536.17
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Renals,Valerie,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Weighell,Rowena,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Gokani,Karishma,ur.016131021075.86
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Newman,Joseph,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Stokes,Matthew,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Gibney,Jennifer,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Riordan,Andrew,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Gavin,John,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Buadi,Amanda,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Robinson,Hannah,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Wagstaff,Lynda,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Mouland,Johanna,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Wilson-Goldsmith,Jaimie,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Seaton,Andrew,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Freedman,Andrew,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Holliday,Kyra,ur.014534566274.55
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Choi,Bea,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Phillips,Rachael,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Seath,Ingrid,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Habash-Bailey,Haniah,ur.010324217661.39
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",van Welsenes,Donald,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Baker,Helena,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Palfreeman,Adrian,ur.01200206104.82
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Brown,Claire,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Evans,Julie,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Cornelius,Victoria,ur.01205756377.89
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Cutts,Rebecca,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Mansfield,Becky,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Baker,Jonathan,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Chatterjee,Krishna,ur.010766225754.87
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hallis,Bassam,ur.01127251360.63
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Campbell,Marion,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Trinham,Charlotte,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Wilkins,Suzanne,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Farooqi,Sadaf,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Pickup,Lorinda,ur.012056450475.12
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Whittington,Ashley,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Kamal,Mohammed,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Horsfall,Emily,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Minassian,Angela M,ur.01237421066.88
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Shenoy,Anil,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Sturdy,Ann,ur.013703350736.01
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Bousfield,Rachel,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Nightingale,Kari,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Irwin,Margaret,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Shaw,Robert H,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Whittley,Sarah,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Moon,Maria,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Baker,Holly,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Saich,Stephen,ur.015647400175.43
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Davies,Ceri,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Hogan,Alison,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Tandy,Bridget,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",John,Laurence,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Green,Christopher A,ur.0603753333.19
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Sakagami,Yukari,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Baker,Natalie,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Nabunjo,Martha,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Gouriet,Jade,ur.014551266061.15
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Grundy,Lynne,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Ellis,Kate,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",King,Mikayala,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Eadsforth,Tom,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Kownacka,Alicja,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Jones,Lona Tudor,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Graham,Victoria,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Guha,Arpan,ur.01272123771.51
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Corrah,Tumena,ur.01062737475.85
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Magee,Alan,
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Qureshi,Ehsaan,ur.07517323271.46
7074,"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",Savage,Mary,
7073,Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants,Abu-Raddad,Laith J,ur.01043443217.45
7073,Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants,Butt,Adeel A,ur.01045474042.31
7073,Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants,Chemaitelly,Hiam,ur.01154030517.73
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Riddell,Andrew,ur.0723427165.72
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Ambrose,Karen,ur.014211152021.01
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Sawyer,Chelsea,ur.015307355035.25
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Howell,Michael,ur.01261105012.50
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Daniels,Rodney,ur.016115464152.46
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Ngai,Yenting,ur.0652436522.25
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Gamblin,Steve,ur.016140216004.13
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Swanton,Charles,ur.0610422247.65
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Kelly,Gavin,ur.01101311217.22
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Hobson,Philip,ur.015651273447.51
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Wu,Mary,ur.011055233443.57
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Gandhi,Sonia,ur.01030062701.07
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Bauer,David Lv,ur.01133121170.45
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Williams,Bryan,ur.01322330244.74
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Libri,Vincenzo,ur.01256064600.37
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Warchal,Scott,ur.011460613017.09
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Nicod,Jerome,ur.01005650641.41
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Goldstone,Robert,
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Hatipoglu,Emine,ur.014176435205.06
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Hindmarsh,Steve,ur.014106217145.54
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Harvey,Ruth,ur.01366003555.84
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Wall,Emma C,ur.01313153217.26
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Beale,Rupert,ur.01250034406.34
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Hussain,Saira,ur.013342424677.47
7052,Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination,Kassiotis,George,ur.01222550311.43
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Phillips,Elizabeth,
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Tarke,Alison,ur.016663632607.82
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Greenbaum,Jason,ur.01147567650.98
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Rubiro,Paul,ur.07765167613.39
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Sidney,John,ur.01027013077.15
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Peters,Bjoern,ur.07447331037.97
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Yu,Esther Dawen,ur.01226366503.73
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Crotty,Shane,ur.01312261077.26
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Sette,Alessandro,ur.016527313277.78
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Dan,Jennifer M,ur.01265515227.13
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Grifoni,Alba,ur.01314176576.29
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Markmann,Alena J,ur.010402226115.05
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Quiambao,Lorenzo,ur.01337727463.98
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Mateus,Jose,ur.010331064057.40
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,de Silva,Aravinda,ur.01230210257.19
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Mallal,Simon,ur.01042305653.45
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Smith,Davey M,ur.011615110604.77
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Lammers,Marshall,ur.011177166627.44
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Burger,Zoe C,ur.012524014427.99
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Sutherland,Aaron,ur.010654151463.18
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Rawlings,Stephen A,ur.01052460632.32
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Premkumar,Lakshmanane,ur.01150126507.16
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Frazier,April,ur.01253340356.82
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,da Silva Antunes,Ricardo,ur.01252146007.33
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Weiskopf,Daniela,ur.0602150374.89
7049,Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,Ramirez,Sydney I,ur.01067126700.43
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Ferreira,Alexander P.,
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Mentzer,Alexander J.,ur.01260434061.14
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Horner,Emily,ur.016441635655.49
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Pöyry,Tuija,ur.01163540170.10
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Dunachie,Susanna,ur.01041133025.01
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Kalmar,Lajos,ur.01332473123.15
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Stoneley,Mark,ur.01351152265.48
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,von der Haar,Tobias,ur.01202567453.20
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Turtle,Lance,ur.01133171523.79
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Yam-Puc,Juan Carlos,ur.0703715223.38
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Rust,Maria,ur.012034663146.14
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Mulroney,Thomas E.,ur.010350325233.95
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Booth,Lucy,ur.016670565772.86
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Klenerman,Paul,ur.01366404500.15
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Thaventhiran,James E. D.,ur.0713100276.71
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Willis,Anne E.,ur.0752776553.61
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Lilley,Kathryn S.,ur.0673527050.80
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Harvey,Robert F.,ur.012520125177.60
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Smales,C. Mark,ur.01133412650.17
7039,N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting,Sawarkar,Ritwick,ur.01020044573.04
7013,Cardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents,Mansanguan,Suyanee,
7013,Cardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents,Poolcharoen,Akkapon,ur.015745464407.21
7013,Cardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents,Dechkhajorn,Wilanee,ur.011244464211.16
7013,Cardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents,Mansanguan,Chayasin,ur.01315320106.10
7013,Cardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents,Piyaphanee,Watcharapong,ur.01036500151.31
7013,Cardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents,Charunwatthana,Prakaykaew,ur.01176312602.90
7011,Endonuclease fingerprint indicates a synthetic origin of SARS-CoV-2,Washburne,Alex,
7011,Endonuclease fingerprint indicates a synthetic origin of SARS-CoV-2,VanDongen,Antonius,ur.0644453245.13
7011,Endonuclease fingerprint indicates a synthetic origin of SARS-CoV-2,Bruttel,Valentin,ur.0655360534.81
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Patel,Ankit B,ur.01355714337.45
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Shui,Jessica E,ur.016643725141.92
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",D'Avino,Paolo,ur.010717705347.92
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Fialkowski,Allison,ur.015243216361.26
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",St John,Anita,
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Yonker,Lael M,ur.01315443731.68
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Chiu,Michelle L,
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Yockey,Laura J,ur.0713154160.21
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Park,Grace,
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Yu,Xu G,ur.012256737177.41
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Lima,Rosiane,
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Li,Jonathan Z,
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Fischinger,Stephanie,ur.07457313034.45
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Bartsch,Yannic,ur.0706564236.09
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Fasano,Alessio,ur.01007715271.18
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Irimia,Daniel,ur.01333311437.26
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Neilan,Anne M,ur.0623652112.14
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Bonventre,Joseph V,ur.015404210257.76
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Arya,Puneeta,ur.0663667643.52
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Gootkind,Elizabeth,ur.012244533147.58
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Appleman,Lori,ur.015427415613.04
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Hardcastle,Margot,
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Alter,Galit,ur.01216077501.34
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Bassett,Ingrid V,ur.01241744016.33
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",De la Flor,Denis,ur.013155455615.55
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Bordt,Evan A,ur.0602266524.07
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Edlow,Andrea G,ur.0723176517.18
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Regan,James,ur.014561037511.56
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Lerou,Paul H,ur.01071737774.79
7007,"Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses",Ryan,Edward T,ur.0666250555.97
7000,Heavily mutated Omicron variant puts scientists on alert,Callaway,Ewen,
6977,Association between vitamin D supplementation and COVID-19 infection and mortality,Meltzer,David O.,ur.01246417251.29
6977,Association between vitamin D supplementation and COVID-19 infection and mortality,Gibbons,Robert D.,ur.015652737750.07
6977,Association between vitamin D supplementation and COVID-19 infection and mortality,Fiedler,Virginia C.,
6977,Association between vitamin D supplementation and COVID-19 infection and mortality,Norton,Edward C.,ur.0714030376.28
6977,Association between vitamin D supplementation and COVID-19 infection and mortality,Gibbons,Jason B.,ur.016223542006.47
6977,Association between vitamin D supplementation and COVID-19 infection and mortality,McCullough,Jeffrey S.,ur.012665035750.12
6977,Association between vitamin D supplementation and COVID-19 infection and mortality,Lavigne,Jill,ur.01062636273.82
6955,Airborne transmission of SARS-CoV-2,McDiarmid,Melissa A,ur.01275472542.18
6955,Airborne transmission of SARS-CoV-2,Milton,Donald K,ur.0771763124.46
6955,Airborne transmission of SARS-CoV-2,Marr,Linsey C,ur.0653376160.71
6955,Airborne transmission of SARS-CoV-2,Prather,Kimberly A,ur.0576263513.15
6955,Airborne transmission of SARS-CoV-2,Schooley,Robert T,ur.0577053102.12
6955,Airborne transmission of SARS-CoV-2,Wilson,Mary E,
6931,Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2,Steves,Claire J,ur.0624116417.81
6931,Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2,Antonelli,Michela,ur.010230774161.66
6931,Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2,Pujol,Joan Capdevila,ur.011612413713.08
6931,Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2,Spector,Tim D,ur.014424006237.85
6931,Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2,Ourselin,Sebastien,ur.0731256650.39
6925,"Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021",Shimabukuro,Tom T,ur.0613726743.13
6925,"Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021",Su,John R,ur.01012253516.19
6925,"Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021",Cole,Matthew,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Rodriguez,Luis,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Knust,Barbara,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",White,Stefanie,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Curren,Emily,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Cohen,Nicole J.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Dooling,Kathleen,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Miller,Glen,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Acosta,Anna,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Blocher,Tricia,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Campbell,Stefanie,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Tobolowsky,Farrell,ur.015442117105.53
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Campos,Kevin,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Barry,Pennan,ur.01271061520.14
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Wong,Cindy,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Richards,Jayleen,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Lamba,Katherine,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Readhead,Adam,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Poser,Sarah,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",,,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Smith,Paul W.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Bozio,Catherine,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Shockey,Caitlin,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Chai,Shua,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Stewart,Andrea,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Stockman,Lauren,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Canty,Paul T.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",,,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",,,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Myers,Jennifer F.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Friedman,Cindy R.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Bregman,Brooke,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Schneider,Zachary,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Bertulfo,Mary Catherine,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Treffiletti,Aimee,ur.0710150507.28
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Murray,Rachel,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Guevara,Hugo,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Brown,Clive,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Herzig,Carolyn,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Chatham-Stephens,Kevin,ur.0774155407.97
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",McColloch,Audrey,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Pan,Chao-Yang,ur.01337473445.46
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Naramore,Sara,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Tardivel,Kara,ur.010303602721.43
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Ritter,Troy,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Rose,Dale,ur.01074740430.41
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Kurylo,Elizabeth,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Knight,Nancy,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Regan,Joanna J.,ur.01372251705.04
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Medley,Alexandra M.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Toda,Mitsuru,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Ryan,Matthew,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Matyas,Bela,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Rinker,Robin A.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Pesik,Nicki,ur.0607234240.43
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Weinberg,Michelle,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Moriarty,Leah F.,ur.0662257432.29
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Jacobson,Kathleen R.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Plucinski,Mateusz M.,ur.0744552313.48
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Scheuer,Tara,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Morales,Christina,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Marlow,Mariel,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Yen,Cynthia,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Kapella,Bryan K,ur.0727272514.31
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",,,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Vugia,Duc,ur.012143517701.85
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Kobayashi,Miwako,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Green,Gary,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Hacker,Jill,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Halsey,Eric S.,ur.01303413254.20
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Ntui,Asundep,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Freeland,Amy,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Ivey,Kathryn,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Charles,Julia,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Wittry,Beth,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Fitter,David,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Saguar,Estela,ur.012410136035.63
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Shugart,Jill,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",,,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Behravesh,Casey Barton,ur.01137021646.39
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Braden,Zachary,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Mead,Paul S.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Salas,Maria,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Morris,Mary Kate,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",,,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Wallace,Megan,ur.014443542624.59
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Murphy,Ryan,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Weidle,Paul,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Glenn-Finer,Rosie,ur.012342022635.82
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Berumen,Ricardo,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Marston,Barbara J.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Novak,Ryan T.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Kurbatova,Ekaterina V.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Snyder,Robert E.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Cooper,Barbara,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Watt,James,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",,,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Honein,Margaret A.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Bjork,Adam,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Dubray,Christine,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Kadzik,Melissa,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Cetron,Martin,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Acosta,Meileen,ur.01106342363.23
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Wagner,Riley,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Kapuszinsky,Beatrix,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Ishizumi,Atsuyoshi,ur.016352121135.63
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Davis,Shai,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Svendsen,Erik,ur.01046047210.78
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Jones,Jefferson,ur.01317072007.53
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",,,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Murray,Erin L.,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",,,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",McDonald,Robert,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Yoder,Jonathan,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Sarisky,John,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Padilla,Tasha,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Hsieh,Kristina,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Klevos,Andrew,ur.01362320554.94
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Wu,Christine,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Bower,William,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Silver,Margaret,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Wadford,Debra A.,ur.01040602272.88
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Daigle,David,
6910,"Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020",Chu,Victoria,
6885,Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,Zhang,Leike,ur.014150670465.18
6885,Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,Wang,Manli,ur.01076711313.23
6885,Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,Xu,Mingyue,ur.01330651401.04
6885,Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,Hu,Zhihong,ur.0661227375.88
6885,Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,Shi,Zhengli,ur.012321453367.61
6885,Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,Cao,Ruiyuan,ur.01112354305.12
6885,Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,Liu,Jia,ur.0663456334.07
6885,Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,Yang,Xinglou,ur.0774167565.71
6885,Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,Zhong,Wu,ur.01305463356.23
6885,Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro,Xiao,Gengfu,ur.0666617712.38
6881,"DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events.",Speicher,David J,ur.01252342723.45
6881,"DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events.",Wiseman,David M,ur.0636272557.76
6881,"DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events.",Rose,Jessica,ur.010036210353.24
6881,"DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events.",Gutschi,L. Maria,ur.016652432066.86
6881,"DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events.",McKernan,Kevin,ur.0614733731.46
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Georgian,Elizabeth,ur.011637470534.02
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Marquez,Carina,ur.01344426730.36
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Rojas,Susana,ur.012766620303.97
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Mitchell,Anthea M.,ur.013666303600.75
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Michelmore,Richard,ur.01251712650.72
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Pilarowski,Genay,ur.011307001265.50
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Wang,Chung Yu,ur.016152220334.17
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Acharya,Charlotte B.,ur.01320715336.20
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Schrom,John,ur.012366735734.32
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Coil,David A.,ur.0710356232.13
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Petersen,Maya,ur.0777510174.77
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Havlir,Diane,ur.015550410357.00
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Solis,Leslie,ur.011042110134.44
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",DeRisi,Joseph,ur.01165231645.30
6870,"No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant",Liu,Jamin,ur.014115624310.10
6864,Over half of known human pathogenic diseases can be aggravated by climate change,Franklin,Erik C.,ur.0637467001.13
6864,Over half of known human pathogenic diseases can be aggravated by climate change,Mora,Camilo,ur.01063706626.66
6864,Over half of known human pathogenic diseases can be aggravated by climate change,von Hammerstein,Hannah,
6864,Over half of known human pathogenic diseases can be aggravated by climate change,Gaw,Isabella M.,ur.013304057522.56
6864,Over half of known human pathogenic diseases can be aggravated by climate change,Smith,Charlotte Z.,ur.011137734403.87
6864,Over half of known human pathogenic diseases can be aggravated by climate change,Webster,Kira M.,ur.012765731004.14
6864,Over half of known human pathogenic diseases can be aggravated by climate change,McKenzie,Tristan,ur.011577214536.56
6864,Over half of known human pathogenic diseases can be aggravated by climate change,Knudson,Tabatha A.,ur.015474401122.39
6864,Over half of known human pathogenic diseases can be aggravated by climate change,Setter,Renee O.,ur.015066166104.04
6864,Over half of known human pathogenic diseases can be aggravated by climate change,Dean,Jacqueline M.,
6864,Over half of known human pathogenic diseases can be aggravated by climate change,Patz,Jonathan A.,ur.01132242375.65
6851,Long-term neurologic outcomes of COVID-19,Xie,Yan,ur.0737732757.38
6851,Long-term neurologic outcomes of COVID-19,Xu,Evan,ur.015100372457.77
6851,Long-term neurologic outcomes of COVID-19,Al-Aly,Ziyad,ur.0756001054.57
6849,Mechanisms of SARS-CoV‑2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America,Chen,Jiahui,ur.010427271673.11
6849,Mechanisms of SARS-CoV‑2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America,Wei,Guo-Wei,ur.016623371715.93
6849,Mechanisms of SARS-CoV‑2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America,Wang,Rui,ur.012517737613.46
6848,Face masks considerably reduce COVID-19 cases in Germany,Mitze,Timo,ur.016010522621.89
6848,Face masks considerably reduce COVID-19 cases in Germany,Rode,Johannes,ur.012405403701.25
6848,Face masks considerably reduce COVID-19 cases in Germany,Kosfeld,Reinhold,ur.013140500561.11
6848,Face masks considerably reduce COVID-19 cases in Germany,Wälde,Klaus,ur.012564617637.33
6838,Virological assessment of hospitalized patients with COVID-2019,Brünink,Sebastian,ur.01251423776.24
6838,Virological assessment of hospitalized patients with COVID-2019,Corman,Victor M.,ur.01010416173.31
6838,Virological assessment of hospitalized patients with COVID-2019,Wölfel,Roman,ur.01011523753.14
6838,Virological assessment of hospitalized patients with COVID-2019,Schneider,Julia,ur.016330741567.89
6838,Virological assessment of hospitalized patients with COVID-2019,Seilmaier,Michael,ur.01076545541.08
6838,Virological assessment of hospitalized patients with COVID-2019,Vollmar,Patrick,ur.0621033620.86
6838,Virological assessment of hospitalized patients with COVID-2019,Hoelscher,Michael,ur.0775601074.81
6838,Virological assessment of hospitalized patients with COVID-2019,Zange,Sabine,ur.0667147020.04
6838,Virological assessment of hospitalized patients with COVID-2019,Zwirglmaier,Katrin,ur.01314277614.98
6838,Virological assessment of hospitalized patients with COVID-2019,Jones,Terry C.,ur.01052234046.80
6838,Virological assessment of hospitalized patients with COVID-2019,Guggemos,Wolfgang,ur.01212774141.45
6838,Virological assessment of hospitalized patients with COVID-2019,Bleicker,Tobias,ur.01174546340.84
6838,Virological assessment of hospitalized patients with COVID-2019,Wendtner,Clemens,ur.01115432015.20
6838,Virological assessment of hospitalized patients with COVID-2019,Rothe,Camilla,ur.01307554615.45
6838,Virological assessment of hospitalized patients with COVID-2019,Müller,Marcel A.,ur.01077427726.16
6838,Virological assessment of hospitalized patients with COVID-2019,Ehmann,Rosina,ur.012515605157.36
6838,Virological assessment of hospitalized patients with COVID-2019,Drosten,Christian,ur.010432516417.62
6838,Virological assessment of hospitalized patients with COVID-2019,Niemeyer,Daniela,ur.01152237266.39
6808,Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections,Chemaitelly,Hiam,ur.01154030517.73
6808,Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections,Bertollini,Roberto,ur.01364646142.66
6808,Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections,Abu-Raddad,Laith J,ur.01043443217.45
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Butt,Adeel A,ur.01045474042.31
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Jeremijenko,Andrew,ur.07636202443.89
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Chemaitelly,Hiam,ur.01154030517.73
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Nasrallah,Gheyath K,ur.0756134516.24
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Altarawneh,Heba N,ur.012723106650.86
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Tang,Patrick,ur.01315302317.29
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Kaleeckal,Anvar H,ur.010433563043.34
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Abdul-Rahim,Hanan F,ur.0761773610.33
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Ayoub,Houssein H,ur.01372234200.88
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Al-Khatib,Hebah A,ur.01241074153.14
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Yassine,Hadi M,ur.0725212610.28
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Smatti,Maria K,ur.0627501117.43
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Al-Romaihi,Hamad E,ur.01154514422.40
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Al-Thani,Mohamed H,ur.01124347026.26
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Coyle,Peter,ur.01031610232.70
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Al-Kuwari,Einas,ur.016117301117.66
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Al-Kuwari,Mohamed G,ur.01070467721.92
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Abu-Raddad,Laith J,
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Bertollini,Roberto,ur.01364646142.66
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Hasan,Mohammad R,ur.01170641002.25
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Al-Kanaani,Zaina,ur.01342334246.57
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Shaik,Riyazuddin M,ur.010555214011.24
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Latif,Ali N,ur.013203656657.40
6793,Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,Al-Khal,Abdullatif,ur.0775653371.99
6792,Household COVID-19 risk and in-person schooling,Stuart,Elizabeth A.,ur.0577304143.29
6792,Household COVID-19 risk and in-person schooling,Metcalf,C. Jessica E.,ur.016452515157.97
6792,Household COVID-19 risk and in-person schooling,Badillo-Goicoechea,Elena,ur.016330302047.62
6792,Household COVID-19 risk and in-person schooling,Lupton-Smith,Carly,ur.012070641042.64
6792,Household COVID-19 risk and in-person schooling,Azman,Andrew S.,ur.01153520222.87
6792,Household COVID-19 risk and in-person schooling,Grantz,Kyra H.,ur.07636400475.34
6792,Household COVID-19 risk and in-person schooling,Lessler,Justin,ur.0775017522.46
6792,Household COVID-19 risk and in-person schooling,Grabowski,M. Kate,ur.0754414214.71
6754,The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission,Peto,Tim EA,ur.011213750437.09
6754,The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission,Taylor,Donald,
6754,The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission,Chapman,David,ur.016620312274.41
6754,The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission,Pouwels,Koen B,ur.01123752003.47
6754,The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission,Walker,A Sarah,ur.014661724572.21
6754,The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission,Fowler,Tom,ur.01150350005.09
6754,The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission,Purver,Mark,ur.016374014630.27
6754,The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission,Eyre,David W,ur.015076066434.76
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Glass,Allison,ur.013536626123.85
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Amoako,Daniel Gyamfi,ur.01221263053.52
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Davies,Mary-Ann,
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Jassat,Waasila,ur.01334613101.08
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Treurnicht,Florette K.,ur.01071634205.66
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Ismail,Arshad,ur.015422132323.74
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Parboosing,Raveen,ur.01127452777.71
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Wolter,Nicole,ur.0663453625.44
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Scheepers,Cathrine,ur.01337014175.87
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Makatini,Zinhle,ur.014231235563.03
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Tebeila,Naume,
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Everatt,Josie,ur.015655446664.07
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Boulle,Andrew,ur.0761230764.33
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Mlisana,Koleka,ur.0730170124.78
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Govender,Nevashan,ur.01110241044.33
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Cohen,Cheryl,ur.01077665046.14
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Chiwandire,Nicola,ur.07662475642.15
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,du Plessis,Mignon,ur.0715725455.22
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Groome,Michelle,ur.01173734524.78
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,von Gottberg,Anne,ur.0731567025.04
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Hsiao,Nei-yuan,ur.0620637470.24
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Welch,Richard,ur.014620133602.86
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Stevens,Wendy,ur.011463270162.41
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Moultrie,Harry,ur.01211705764.13
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Hussey,Hannah,
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Bhiman,Jinal N.,ur.01217220246.13
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Wadula,Jeannette,ur.011657451037.54
6738,Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,Walaza,Sibongile,ur.0752327112.09
6735,The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice,Williams,Lindsey M.,ur.012655420217.17
6735,The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice,Hansen,Kim M.,ur.01166652771.09
6735,The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice,Rhea,Elizabeth M.,ur.011067532735.50
6735,The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice,Reed,May J.,ur.01325343371.43
6735,The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice,Baumann,Kristen K.,ur.016440702617.43
6735,The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice,Raber,Jacob,ur.0702607432.63
6735,The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice,Logsdon,Aric F.,ur.01245705024.56
6735,The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice,Banks,William A.,ur.01333450725.21
6735,The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice,Holden,Sarah J.,ur.07735631417.25
6735,The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice,Erickson,Michelle A.,ur.0727451017.03
6734,"COVID-19 Cases and Transmission in 17 K–12 Schools — Wood County, Wisconsin, August 31–November 29, 2020",Høeg,Tracy Beth,ur.01044166575.20
6734,"COVID-19 Cases and Transmission in 17 K–12 Schools — Wood County, Wisconsin, August 31–November 29, 2020",Steffen,Sarah,ur.07362522433.21
6734,"COVID-19 Cases and Transmission in 17 K–12 Schools — Wood County, Wisconsin, August 31–November 29, 2020",Falk,Amy,ur.012276450133.84
6734,"COVID-19 Cases and Transmission in 17 K–12 Schools — Wood County, Wisconsin, August 31–November 29, 2020",Benda,Alison,ur.013671411133.03
6734,"COVID-19 Cases and Transmission in 17 K–12 Schools — Wood County, Wisconsin, August 31–November 29, 2020",Falk,Peter,ur.015264352133.96
6734,"COVID-19 Cases and Transmission in 17 K–12 Schools — Wood County, Wisconsin, August 31–November 29, 2020",Wallace,Zachary,ur.010755463433.29
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Ertürk,Ali,ur.01052507623.11
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Mai,Hongcheng,ur.01122505242.79
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Cherif,Fatma,
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Tahirovic,Sabina,ur.01007342740.34
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Kolabas,Zeynep Ilgin,ur.010530751067.66
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Protzer,Ulrike,ur.0701243645.67
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Vering,Jessica,
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Schädler,Julia,
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Horvath,Izabela,ur.013771306225.59
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Czogalla,Jan,ur.010561664727.05
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Delbridge,Claire,
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Ulukaya,Selin,ur.012414565760.43
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Huber,Tobias B.,ur.0655111754.84
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Rong,Zhouyi,ur.011441432061.84
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Frenzel,Hannah,
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Steinke,Hanno,ur.01073104647.95
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Hellal,Farida,ur.01026710722.18
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Krahmer,Natalie,ur.01337513650.59
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Schmidt,Katja,
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Ali,Mayar,
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Puelles,Victor G.,ur.01057143120.17
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Bhatia,Harsharan Singh,ur.0577027601.52
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Ondruschka,Benjamin,ur.01213225177.20
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Ebert,Gregor,
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Zhao,Shan,
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Bechmann,Ingo,ur.01242770417.97
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Wettengel,Jochen Martin,ur.01064303015.77
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Caliskan,Özüm Sehnaz,ur.07361011755.96
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Kapoor,Saketh,ur.014264662276.15
6729,SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19,Yildirim,Ali Önder,ur.0757013146.18
6713,Age-stratified infection fatality rate of COVID-19 in the non-elderly informed from pre-vaccination national seroprevalence studies,Axfors,Cathrine,ur.010232432033.00
6713,Age-stratified infection fatality rate of COVID-19 in the non-elderly informed from pre-vaccination national seroprevalence studies,Pezzullo,Angelo Maria,ur.01117056265.13
6713,Age-stratified infection fatality rate of COVID-19 in the non-elderly informed from pre-vaccination national seroprevalence studies,Ioannidis,John P.A.,ur.015607417277.46
6713,Age-stratified infection fatality rate of COVID-19 in the non-elderly informed from pre-vaccination national seroprevalence studies,Contopoulos-Ioannidis,Despina G.,ur.01312540565.55
6713,Age-stratified infection fatality rate of COVID-19 in the non-elderly informed from pre-vaccination national seroprevalence studies,Apostolatos,Alexandre,ur.016346251612.77
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Yokote,Koutaro,ur.01167375325.46
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,McGowan,Barbara M,ur.01067103203.76
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Tran,Marie T D,ur.0741270110.34
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Rosenstock,Julio,ur.0661716557.12
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Van Gaal,Luc F,ur.01247356256.99
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Wharton,Sean,ur.0626775175.24
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Davies,Melanie,ur.014257756332.18
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Wilding,John P H,ur.016404705217.98
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Lingvay,Ildiko,ur.0767170500.53
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Wadden,Thomas A,ur.0761244115.68
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Calanna,Salvatore,ur.01076127217.27
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Kushner,Robert F,ur.0656076605.44
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Zeuthen,Niels,ur.014317460335.00
6709,Once-Weekly Semaglutide in Adults with Overweight or Obesity,Batterham,Rachel L,ur.01145676714.01
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Liu,Fei-Fei,ur.015032632233.09
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Jin,Dong-Yan,ur.0730354326.01
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,To,Kelvin Kai-Wang,ur.014242120072.04
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Zhang,Anna Jinxia,ur.01360433371.85
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Song,Wenchen,ur.016023456241.08
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Cai,Jian-Piao,ur.0613012444.37
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Chen,Yanxia,ur.012367177170.95
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Yip,Cyril Chik-Yan,ur.012575275252.07
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Kok,Kin-Hang,ur.01314135406.17
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Chan,Jasper Fuk-Woo,ur.014621347512.77
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Zhao,Yan,ur.011315463033.79
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Wong,Wan-Man,ur.0773041271.49
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Sridhar,Siddharth,ur.0760564620.18
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Yuen,Kwok-Yung,ur.0652735016.56
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Ye,Zhanhong,ur.012710424033.71
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Lung,David Christopher,ur.01030467317.18
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Chu,Hin,ur.01171275445.04
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Li,Can,ur.01305652046.06
6705,Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model,Hung,Ivan Fan-Ngai,ur.07537173544.90
6690,Myocarditis and Pericarditis After Vaccination for COVID-19,Gering,Sara K.,
6690,Myocarditis and Pericarditis After Vaccination for COVID-19,Parsons,Guilford T.,ur.011115764041.47
6690,Myocarditis and Pericarditis After Vaccination for COVID-19,Meier,Audrey R.,ur.013166012351.95
6690,Myocarditis and Pericarditis After Vaccination for COVID-19,Diaz,George A.,ur.016375424165.69
6690,Myocarditis and Pericarditis After Vaccination for COVID-19,Robicsek,Ari,ur.01372673027.09
6690,Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks,Prakash,Abhinav,ur.014204465621.09
6690,Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks,Grant,Gregory D.,ur.011225322175.59
6690,Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks,Guha,Supratik,ur.010372430665.96
6690,Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks,Konda,Abhiteja,ur.01306413245.06
6690,Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks,Schmoldt,Michael,ur.010427741575.33
6690,Myocarditis and Pericarditis After Vaccination for COVID-19,Hutchinson,Ian V.,
6690,Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks,Moss,Gregory A.,ur.07632361175.66
6677,Excess Death Rates for Republican and Democratic Registered Voters in Florida and Ohio During the COVID-19 Pandemic,Schwartz,Jason L.,ur.011141146656.15
6677,Excess Death Rates for Republican and Democratic Registered Voters in Florida and Ohio During the COVID-19 Pandemic,Wallace,Jacob,ur.012544364121.10
6677,Excess Death Rates for Republican and Democratic Registered Voters in Florida and Ohio During the COVID-19 Pandemic,Goldsmith-Pinkham,Paul,ur.012101254511.54
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Mevorach,Dror,ur.01307701217.80
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Levi,Nir,ur.014632432337.14
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Miskin,Ian,ur.0753726370.08
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Cedar,Noa,ur.01062673726.28
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Muhsen,Khitam,ur.016624613147.07
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Dagan,Ron,ur.0672051772.28
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Keinan-Boker,Lital,ur.01210646462.86
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Saliba,Walid,
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Arad,Dana,
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Alroy-Preis,Sharon,ur.01061334326.15
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Levi,Yehezkel,
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Olsha-Castell,Sharon,
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Cohen,Dotan,ur.012555413453.52
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Dichtiar,Rita,ur.01173316026.21
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Meir,Karen,ur.01205625340.25
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Asleh,Rabea,ur.01275574701.40
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Hasin,Tal,ur.01072761276.23
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Nadir,Eyal,ur.01065157530.52
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Green,Manfred S,
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Anis,Emilia,ur.01263023362.59
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Leitersdorf,Iris,
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Ben-Ami,Ronen,ur.01175561036.22
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Amir,Offer,ur.01140536001.72
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Hershkovitz,Yael,ur.01305400140.82
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Haas,Eric J,ur.01132143134.04
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Bromberg,Michal,
6668,Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,Novick,Deborah,
6661,Reviving the US CDC,Lancet,The,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Tanaka,Yuri L,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Consortium,The Genotype to Phenotype Japan,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Uriu,Keiya,ur.015436303555.51
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Shirakawa,Kotaro,ur.01340206741.80
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Sadamasu,Kenji,ur.01055610137.59
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Sasaki,Michihito,ur.01035400335.13
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Ikeda,Terumasa,ur.0741654565.08
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Nagashima,Mami,ur.0614337136.53
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Kosugi,Yusuke,ur.015050131253.04
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Suzuki,Takuji,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Butlertanaka,Erika P,ur.016266175445.11
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Toyoda,Mako,ur.01037524127.04
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Ishii,Ken J,ur.011435260572.38
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Nao,Naganori,ur.01237450052.43
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Yamasoba,Daichi,ur.0671555150.92
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Wang,Lei,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Kuramochi,Jin,ur.01371154041.06
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Nasser,Hesham,ur.0764066606.70
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Ito,Jumpei,ur.0657610035.26
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Takaori-Kondo,Akifumi,ur.0743352217.37
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Yoshimatsu,Kumiko,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Morioka,Yuhei,ur.015776500143.88
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Fukuhara,Takasuke,ur.0776043577.62
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Tanaka,Shinya,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Shimada,Tadanaga,ur.0713135374.09
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Sakao,Seiichiro,ur.01233630525.44
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Kimura,Izumi,ur.014355352764.09
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Ito,Hayato,ur.010567504470.93
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Sato,Kei,ur.0710074174.33
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Nakada,Taka-aki,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Kishimoto,Mai,ur.01121015373.71
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Suzuki,Rigel,ur.016645667751.52
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Matsuno,Keita,ur.01032407141.04
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Orba,Yasuko,ur.0751337777.54
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Irie,Takashi,ur.01151454305.59
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Seki,Motoaki,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Sawa,Hirofumi,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Shimizu,Ryo,ur.01235452412.44
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Ueno,Takamasa,ur.012635140262.79
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Yoshimura,Kazuhisa,ur.01162214372.88
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Saito,Akatsuki,ur.01176047565.20
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Zahradnik,Jiri,ur.010006010605.38
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Schreiber,Gideon,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Kobiyama,Kouji,ur.0747121771.85
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Oda,Yoshitaka,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Hara,Teppei,ur.014304653670.78
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Nagata,Kayoko,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Asakura,Hiroyuki,ur.011750330114.13
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Tsuda,Masumi,ur.0671234072.10
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Kaneda,Atsushi,
6654,Virological characteristics of SARS-CoV-2 BA.2 variant,Fujiki,Ryoji,ur.0632175302.91
6644,Mix-and-match COVID vaccines trigger potent immune response,Callaway,Ewen,
6630,Epidemiology of COVID-19 Among Children in China,Qi,Xin,
6630,Epidemiology of COVID-19 Among Children in China,Jiang,Zhongyi,
6630,Epidemiology of COVID-19 Among Children in China,Jiang,Fan,ur.01215141216.39
6630,Epidemiology of COVID-19 Among Children in China,Hu,Yabin,ur.014650505455.44
6630,Epidemiology of COVID-19 Among Children in China,Tong,Shilu,ur.0663133575.19
6630,Epidemiology of COVID-19 Among Children in China,Mo,Xi,ur.01161563324.88
6630,Epidemiology of COVID-19 Among Children in China,Dong,Yuanyuan,ur.015207233320.52
6620,Pollution and health: a progress update,Cropper,Maureen,
6620,Pollution and health: a progress update,Mustapha,Adetoun,ur.016421347056.40
6620,Pollution and health: a progress update,Caravanos,Jack,ur.01136014506.94
6620,Pollution and health: a progress update,Balakrishnan,Kalpana,ur.0721777650.06
6620,Pollution and health: a progress update,Hanrahan,David,ur.01257446525.34
6620,Pollution and health: a progress update,Sanchez-Triana,Ernesto,ur.012377713673.58
6620,Pollution and health: a progress update,Fuller,Richard,
6620,Pollution and health: a progress update,Bathan,Glynda,
6620,Pollution and health: a progress update,Téllez-Rojo,Martha María,ur.011351205777.19
6620,Pollution and health: a progress update,Janata,Gloria,
6620,Pollution and health: a progress update,Chiles,Tom,
6620,Pollution and health: a progress update,Shaw,Joseph,
6620,Pollution and health: a progress update,Lichtveld,Maureen,ur.0634004120.13
6620,Pollution and health: a progress update,Hunter,David,ur.015167661273.24
6620,Pollution and health: a progress update,Brauer,Michael,ur.01206007745.28
6620,Pollution and health: a progress update,Seddon,Jessica,ur.014550653777.32
6620,Pollution and health: a progress update,Ferraro,Greg,ur.016305545523.01
6620,Pollution and health: a progress update,Bose-O'Reilly,Stephan,ur.01354756052.49
6620,Pollution and health: a progress update,Hanna,Jill,
6620,Pollution and health: a progress update,Lanphear,Bruce,ur.01343040706.62
6620,Pollution and health: a progress update,Kupka,Rachael,ur.012546613417.50
6620,Pollution and health: a progress update,Schaefli,Laura,ur.015325146563.76
6620,Pollution and health: a progress update,Sandilya,Karti,ur.07430433453.92
6620,Pollution and health: a progress update,Suk,William,ur.01203706464.01
6620,Pollution and health: a progress update,Landrigan,Philip J,ur.012546736624.64
6620,Pollution and health: a progress update,Yan,Chonghuai,ur.01240331334.21
6620,Pollution and health: a progress update,Corra,Lilian,
6620,Pollution and health: a progress update,Martin,Keith,
6620,Pollution and health: a progress update,Hu,Howard,ur.0742043651.66
6620,Pollution and health: a progress update,Cohen,Aaron,
6620,The psychological impact of quarantine and how to reduce it: rapid review of the evidence,Woodland,Lisa,ur.013327622253.96
6620,The psychological impact of quarantine and how to reduce it: rapid review of the evidence,Greenberg,Neil,ur.0630476676.11
6620,The psychological impact of quarantine and how to reduce it: rapid review of the evidence,Rubin,Gideon James,ur.0655500551.77
6620,The psychological impact of quarantine and how to reduce it: rapid review of the evidence,Smith,Louise E,ur.016412115277.66
6620,The psychological impact of quarantine and how to reduce it: rapid review of the evidence,Webster,Rebecca K,ur.07707044077.31
6620,The psychological impact of quarantine and how to reduce it: rapid review of the evidence,Brooks,Samantha K,ur.0773006473.23
6620,The psychological impact of quarantine and how to reduce it: rapid review of the evidence,Wessely,Simon,ur.01160560163.47
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Karlsen,Tom H,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Fracanzani,Anna Ludovica,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Voza,Antonio,ur.01215777650.96
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Bocciolone,Monica,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Peter,Wolfgang,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Hemmrich-Stanisak,Georg,ur.01012357432.31
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Pumarola,Tomas,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Nafria Jimenez,Beatriz,ur.07454773433.11
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Albillos,Agustín,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Ceriotti,Ferruccio,ur.01033111217.07
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Caballero-Garralda,Andrea,ur.013417630637.21
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,May,Sandra,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Rodriguez-Frias,Francisco,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Bandera,Alessandra,ur.01304527667.81
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Ferrusquía-Acosta,Jose,ur.010564750707.65
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Mateos,Beatriz,ur.013111456521.85
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Jiménez,David,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Muñiz-Diaz,Eduardo,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Costantino,Giorgio,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Lenz,Tobias L,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Angelini,Claudio,ur.07735472371.88
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Faverio,Paola,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Figuera Basso,Maria E,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Julià,Antonio,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Sandoval,Elena,ur.01035101026.38
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Badalamenti,Salvatore,ur.0764751314.50
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Cardamone,Giulia,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Acosta-Herrera,Marialbert,ur.01360634555.49
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Terranova,Leonardo,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Folseraas,Trine,ur.01155575272.16
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Pelusi,Serena,ur.0702037122.88
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Prati,Daniele,ur.01317362673.22
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Ferrer,Ricard,ur.01103311207.17
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Cea,Cristina,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Lleo,Ana,ur.01214520325.65
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Ellinghaus,David,ur.0657147326.24
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Hernandez-Tejero,María,ur.01347425253.88
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Erdmann,Jeanette,ur.01332367622.23
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Kässens,Jan,ur.012473114403.23
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Bosari,Silvano,ur.01026712752.94
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Aziz,Fátima,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Moreno,Victor,ur.010307476557.32
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Braun,Nicole,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Grasselli,Giacomo,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Peschuck,Anna,ur.012374562233.23
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Albrecht,Wolfgang,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Latiano,Anna,ur.0602015303.44
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Aneli,Serena,ur.01233147461.61
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Nieto,Rosa,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Sumoy,Lauro,ur.01261024664.06
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Cecconi,Maurizio,ur.0602475235.35
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Moreira,Leticia,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Bonfanti,Paolo,ur.0605621126.06
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Özer,Onur,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Yi,Xiaoli,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Navas,Enrique,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Rimoldi,Valeria,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Galván-Femenia,Iván,ur.01002514237.17
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Degenhardt,Frauke,ur.01132535421.44
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Sacchi,Nicoletta,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Miozzo,Monica,ur.01114434672.01
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Milani,Chiara,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Foti,Giuseppe,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,My,Ilaria,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Montano,Nicola,ur.0644125135.35
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,D'Angiò,Mariella,ur.01070252633.22
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Pestaña,David,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Baselli,Guido,ur.011750062677.28
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Buti,Maria,ur.0777064516.22
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Blandino Ortiz,Aaron,ur.0647123431.56
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Chercoles,Adolfo G,ur.011251161103.65
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Garcia-Etxebarria,Koldo,ur.0673341741.15
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,ElAbd,Hesham,ur.012420613567.56
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Tanck,Anja,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Bettini,Laura R,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Kurihara,Hayato,ur.01305630615.78
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Preatoni,Paoletta,ur.0730325337.33
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,de Pablo,Raúl,ur.01237025247.34
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Palom,Adriana,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Matullo,Giuseppe,ur.01056350305.56
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Invernizzi,Pietro,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Mesonero,Francisco,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Juzenas,Simonas,ur.0646066007.02
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,de Cid,Rafael,ur.01155176544.40
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Wittig,Michael,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Izquierdo-Sanchez,Laura,ur.012411040437.29
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Aghemo,Alessio,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Ciccarelli,Michele,ur.012174272217.86
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Aliberti,Stefano,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Peyvandi,Flora,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,D'Amato,Mauro,ur.013034560020.81
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Monzani,Valter,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,García Sánchez,Félix,ur.01076564436.90
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Tentorio,Paolo,ur.0763315121.29
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Gassner,Christoph,ur.01133111332.40
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Omodei,Paolo,ur.01133115401.26
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Wienbrandt,Lars,ur.014066500617.27
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Palmieri,Orazio,ur.0735034251.49
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Martín,Javier,ur.01357677605.16
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Roade,Luisa,ur.012716505005.34
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Protti,Alessandro,ur.0602726156.41
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Valsecchi,Maria G,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Scudeller,Luigia,ur.01044115711.08
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Carreras Nolla,Anna,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Castro,Pedro,ur.010517016753.40
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Solier,Aurora,ur.015266426067.01
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Rodrigues,Pedro M,ur.016521113110.42
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Hov,Johannes R,ur.01071254111.20
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Bujanda,Luis,ur.01270567120.20
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Goerg,Siegfried,ur.014570744733.68
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Wendorff,Mareike,ur.012272240643.60
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Duga,Stefano,ur.0616663563.02
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Paraboschi,Elvezia M,ur.01060145417.93
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Schulzky,Martin,ur.015522744167.18
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Marsal,Sara,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Paccapelo,Cinzia,ur.01153563367.04
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Uellendahl-Werth,Florian,ur.016037330315.45
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Romero-Gómez,Manuel,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Rodríguez-Gandía,Miguel,ur.01154006241.88
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Baldini,Marina,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Biondi,Andrea,ur.0603167335.01
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Santoro,Luigi,ur.013413165755.65
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Grimsrud,Marit M,ur.010414135265.97
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Martinelli-Boneschi,Filippo,ur.01353012207.30
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Asselta,Rosanna,ur.01157726063.31
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Wesse,Tanja,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Banales,Jesus M,ur.0716337100.28
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Blasi,Francesco,ur.012077571007.79
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Quereda,Carmen,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Blanco-Grau,Albert,ur.01232354241.26
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Cazzaniga,Marina,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Carrabba,Maria,ur.01071613451.14
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Schaefer,Marco,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Martínez,Nilda,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Zheng,Tenghao,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Garcia-Fernandez,Alba-Estela,ur.012761656067.35
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Valenti,Luca,ur.0752025053.25
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Téllez,Luis,ur.0732743045.40
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Riveiro-Barciela,Mar,ur.01326177113.98
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Gualtierotti,Roberta,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Rühlemann,Malte C,ur.0711040521.55
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Pesenti,Antonio,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Zanella,Alberto,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Franke,Andre,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Gori,Andrea,
6587,Genomewide Association Study of Severe Covid-19 with Respiratory Failure,Fernández,Javier,
6581,Long COVID in a prospective cohort of home-isolated patients,Linchausen,Dagrun Waag,ur.014106670103.15
6581,Long COVID in a prospective cohort of home-isolated patients,Brokstad,Karl Albert,ur.0632142415.60
6581,Long COVID in a prospective cohort of home-isolated patients,Kittang,Bård Reiakvam,ur.01351446531.27
6581,Long COVID in a prospective cohort of home-isolated patients,Zhou,Fan,ur.01141422675.59
6581,Long COVID in a prospective cohort of home-isolated patients,Onyango,Therese Bredholt,ur.013731024671.97
6581,Long COVID in a prospective cohort of home-isolated patients,Sævik,Marianne,ur.01230717244.52
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Baca,Georgina L.,ur.07510073033.50
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Couto de Sousa,Jorge,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Welch,Sophie,ur.014430645601.53
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Veerapen,Jessry,ur.01272541335.09
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Rannigan,Lisa,ur.01134304637.47
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Alfarih,Mashael,ur.010311362703.28
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Varghese,Ann,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Cutino-Moguel,Teresa,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Tucker,Art,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Moon,James C.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Di Genova,Cecilia,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Sugimoto,Michelle,ur.01137172425.56
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,D’Arcangelo,Silvia,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Thornton,George D.,ur.015317536121.14
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Harker,Gabrielle,
6581,Long COVID in a prospective cohort of home-isolated patients,Lartey,Sarah,ur.01025174275.32
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Rowe,Cathy,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Patel,Kush,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Gilroy,Derek,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Lloyd,Aaron,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Reynolds,Catherine J.,ur.01136306426.43
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Captur,Gabriella,ur.01140236316.66
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Temperton,Nigel,ur.0677674666.08
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Wodehouse,Theresa,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Petersen,Steffen E.,ur.01034050664.77
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Simion,Mihaela,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Lambourne,Jonathan,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Otter,Ashley,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Fontana,Marianna,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Davies,Rhodri H.,ur.016532317754.45
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,,,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Bhuva,Anish N.,ur.012670323143.31
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,McKnight,Áine,ur.01021562115.75
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Hemingway,Georgia,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Butler,David K.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Bowles,Ruth,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Boulter,Alex,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Gibbons,Joseph M.,ur.016376440560.17
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Champion,Nicola,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Abbass,Hakam,ur.07626756504.64
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Jardim,Victor,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Chain,Benjamin,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Semper,Amanda,ur.0603714245.69
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Moon,James C.,ur.0634503670.28
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Menacho,Katia,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Hingorani,Aroon D.,ur.0704503310.11
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Robathan,Matthew,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Jones,Jessica,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,McKnight,Áine,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Louth,Sarah,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Bailey,Sasha N. L.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Butler,David K.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Feehan,Karen,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Liu,Siyi,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Chan,Carmen,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Richards,Amy,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Kurdi,Hibba,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Thomas,Stephen,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,White,Hannah,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Altmann,Daniel M.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Hickling,Lauren M.,ur.07361442171.15
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Gibbons,Joseph M.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Boyton,Rosemary J.,ur.0600106261.73
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Maini,Mala K.,ur.01051024350.31
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Diniz,Mariana O.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,,,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Brooks,Tim,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Smit,Angelique,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Artico,Jessica,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Lin,Kai-Min,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Treibel,Thomas A.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Dieobi-Anene,Keenan,ur.010421702033.70
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Manisty,Charlotte,ur.01046375544.39
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Mills,Kevin,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Carr,Olivia,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Rapala,Alicja,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Muñoz Sandoval,Diana,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Pieper,Franziska P.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Moon,Christopher,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Kapil,Vikas,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Murray,Sam M.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Coleman,Tom,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Joy,George,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Mfuko,Celina,ur.010123111633.95
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Semper,Amanda,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Millward,Sebastian,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Warner,Tim,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Taylor,Stephen,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Sackville West,Jane,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Kelly,Caoimhe,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Lin,Kai-Min,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Parker,Ruth,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Rosenheim,Joshua,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Pawarova,Mihaela,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Selman,Hannah,ur.011061571622.41
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Boyton,Rosemary J.,ur.013055050070.13
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Forooghi,Nasim,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Hamblin,Matt,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Augusto,João B.,ur.015136757742.54
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Pade,Corinna,ur.01040430126.01
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Vijayakumar,Mohit,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Hewson,Jacqueline,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Sambile,Genine,ur.016217005333.62
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Alldis,Zoe,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Heywood,Wendy,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Palma,Susana,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Royds,Matthew,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Altmann,Daniel M.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Muñoz Sandoval,Diana,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Bullock,Natalie,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,O’Brien,Ben,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Mandadapu,Vineela,ur.015233222033.42
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Otter,Ashley D.,ur.013456233317.29
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Ellis,Anaya,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Reynolds,Catherine J.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Treibel,Thomas A.,ur.01273147146.46
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Finlay,Malcolm,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Piniera,Brian,ur.013760350533.00
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Schmidt,Nathalie M.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Joy,George,ur.015522532377.98
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Zahedi,Dan,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Liu,Siyi,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Seraphim,Andreas,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Itua,Ivie,ur.011401624233.88
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Francis,Sasha,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Brooks,Tim,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Howes,Lee,ur.016511734433.11
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Cross,Eleanor,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Chandran,Aneesh,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Lee,Wing-Yiu Jason,ur.011266330360.25
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Swadling,Leo,ur.01162467633.13
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Pieper,Franziska P.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Bracken,Olivia V.,ur.011235126551.02
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Noursadeghi,Mahdad,ur.01075424414.09
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Jensen,Melaniepetra,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Forooghi,Nasim,ur.014253277633.23
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Douglas,Brooke,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Pade,Corinna,ur.010646460732.38
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Hicks,Bethany,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Amin,Oliver E.,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Abiodun,Aderonke,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Manisty,Charlotte,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Jones,Meleri,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Andiapen,Mervyn,ur.01242666540.22
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Mitchelmore,Oliver,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Moon,James,ur.011536750206.59
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Gillespie,David,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Wynne,Lucinda,
6581,Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure,Couto-Parada,Xose,ur.01250146536.87
6581,Long COVID in a prospective cohort of home-isolated patients,Cox,Rebecca Jane,ur.01040251001.20
6581,Long COVID in a prospective cohort of home-isolated patients,Mohn,Kristin Greve-Isdahl,ur.01166350504.78
6581,Long COVID in a prospective cohort of home-isolated patients,Langeland,Nina,ur.01201003503.98
6581,Long COVID in a prospective cohort of home-isolated patients,Blomberg,Bjørn,ur.01277107456.48
6581,Long COVID in a prospective cohort of home-isolated patients,Tøndel,Camilla,ur.01345163226.27
6581,Long COVID in a prospective cohort of home-isolated patients,Bartsch,Hauke,ur.0740357125.84
6581,Long COVID in a prospective cohort of home-isolated patients,Kuwelker,Kanika,ur.012513727103.87
6581,Long COVID in a prospective cohort of home-isolated patients,Hansen,Bent-Are,ur.01147321125.89
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",,,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Teno,Kenzie,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Hill,Mary,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Hall,Aron J.,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Openo,Kyle P.,ur.01275337565.54
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Holstein,Rachel,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",McMorrow,Meredith,ur.0751351640.51
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Bennett,Nancy M.,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Khanlian,Sarah,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Billing,Laurie M.,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Thomas,Ann,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Chai,Shua J.,ur.010375703527.43
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Danila,Richard,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Whitaker,Michael,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Anglin,Onika,ur.012636150535.97
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Engesser,Kerianne,ur.015617354704.54
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Milucky,Jennifer,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",O'Halloran,Alissa,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Meek,James,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Burns,Erin,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Rowe,Adam,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",George,Andrea,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Yousey-Hindes,Kimberly,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Como-Sabetti,Kathryn,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Reed,Carrie,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",West,Nicole,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Popham,Kevin,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Bushey,Sophrena,ur.07401353357.79
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Anderson,Evan J.,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Leegwater,Lauren,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Ward,Katelyn,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Felsen,Christina,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Fawcett,Emily,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Schaffner,William,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Talbot,H. Keipp,ur.01272421651.57
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Sutton,Melissa,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Taylor,Christopher A.,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Kawasaki,Breanna,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",,,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Muse,Alison,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",McLafferty,Sarah,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",McCaffrey,Keegan,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Havers,Fiona P.,ur.01245266327.24
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Angeles,Kathy,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Delahoy,Miranda J.,ur.014251434203.93
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",,,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Weigel,Andy,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Pham,Huong,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Kambhampati,Anita K.,ur.01307622037.55
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Bye,Erica,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Alden,Nisha B.,ur.01100337767.78
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Reingold,Arthur,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Kirley,Pam Daily,ur.01313115161.84
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Rudin,Dominic,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Spina,Nancy,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Garg,Shikha,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Kim,Sue,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Abdullah,Nasreen,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Crossland,Melanie T.,ur.010373016104.10
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Cummings,Charisse,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Ujamaa,Dawud,ur.01246251232.31
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Lynfield,Ruth,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Fry,Alicia M.,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Armistead,Isaac,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Ropp,Susan,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Shiltz,Eli,ur.012310015724.33
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Patel,Kadam,
6549,"Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021",Markus,Tiffanie,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Labarthe,Darwin,ur.01072275126.03
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Li,Ka-Chun,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Duan,Peifen,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Wang,Faxuan,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Zhang,Yuhong,ur.01010121602.08
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Yu,Jie,ur.012047225331.44
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Sun,Jixin,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Hao,Zhixin,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Zhao,Yi,ur.014671072245.62
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Zhang,Ruijuan,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Li,Nicole,ur.01351106313.00
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Shi,Jingpu,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Yu,Yan,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Zhang,Xinyi,ur.010503727506.36
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Liu,Yishu,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Zhang,Jianxin,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Feng,Xiangxian,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Yin,Xuejun,ur.01254645346.47
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Wu,Yangfeng,ur.0630247557.51
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Yan,Lijing L,ur.01305540457.34
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Elliott,Paul,ur.01014232611.51
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Di Tanna,Gian Luca,ur.011273764347.36
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Stepien,Sandrine,ur.0731614271.96
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Huang,Liping,ur.0705736607.37
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Shan,Sana,ur.014007642674.95
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Tian,Maoyi,ur.01220400350.82
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Ma,Bing,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Pearson,Sallie-Anne,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Shi,Weiwei,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Neal,Bruce,ur.01320054222.17
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Li,Zhifang,
6546,Effect of Salt Substitution on Cardiovascular Events and Death,Zhou,Bo,
6545,"SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis",Cevik,Muge,ur.01326324260.32
6545,"SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis",Lloyd,Ollie,ur.010556036601.72
6545,"SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis",Ho,Antonia,ur.01240621736.84
6545,"SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis",Maraolo,Alberto Enrico,ur.01211616664.17
6545,"SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis",Tate,Matthew,ur.010630750203.62
6545,"SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis",Schafers,Jenna,ur.014414232603.19
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Zhao,Wenjie,
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Liu,Xing,
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Gong,Shuran,ur.012007624234.12
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Lv,Qi,ur.01115507325.93
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Yu,Haisheng,
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Xue,Jing,ur.01106375644.37
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Deng,Wei,ur.0730643345.99
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Xu,Yanfeng,ur.01231156021.46
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Qu,Yajin,ur.015662310363.79
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Liu,Mingya,ur.07400443443.10
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Han,Yunlin,ur.01006027202.60
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Song,Zhiqi,ur.012077025763.06
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Wei,Qiang,ur.0740033524.47
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Wang,Guanpeng,ur.015354247443.37
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Wang,Shunyi,ur.07556075171.22
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Liu,Jiayi,
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Liu,Jiangning,ur.01304204223.02
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Bao,Linlin,ur.01340021045.05
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Liu,Ying,
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Gao,Hong,ur.01045071745.77
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Yu,Pin,ur.01204654354.26
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Xiao,Chong,ur.01233133366.09
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Li,Fengdi,ur.01275546745.65
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Xiang,Zhiguang,
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Qi,Feifei,ur.012024237707.21
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Qin,Chuan,ur.0666371245.12
6543,Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2,Zhao,Linna,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Wang,Xiaoye,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Luo,Yinbo,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Wu,Peng,ur.01021644616.05
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Liu,Tian,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Chen,Chuding,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Yang,Yang,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Liu,Hui,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Guan,Xuhua,ur.0745013005.13
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Jin,Lianmei,ur.01360661567.91
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Lam,Tommy T Y,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Wong,Jessica Y,ur.01115120141.84
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Liu,Yuan,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Wu,Joseph T,ur.015354656554.71
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Tao,Zhongfa,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Wang,Rui,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Ren,Ruiqi,ur.01303136351.83
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Yang,Rui,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Feng,Zijian,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Tu,Wenxiao,ur.01110163040.66
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Ma,Zhitao,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Leung,Kathy S M,ur.0776352120.84
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Xiang,Nijuan,ur.01145635315.54
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Liu,Man,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Wu,Yang,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Yang,Bo,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Liu,Boxi,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Chen,Qi,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Shi,Guoqing,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Li,Qun,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Deng,Zhiqiang,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Tong,Yeqing,ur.0700173021.32
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Wang,Qi,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Cowling,Benjamin J,ur.07675207637.48
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Zhao,Jing,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Xing,Xuesen,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Li,Huan,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Li,Dan,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Zhou,Suhua,ur.01134045667.85
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Leung,Gabriel M,ur.0665764620.02
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Lau,Eric H Y,ur.011341514222.36
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Li,Chao,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Shao,Ge,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Zhang,Yanping,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Gao,George F,
6542,"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia",Zhou,Lei,
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Preston,Leigh Ellyn,ur.011211725233.41
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Danielson,Melissa L.,ur.0737225500.79
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Summers,April D.,ur.010750712575.89
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Belay,Brook,ur.01071671675.15
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Wong,Karen K.,ur.0611535627.68
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Namulanda,Gonza,ur.01267737043.75
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Rosenblum,Hannah G.,ur.014507624171.82
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Boehmer,Tegan K.,ur.01033040015.24
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Pennington,Audrey F.,ur.07550746515.72
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Kompaniyets,Lyudmyla,ur.010442441237.37
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Gundlapalli,Adi V.,ur.0611305711.53
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Chevinsky,Jennifer R.,ur.011470543471.04
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Lavery,Amy M.,ur.010707064472.69
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Yusuf,Hussain,ur.01244344614.33
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Schieber,Lyna Z.,ur.012075660707.72
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Ko,Jean Y.,ur.01032665656.06
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Kenzie,William R. Mac,ur.014135527247.68
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Goodman,Alyson B.,ur.01337544064.62
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Cui,Zhaohui,
6538,"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021",Baggs,James,ur.01014156616.14
6523,"Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020",Kim,Ahra,ur.014037350035.43
6523,"Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020",Talbot,H. Keipp,ur.01272421651.57
6523,"Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020",Halasa,Natasha B.,ur.01007114735.71
6523,"Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020",Reed,Carrie,ur.0776315745.91
6523,"Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020",Rolfes,Melissa A.,ur.01071264514.13
6523,"Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020",Hanson,Kayla E.,ur.011222471050.30
6523,"Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020",Fry,Alicia M.,ur.01343334545.02
6523,"Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020",Belongia,Edward A.,ur.0746336125.41
6523,"Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020",McLean,Huong Q.,ur.0711430164.40
6523,"Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020",Zhu,Yuwei,ur.01043517557.26
6523,"Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020",Grijalva,Carlos G.,ur.01247261255.44
6497,Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic,Li,Xia,
6497,Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic,Woolford,Susan J.,ur.01317417532.00
6497,Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic,Else,Veronica,ur.010724553157.99
6497,Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic,Koebnick,Corinna,ur.01237401137.93
6497,Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic,Sidell,Margo,ur.01020565126.02
6497,Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic,Young,Deborah R.,ur.07516515612.57
6497,Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic,Resnicow,Ken,ur.015065551054.44
6487,Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies,Lee,Wen Shi,ur.0766661150.13
6487,Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies,Wheatley,Adam K.,ur.0771337646.65
6487,Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies,DeKosky,Brandon J.,ur.0755511770.44
6487,Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies,Kent,Stephen J.,ur.016400433202.30
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Meijer,Adam,ur.014631565732.21
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Brünink,Sebastian,ur.01251423776.24
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Ellis,Joanna,ur.01317471406.97
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Drosten,Christian,ur.010432516417.62
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Peiris,Malik,ur.01013234650.33
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,van den Brink,Sharon,ur.07664602106.63
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Schmidt,Marie Luisa,ur.010423250767.76
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Chu,Daniel KW,ur.010457424472.22
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Reusken,Chantal,ur.011471250107.18
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Romette,Jean-Louis,ur.012661705567.91
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Zambon,Maria,ur.0756427106.18
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Molenkamp,Richard,ur.0604622045.16
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Kaiser,Marco,ur.015465245767.24
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Haagmans,Bart L,ur.015465550657.43
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Koopmans,Marion PG,ur.013117453357.11
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Mulders,Daphne GJC,ur.011737013743.42
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Goderski,Gabriel,ur.011266744567.26
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Landt,Olfert,ur.0702466420.37
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Wijsman,Lisa,ur.010462162506.91
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Schneider,Julia,ur.016330741567.89
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Goossens,Herman,ur.0711125233.20
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,van der Veer,Bas,ur.01156417326.97
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Corman,Victor M,ur.01010416173.31
6486,Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR,Bleicker,Tobias,ur.01174546340.84
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Tucker,Rachel M.,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Parker,Matthew D.,ur.013006135411.00
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Fischer,Will M.,ur.014405433757.03
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Yoon,Hyejin,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Hengartner,Nick,ur.011615154651.39
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Smith,Nikki,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Brown,Rebecca L.,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Wyles,Matthew D.,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,de Silva,Thushan I.,ur.01062173617.58
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Green,Luke R.,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Evans,Cariad M.,ur.013002455123.20
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Hastie,Kathryn M.,ur.0744155426.63
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Group,Members of Sheffield COVID-19 Genomics,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Parsons,Paul J.,ur.01131013622.65
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Johnson,Katie J.,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,LaBranche,Celia C.,ur.01207706331.91
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Korber,Bette,ur.01237531654.86
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Rowland-Jones,Sarah,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Montefiori,David C.,ur.01276277760.85
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Gnanakaran,Sandrasegaram,ur.01353002606.54
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Group,Sheffield COVID-19 Genomics,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Abfalterer,Werner,ur.015555554740.16
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Angyal,Adrienne,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Freeman,Timothy M.,ur.0617713637.23
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Lindsey,Benjamin B.,ur.0770264003.23
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Saphire,Erica O.,ur.01212305166.45
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,McDanal,Charlene,ur.0743572030.92
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Wang,Dennis,ur.0633450110.12
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Theiler,James,ur.012475206625.77
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Bhattacharya,Tanmoy,ur.01177233546.94
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Giorgi,Elena E.,ur.01120001244.70
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Perez,Lautaro G.,ur.0734224504.81
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Moon-Walker,Alex,ur.015655307577.34
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Groves,Danielle C.,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Raza,Mohammad,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Keeley,Alexander J.,ur.010410322301.11
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Foley,Brian,ur.0711231703.32
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Partridge,David G.,ur.014634502124.06
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Tang,Haili,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Carrilero,Laura,
6463,Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus,Whelan,Sean P.,ur.01130727512.27
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Barnes,Peter J,ur.01045564377.55
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Jeffers,Helen,ur.07743314114.56
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Matthews,Philippa C,ur.01141516000.11
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Bengtsson,Thomas,ur.0701325147.48
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Cane,Jennifer L,ur.0726016574.16
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Donnelly,Louise E,ur.01150005362.29
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Simpson,Jodie L,ur.01216620323.30
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Glover,Victoria,ur.015143424537.89
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Peterson,Stefan,ur.0776600723.35
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Binnian,Ian,ur.012753103137.84
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Mwasuku,Christine,ur.011363570317.71
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Halner,Andreas,ur.010537673523.10
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Krassowska,Karolina,
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Fadai,Nabil T,ur.016575452011.14
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Baker,Jonathan R,ur.015557315345.82
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Langford,Beverly,ur.011312026737.45
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Russell,Richard E K,ur.011122741702.36
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Bafadhel,Mona,ur.01077506416.18
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Fox,Robin,ur.012155522537.58
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Butler,Christopher,ur.014541066757.90
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Nicolau,Dan V,ur.01260431500.57
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Bright,Stephen,ur.016536365537.93
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Ramakrishnan,Sanjay,ur.014010644005.15
6462,"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial",Mahdi,Mahdi,ur.013502350337.12
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Hong,Sang-Bum,ur.01262477346.11
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Lim,Joon Seo,ur.0606156635.29
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Oh,Dong Kyu,ur.0734106454.51
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Chung,Jin-Won,ur.01201031350.15
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Jung,Jiwon,ur.01142244765.78
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Kim,Min-Chul,ur.0625004567.02
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Choi,Seong-Ho,ur.01042104746.10
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Kim,Min-Jae,ur.016065306420.13
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Cha,Hye-Hee,ur.010562552516.73
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Bae,Seongman,ur.0646545367.73
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Sung,Minki,ur.0601702655.09
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Lee,Mi-Kyung,ur.01275003662.98
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Kim,Sung-Han,ur.013545476360.75
6455,Effectiveness of Surgical and Cotton Masks in Blocking SARS–CoV-2: A Controlled Comparison in 4 Patients,Kim,Ji Yeun,ur.013412356661.02
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Li,Jing-Xin,ur.010777673534.70
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Chen,Wei,ur.015544231620.10
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Xu,Sha-Bei,ur.01176720560.05
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Wang,Bu-Sen,ur.015702105551.46
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Hu,Yi,
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Wu,Shi-Po,ur.01063520031.77
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Jiang,Tao,ur.014605331370.10
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Li,Yu-Hua,ur.0625723364.18
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Hou,Li-Hua,ur.0657132063.94
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Jia,Si-Yue,ur.07571741735.42
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Wang,Lei,
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Guan,Xu-Hua,ur.0745013005.13
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Wang,Zhao,
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Gou,Jin-Bo,ur.012167705064.53
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Zhu,Feng-Cai,ur.01003672563.32
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Wang,Ling,ur.016366503167.10
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Wang,Xue-Wen,
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Jiang,Hu-Dachuan,ur.012164736351.04
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Xu,Jun-Jie,ur.01362310231.84
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Wang,Wen-Juan,ur.016517776535.68
6450,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",Wang,Wei,ur.07401700232.38
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Herrmann,Alexandra,ur.014030102775.57
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Conway,Hasahn L.,ur.010524012237.04
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Connor,John H.,ur.01262703671.74
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Li,Jonathan Z.,ur.012171007070.63
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Bosmann,Markus,ur.01001676155.45
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Gack,Michaela U.,ur.01130076547.17
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Baker,Susan C.,ur.01026270027.82
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Douam,Florian,ur.01340233573.10
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Liu,GuanQun,ur.01223174175.53
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Kotton,Darrell N.,ur.01156612166.12
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Crossland,Nicholas A.,ur.01004113101.49
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Tavares,Alexander H.,ur.015600265360.01
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Kirchdoerfer,Robert N.,ur.0725634217.41
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Chin,Chue Vin,ur.012247746445.03
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Kenney,Devin,ur.015023706651.44
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Kataria,Yachana,ur.01203716167.30
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Ensser,Armin,ur.01067301523.40
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Choudhary,Manish C.,ur.0771646136.40
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Khan,Nazimuddin,ur.013472027731.35
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Saeed,Mohsan,ur.01212150531.80
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Chen,Da-Yuan,ur.012061335555.55
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,Gertje,Hans P.,ur.014063062767.24
6445,Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron,O’Connell,Aoife K.,ur.014530036467.24
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Bashir,Nasir,ur.015540175171.53
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Haroon,Shamil,ur.01062226547.00
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Singh,Megha,
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Nirantharakumar,Krishnarajah,ur.01330274175.18
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Jackson,Louise J.,ur.01336662302.86
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,McMullan,Christel,ur.01070105237.40
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Myles,Puja,ur.01131371215.23
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Hotham,Richard,ur.014014054040.17
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Chandan,Joht Singh,ur.01103252541.22
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Iles,Clare,ur.011132123462.44
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Calvert,Melanie,ur.010057502377.53
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Okoth,Kelvin,ur.016654531725.39
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Gkoutos,Georgios V.,ur.01211760721.03
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Marwaha,Steven,ur.0727205030.06
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Cockburn,Neil,ur.010467162273.94
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Matthews,Karen L.,
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Gokhale,Krishna M.,
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Lee,Siang Ing,
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Wraith,David C.,ur.01325131424.52
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Simms-Williams,Nikita,ur.07605275662.65
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Price,Malcolm J.,ur.0745161571.53
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Lord,Janet M.,ur.0662314224.13
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Camaradou,Jenny,ur.011326634456.94
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Sapey,Elizabeth,ur.0771537277.76
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Williams,Tim,
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Kidy,Farah,ur.0724416710.12
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Shah,Anoop D.,ur.0723152150.07
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Davies,Elin Haf,ur.01011101713.40
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Turner,Grace M.,ur.012350671025.17
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Leggett,Edward,ur.010334543062.47
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Aiyegbusi,Olalekan Lee,ur.014040600701.90
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Hughes,Sarah,ur.016126527167.73
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Marshall,Tom,ur.01012625637.31
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Subramanian,Anuradhaa,ur.011347243776.27
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Denniston,Alastair K.,ur.012247703727.34
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Taverner,Tom,
6444,Symptoms and risk factors for long COVID in non-hospitalized adults,Brown,Kirsty,ur.010402656262.01
6408,"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses",Morens,David M,ur.0774545665.81
6408,"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses",Fauci,Anthony S,ur.01314336573.76
6408,"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses",Taubenberger,Jeffery K,ur.014517600177.92
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Thomas,Merin,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Malamatsho,Ross,ur.07645227454.09
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Richards,Alexander,ur.015272022023.24
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Trivett,Rose,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tomasicchio,Michele,ur.0620352343.02
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Olchawski,Victoria,ur.016643061071.83
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Roche,Sophie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Dantas,Maria T.D.C.,ur.015444025775.18
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sampaio,Milla Dias,ur.015412111523.48
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ratcliffe,Helen,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Luz,Kleber Giovanni,ur.01137317526.35
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lelliott,Alice,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rand,Jade,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gordon-Quayle,Katherine,ur.010124444371.23
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Dos Santos,Thainá G.,ur.01256174165.72
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cunningham,Christina J.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tarrant,Richard,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,O'Reilly,Paula,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Muller,Jilly,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Samson,Annette D.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Klenerman,Paul,ur.01366404500.15
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Brenner,Tanja,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,McGregor,Alastair,ur.07642556135.34
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Senger,Roberta,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Li,Yuanyuan,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Verheul,Marije K.,ur.0673177445.34
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Thombrayil,Asha,ur.013110347175.40
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Berg,Adam,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Verbart,Dennis,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Dos Santos,Tannyth Gomes,ur.016420742523.92
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Philip,Tricia,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sprinz,Eduardo,ur.01305160123.16
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Knott,Daniel,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pacurar,Mihaela,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Baleanu,Ioana,ur.014362651427.74
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Serrano,Sonia,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kelly,Debbie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bates,Louise,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Jones,Elizabeth,ur.010660132763.59
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Jones,Carina,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Clark,Elizabeth,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Robinson,Hannah,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Beadon,Kirsten,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Andritsou,Foteini,ur.011534307335.15
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sharrocks,Katherine,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,da Silva,Larissa P.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Greenland,Melanie,ur.016245737157.77
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,de M. Carvalho,Yasmin,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Perumal,Rubeshan,ur.01324247612.44
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cuthbertson,Fiona C.,ur.01117716126.95
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Skelly,Donal T.,ur.01132001330.15
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sanchez-Gonzalez,Amada,ur.01275354243.50
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Petkar,Sahir Yusuf,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Moore,Maria,ur.010341141325.62
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lawrie,Alison M.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Dos Santos,Erika Pachecho,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Zuidewind,Peter,ur.011070357333.62
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Presa,Fernando B.,ur.011551501446.08
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sutton,Natalina,ur.0615252606.91
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mendonça,Renata N.Õ.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Saunders,Caroline,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Green,Justin,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Varughese,Rachel,ur.01224121070.54
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rabara,Ria,ur.013544571571.63
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Freire,Marilúcia S.M.,ur.013071142575.33
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Schofield,Ella,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Camara,Susana,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Berry,Lisa,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bletchly,Heather,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Dunachie,Susanna J.,ur.01041133025.01
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pipini,Dimitra,ur.015367104553.46
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Docksey,Claire,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bittaye,Mustapha,ur.0655457677.68
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Strickland,Louise H.,ur.010224667305.94
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Song,Rinn,ur.0730726247.60
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Megson,Clare,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gunawardene,Anishka,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Taylor,Ursula,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tahiri-Alaoui,Abdessamad,ur.0665376020.28
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,McRobert,Nicky,ur.01362212336.93
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Blacow,Rachel,ur.015163577717.88
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Fowler,Jamie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sabine,Charlotte,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Snape,Matthew D,ur.010062135107.44
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Shiham,Farah,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Stuchi,Bruno Pereira Pereira,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Munro,Alasdair,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Owino,Nelly,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Fok,Henry,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lessa,Alvaro Edson Ramos,ur.012320751765.24
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Woodyer,Mark,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Law,Rebecca,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Clark,Matthew,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Dheda,Keertan,ur.01257776220.51
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Grab,Janet,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Jesudason,Natasha,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Templeton,Kate,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Solórzano,Carla,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bermejo,Laura,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hurley,Katrina,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Duncan,Andrew,ur.014315314371.96
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Fofie,Hazel,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Marques,Gabriela N.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Riaz,Tawassal,ur.013677061023.22
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tiongson,Gerlynn Ferreras,ur.013157316023.27
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Damratoski,Brad E.,ur.0710065340.52
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Smith,Andrew,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Birch,Sarah,ur.011173550275.69
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Flaxman,Amy,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Dinesh,Tanya,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mentzer,Alexander J.,ur.01260434061.14
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kerr,David,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Burn,Aileen,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Clutterbuck,Elizabeth A,ur.0715146175.41
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pooley,Jennifer,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Salvador,Natalia,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Drake-Brockman,Rachael,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Nana,Anusha,ur.012033077535.78
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Msomi,Sibekezelo,ur.010710323375.80
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mehdipour,Savviz,ur.014126374426.20
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Jones,Christopher,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Owen,David R.J.,ur.01206630115.21
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Wroblewska,Marzena,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bhorat,Zaheda E.,ur.016303660475.87
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ferreira,Daniela M,ur.012446116335.41
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mugodi,Yvonne,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Zimmer,Rafael Leal,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Datta,Chandrabali,ur.015575617071.16
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Spencer,Alexandra J.,ur.0630046341.05
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ricamara,Marivic,ur.010206511504.89
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Schwarzbold,Alexandre V,ur.01122663254.27
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Watson,Marion E.E.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tsheko,Betty Lebogang,ur.012433056275.21
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Duncan,Christopher J A,ur.0702456546.95
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Souza,Cinthia M.C.D.L.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,van Eck,Samual,ur.012706600775.38
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Davids,Malika,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mnyakeni,Sibusiso,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Noal,Helena C.,ur.01363464426.27
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cunha,Debora R.M.F.,ur.010265602375.60
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Colton,Hayley,ur.07661055101.41
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mweu,Philomena,ur.011317353266.17
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Owen,Lydia,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lang,Matilda,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Oelofse,Suzette,ur.016120036357.51
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Budd,William,ur.015670641675.05
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Haughney,John,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Robbins,Alexander J.,ur.011307146537.95
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Iyer,Vidyashankara,ur.01055057001.26
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Chadwick,Jim,ur.010670606670.78
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Stafford,Lizzie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Oldfield,Neil J.,ur.01004240202.63
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cooper,Rachel,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Fedosyuk,Sofiya,ur.0767456552.13
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Matshidiso,Kedidimetse,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tomic,Adriana,ur.011666565147.73
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Blundell,Susannah R.,ur.015341300771.80
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Collins,Sarah L.K.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Heath,Paul T.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Jenkin,Daniel,ur.011650637135.21
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Moultrie,Andrew,ur.015432706003.74
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Farooq,Mutjaba,ur.012754714175.53
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,McSwiggan,Steve,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Babbage,Gavin,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Chester,Oliver,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Darton,Thomas C,ur.01024704614.49
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Corrah,Tumena,ur.01062737475.85
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Harris,Clair,ur.016657651055.57
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Myerscough,Christopher,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,O'Connor,Daniel,ur.01034434167.27
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Murphy,Sarah,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rhead,Sarah,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Warimwe,George M.,ur.01255275505.20
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cox,Tony,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cardoso,João R.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Emary,Katherine R W,ur.0664315206.68
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Abeyskera,Kushala W.M.,ur.013610402335.42
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kelly,Sarah,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Williams,Paul,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hamaluba,Mainga,ur.01200260500.93
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Felle,Sally,ur.013416024245.17
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Danos,Zsofia,ur.01331353015.14
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Collins,Andrea M,ur.0763041014.30
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bowring,Francesca,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Di Maso,Claudio,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Crosbie,Sarah,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kar,Arnab,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Thompson,Kevin,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Blundell,Caitlin L.,ur.07555172527.18
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,McInroy,Lorna,ur.012705421567.36
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Guerra,Mayara F.S. Santos,ur.07507426375.34
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Berzenyi,Daniella,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Trillana,Gerry,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Török,M Estée,ur.01254430354.80
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Taoushanis,Carol,ur.010354501503.45
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Stockdale,Lisa,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lambe,Teresa,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Frater,John,ur.0600756740.23
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Robinson,Ryan E.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Wright,Johanna Kellett,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Smith,Nick,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mitton,Celia,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kinch,Patrick,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Salman,Ahmed M.,ur.0705700051.57
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Zizi,Dalila,ur.016013257451.26
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cathie,Katrina,ur.0600477345.34
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sale,Jessica C.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Smith,Catherine C.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Szigeti,Anna,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Elmore,Michael J.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ahmed,Khatija,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Morselli,Franca,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Baillie,Vicky L,ur.01235513461.21
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Galiza,Eva,ur.01076060444.87
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,McEwan,Joanne,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Powers,Claire,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cardona,Rita,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Howe,Elizabeth,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mesquita,Ana Carolina F.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Berrie,Eleanor,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Thomas,Kelly,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Júnior,Eduardo A.M.S.,ur.015151076675.51
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ford,Karen J.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Marchevsky,Natalie G,ur.014735571175.69
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Webb,Stewart,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Thornton-Jones,Viv,ur.013665210151.75
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Moghaddas,Fiona,ur.01011516141.40
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ewer,Katie J,ur.01066421140.67
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Khan,Liaquat,ur.014522145527.44
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Adewatan,Gbadebo,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hanumunthadu,Brama,ur.010034637473.04
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Killen,Annabel,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Price,Vivien,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mujadidi,Yama F,ur.011600027201.23
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gupta,Gaurav,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cooper,Cushla,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tarr,Alexander W.,ur.01234272560.04
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Royal,Simon,ur.0742242054.46
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hodges,Gina,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hill,Adrian V S,ur.010475203247.10
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mathew,Moncy,ur.015717151627.91
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Masilela,Mduduzi,ur.07662265775.54
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Humphries,Holly E.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Beveridge,Amy,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Barrett,Jessica,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tighe,Patrick J.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lias,Amelia M.,ur.015736711267.11
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Shepherd,Amy,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Knapper,Francesca,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Novaes,Gabrielle,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Themistocleous,Yrene,ur.010272223741.46
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Clemens,Sue Ann Costa,ur.01360235121.76
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Arns,Beatriz,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Costa,Fernanda Barroso,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tinoco,Lygia Accioly,ur.010772002075.63
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Stein,Ricardo,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Singh,Nisha,ur.01041400576.85
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Goodwin,Jayne,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Edwards,Nick J.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hawkins,Sophia,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Harris,Stephanie A.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Palmer,Susan,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Marshall,Richard P,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Joe,Carina C D,ur.011036005727.59
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hodgson,Susanne,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Wright,Danny,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Keen,Jade,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Alvarez,Marco Polo Peralta,ur.016577734437.47
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cheliotis,Katerina S.,ur.07464311514.42
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,de Jesus,Sergio,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Marriott,Paula,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Moran,Marni,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bell,Jonathan,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lees,Emily A.,ur.012225442604.54
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Zambrano,Marina Bauer,ur.0650772606.96
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bhikha,Sutika,ur.011647423403.19
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Willingham,Silvia,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ramasamy,Maheshi N,ur.0773236364.40
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Oosthuizen,Angela,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Masters,Shauna K.,ur.010457646375.06
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bull,Melanie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gavrila,Madita,ur.010605576371.33
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hou,Mimi M.,ur.011650472127.74
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hallis,Bassam,ur.01127251360.63
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Silk,Sarah E.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Barrett,Jordan R.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Wells,Jeanette H.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Furze,Julie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bellamy,Duncan,ur.011416433554.65
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Francis,Emma,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Byard,Nicholas,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Poulton,Ian,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Knight,Julian C.,ur.0613306061.55
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Koen,Anthonet,ur.01050512507.64
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Di Marco,Stefania,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Dold,Christina,ur.01030672752.86
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Harrison,Thomas D.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Desai,Amisha,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tladinyane,Bonolo,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Nikolaou,Elissavet,ur.01254160270.80
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Briner,Carmen,ur.013525042277.44
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Palhares,Edna M.F.,ur.07551700475.45
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Nugent,Fay L.,ur.01064464603.23
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Saich,Stephen,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Minassian,Angela M,ur.01237421066.88
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Thompson,Julia,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Osborne,Piper,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Fothergill,Ross,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Khurana,Ankush,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Marlow,Emma,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lloyd,Adam,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Birch,Gurpreet,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mukhopadhyay,Ekta,ur.016006427357.30
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Borthwick,Nicola,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Soares,Airanuédida S.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Thomas,Tonia M.,ur.07774724142.44
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Liatsikos,Konstantinos,ur.016322242603.06
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bulbulia,Yusuf A.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Toshner,Mark,ur.01171665572.31
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hamlyn,Joseph,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Folegatti,Pedro M,ur.014140042217.03
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Price,David A.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Akhalwaya,Saajida,ur.013061135135.85
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kluczna,Diana M.,ur.014461245665.47
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gonzalez,Isabela G.S.,ur.01045365142.13
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Finn,Adam,ur.01160253315.45
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kingham,Lucy,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Patrick-Smith,Maia,ur.013441643467.08
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Jackson,Frederic,ur.013662310713.48
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Perring,James,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sturdy,Ann,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cashen,Paul,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Loew,Lisa,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Nastouli,Eleni,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Souza,Bruno S.D.F.,ur.016006103112.29
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bewley,Kevin R.,ur.01035117350.51
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Coombes,Naomi,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Yao,Andy,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Jones,Kathryn,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,da Silva Moraes,Antonio Carlos,ur.014406710247.76
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Plested,Emma,ur.01177370146.35
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ritchie,Adam J,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Naik,Gurudutt,ur.01127672743.18
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Franco,Marilia M.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Allen,Lauren,ur.0600226653.15
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,De Almeida Azi,Paula,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Richter,Alex,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ferguson,Susie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bibi,Sagida,ur.01123243761.16
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rossouw,Lindie,ur.010516550503.21
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Taylor,Iona Jennifer,ur.015575141333.31
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hirsch,Ian,ur.011121270535.39
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bisnauthsing,Karen,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Jorge,Marianna Rocha,ur.012760555275.14
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Truby,Adam,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Fry,Samantha H.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sanders,Helen,ur.012166772167.99
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Moyo,Nathifa,ur.01071757320.32
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Silva-Reyes,Laura,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Turner,Cheryl,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Castro,Thais R.Y.,ur.010737562363.91
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Phillips,Jennifer,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Buttigieg,Karen R.,ur.01172213764.64
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Makambwa,Edson,ur.0666133137.35
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Woods,Danielle,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Colin-Jones,Rachel,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Walker,Gemma,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Linder,Aline,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Drake,Jonathan,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cezar,Luiz Fernando F.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sanders,Katherine,ur.014357313567.36
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Russell,Amy L. Ross,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ulaszewska,Marta,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tyagi,Bhavya,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kasanyinga,Mwila,ur.011433727475.26
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mendes,Ana V A,ur.012451675302.27
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Welch,Jessica,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Brown,Phillip,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cho,Jee-Sun,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Stockwell,Lisa V.,ur.015735442051.93
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Satti,Iman,ur.01004271763.71
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,De Oliveira Kalid,Lis Moreno,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Morgans,Róisín,ur.015017443071.16
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,White,Thomas,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Manning,Nicola,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Smith,David J.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Libri,Vincenzo,ur.01256064600.37
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Goondiwala,Amina,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Barbosa,Marcella A.S.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Elias,Sean C.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Wellbelove,Zoe,ur.013236163325.00
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Fairlie,Lee,ur.01072731604.87
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Birchall,Kathryn,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hyams,Catherine,ur.0750212163.87
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Humphreys,Jonathan,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kwatra,Gaurav,ur.01340446423.72
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Malahleha,Mookho,ur.0732276355.01
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ritchie,Adam J.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Morrison,Hazel,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,White,Rachel,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Seddiqi,Samiullah,ur.016260612775.30
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Dong,Tao,ur.01007343554.07
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Thompson,Fawziyah,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,De Jager,Jeanne,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Arruda,Laiana,ur.016115152335.94
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mazzella,Andrea,ur.0724713116.42
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Boyd,Amy,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Patel,Faeezah,ur.01076006342.03
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gilbert,Sarah C,ur.0762502203.86
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Filho,Renato Furlan,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bradley,Penny,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Da Silva,Carla Ferreira,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,West,Alison J.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,McCaughan,Hugh,ur.01342267757.78
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Liu,Xinxue,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Morris,Sheila,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Vekemans,Johan,ur.012147326135.61
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Oliveira,Marianne G.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Group,Oxford COVID Vaccine Trial,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Brown-O'Sullivan,Charlie,ur.010535114727.33
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Oguti,Blanche,ur.012157012177.37
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Groenewald,Marisa M.,ur.011067024075.12
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bara,Anna,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Adamson,James P.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mpelembue,Mushiya,ur.011504545415.76
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Davies,Hannah,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Watson,Ekaterina,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hanrath,Aidan T.,ur.011353437246.04
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Stamford,Imogen,ur.07761636051.37
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Phohu,Mary Kgomotso,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Belton,Sue,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Oliveira,Isabelle Silva Queiroz,ur.012466461623.86
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Saunders,Jack E.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Masenya,Masebole,ur.015714736755.26
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Noé,Andrés,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,MacDonald,Jonathan C.,ur.012552634035.15
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Burbage,Jamie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Patel,Dipak,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tonks,Susan,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cosgrove,Catherine A.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mottay,Lynelle,ur.01203550146.23
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,King,Lloyd D.W.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rajeswaran,Thurkka,ur.016710765446.45
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Casey,Helen R.,ur.01140263262.59
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Barker,Debbie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Thotusi,Larissa H.S.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sayed,Aakifah Bibi Arif,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sheehan,Emma,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Easom,Nicholas J.W.,ur.01046161130.34
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Godwin,Kerry,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gilbride,Ciaran,ur.07450134035.32
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Houlihan,Catherine F.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Webster,Angela,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lopez,Thamyres Souza,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pulido,David,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cerbino-Neto,José,ur.0771146726.47
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Du Plessis,Joan,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Aboagye,Jeremy,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Radia,Kajal,ur.07431545167.52
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cavey,Ana,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Goodman,Anna L,ur.01175716171.37
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gibbons,Karyna A.,ur.012345536475.33
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Owens,Daniel,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Assad,Luiza,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rea,David,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Goyanna,Alvaro,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Barlow,Gavin D.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bolam,Emma,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Allen,Elizabeth R.,ur.0620560743.21
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Beckley,Rebecca,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Underwood,Benjamin R.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Barrett,Kelly,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Thompson,Amber,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hill,Helen C,ur.010323710135.22
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Adam,Matthew,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,McGlashan,Joanna,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Galian-Rubio,Pablo,ur.011335043571.64
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,O'Reilly,Peter J.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Edwards,Frances,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Aban,Marites,ur.011315125537.89
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Herrera,Macarena Hermosin,ur.07677630471.80
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Nunes,Géssika Lanzillo A.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Green,Christopher A,ur.0603753333.19
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sorley,Kim,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Karampatsas,Konstantinos,ur.01123776160.05
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Morter,Richard,ur.0706024053.03
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Connarty,Sean,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kay,Linda,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Carroll,Miles W.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rose,Louisa,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tran,Nguyen,ur.0603111201.92
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Williams,Rachel L.,ur.012615420075.39
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mallett,Garry,ur.015525623750.06
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pooran,Anil,ur.01274610013.05
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Khozoee,Baktash,ur.013743443371.13
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Oommen-Jose,Aylin,ur.013264042223.49
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Esmail,Alisgair,ur.010564372575.90
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lages,Pedro M.,ur.014605300475.69
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mansatta,Kushal,ur.016125114167.98
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Naude,Rebecca te Water,ur.011420075633.86
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sutherland,Rebecca K,ur.0704534163.40
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rawlinson,Tom,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Huson,Claire,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lemm,Nana-Marie,ur.013546367667.11
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tanner,Rachel,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ramos,Leonardo,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Batten,Alexander,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cicconi,Paola,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Villafana,Tonya L,ur.01160651642.84
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Baker,Megan,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Vichos,Iason,ur.011401113767.18
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ramon,Raquel Lopez,ur.01120177760.87
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Downing,Charlotte,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Belij-Rammerstorfer,Sandra,ur.01250612323.91
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Charlton,Sue,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Chapman,David,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Fudge,Sabrina,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pinheiro,Jessica Morgana,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sorio,Guilherme L.,ur.016443154575.74
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Fraiman,Pedro H.A.,ur.07650602535.99
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Naker,Kush,ur.015226455127.67
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Muhanna,Omar M. El,ur.015077122375.34
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kelly,Dearbhla M.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Barr,Andrew S.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Makinson,Rebecca,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Turner,David P J,ur.016223771242.38
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hettle,David B.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bormans,Daan,ur.015407414171.66
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Amorim,Fabio Santos,ur.015024430737.41
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mainwaring,David O.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Vieira,Taiane A.,ur.0645773343.68
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Milan,Eveline P,ur.01253775040.00
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Shaw,Robert,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Turner,Richard,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,White,Caroline,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pabon,Emilia Reyes,ur.014456400571.31
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Taylor,Keja,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,San Francisco Ramos,Alberto,ur.010303057150.16
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Fletcher,James,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rajapaska,Durga,ur.014363220475.31
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lazarus,Rajeka,ur.0763261375.07
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bodalia,Pritesh,ur.011241663475.06
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cullen,Dan,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Blackwell,Luke,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Shea,Adam,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pickup,Lorinda,ur.012056450475.12
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Watkins,Bridget,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pollard,Andrew J,ur.01027121051.13
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pollock,Katrina M,ur.0707316513.65
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Da Guarda,Suzete N. Farias,ur.0771654615.24
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Datoo,Mehreen S.,ur.012440662217.69
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pueschel,Sophie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Themistocleous,Andreas,ur.0705744303.67
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Leach,Amanda,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Salvador,Stephannie,ur.015704141367.47
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Anslow,Rachel,ur.012653462027.76
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Madhavan,Meera,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rampling,Tommy,ur.0714513761.47
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kidd,Sarah,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Padayachee,Sherman D,ur.013426040535.84
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Henry,John Aaron,ur.012534205043.12
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Souza,Alessandra R.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gonçalves,Maria Luisa Freire,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rudiansyah,Indra,ur.012666334050.54
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Patel,Bhumika,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Morshead,Gertraud,ur.011313574167.85
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Provstgaard-Morys,Samuel,ur.015113337704.57
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Shaik,,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Brown,Claire,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ellison-Handley,Branwen,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Spoors,Louise,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pennington,Anna,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Feng,Shuo,ur.01166404654.25
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,White,Beth,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Carr,Melanie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Adlou,Syed,ur.010670613535.06
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Warren,Sarah C.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Baker,Natalie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Arbe-Barnes,Edward H.,ur.016377711315.52
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Chelysheva,Irina,ur.016204413317.06
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Akhalwaya,Yasmeen,ur.012263554535.63
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Smith,Daniel C.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,de Carvalho,José A.M.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kelly,Elizabeth J.,ur.010623611357.52
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Paiva,Brenda V.B.,ur.010004402746.53
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Douglas,Naomi,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Larkworthy,Colin W.,ur.014161406467.62
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Williams,Christopher J,ur.01167250565.13
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Njenga,Cecilia,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Taylor,Justin,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pollard,Samuel,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Payne,Ruth O.,ur.014167250015.69
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Fisher,Richard,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Davies,Sarah L.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Puig,Ingrid Cabrera,ur.011275015403.78
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Voysey,Merryn,ur.01043520166.14
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Joshi,Amar,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Green,Catherine M,ur.01052521673.91
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bailey,Catherine,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hammersley,Daniel,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Larwood,Jessica P.J.,ur.013215143065.17
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hill,Catherine,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Davis,John,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Calvert,Anna,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,MacGregor,Gordon,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ishwarbhai,Alka,ur.014736052012.31
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mazur,Olga,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kinch,Jasmin,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Harrison,Daisy,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Alcock,Andrew,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Morris,Susan J.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Essack,Yakub Moosa,ur.011361753175.86
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cappuccini,Federica,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Davies,Judith,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bhorat,Asad E.,ur.0662711531.90
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gracie,Lara,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Leung,Stephanie,ur.012767450521.67
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Faust,Saul N,ur.0727576315.70
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lipworth,Samuel,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Chanice,Chanice,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,van der Loeff,Ina Schim,ur.014320540477.22
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Winslow,Rebecca,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gokani,Karishma,ur.016131021075.86
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lloyd,Stephanie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Chita,Sunder,ur.01002675033.11
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Smith,Holly E.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hart,Thomas C.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Thomson,Emma C,ur.01115422445.14
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sharpe,Hannah R.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hyder-Wright,Angela,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ndlovu,Bongani,ur.0654574633.78
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Baker,Philip,ur.014700215704.13
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hackett,Mark,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sowole,Luciana,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Wand,Matthew E.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Demissie,Tesfaye,ur.07402333127.69
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Barnabas,Shaun L,ur.01077552167.43
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Higa,Cristhiane,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Worth,Andrew T.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Matlebjane,Hosea,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Field,Samantha,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Adams,Kirsty,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Quaid,Sheena,ur.013405211463.39
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lopez,Fernando Ramos,ur.07405352245.46
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Fuskova,Michelle,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tree,Julia A.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Horne,Elizea,ur.016361476075.96
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Oliveira,Catarina,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bijker,Else Margreet,ur.01352054134.76
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Weckx,Lily Y,ur.0705415217.20
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bird,Olivia,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Parsons,Karen,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Plant,Sinéad,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Dearlove,David,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Morey,Ella,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Silveira,Mariana B.V.,ur.01202137332.07
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Conlon,Christopher P.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Molapo,Kgaogelo,ur.012764416375.83
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kailath,Reshma,ur.07516247235.83
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cutland,Clare L,ur.014745402454.20
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cao,Michelangelo,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lora,Leandro Bonecker,ur.012101573505.11
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Santos,Erika,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Marinou,Spyridoula,ur.013205325367.57
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Proud,Pamela C.,ur.010621363131.10
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Peng,Yanchun,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Aley,Parvinder K,ur.01144267763.20
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Resuello-Dauti,Mila,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Wardell,Theresa,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Perinpanathan,Tanaraj,ur.010744112313.52
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hartnell,Birgit,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Iveson,Poppy,ur.013301060517.26
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,da Costa,Daniel Marinho,ur.014662474655.00
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cifuentes,Liliana,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Meijs,Wilma,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Drury,Ruth,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Beales,Emily,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Davis,Elizabeth J.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Jaumdally,Shameem,ur.0614312533.55
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Walker,Laura,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Perez,Ana Luiza,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bharaj,Inderjeet,ur.016346462763.45
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pieterse,Sonja,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gorini,Giacomo,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Castro,Lucia Carratala,ur.010674760075.46
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Izu,Alane,ur.01051426511.85
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Segireddy,Rameswara R.,ur.010560202057.79
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lang,Gail,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Maoko,Takalani,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Mirtorabi,Neginsadat,ur.015512075367.40
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Penn,Elizabeth J.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,O'Brien,Katie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Boland,Elena,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rollier,Christine,ur.01126636541.15
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Tubb,Philippa,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Davies,Sophie,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Turner,Nicola,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Marshall,Julia L.,ur.010633404271.60
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Garlant,Harriet,ur.015715706571.57
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ikram,Sabina,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Miralhes,Patricia,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Brunt,Emily,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Greenwood,Nicola,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Cornelissen,Lynne,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Head,Ian,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kana,Faeeza,ur.010040766475.50
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Jackson,Susan,ur.014034470333.32
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Liu,Shuchang,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Yim,Yee Ting Nicole,ur.07740737023.17
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Screaton,Gavin R.,ur.01355002316.56
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Silveira,Lidiana B. T.D.,ur.010775014154.56
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Trinham,Charlotte,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bridges-Webb,Alice,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hill,Jennifer,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Goodall,Jack,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Primeira,Marcelo R.,ur.011360436343.85
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Jeffers,Helen,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Barnes,Eleanor,ur.012157567677.07
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Koleva,Stanislava,ur.014710653667.85
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sosa-Rodriguez,Tiffany,ur.015753757337.97
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bird,Adam,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Davies,Kelly,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Crocker,Wendy E.M.,ur.012202032227.52
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Sinha,Jaisi,ur.01217601337.07
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Douglas,Alexander D,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hamilton,Elizabeth,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Greffrath,Johann,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Parracho,Helena M. R.T.,ur.01075431027.44
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Phillips,Daniel J,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Turabi,Aadil,ur.010752135323.31
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lazarus,Erica M.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Andrade,Claudia Sala,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Plank,Mary,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Marshall,Richard P.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Lillie,Patrick J,ur.01141716161.48
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,De Almeida Azi,Lorena,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Madhi,Shabir A,ur.01165655111.49
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Towner,James,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Edwards,Mandy,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Angus,Brian,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bhorat,Qasim E,ur.016706671635.11
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bruce,Scott,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Roberts,Hannah,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Donnellan,Francesca R.,ur.012431050117.63
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ali,Aabidah,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Alvernaz,Felipe B.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Bandeira,Danieli,ur.07675760313.28
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ritchie,Neil,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Chiplin,Emily,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Thompson,Ameeka,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,English,Marcus Rex,ur.011342177527.86
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Schmid,Annina B.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Baker,Kenneth F.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Pittella,Ana,ur.016343737472.03
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Harris-Wright,Tara A.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Moloi,Mapule,ur.013561776775.26
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Stuart,Arabella,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Gill,Hardeep,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Piper,Jo,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Hayano,Laís Y.M.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,King,Thomas B.,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ariaans,Mark P.,ur.0701367313.06
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Kerridge,Simon,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Howell,Nicola,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Carson-Stevens,Andrew,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Ryalls,Kim,
6397,Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials,Rees,Byron,
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Crandon,Sonja,ur.016636373434.32
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,McElrath,M. Juliana,ur.015371707657.43
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Rajakumar,Kumaravel,ur.0627330462.99
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Roberts,Paul C.,ur.010735416107.57
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Posavad,Christine M.,ur.0720727151.24
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Suthar,Mehul S.,ur.01104271173.59
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Babu,Tara M.,ur.01064230262.18
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Kottkamp,Angelica C.,ur.010773046600.19
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Johnston,Christine,ur.0724722011.24
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Dobryzynski,David,
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Sahly,Hana M. El,ur.011043336567.63
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Branche,Angela R.,ur.01325346774.71
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Neuzil,Kathleen M.,ur.0761006623.40
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Atmar,Robert L.,ur.0672024505.03
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Group,the DMID 21-0012 Study,
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,O’Connell,Sarah E.,ur.015357256613.07
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,McDermott,Adrian B.,ur.01056403462.04
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Brady,Rebecca C.,ur.01335173377.26
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Bäcker,Martín,ur.0642354347.46
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Rupp,Richard E.,
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Brown,Elizabeth R.,
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Rostad,Christina A.,ur.07365610025.61
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Montefiori,David C.,ur.01276277760.85
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Beigel,John H.,ur.0604106525.13
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Zemanek,Jillian,ur.011526263234.54
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Archer,Janet I.,ur.016041013034.48
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Deming,Meagan E.,ur.01007302472.51
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Stephens,David S.,ur.01202223600.32
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Szydlo,Daniel,ur.01026276261.91
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Lyke,Kirsten E.,ur.0602302160.41
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Martin,Judith M.,
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Edupuganti,Srilatha,ur.0703014353.38
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Mulligan,Mark J.,ur.0633747707.55
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Frenck,Robert W.,ur.01157665701.10
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Islas,Clara P. Dominguez,ur.012622054343.18
6388,Safe traveling in public transport amid COVID-19,Hwang,Kiyeon,
6388,Safe traveling in public transport amid COVID-19,Ku,Donggyun,ur.012611607763.51
6388,Safe traveling in public transport amid COVID-19,Wong,Sze Chun,ur.01334452435.74
6388,Safe traveling in public transport amid COVID-19,Lee,Kyuhong,ur.01202504766.50
6388,Safe traveling in public transport amid COVID-19,Lee,Seungjae,ur.011221020024.84
6388,Safe traveling in public transport amid COVID-19,Yeon,Chihyung,
6388,Safe traveling in public transport amid COVID-19,Li,Yuen Chong,
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Eaton,Amanda,
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Jackson,Lisa A.,ur.01322066072.33
6388,Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report,Nayak,Seema U.,ur.015520530557.19
6384,Risk assessment of retinal vascular occlusion after COVID-19 vaccination,Hsu,Shu-Bai,ur.014356323340.94
6384,Risk assessment of retinal vascular occlusion after COVID-19 vaccination,Bair,Henry,ur.07700600627.77
6384,Risk assessment of retinal vascular occlusion after COVID-19 vaccination,Li,Jing-Xing,ur.016626671746.80
6384,Risk assessment of retinal vascular occlusion after COVID-19 vaccination,Wei,James Cheng-Chung,ur.014035457151.36
6384,Risk assessment of retinal vascular occlusion after COVID-19 vaccination,Lin,Chun-Ju,ur.01022267716.24
6384,Risk assessment of retinal vascular occlusion after COVID-19 vaccination,Wang,Yu-Hsun,ur.013116472400.04
6384,Risk assessment of retinal vascular occlusion after COVID-19 vaccination,Chen,Connie,
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Hu,Bo,ur.0770234330.30
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Liu,Xing,ur.013031603455.29
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Wang,Xinghuan,ur.0722405622.36
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Wang,Dawei,ur.016546752655.16
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Li,Yirong,ur.0635013150.69
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Wang,Binbin,ur.014424544455.68
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Cheng,Zhenshun,ur.013624060373.43
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Zhang,Jing,ur.015614153431.73
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Peng,Zhiyong,ur.012145431017.46
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Zhu,Fangfang,ur.010622362234.59
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Hu,Chang,ur.010641262055.81
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Xiang,Hui,ur.01227417617.16
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Zhao,Yan,
6376,"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China",Xiong,Yong,ur.01300457513.30
6376,Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum,Zhu,Zechariah,ur.016225775355.49
6376,Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum,Goodman,Aaron M.,ur.014200370413.36
6376,Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum,Leas,Eric C.,ur.0613712444.83
6376,Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum,Dredze,Mark,ur.0644175200.38
6376,Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum,Hogarth,Michael,ur.0632220303.34
6376,Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum,Ayers,John W.,ur.01152114701.36
6376,Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum,Longhurst,Christopher A.,ur.01160117636.05
6376,Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum,Faix,Dennis J.,ur.01221741065.52
6376,Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum,Poliak,Adam,ur.012304323343.77
6376,Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum,Smith,Davey M.,ur.011615110604.77
6376,Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum,Kelley,Jessica B.,
6369,Autopsy Proven Fatal COVID-19 Vaccine-Induced Myocarditis,Makis,William,ur.0675163676.16
6369,Autopsy Proven Fatal COVID-19 Vaccine-Induced Myocarditis,Hulscher,Nicolas,ur.015226431212.49
6369,Autopsy Proven Fatal COVID-19 Vaccine-Induced Myocarditis,Malhotra,Aseem,
6369,Autopsy Proven Fatal COVID-19 Vaccine-Induced Myocarditis,Hodkinson,Roger,ur.016024011612.79
6369,Autopsy Proven Fatal COVID-19 Vaccine-Induced Myocarditis,McCullough,Peter,ur.01115457467.68
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,Jones,Matthew W.,ur.012051416305.18
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,Peters,Glen P.,ur.01054602012.43
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,Andrew,Robbie M.,ur.015621120147.43
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,Canadell,Josep G.,ur.0663317775.09
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,Creutzig,Felix,ur.016560662511.13
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,Friedlingstein,Pierre,ur.01264150450.19
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,Willis,David R.,
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,Shan,Yuli,ur.011255554775.90
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,Le Quéré,Corinne,ur.0646336020.05
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,Jackson,Robert B.,ur.01210302556.48
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,Smith,Adam J. P.,ur.015003752115.26
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,Abernethy,Sam,ur.012233560067.43
6364,Temporary reduction in daily global CO2 emissions during the COVID-19 forced confinement,De-Gol,Anthony J.,ur.07673641715.52
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Mills,Nicholas L.,ur.01052613263.54
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Zaccardi,Francesco,ur.01360153731.10
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Mei,Xue W.,ur.011010116731.45
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Watkinson,Peter,ur.01152420736.35
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Shankar-Hari,Manu,ur.01242172705.25
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Harnden,Anthony,ur.015444577125.35
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Khunti,Kamlesh,ur.0641072534.04
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Channon,Keith M.,ur.01215026665.66
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Dixon,Sharon,ur.016707314172.43
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Coupland,Carol A.C.,ur.0635076355.31
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Sheikh,Aziz,ur.01125214207.48
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Handunnetthi,Lahiru,ur.0606603643.01
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Patone,Martina,ur.07760251517.54
6360,Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,Hippisley-Cox,Julia,ur.01027557547.88
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Cho,Jeong Gwan,ur.0756702344.53
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Kim,Hyung Yoon,
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Park,Hyukjin,ur.01120731112.07
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Park,Jae-Hyeong,ur.0643450245.09
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Choi,Jin-Oh,ur.01303371104.41
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Jeong,Myung Ho,ur.0702051706.12
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Kim,Kye Hun,ur.010565103204.36
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Cho,Jae Yeong,ur.0725572710.48
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Cho,Soo Hyeon,ur.013120623404.85
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Choi,Eui-Young,ur.01062057020.97
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Kim,Seung Yun,ur.015104756574.08
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Ahn,Youngkeun,ur.015526465242.75
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Kim,Eun Kyoung,ur.010726673673.89
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Yoon,Hyun Ju,ur.01362216744.44
6356,COVID-19 vaccination-related myocarditis: a Korean nationwide study,Lee,Nuri,ur.012552424704.77
6353,"Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020",Team,CDC COVID-19 Response,
6353,"Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020",Administration,Food and Drug,
6341,COVID Vaccine Hesitancy and Risk of a Traffic Crash,Redelmeier,Donald A,ur.01345133755.00
6341,COVID Vaccine Hesitancy and Risk of a Traffic Crash,Thiruchelvam,Deva,ur.0612615217.64
6341,COVID Vaccine Hesitancy and Risk of a Traffic Crash,Wang,Jonathan,ur.011540367214.19
6335,Protection by a Fourth Dose of BNT162b2 against Omicron in Israel,Ash,Nachman,ur.01205514201.07
6335,Protection by a Fourth Dose of BNT162b2 against Omicron in Israel,Bodenheimer,Omri,ur.016326715244.10
6335,Protection by a Fourth Dose of BNT162b2 against Omicron in Israel,Mandel,Micha,ur.01207744736.07
6335,Protection by a Fourth Dose of BNT162b2 against Omicron in Israel,Goldberg,Yair,ur.01051103470.43
6335,Protection by a Fourth Dose of BNT162b2 against Omicron in Israel,Freedman,Laurence,ur.01154263410.83
6335,Protection by a Fourth Dose of BNT162b2 against Omicron in Israel,Bar-On,Yinon M,ur.0665247076.28
6335,Protection by a Fourth Dose of BNT162b2 against Omicron in Israel,Milo,Ron,ur.0774352340.01
6335,Protection by a Fourth Dose of BNT162b2 against Omicron in Israel,Huppert,Amit,ur.01032344140.62
6335,Protection by a Fourth Dose of BNT162b2 against Omicron in Israel,Alroy-Preis,Sharon,ur.01061334326.15
6335,Protection by a Fourth Dose of BNT162b2 against Omicron in Israel,Amir,Ofra,ur.013574144147.14
6332,RETRACTED: Physio-metabolic and clinical consequences of wearing face masks—Systematic review with meta-analysis and comprehensive evaluation,Prescher,Andreas,ur.0751171625.75
6332,RETRACTED: Physio-metabolic and clinical consequences of wearing face masks—Systematic review with meta-analysis and comprehensive evaluation,Sukul,Pritam,ur.01357507000.81
6332,RETRACTED: Physio-metabolic and clinical consequences of wearing face masks—Systematic review with meta-analysis and comprehensive evaluation,Kisielinski,Kai,ur.01167300426.38
6332,RETRACTED: Physio-metabolic and clinical consequences of wearing face masks—Systematic review with meta-analysis and comprehensive evaluation,Wojtasik,Barbara,ur.013556506355.19
6332,RETRACTED: Physio-metabolic and clinical consequences of wearing face masks—Systematic review with meta-analysis and comprehensive evaluation,Wagner,Susanne,ur.012756406600.04
6332,RETRACTED: Physio-metabolic and clinical consequences of wearing face masks—Systematic review with meta-analysis and comprehensive evaluation,Funken,Stefan,ur.012441275655.43
6332,RETRACTED: Physio-metabolic and clinical consequences of wearing face masks—Systematic review with meta-analysis and comprehensive evaluation,Sönnichsen,Andreas,ur.0734776105.84
6332,RETRACTED: Physio-metabolic and clinical consequences of wearing face masks—Systematic review with meta-analysis and comprehensive evaluation,Hirsch,Oliver,ur.0670230011.24
6332,RETRACTED: Physio-metabolic and clinical consequences of wearing face masks—Systematic review with meta-analysis and comprehensive evaluation,Klosterhalfen,Bernd,ur.010743050164.68
6332,RETRACTED: Physio-metabolic and clinical consequences of wearing face masks—Systematic review with meta-analysis and comprehensive evaluation,Manna,Soumen Kanti,ur.01041232165.54
6315,‘It will change everything’: DeepMind’s AI makes gigantic leap in solving protein structures,Callaway,Ewen,
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Rabin,Joseph,ur.07455335540.40
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Kleiner,David E.,ur.0617046406.93
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,McCurdy,Michael T.,ur.0602477172.21
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Yinda,Claude Kwe,ur.01354746125.94
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Boritz,Eli A.,ur.01264266746.13
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Ko,Sung Hee,ur.014656211705.50
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Sun,Junfeng,
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Saharia,Kapil K.,ur.01334010173.39
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Ramelli,Sabrina C.,ur.010203624222.59
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,de Wit,Emmie,ur.01357410457.53
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Herr,Daniel L.,ur.016160406740.25
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Ylaya,Kris,ur.01257263316.29
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Ramos-Benitez,Marcos J.,ur.016662743653.51
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Grazioli,Alison,ur.012043363664.70
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Peterson,Karin E.,ur.012366334557.06
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Quezado,Martha,ur.01050652016.54
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Dickey,James M.,ur.014513471440.93
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Singh,Manmeet,ur.011640671077.58
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Tabatabai,Ali,ur.012661764737.28
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Belinky,Frida,ur.0660667006.06
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Lach,Izabella A.,ur.014020102160.73
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Hewitt,Stephen M.,ur.016463400357.43
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Winkler,Clayton W.,ur.0614434462.84
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Pittaluga,Stefania,ur.01026606316.51
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Cohen,Jeffrey I.,ur.01325554464.07
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Burbelo,Peter D.,ur.01340046461.15
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Madathil,Ronson J.,ur.0575601601.15
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Munster,Vincent J.,ur.01334105063.89
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Stein,Sydney R.,ur.011045237707.93
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Platt,Andrew P.,ur.016704013040.71
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Purcell,Madeleine,
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Chertow,Daniel S.,ur.0734560734.09
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Vannella,Kevin M.,ur.01317134243.33
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Chung,Joon-Yong,ur.01252654477.56
6314,SARS-CoV-2 infection and persistence in the human body and brain at autopsy,Soherwardi,Shahabuddin,ur.011621744463.82
6310,The major genetic risk factor for severe COVID-19 is inherited from Neanderthals,Zeberg,Hugo,ur.0635227346.69
6310,The major genetic risk factor for severe COVID-19 is inherited from Neanderthals,Pääbo,Svante,ur.01330431426.48
6302,An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study,D'Antiga,Lorenzo,ur.01341772205.65
6302,An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study,Bonanomi,Ezio,ur.01240651733.10
6302,An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study,Verdoni,Lucio,ur.01057615261.51
6302,An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study,Ciuffreda,Matteo,ur.01051126500.09
6302,An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study,Gervasoni,Annalisa,ur.016257514425.13
6302,An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study,Martelli,Laura,ur.011116044260.11
6302,An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study,Ruggeri,Maurizio,ur.01177247552.81
6302,An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study,Mazza,Angelo,ur.016262165674.20
6301,"SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021",Traub,Elizabeth,ur.012023514217.18
6301,"SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021",Gounder,Prabhu,ur.01365754430.42
6301,"SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021",Danza,Phoebe,ur.011666606523.56
6301,"SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021",Griffin,Jennifer B.,
6301,"SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021",Jarashow,Claire,ur.016540364445.66
6301,"SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021",Fisher,Rebecca,ur.011156455427.86
6301,"SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021",Koo,Tae Hee,ur.010355472744.06
6301,"SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021",Haddix,Meredith,ur.016446643451.35
6301,"SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021",Balter,Sharon,ur.0720406272.70
6299,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data,Stuart,Arabella,ur.012453520651.22
6299,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data,Shaw,Robert H,ur.010240754613.97
6299,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data,Liu,Xinxue,ur.012403434465.77
6299,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data,Greenland,Melanie,ur.016245737157.77
6299,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data,Van-Tam,Jonathan S Nguyen,ur.014701425115.57
6299,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data,Snape,Matthew D,ur.010062135107.44
6299,Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data,Group,Com-COV Study,
6295,"Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses, a Systematic Review",Malekinejad,Mohsen,ur.01112012035.25
6295,"Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses, a Systematic Review",Bulfone,Tommaso Celeste,ur.011235466610.93
6295,"Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses, a Systematic Review",Rutherford,George W,ur.013173452305.46
6295,"Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses, a Systematic Review",Razani,Nooshin,ur.01252543617.12
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Barredo,Lauren,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Torres,Emma,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Karadag,Ozge,ur.012572066110.10
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Khandelwal,Shweta,ur.01272061762.28
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Michie,Susan,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Gaspar,Vitor,ur.07605465742.32
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Lazarus,Jeffrey V,ur.016271461132.15
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Colombo,Francesca,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Espinosa,María Fernanda,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Ben Amor,Yanis,ur.01247353724.81
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Pate,Muhammad Ali,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Bahadur,Chandrika,ur.012203355733.09
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Huynh,Uyen Kim,ur.014771101721.03
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Ramos,Gabriela,ur.016246740116.70
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Lee,Jong-Koo,ur.0636160167.61
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Were,Miriam Khamadi,ur.013214616711.95
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Koundouri,Phoebe,ur.013174660410.94
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Hellard,Margaret,ur.01343233200.02
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Xue,Lan,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Wang,Chen,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Hotez,Peter J,ur.0742445763.83
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Lafortune,Guillaume,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Haines,Andy,ur.01175642011.84
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Serageldin,Ismail,ur.015451105634.49
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Allen,Joseph,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Bartels,Juliana G E,ur.010656530133.42
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Aknin,Lara,ur.01370231033.79
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Barron,Gabriela Cuevas,ur.011271546733.22
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Bottazzi,Maria Elena,ur.0706614573.74
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Joshi,Neena,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Vike-Freiberga,Vaira,ur.016420062145.37
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Gaviria,Alejandro,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Bullen,Chris,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Laryea-Adjei,George,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Karim,Salim S Abdool,ur.07661104677.02
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Bascuñán,Felipe Larraín,ur.07744721133.42
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Reddy,K Srinath,ur.010100474372.19
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Thwaites,John,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Sachs,Jeffrey D,
6293,The Lancet Commission on lessons for the future from the COVID-19 pandemic,Brosbøl,Kirsten,ur.010474166333.33
6293,Characterizing long COVID in an international cohort: 7 months of symptoms and their impact,Wei,Hannah,ur.013133122735.43
6293,Characterizing long COVID in an international cohort: 7 months of symptoms and their impact,McCorkell,Lisa,ur.015317277775.32
6293,Characterizing long COVID in an international cohort: 7 months of symptoms and their impact,Redfield,Signe,ur.013567053627.46
6293,Characterizing long COVID in an international cohort: 7 months of symptoms and their impact,Re'em,Yochai,ur.0766730606.30
6293,Characterizing long COVID in an international cohort: 7 months of symptoms and their impact,Akrami,Athena,ur.01223615375.68
6293,Characterizing long COVID in an international cohort: 7 months of symptoms and their impact,Davis,Hannah E.,ur.011540161735.06
6293,Characterizing long COVID in an international cohort: 7 months of symptoms and their impact,Low,Ryan J.,ur.013545453105.45
6293,Characterizing long COVID in an international cohort: 7 months of symptoms and their impact,Assaf,Gina S.,ur.016712240775.45
6293,Characterizing long COVID in an international cohort: 7 months of symptoms and their impact,Austin,Jared P.,ur.015327471445.14
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Sapiano,Matthew R P,ur.013743345517.96
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Epperson,Monica,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Havers,Fiona,ur.01245266327.24
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Stramer,Susan L,ur.01201712136.75
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Park,So Hee,ur.011645676365.64
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Gerber,Susan,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Schiffer,Jarad,ur.0631723217.11
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Moss,Kimberly,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Patel,Palak,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Reed,Carrie,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Patton,Monica E,ur.0627055264.31
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Ortiz,Kristina,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Desai,Rita,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Boulay,Darbi,ur.01316500304.28
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Freeman,Brandi,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Tamin,Azaibi,ur.0730465355.70
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Cronin,Li,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Stumpf,Megan,ur.016331061567.11
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Vogan,Andrew,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Alston,Bailey,ur.014037477517.44
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Jia,Tao,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Zellner,Briana,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Tatum,Heather,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Qin,Yunlong,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Rasheed,Mohammed Ata Ur,ur.0675407700.28
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Steward-Clark,Evelene,ur.01144126566.03
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Grimm,Kacie,ur.016053325064.39
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Thornburg,Natalie J,ur.0606700201.50
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Maniatis,Panagiotis,ur.0673713066.97
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Bolcen,Shanna,ur.01072622547.83
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Lester,Sandra,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,David,Ebenezer,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Harcourt,Jennifer,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Gorantla,Yamini,ur.0663720037.34
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Drobeniuc,Jan,ur.01233377256.12
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Basavaraju,Sridhar V,ur.01051040570.07
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Browning,Peter,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Ategbole,Muyiwa,ur.011772443313.13
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Mills,Lisa,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Li,Han,
6286,Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020,Semenova,Vera,
6279,Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients,Desjardins,Michaël,ur.011637277750.09
6279,Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients,Powell,Megan,ur.013156164231.29
6279,Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients,Walt,David R,ur.01126017715.90
6279,Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients,Sherman,Amy C,ur.015206755675.68
6279,Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients,Senussi,Yasmeen,ur.014477150731.13
6279,Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients,Baden,Lindsey R,ur.0750725460.01
6279,Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients,Von,Salena,ur.012234027661.15
6279,Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients,Novack,Lewis,ur.011500432071.42
6279,Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients,Cheng,Chi-An,ur.012330742504.28
6279,Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients,Ogata,Alana F,ur.015034556503.34
6279,Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients,Li,Xiaofang,ur.011677451631.71
6274,Bivalent Covid-19 Vaccines — A Cautionary Tale,Offit,Paul A,
6269,The UK’s public health response to covid-19,Abbasi,Kamran,ur.0627346562.75
6269,The UK’s public health response to covid-19,Scally,Gabriel,ur.0731257347.22
6269,The UK’s public health response to covid-19,Jacobson,Bobbie,
6259,The Foegen effect,Fögen,Zacharias,ur.011222517273.77
6255,Reconciling estimates of global spread and infection fatality rates of COVID‐19: An overview of systematic evaluations,Ioannidis,John P. A.,ur.015607417277.46
6235,“Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”,Alcalá Díaz,Juan Francisco,ur.0637107646.61
6235,“Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”,Bouillon,Roger,ur.01126737302.39
6235,“Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”,López Miranda,José,ur.01357715345.63
6235,“Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”,Quesada Gomez,José Manuel,ur.01015005174.40
6235,“Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”,Vaquero Barrios,José Manuel,ur.01345636611.52
6235,“Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”,Entrenas Castillo,Marta,ur.010277236477.30
6235,“Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”,Entrenas Costa,Luis Manuel,ur.013003103073.12
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Kamarulzaman,Adeeba,
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Matičič,Mojca,ur.073527240.33
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Saenz,Rocio,ur.01321413726.38
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Chiou,Shu-Ti,ur.01226366654.24
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Barreto,Mauricio L.,ur.01070225647.59
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Trock-Hempler,Malene,
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Rabin,Kenneth,ur.012642165223.14
6233,A multinational Delphi consensus to end the COVID-19 public health threat,del Rio,Carlos,
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Baptista-Leite,Ricardo,ur.01176424551.05
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Bar-Yam,Yaneer,ur.0771274344.77
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Villapol,Sonia,ur.0704206665.91
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Pradelski,Bary,ur.011456304775.85
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Batista,Carolina,ur.01025641337.43
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Rathe,Magdalena,ur.016472201210.05
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Oliu-Barton,Miquel,ur.014711655201.19
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Lee,Nancy,
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Nsanzimana,Sabin,ur.01275757762.00
6233,A multinational Delphi consensus to end the COVID-19 public health threat,El-Mohandes,Ayman,ur.013265312327.10
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Singh,Sudhvir,ur.0604067551.44
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Gostin,Lawrence O.,ur.01321750771.84
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Romero,Diana,ur.0670537352.38
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Karim,Salim Abdool,ur.015035052454.03
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Bassat,Quique,ur.01074511734.95
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Bazilian,Morgan,ur.012705300017.59
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Almeida,Gisele,
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Binagwaho,Agnes,ur.01112061632.05
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Kopka,Christopher J.,ur.010207561540.01
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Raina,Sunil,ur.0635703464.52
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Barocas,Joshua A.,ur.0775554542.40
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Pyzik,Oksana,ur.016206116775.18
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Yap,Peiling,ur.015713560402.00
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Hellard,Margaret,ur.01343233200.02
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Gao,George F.,
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Abu-Raddad,Laith J.,ur.01043443217.45
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Kang,Gagandeep,
6233,A multinational Delphi consensus to end the COVID-19 public health threat,McKee,Martin,ur.01367673420.84
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Jimenez,Jose L.,ur.01051427102.20
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Dore,Gregory J.,
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Lazarus,Jeffrey V.,ur.016271461132.15
6233,A multinational Delphi consensus to end the COVID-19 public health threat,Rashid,Sabina Faiz,ur.01142070574.31
6210,mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues,Banoun,Helene,
6210,"Association Between K–12 School Mask Policies and School-Associated COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August 2021",Jehn,Megan,ur.01157376544.37
6210,"Association Between K–12 School Mask Policies and School-Associated COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August 2021",Gue,Matthew,ur.014776630514.14
6210,"Association Between K–12 School Mask Policies and School-Associated COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August 2021",Eller,Brian,
6210,"Association Between K–12 School Mask Policies and School-Associated COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August 2021",Dale,Ariella P.,ur.015760605233.06
6210,"Association Between K–12 School Mask Policies and School-Associated COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August 2021",McCullough,J. Mac,ur.01312410733.14
6210,"Association Between K–12 School Mask Policies and School-Associated COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August 2021",Cullen,Theresa,ur.014625071065.42
6210,"Association Between K–12 School Mask Policies and School-Associated COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August 2021",Scott,Sarah E.,ur.012326203271.38
6208,"Transplacental transmission of the COVID-19 vaccine messenger RNA: evidence from placental, maternal, and cord blood analyses postvaccination",Botros,Bishoy,ur.013351127573.60
6208,"Transplacental transmission of the COVID-19 vaccine messenger RNA: evidence from placental, maternal, and cord blood analyses postvaccination",De Mejia,Claudia Manzano,ur.015541451173.10
6208,"Transplacental transmission of the COVID-19 vaccine messenger RNA: evidence from placental, maternal, and cord blood analyses postvaccination",Gurzenda,Ellen,ur.0713057157.88
6208,"Transplacental transmission of the COVID-19 vaccine messenger RNA: evidence from placental, maternal, and cord blood analyses postvaccination",Lin,Xinhua,ur.016606376323.21
6208,"Transplacental transmission of the COVID-19 vaccine messenger RNA: evidence from placental, maternal, and cord blood analyses postvaccination",Hanna,Monica,
6208,"Transplacental transmission of the COVID-19 vaccine messenger RNA: evidence from placental, maternal, and cord blood analyses postvaccination",Chavez,Martin,ur.0632605224.02
6208,"Transplacental transmission of the COVID-19 vaccine messenger RNA: evidence from placental, maternal, and cord blood analyses postvaccination",Hanna,Nazeeh,ur.0665307560.18
6170,Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination,Eichinger,Sabine,ur.01350550752.90
6170,Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination,Kyrle,Paul A,ur.0766463563.20
6170,Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination,Weisser,Karin,ur.0611324427.06
6170,Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination,Warkentin,Theodore E,ur.01115406067.97
6170,Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination,Greinacher,Andreas,ur.01117562752.15
6170,Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination,Thiele,Thomas,ur.0721730445.86
6163,"A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes",Chaudhry,Rabail,ur.011072761351.74
6163,"A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes",Riazi,Sheila,ur.01144772706.07
6163,"A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes",Mubashir,Talha,ur.016301443020.69
6163,"A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes",Dranitsaris,George,ur.01036510774.09
6163,"A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes",Bartoszko,Justyna,ur.01054635176.45
6150,Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens,Brodin,Petter,ur.01206525305.88
6150,Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens,Arditi,Moshe,ur.0654651335.30
6149,Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19,Semple,Malcolm G,ur.013275555725.42
6149,Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19,Peto,Tim E,ur.011213750437.09
6149,Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19,Mina,Michael J,ur.01372163001.70
6149,Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19,Buchan,Iain E,ur.01156663240.67
6149,Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19,García-Fiñana,Marta,ur.01067544635.39
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Niu,Xiao,
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Yang,Sijie,ur.012450270146.49
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Cao,Yunlong,ur.012175153617.29
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Hao,Xiaohua,ur.01051065746.97
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Zhang,Na,ur.011441235122.21
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Yu,Lingling,ur.015311264532.44
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Wang,Peng,
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Yu,Yuanling,ur.014553302071.71
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Song,Weiliang,ur.011510603436.30
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Xie,Xiaoliang Sunney,ur.01154123474.53
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Jian,Fanchong,ur.011604574346.52
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Wang,Youchun,ur.01353360710.43
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Wang,Yao,
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Shao,Fei,ur.014565660432.51
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Wang,Jing,
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Jin,Ronghua,ur.01074607307.99
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Shen,Zhongyang,ur.01136266737.27
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Xiao,Tianhe,ur.012402154746.38
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Gu,Qingqing,ur.013770300032.09
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Chen,Xiaosu,
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Wang,Jing,
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,An,Ran,ur.014473565552.43
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Yisimayi,Ayijiang,ur.012243267017.00
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Xu,Yanli,ur.014427137122.54
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Zhao,Lijuan,
6144,Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution,Sun,Haiyan,ur.011526002132.60
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Hartnett,Kathleen,ur.01340663301.38
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Law,,ur.0651512053.64
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Idaikkadar,Nimi,ur.016450445131.46
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Radhakrishnan,Lakshmi,ur.015117454205.34
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Martinez,Pedro,ur.015206211167.42
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Adjemian,Jennifer,ur.01337703241.18
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Yard,Ellen,ur.0740435173.97
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Holland,Kristin,ur.0630147370.78
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Ballesteros,Michael F.,ur.01355544032.05
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Stein,Zachary,ur.016354771007.49
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Ivey-Stephenson,Asha,ur.013462314133.16
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Ehlman,Daniel C.,ur.0654532715.48
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Stone,Deborah M.,ur.01172617662.42
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Rodgers,Loren,ur.01266512223.40
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Sheppard,Michael,ur.013662016107.20
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Kite-Powell,Aaron,ur.01235547503.46
6140,"Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12–25 Years Before and During the COVID-19 Pandemic — United States, January 2019–May 2021",Gates,Abigail,ur.013420717551.39
6131,BNT162b2 Vaccine Booster and Mortality Due to Covid-19,Sergienko,Ruslan,ur.0751171271.58
6131,BNT162b2 Vaccine Booster and Mortality Due to Covid-19,Arbel,Ronen,ur.01077611717.94
6131,BNT162b2 Vaccine Booster and Mortality Due to Covid-19,Friger,Michael,ur.01105317467.38
6131,BNT162b2 Vaccine Booster and Mortality Due to Covid-19,Yaron,Shlomit,ur.010525322531.52
6131,BNT162b2 Vaccine Booster and Mortality Due to Covid-19,Peretz,Alon,ur.01104577653.74
6131,BNT162b2 Vaccine Booster and Mortality Due to Covid-19,Hammerman,Ariel,ur.0643353666.17
6131,BNT162b2 Vaccine Booster and Mortality Due to Covid-19,Netzer,Doron,ur.013222005241.14
6116,Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?,Fang,Lei,ur.01077525350.46
6116,Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?,Roth,Michael,ur.014257130740.79
6116,Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?,Karakiulakis,George,ur.01261407345.05
6099,Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age,Cook,Alex R,ur.01034341733.34
6099,Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age,Tan,Sharon H X,ur.013122613543.44
6099,"The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good",de Figueiredo,Alex,ur.07672400154.06
6099,Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age,Ong,Benjamin,ur.01014122301.52
6099,"The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good",Bardosh,Kevin,ur.01253246524.87
6099,Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age,Tan,Kelvin B,ur.07650150513.57
6099,"The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good",Gur-Arie,Rachel,ur.012561773456.60
6099,"The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good",Graham,Janice E,ur.01051754375.74
6099,"The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good",Baral,Stefan,ur.01213025046.15
6099,"The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good",Keshavjee,Salmaan,ur.01101124045.64
6099,"The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good",Jamrozik,Euzebiusz,ur.01150606074.87
6099,"The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good",Doidge,James,ur.01030652545.46
6099,Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age,Heng,Derrick,ur.015501727204.52
6099,Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age,Lye,David C,ur.010714562317.26
6099,"The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good",Lemmens,Trudo,ur.0640055046.19
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Hanch-Hansen,Kristian E.,
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Nygård,Karin,ur.01015421463.35
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Hungnes,Olav,ur.0730566771.86
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Brandal,Lin T.,ur.01213303523.34
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Watle,Sara Viksmoen,ur.0610551302.46
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Taxt,Arne M.,ur.0725243205.69
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Hagen,Frode,ur.013155500523.86
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Naseer,Umaer,ur.0637662207.58
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Ødeskaug,Liz E.,ur.011245303242.10
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Lind,Andreas,ur.0721744534.16
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",MacDonald,Emily,ur.0701173063.94
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Veneti,Lamprini,ur.01301630161.15
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Feruglio,Siri,ur.0734544107.21
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Bragstad,Karoline,ur.01027342027.98
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Aavitsland,Preben,ur.01252216012.75
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Lange,Heidi,ur.01124710622.69
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Vold,Line,ur.0636720763.38
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Johansen,Mia,ur.07520734001.08
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Madslien,Elisabeth H.,ur.0722062776.42
6097,"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021",Ravlo,Tine,
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Zoldan,Katharina,ur.07741752064.57
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Neumann-Haefelin,Christoph,ur.0747555757.47
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Salimi Alizei,Elahe,ur.012103116524.39
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Luxenburger,Hendrik,ur.015767745675.47
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Thimme,Robert,ur.01067645457.52
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Prinz,Marco,ur.0732026257.14
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Bengsch,Bertram,ur.0611425616.58
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Krimmel,Laurenz,ur.014325562544.69
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Hofmann,Maike,ur.01312323431.83
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Bronsert,Peter,ur.01326471612.47
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Mogler,Carolin,ur.0707236452.39
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Boettler,Tobias,ur.0776176542.34
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Csernalabics,Benedikt,ur.015142412207.69
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Schwabenland,Marius,ur.013733645361.01
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Salié,Henrike,ur.014670574317.31
6092,SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis,Wischer,Lara,ur.013756471636.02
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Chung,Joon-Yong,ur.01252654477.56
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Rabin,Joseph,ur.015734014552.24
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Herr,Daniel,
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Ko,Sung Hee,
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Ylaya,Kris,ur.01257263316.29
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Saharia,Kapil,ur.01334010173.39
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Winkler,Clayton,ur.0614434462.84
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,de Wit,Emmie,ur.01357410457.53
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Chertow,Daniel,ur.0734560734.09
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Pittaluga,Stefania,ur.01026606316.51
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Stein,Sydney,ur.011045237707.93
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Ramelli,Sabrina,ur.010203624222.59
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Ramos-Benitez,Marcos,ur.016662743653.51
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Dickey,James,
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Singh,Manmeet,ur.011640671077.58
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Yinda,Claude Kwe,ur.01354746125.94
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,McCurdy,Michael,ur.0602477172.21
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Cohen,Jeffrey,ur.01325554464.07
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Belinky,Frida,ur.0660667006.06
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Vannella,Kevin,ur.01317134243.33
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Platt,Andrew,ur.016704013040.71
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Quezado,Martha,ur.01050652016.54
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Madathil,Ronson,ur.0575601601.15
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Purcell,Madeleine,
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Peterson,Karin,ur.012366334557.06
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Soherwardi,Shahabuddin,ur.011621744463.82
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Boritz,Eli,ur.01264266746.13
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Grazioli,Alison,ur.012043363664.70
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Munster,Vincent,ur.01334105063.89
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Burbelo,Peter,ur.01340046461.15
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Tabatabai,Ali,
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Kleiner,David,ur.0617046406.93
6084,SARS-CoV-2 infection and persistence throughout the human body and brain,Hewitt,Stephen,ur.016463400357.43
6073,"Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022",Iachan,Ronaldo,ur.01335234672.96
6073,"Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022",Jones,Jefferson M.,ur.01317072007.53
6073,"Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022",MacNeil,Adam,ur.015567114370.98
6073,"Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022",Deng,Yangyang,ur.07525403771.28
6073,"Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022",Nycz,Elise,ur.010156346310.45
6073,"Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022",Hall,Aron J.,ur.0732265520.71
6073,"Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022",Lee,Adam,ur.013161575501.75
6073,"Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022",Clarke,Kristie E.N.,ur.0773735367.67
6073,"Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022",Gundlapalli,Adi V.,ur.0611305711.53
6068,How Trump damaged science — and why it could take decades to recover,Tollefson,Jeff,
6041,Do us a favor,Thorp,H Holden,ur.0661605552.03
6034,The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis,Henein,Michael Y,ur.01314315220.17
6034,The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis,Reiner,Željko,ur.01175766026.74
6034,The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis,Surma,Stanisław,ur.015113143467.05
6034,The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis,Martin,Seth S,ur.01134432546.53
6034,The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis,Bytyçi,Ibadete,ur.0730320206.71
6034,The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis,Bajraktari,Gani,
6034,The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis,Bielecka-Dąbrowa,Agata,ur.0654056630.95
6034,The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis,Banach,Maciej,ur.01254700671.30
6034,The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis,Sahebkar,Amirhossein,
6034,The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis,Lewek,Joanna,ur.0726067303.48
6034,The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis,Penson,Peter E,ur.01137726373.15
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Polack,Fernando P,ur.0705247414.83
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Tresnan,Dina B,ur.011115233157.53
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Absalon,Judith,ur.0726712623.28
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Kitchin,Nicholas,ur.01343436707.36
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Ünal,Serhat,ur.01115453237.24
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Lockhart,Stephen,ur.01155017074.41
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Dormitzer,Philip R,ur.01124563153.82
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Kalina,Warren V,ur.0577211724.06
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Hammitt,Laura L,ur.011373562250.32
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Gurtman,Alejandra,ur.0766540106.68
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Jansen,Kathrin U,
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Schaefer,Axel,
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Zerbini,Cristiano,ur.011325447050.77
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Mather,Susan,ur.012742202221.19
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Cooper,David,
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Liberator,Paul,
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Bouguermouh,Salim,ur.01264006673.59
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Frenck,Robert W,ur.01157665701.10
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Pérez Marc,Gonzalo,ur.014352732673.49
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Şahin,Uğur,ur.0657734236.08
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Türeci,Özlem,ur.01237100335.34
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Thomas,Stephen J,ur.01250631625.48
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Roychoudhury,Satrajit,ur.01075070035.40
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Nell,Haylene,ur.01051056763.52
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Swanson,Kena A,ur.0720727651.67
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Moreira,Edson D,ur.016320742232.37
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Bailey,Ruth,
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Perez,John L,
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Gruber,William C,ur.0735756071.23
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Xu,Xia,
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Yang,Qi,
6029,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,Koury,Kenneth,ur.01252412675.84
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Cluver,Lucie,ur.01204305732.85
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Nelson,Charles A.,ur.01310632425.78
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Donnelly,Christl A.,ur.01305160526.54
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Mercy,James A.,ur.01133173101.36
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Blenkinsop,Alexandra,ur.015770121133.51
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Hillis,Susan D.,ur.015360521217.92
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Massetti,Greta M.,ur.013507073627.31
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Liburd,Leandris,ur.01016122057.37
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Sherr,Lorraine,ur.01321440243.14
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Flaxman,Seth,ur.0640410710.66
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Demissie,Zewditu,ur.01202657232.66
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Villaveces,Andrés,ur.01301257547.91
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Annor,Francis B.,ur.0611642751.07
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Ratmann,Oliver,ur.0760341634.14
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Sherr,Lorraine,ur.01321440243.14
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Liburd,Leandris,ur.01016122057.37
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Flaxman,Seth,ur.0640410710.66
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Massetti,Greta M.,ur.013507073627.31
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Annor,Francis B.,ur.0611642751.07
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Blenkinsop,Alexandra,ur.015770121133.51
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Ratmann,Oliver,ur.0760341634.14
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Nelson,Charles A.,ur.01310632425.78
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Cluver,Lucie,ur.01204305732.85
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Hillis,Susan D.,ur.015360521217.92
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Mercy,James A.,ur.01133173101.36
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Donnelly,Christl A.,ur.01305160526.54
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Villaveces,Andrés,ur.01301257547.91
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Unwin,H. Juliette T.,ur.012651002370.79
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Demissie,Zewditu,ur.01202657232.66
6024,COVID-19-Associated Orphanhood and Caregiver Death in the United States,Unwin,H. Juliette T.,ur.012651002370.79
5998,A modelling framework to assess the likely effectiveness of facemasks in combination with lock-down in managing the COVID-19 pandemic,Gilligan,Christopher A.,ur.01356417173.74
5998,A modelling framework to assess the likely effectiveness of facemasks in combination with lock-down in managing the COVID-19 pandemic,Stutt,Richard O. J. H.,ur.0633470061.89
5998,A modelling framework to assess the likely effectiveness of facemasks in combination with lock-down in managing the COVID-19 pandemic,Retkute,Renata,ur.01112722034.76
5998,A modelling framework to assess the likely effectiveness of facemasks in combination with lock-down in managing the COVID-19 pandemic,Colvin,John,ur.0677122363.80
5998,A modelling framework to assess the likely effectiveness of facemasks in combination with lock-down in managing the COVID-19 pandemic,Bradley,Michael,
5994,On the origin and continuing evolution of SARS-CoV-2,Yao,Xinmin,ur.010201306247.99
5994,On the origin and continuing evolution of SARS-CoV-2,Tang,Xiaolu,ur.010475121465.28
5994,On the origin and continuing evolution of SARS-CoV-2,Song,Yuhe,ur.010635755671.09
5994,On the origin and continuing evolution of SARS-CoV-2,Li,Xiang,ur.011161254067.33
5994,On the origin and continuing evolution of SARS-CoV-2,Wang,Yirong,ur.012565717065.69
5994,On the origin and continuing evolution of SARS-CoV-2,Cui,Jie,ur.0606754251.57
5994,On the origin and continuing evolution of SARS-CoV-2,Zhang,Hong,ur.015477150717.13
5994,On the origin and continuing evolution of SARS-CoV-2,Qian,Zhaohui,ur.0743270650.70
5994,On the origin and continuing evolution of SARS-CoV-2,Duan,Yuange,ur.013306627317.55
5994,On the origin and continuing evolution of SARS-CoV-2,Wu,Changcheng,ur.013406427033.42
5994,On the origin and continuing evolution of SARS-CoV-2,Lu,Jian,ur.01002335613.56
5994,On the origin and continuing evolution of SARS-CoV-2,Wu,Xinkai,ur.010543234665.06